-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Two CD O
modes NNS O
of IN O
microsatellite JJ O
instability NN O
in IN O
human JJ O
cancer NN O
: : O
differential JJ O
connection NN O
of IN O
defective JJ O
DNA NN O
mismatch NN O
repair NN O
to TO O
dinucleotide VB O
repeat NN O
instability NN O

Abstract NN O

Microsatellite NNP O
instability NN O
( -LRB- O
MSI) NNP O
is VBZ O
associated VBN O
with IN O
defective JJ O
DNA NN O
mismatch NN O
repair NN O
in IN O
various JJ O
human JJ O
malignancies NNS O
. . O

Using VBG O
a DT O
unique JJ O
fluorescent JJ O
technique NN O
, , O
we PRP O
have VBP O
observed VBN O
two CD O
distinct JJ O
modes NNS O
of IN O
dinucleotide NN O
microsatellite NN O
alterations NNS O
in IN O
human JJ O
colorectal NN O
cancer NN O
. . O

Type JJ O
A DT O
alterations NNS O
are VBP O
defined VBN O
as IN O
length NN O
changes NNS O
of IN O
≤6 DT O
bp NN O
. . O

Type NNP O
B NNP O
changes NNS O
are VBP O
more RBR O
drastic JJ O
and CC O
involve VBP O
modifications NNS O
of IN O
≥8 CD O
bp NN O
. . O

We PRP O
show VBP O
here RB O
that IN O
defective JJ O
mismatch NN O
repair NN O
is VBZ O
necessary JJ O
and CC O
sufficient JJ O
for IN O
Type NNP O
A DT O
changes NNS O
. . O

These DT O
changes NNS O
were VBD O
observed VBN O
in IN O
cell NN O
lines NNS O
and CC O
in IN O
tumours NNS O
from IN O
mismatch NN B-NP
repair NN I-NP
gene-knockout JJ I-NP
mice NNS O
. . O

No DT O
Type NNP O
B NNP O
instability NN O
was VBD O
seen VBN O
in IN O
these DT O
cells NNS O
or CC O
tumours NNS O
. . O

In IN O
a DT O
panel NN O
of IN O
human JJ O
colorectal NN O
tumours NNS O
, , O
both DT O
Type NNP O
A DT O
MSI NNP O
and CC O
Type NNP O
B NNP O
instability NN O
were VBD O
observed VBN O
. . O

Both DT O
types NNS O
of IN O
MSI NNP O
were VBD O
associated VBN O
with IN O
hMSH2 NN B-NP
or CC O
hMLH1 JJ B-NP
mismatch NN B-NP
repair NN I-NP
gene NN I-NP
alterations NNS O
. . O

Intriguingly RB O
, , O
p53 NN B-NP
mutations NNS O
, , O
which WDT O
are VBP O
generally RB O
regarded VBN O
as IN O
uncommon JJ O
in IN O
human JJ O
tumours NNS O
of IN O
the DT O
MSI+ NNP O
phenotype NN O
, , O
were VBD O
frequently RB O
associated VBN O
with IN O
Type NNP O
A DT O
instability NN O
, , O
whereas IN O
none NN O
was VBD O
found VBN O
in IN O
tumours NNS O
with IN O
Type NNP O
B NNP O
instability NN O
, , O
reflecting VBG O
the DT O
prevailing JJ O
viewpoint NN O
. . O

Inspection NNP O
of IN O
published VBN O
data NNS O
reveals VBZ O
that IN O
the DT O
microsatellite NN O
instability NN O
that WDT O
has VBZ O
been VBN O
observed VBN O
in IN O
various JJ O
malignancies NNS O
, , O
including VBG O
those DT O
associated VBN O
with IN O
Hereditary NNP O
Non-Polyposis NNP O
Colorectal NNP O
Cancer NNP O
( -LRB- O
HNPCC) NN O
, , O
is VBZ O
predominantly RB O
Type JJ O
B. NNP O
Our PRP$ O
findings NNS O
indicate VBP O
that IN O
Type NNP O
B NNP O
instability NN O
is VBZ O
not RB O
a DT O
simple JJ O
reflection NN O
of IN O
a DT O
repair NN O
defect NN O
. . O

We PRP O
suggest VBP O
that IN O
there EX O
are VBP O
at IN O
least JJS O
two CD O
qualitatively JJ O
distinct JJ O
modes NNS O
of IN O
dinucleotide NN O
MSI NNP O
in IN O
human JJ O
colorectal NN O
cancer NN O
, , O
and CC O
that IN O
different JJ O
molecular JJ O
mechanisms NNS O
may MD O
underlie VB O
these DT O
modes NNS O
of IN O
MSI. NNP O

The DT O
relationship NN O
between IN O
MSI NNP O
and CC O
defective JJ O
mismatch NN O
repair NN O
may MD O
be VB O
more RBR O
complex JJ O
than IN O
hitherto PRP O
suspected VBD O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Analysis NN O
of IN O
microsatellites NNS O
in IN O
MEFs NNP O
and CC O
tumours NNS O
from IN O
MMR-defective JJ B-NP
animals NNS O
therefore RB O
indicates VBZ O
that IN O
Type NNP O
A DT O
MSI NNP O
is VBZ O
a DT O
direct JJ O
consequence NN O
of IN O
defective JJ O
MMR. NNP B-NP

The DT O
absence NN O
of IN O
more RBR O
extensive JJ O
microsatellite JJ O
length NN O
changes NNS O
may MD O
indicate VB O
further RB O
that IN O
an DT O
Msh2 NNP B-NP
or CC O
Mlh1 NNP B-NP
defect NN O
is VBZ O
insufficient JJ O
for IN O
the DT O
development NN O
of IN O
Type NNP O
B NNP O
instability NN O
. . O

Mismatch NNP B-NP
repair NN I-NP
gene NN I-NP
inactivation NN O
is VBZ O
associated VBN O
with IN O
both DT O
Type NNP O
A NNP O
and CC O
Type NNP O
B NNP O
MSI NNP O
in IN O
human JJ O
colorectal NN O
cancer NN O

HNPCC NNP O
patients NNS O
inherit VBP O
mutations NNS O
in IN O
MMR NNP B-NP
genes NNS O
(6,7 VBP O
) -RRB- O
. . O

More JJR O
than IN O
90 CD O
% NN O
of IN O
HNPCC NNP O
tumours NNS O
are VBP O
MSI+ JJ O
( -LRB- O
20 CD O
) -RRB- O
. . O

The DT O
MSI+ NNP O
phenotype NN O
is VBZ O
also RB O
frequent JJ O
among IN O
sporadic JJ O
colorectal NN O
carcinomas NNS O
( -LRB- O
2–4,6,21 CD O
) -RRB- O
. . O

Inspection NNP O
of IN O
published VBN O
data NNS O
derived VBN O
from IN O
the DT O
conventional JJ O
microsatellite NN O
analysis NN O
reveals VBZ O
that IN O
microsatellite NN O
changes NNS O
thus RB O
far RB O
reported VBN O
in IN O
various JJ O
tumours NNS O
, , O
including VBG O
those DT O
in IN O
HNPCC NNP O
individuals NNS O
, , O
are VBP O
largely RB O
Type JJ O
B NNP O
( -LRB- O
2–4,20–22 CD O
) -RRB- O
. . O

We PRP O
considered VBD O
the DT O
possibility NN O
that IN O
the DT O
more RBR O
subtle JJ O
Type NN O
A DT O
MSI NNP O
might MD O
have VB O
remained VBN O
undetected JJ O
in IN O
some DT O
cases NNS O
. . O

Using VBG O
our PRP$ O
fluorescent NN O
assay NN O
with IN O
a DT O
panel NN O
of IN O
five CD O
dinucleotide NN O
repeat NN O
microsatellites NNS O
, , O
we PRP O
found VBD O
that IN O
the DT O
frequencies NNS O
of IN O
Type NNP O
A NNP O
and CC O
Type NNP O
B NNP O
MSI NNP O
among IN O
79 CD O
colorectal JJ O
carcinomas NNS O
were VBD O
30 CD O
% NN O
and CC O
17 CD O
% NN O
, , O
respectively RB O
. . O

In IN O
agreement NN O
with IN O
previous JJ O
observations NNS O
that IN O
Type NNP O
B NNP O
instability NN O
is VBZ O
common JJ O
in IN O
HNPCC NNP O
colon NN O
tumours NNS O
, , O
the DT O
IC690 NNP O
tumour NN O
and CC O
the DT O
colorectal JJ O
carcinoma NN O
cell NN O
line NN O
, , O
NoTa NNP O
( -LRB- O
Table NN O
1 CD O
) -RRB- O
, , O
both DT O
of IN O
which WDT O
were VBD O
derived VBN O
from IN O
patients NNS O
who WP O
fulfilled VBD O
the DT O
Amsterdam NNP O
Criteria NNP O
II NNP O
for IN O
HNPCC NNP O
( -LRB- O
23 CD O
) -RRB- O
, , O
exhibited VBD O
Type NNP O
B NNP O
instability NN O
( -LRB- O
Figure NN O
1G JJ O
and CC O
H) NNP O
. . O

Our PRP$ O
finding NN O
that IN O
17 CD O
% NN O
of IN O
colorectal JJ O
tumours NNS O
display VBP O
Type NNP O
B NNP O
MSI NNP O
is VBZ O
consistent JJ O
with IN O
the DT O
generally RB O
reported VBN O
figure NN O
of IN O
around RB O
20 CD O
% NN O
for IN O
MSI NNP O
among IN O
colorectal JJ O
carcinomas NNS O
( -LRB- O
20,24,25 CD O
) -RRB- O
. . O

The DT O
observation NN O
that IN O
a DT O
further JJ O
30 CD O
% NN O
of IN O
tumours NNS O
displayed VBN O
Type NNP O
A DT O
MSI NNP O
suggests VBZ O
that IN O
the DT O
frequency NN O
of IN O
MSI NNP O
, , O
at IN O
least JJS O
in IN O
colorectal JJ O
carcinomas NNS O
, , O
has VBZ O
previously RB O
been VBN O
underestimated VBN O
. . O

The DT O
relationship NN O
between IN O
MSI NNP O
and CC O
defective JJ O
MMR NN B-NP
in IN O
our PRP$ O
set NN O
of IN O
colorectal JJ O
tumours NNS O
was VBD O
investigated VBN O
further RB O
. . O

hMSH2 NN B-NP
and CC O
hMLH1 VB B-NP
MMR NNP B-NP
genes NNS O
of IN O
12 CD O
tumours NNS O
with IN O
Type NNP O
A NNP O
and CC O
9 CD O
with IN O
Type NNP O
B NNP O
MSI NNP O
were VBD O
sequenced VBN O
. . O

The DT O
same JJ O
genes NNS O
in IN O
the DT O
NoTa NNP O
cell NN O
line NN O
were VBD O
also RB O
sequenced VBN O
( -LRB- O
Figure NN O
3A NN O
and CC O
Table NN O
1 CD O
) -RRB- O
. . O

Sequence NN O
alterations NNS O
causing VBG O
amino IN O
acid NN O
substitutions NNS O
were VBD O
identified VBN O
in IN O
5 CD O
of IN O
the DT O
21 CD O
tumours NNS O
. . O

Four CD O
of IN O
these DT O
( -LRB- O
80 CD O
% NN O
) -RRB- O
were VBD O
associated VBN O
with IN O
Type NNP O
A NNP O
MSI. . O

In IN O
addition NN O
, , O
one CD O
patient NN O
with IN O
Type JJ O
A DT O
MSI NNP O
( -LRB- O
IC793 NN O
) -RRB- O
in IN O
whom WP O
no DT O
mutation NN O
was VBD O
identified VBN O
was VBD O
negative JJ O
for IN O
immunohistochemical JJ O
staining NN O
of IN O
hMLH1 NN B-NP
( -LRB- O
Figure NN O
3B CD O
, , O
panel NN O
b NN O
) -RRB- O
. . O

This DT O
is VBZ O
consistent JJ O
with IN O
a DT O
possible JJ O
epigenetic NN O
hMLH1 . B-NP
gene NN O
silencing NN O
( -LRB- O
26–28 CD O
) -RRB- O
. . O

In IN O
one CD O
other JJ O
Type JJ O
A DT O
case NN O
( -LRB- O
IC669 IN O
) -RRB- O
and CC O
one CD O
Type NNP O
B NNP O
case NN O
( -LRB- O
IC690 IN O
) -RRB- O
, , O
there EX O
was VBD O
an DT O
abnormal JJ O
intracellular JJ O
distribution NN O
of IN O
hMLH1 NN B-NP
which WDT O
remained VBD O
predominantly RB O
cytoplasmic JJ O
( -LRB- O
Figure NN O
3B NN O
, , O
panels NNS O
c NNS O
and CC O
d VBD O
) -RRB- O
. . O

Among IN O
the DT O
10 CD O
tumours NNS O
displaying VBG O
Type JJ O
B NNP O
MSI NNP O
, , O
there EX O
was VBD O
an DT O
example NN O
of IN O
base NN O
substitutions NNS O
causing VBG O
amino IN O
acid NN O
change NN O
in IN O
hMLH1 NN B-NP
. . O

In IN O
this DT O
case NN O
, , O
IC690 NNP O
, , O
the DT O
failure NN O
of IN O
hMLH1 JJ B-NP
to TO O
localize VB O
to TO O
the DT O
nucleus NN O
was VBD O
associated VBN O
with IN O
the DT O
codon NN O
226 CD O
mutation NN O
in IN O
exon NN O
8 CD O
( -LRB- O
Figure NN O
3A CD O
, , O
panel NN O
c NN O
) -RRB- O
. . O

These DT O
findings NNS O
suggest VBP O
that IN O
Type JJ O
A DT O
instability NN O
, , O
as RB O
well RB O
as IN O
Type NNP O
B NNP O
, , O
is VBZ O
indeed RB O
associated VBN O
with IN O
MMR NNP B-NP
defects NNS O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

DISCUSSION NN O

The DT O
fluorescent JJ O
technique NN O
we PRP O
used VBD O
here RB O
allows VBZ O
the DT O
unequivocal JJ O
designation NN O
of IN O
Type NNP O
A NNP O
and CC O
Type NNP O
B NNP O
MSI NNP O
, , O
and CC O
has VBZ O
revealed VBN O
a DT O
previously RB O
unrecognized JJ O
complexity NN O
in IN O
the DT O
relationship NN O
between IN O
dinucleotide NN O
MSI NNP O
and CC O
defective JJ O
DNA NN O
MMR NNP B-NP
in IN O
human JJ O
cancer NN O
. . O

Type JJ O
A DT O
MSI FW O
( -LRB- O
changes NNS O
≤ VBP O
6 CD O
bp NN O
) -RRB- O
is VBZ O
clearly RB O
linked VBN O
with IN O
MMR NNP B-NP
inactivation NN O
in IN O
both DT O
mice NNS O
and CC O
humans NNS O
, , O
which WDT O
implies VBZ O
that IN O
Type NNP O
A DT O
MSI NNP O
is VBZ O
a DT O
direct JJ O
consequence NN O
of IN O
defective JJ O
MMR. NNP B-NP

Since IN O
we PRP O
found VBD O
no DT O
evidence NN O
of IN O
Type NNP O
B NNP O
instability NN O
( -LRB- O
changes NNS O
≥ VBP O
8 CD O
bp NN O
) -RRB- O
in IN O
MMR-defective JJ B-NP
animals NNS O
, , O
it PRP O
is VBZ O
possible JJ O
that IN O
changes NNS O
in IN O
addition NN O
to TO O
repair VB O
deficiency NN O
contribute VB O
to TO O
, , O
or CC O
are VBP O
responsible JJ O
for IN O
, , O
Type NNP O
B NNP O
MSI. . O

One CD O
important JJ O
finding NN O
of IN O
this DT O
study NN O
is VBZ O
that IN O
Type JJ O
A DT O
instability NN O
is VBZ O
frequent JJ O
among IN O
human JJ O
tumours NNS O
. . O

Type JJ O
A DT O
MSI NNP O
predominated VBD O
in IN O
our PRP$ O
large JJ O
panel NN O
of IN O
colorectal JJ O
carcinomas NNS O
. . O

We PRP O
suggest VBP O
that IN O
, , O
because IN O
the DT O
changes NNS O
associated VBN O
with IN O
Type NNP O
A DT O
instability NN O
are VBP O
more RBR O
subtle JJ O
, , O
the DT O
frequency NN O
of IN O
MSI NNP O
among IN O
colorectal JJ O
tumours NNS O
may MD O
have VB O
been VBN O
considerably RB O
underestimated VBN O
. . O

Our PRP$ O
findings NNS O
also RB O
reveal VBP O
a DT O
hitherto NN O
unrecognized JJ O
association NN O
between IN O
defective JJ O
MMR NNP B-NP
and CC O
p53 NN B-NP
mutation NN O
. . O

Significantly RB O
, , O
Type NNP O
A NNP O
MSI NNP O
was VBD O
strongly RB O
associated VBN O
with IN O
p53 NN B-NP
mutation NN O
in IN O
human JJ O
colorectal NN O
tumours NNS O
. . O

Since IN O
Type NNP O
A DT O
instability NN O
is VBZ O
unequivocally RB O
associated VBN O
with IN O
MMR NNP B-NP
deficiency NN O
, , O
this DT O
novel NN O
finding NN O
implies VBZ O
that IN O
, , O
in IN O
contrast NN O
to TO O
prevailing VBG O
opinion NN O
, , O
p53 NN B-NP
mutations NNS O
are VBP O
common JJ O
in IN O
MMR-defective JJ B-NP
tumours NNS O
, , O
at IN O
least JJS O
in IN O
human JJ O
colorectal NN O
cancer NN O
. . O

Established VBN O
guidelines NNS O
for IN O
classification NN O
of IN O
MSI NNP O
utilize VB O
the DT O
frequency NN O
of IN O
changes NNS O
in IN O
a DT O
defined VBN O
set NN O
of IN O
microsatellite NN O
markers NNS O
, , O
i IN O
.e NN O
. . O

MSI-H NNP O
and CC O
-L NNP O
( -LRB- O
10 CD O
) -RRB- O
. . O

However RB O
, , O
qualitative JJ O
differences NNS O
in IN O
microsatellite JJ O
changes NNS O
are VBP O
not RB O
widely RB O
discussed VBN O
. . O

In IN O
one CD O
of IN O
the DT O
earliest JJS O
report NN O
of IN O
the DT O
MSI NNP O
phenomenon NN O
, , O
however RB O
, , O
Thibodeau NNP O
et NNP O
al JJ O
. . O
divided VBN O
microsatellite NN O
changes NNS O
into IN O
two CD O
categories NNS O
; : O
Type NN O
I PRP O
and CC O
II NNP O
mutations NNS O
( -LRB- O
3 CD O
) -RRB- O
. . O

The DT O
former JJ O
was VBD O
defined VBN O
a DT O
‘significant JJ O
increase NN O
( -LRB- O
expansion NN O
) -RRB- O
or CC O
decrease VB O
( -LRB- O
deletion NN O
) -RRB- O
in IN O
the DT O
apparent JJ O
fragment NN O
size NN O
’ NN O
and CC O
the DT O
latter JJ O
as IN O
a DT O
‘single NN O
2 CD O
bp NN O
change’ NN O
. . O

This DT O
distinction NN O
has VBZ O
received VBN O
little JJ O
attention NN O
since IN O
then RB O
. . O

Our PRP$ O
data NNS O
indicate VBP O
that IN O
Type NNP O
A DT O
MSI NNP O
, , O
which WDT O
appears VBZ O
similar JJ O
to TO O
their PRP$ O
Type NNP O
II NNP O
mutation NN O
, , O
is VBZ O
more RBR O
frequent JJ O
than IN O
hitherto PRP O
suspected VBD O
, , O
and CC O
suggest VBP O
that IN O
it PRP O
represents VBZ O
the DT O
bona NN O
fide NN O
MMR-deficient JJ B-NP
phenotype NN O
. . O

On IN O
the DT O
other JJ O
hand NN O
, , O
Type NNP O
I PRP O
mutations NNS O
may MD O
correspond VB O
to TO O
our PRP$ O
Type NNP O
B NNP O
instability NN O
. . O

The DT O
problem NN O
is VBZ O
that DT O
mutations NNS O
in IN O
MMR NNP B-NP
genes NNS O
have VBP O
been VBN O
reported VBN O
in IN O
tumours NNS O
displaying VBG O
this DT O
type NN O
of IN O
instability NN O
. . O

More JJR O
than IN O
90 CD O
% NN O
of IN O
HNPCC NNP O
tumours NNS O
are VBP O
MSI+ JJ O
( -LRB- O
20 CD O
) -RRB- O
, , O
and CC O
this DT O
type NN O
of IN O
MSI NNP O
can MD O
be VB O
categorized VBN O
as IN O
Type JJ O
B/Type NN O
I PRP O
( -LRB- O
2–4,20–22 CD O
) -RRB- O
. . O

However RB O
, , O
the DT O
frequencies NNS O
of IN O
mutation NN O
in IN O
the DT O
two CD O
major JJ O
MMR NNP B-NP
genes NNS O
, , O
hMSH2 VB B-NP
and CC O
hMLH1 VB B-NP
, , O
in IN O
HNPCC NNP O
kindred CC O
are VBP O
not RB O
high JJ O
in IN O
some DT O
reports NNS O
( -LRB- O
35–40 CD O
) -RRB- O
. . O

Among IN O
the DT O
panel NN O
of IN O
tumours NNS O
displaying VBG O
Type JJ O
B NNP O
MSI NNP O
, , O
we PRP O
found VBD O
a DT O
base NN O
substitution NN O
mutation NN O
in IN O
hMLH1 NN B-NP
and CC O
one CD O
case NN O
with IN O
a DT O
possible JJ O
hMLH1 NN B-NP
silencing NN O
. . O

This DT O
incidence NN O
of IN O
MMR NNP B-NP
gene NN O
inactivation NN O
in IN O
the DT O
Type NNP O
B NNP O
group NN O
is VBZ O
not RB O
unduly RB O
low JJ O
, , O
compared VBN O
with IN O
the DT O
reported JJ O
frequencies NNS O
in IN O
the DT O
literature NN O
( -LRB- O
25,36,41–43 CD O
) -RRB- O
. . O

The DT O
relationship NN O
between IN O
Type NNP O
B NNP O
MSI NNP O
and CC O
defective JJ O
MMR NNP B-NP
is VBZ O
probably RB O
more RBR O
complex JJ O
than IN O
hitherto PRP O
suspected VBD O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Background CC O

Cancer NNP O
is VBZ O
thought VBN O
to TO O
arise VB O
through IN O
a DT O
multistep JJ O
process NN O
involving VBG O
sequential JJ O
cycles NNS O
of IN O
mutation NN O
and CC O
selection NN O
[1] NN O
. . O

The DT O
identities NNS O
and CC O
numbers NNS O
of IN O
mutations NNS O
required VBN O
for IN O
transformation NN O
are VBP O
uncertain JJ O
, , O
but CC O
perhaps RB O
six CD O
general JJ O
cellular JJ O
functions NNS O
are VBP O
typically RB O
altered VBN O
[2] NNS O
. . O

Numbers NNS O
of IN O
oncogenic JJ O
mutations NNS O
may MD O
also RB O
be VB O
inferred VBN O
from IN O
the DT O
age-related JJ O
increases NNS O
in IN O
frequencies NNS O
observed VBN O
with IN O
many JJ O
cancer NN O
types NNS O
. . O

For IN O
example NN O
, , O
logarithms NNS O
of IN O
cancer NN O
frequencies NNS O
versus JJ O
age NN O
typically RB O
yield VBP O
straight RB O
lines NNS O
, , O
with IN O
slopes NNS O
proportional JJ O
to TO O
numbers NNS O
of IN O
cancer NN O
mutations NNS O
[3] VBP O
. . O

Colorectal NNP O
cancer NN O
epidemiology NN O
is VBZ O
consistent JJ O
with IN O
approximately RB O
five CD O
to TO O
seven CD O
oncogenic JJ O
mutations NNS O
before IN O
transformation NN O
[3-6] NN O
. . O

The DT O
variability NN O
in IN O
estimated JJ O
numbers NNS O
of IN O
mutations NNS O
may MD O
reflect VB O
a DT O
number NN O
of IN O
differences NNS O
. . O

For IN O
example NN O
, , O
estimates NNS O
vary VBP O
between IN O
populations NNS O
, , O
with IN O
five CD O
to TO O
six CD O
mutations NNS O
in IN O
England NNP O
and CC O
six CD O
to TO O
seven CD O
mutations NNS O
in IN O
Finland NNP O
[4] NNP O
. . O

Recent JJ O
advances NNS O
in IN O
cancer NN O
genetics NNS O
also RB O
reveal VBP O
biologic NN O
colorectal NN O
cancer NN O
heterogeneity NN O
. . O

Approximately RB O
5 CD O
% NN O
of IN O
all DT O
colorectal JJ O
cancers NNS O
have VBP O
strong JJ O
familial JJ O
predispositions NNS O
and CC O
arise VB O
in IN O
individuals NNS O
with IN O
germline NN O
mutations NNS O
in IN O
critical JJ O
susceptibility NN O
loci NNS O
[7] VBP O
. . O

Such JJ O
hereditary JJ O
cancers NNS O
( -LRB- O
familial NN O
adenomatous JJ O
polyposis NN O
( -LRB- O
FAP NNP O
) -RRB- O
and CC O
hereditary JJ O
nonpolyposis NN O
colorectal NN O
cancer NN O
( -LRB- O
HNPCC) NN O
) -RRB- O
typically RB O
present RB O
at IN O
younger JJR O
ages NNS O
and CC O
should MD O
require VB O
fewer JJR O
somatic JJ O
mutations NNS O
than IN O
their PRP$ O
sporadic JJ O
counterparts NNS O
because IN O
one CD O
mutation NN O
is VBZ O
inherited VBN O
. . O

Genetic JJ O
instability NN O
also RB O
divides VBZ O
colorectal JJ O
cancers NNS O
into IN O
two CD O
groups NNS O
[8] VBP O
. . O

Approximately RB O
10 CD O
to TO O
15 CD O
% NN O
of IN O
sporadic JJ O
cancers NNS O
exhibit VBP O
microsatellite JJ O
instability NN O
( -LRB- O
MSI) NNP O
secondary JJ O
to TO O
somatic JJ O
loss NN O
of IN O
DNA NNP O
mismatch NN O
repair NN O
( -LRB- O
MMR NNP B-NP
) -RRB- O
. . O

Most JJS O
other JJ O
cancers NNS O
exhibit VBP O
chromosomal JJ O
instability NN O
( -LRB- O
CIN NNP O
) -RRB- O
characterized VBN O
by IN O
aneuploidy NN O
and CC O
loss NN O
of IN O
heterozygosity NN O
( -LRB- O
LOH) NNP O
[7,8] NNP O
. . O

CIN NNP O
and CC O
MSI+ NNP O
colorectal NN O
cancers NNS O
have VBP O
different JJ O
characteristics NNS O
with IN O
respect NN O
to TO O
mutated JJ O
loci NNS O
, , O
tumor NN O
location NN O
, , O
morphology NN O
, , O
and CC O
clinical JJ O
outcomes NNS O
[7,8] VBP O
. . O

Numbers NNS O
of IN O
oncogenic JJ O
mutations NNS O
may MD O
differ VB O
between IN O
cancer NN O
subtypes NNS O
. . O

Therefore RB O
, , O
colorectal NN O
cancers NNS O
arising VBG O
in IN O
a DT O
population-based JJ O
setting NN O
were VBD O
molecularly RB O
classified VBN O
as IN O
either DT O
sporadic JJ O
or CC O
hereditary JJ O
, , O
and CC O
MSI+ NNP O
or CC O
MSI-. NNP O

Cancers NNS O
were VBD O
also RB O
classified VBN O
with IN O
respect NN O
to TO O
clinical JJ O
stage NN O
because IN O
additional JJ O
mutations NNS O
may MD O
be VB O
required VBN O
for IN O
invasion NN O
or CC O
metastasis NN O
. . O

Ages NNP O
at IN O
cancer NN O
for IN O
each DT O
subgroup NN O
were VBD O
used VBN O
to TO O
infer VB O
numbers NNS O
of IN O
mutations NNS O
required VBN O
for IN O
each DT O
type NN O
of IN O
colorectal JJ O
cancer NN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Conclusion NN O

The DT O
biology NN O
of IN O
cancer NN O
must MD O
underlie VB O
the DT O
epidemiology NN O
of IN O
cancer NN O
. . O

Here RB O
we PRP O
illustrate VBP O
that DT O
multistage NN O
models NNS O
provide VBP O
conceptually RB O
plausible JJ O
solutions NNS O
even RB O
when WRB O
colorectal JJ O
cancers NNS O
are VBP O
divided VBN O
into IN O
biologically RB O
relevant JJ O
and CC O
quite RB O
different JJ O
subtypes NNS O
. . O

Ages NNP O
at IN O
cancer NN O
are VBP O
consistent JJ O
with IN O
five CD O
or CC O
six CD O
somatic JJ O
oncogenic JJ O
mutations NNS O
for IN O
hereditary PRP O
( -LRB- O
HNPCC NNP O
) -RRB- O
MSI+ NNP O
cancers NNS O
and CC O
seven CD O
or CC O
eight CD O
mutations NNS O
for IN O
its PRP$ O
sporadic JJ O
counterpart NN O
. . O

The DT O
apparent JJ O
requirement NN O
for IN O
more JJR O
than IN O
one CD O
additional JJ O
somatic JJ O
mutation NN O
in IN O
sporadic JJ O
MSI+ NN O
cancers NNS O
may MD O
reflect VB O
that DT O
MMR NNP O
inactivation NN O
is VBZ O
commonly RB O
epigenetic JJ O
, , O
which WDT O
may MD O
involve VB O
multiple JJ O
steps NNS O
. . O

Ages NNP O
at IN O
MSI- NNP O
cancers NNS O
were VBD O
consistent JJ O
with IN O
six CD O
or CC O
seven CD O
oncogenic JJ O
mutations NNS O
, , O
with IN O
similar JJ O
estimates NNS O
for IN O
all DT O
clinical JJ O
stages NNS O
, , O
suggesting VBG O
that IN O
mutations NNS O
acquired VBN O
very RB O
early JJ O
in IN O
life NN O
dictate VBP O
the DT O
cancer NN O
phenotype NN O
at IN O
the DT O
time NN O
of IN O
transformation NN O
. . O

Better NNP O
integration NN O
of IN O
cancer NN O
epidemiology NN O
with IN O
its PRP$ O
biology NN O
remains VBZ O
a DT O
further JJ O
challenge NN O
. . O

-DOCSTART- X X O

Background CC O

Carcinogenesis NNP O
is VBZ O
a DT O
multi-step JJ O
process NN O
that WDT O
involves VBZ O
the DT O
accumulation NN O
of IN O
numerous JJ O
genetic JJ O
and CC O
epigenetic JJ O
changes NNS O
in IN O
cells NNS O
[1] JJ O
. . O

These DT O
genetic JJ O
aberrations NNS O
affect VBP O
a DT O
limited JJ O
number NN O
of IN O
identified VBN O
pathways NNS O
that WDT O
are VBP O
involved VBN O
in IN O
( -LRB- O
colorectal NN O
) -RRB- O
carcinogenesis NN O
[2] NN O
. . O

A DT O
genetic JJ O
model NN O
for IN O
sporadic JJ O
colorectal NN O
cancer NN O
has VBZ O
been VBN O
proposed VBN O
, , O
which WDT O
describes VBZ O
the DT O
sequential JJ O
accumulation NN O
of IN O
specific JJ O
genetic JJ O
alterations NNS O
in IN O
various JJ O
pathways NNS O
, , O
involving VBG O
tumour NN O
suppressor NN O
genes NNS O
( -LRB- O
e NN O
.g NN O
. . O

APC NNP B-NP
, , O
SMAD4 NNP B-NP
, , O
TP53 NNP B-NP
) -RRB- O
and CC O
oncogenes NNS O
( -LRB- O
e NN O
.g NN O
. . O

CTNNB1 NNP B-NP
, , O
K-ras NNP B-NP
) -RRB- O
[3,4] VBP O
. . O

Important JJ O
molecular JJ O
pathways NNS O
that IN O
upon IN O
activation NN O
affect VBP O
the DT O
early JJ O
and CC O
intermediate JJ O
stages NNS O
of IN O
colorectal JJ O
carcinogenesis NN O
are VBP O
the DT O
Wnt NNP O
and CC O
Ras NNP O
signalling NN O
pathways NNS O
, , O
whereas IN O
TP53 DT B-NP
inactivation NN O
is VBZ O
considered VBN O
a DT O
late JJ O
event NN O
. . O

Activation NN O
of IN O
the DT O
Wnt NNP O
pathway NN O
plays VBZ O
a DT O
central JJ O
role NN O
in IN O
the DT O
aetiology NN O
of IN O
most JJS O
colorectal JJ O
cancers NNS O
and CC O
is VBZ O
often RB O
the DT O
result NN O
of IN O
mutations NNS O
in IN O
the DT O
N-terminal JJ O
domain NN O
of IN O
the DT O
APC NNP B-NP
gene NN O
, , O
that WDT O
lead VBP O
to TO O
partial JJ O
or CC O
complete JJ O
loss NN O
of IN O
this DT O
region NN O
and CC O
thereby RB O
to TO O
loss NN O
of IN O
the DT O
β-catenin NN O
regulating VBG O
function NN O
[5,6] NN O
. . O

Conversely RB O
, , O
in IN O
tumours NNS O
lacking VBG O
these DT O
APC NNP B-NP
mutations NNS O
[7] VBD O
, , O
activating VBG O
missense NN O
mutations NNS O
at IN O
one CD O
of IN O
the DT O
phosphorylation NN O
sites NNS O
at IN O
codons NNS O
31 CD O
, , O
33 CD O
, , O
37 CD O
and CC O
45 CD O
of IN O
exon NN O
3 CD O
of IN O
the DT O
CTNNB1 NNP B-NP
gene NN O
( -LRB- O
encoding VBG O
the DT O
β-catenin JJ O
protein NN O
) -RRB- O
can MD O
render VB O
it PRP O
stable JJ O
as IN O
it PRP O
can MD O
no RB O
longer RB O
be VB O
tagged VBN O
for IN O
cellular JJ O
degradation NN O
. . O

Activation NN O
of IN O
the DT O
Ras NNP O
pathway NN O
in IN O
cancer NN O
is VBZ O
marked VBN O
by IN O
the DT O
loss NN O
of IN O
the DT O
intrinsic JJ O
GTPase NNP O
activity NN O
of IN O
the DT O
Ras NNP O
protein NN O
, , O
which WDT O
can MD O
be VB O
ascribed VBN O
to TO O
missense VB O
mutations NNS O
in IN O
codons NNS O
12 CD O
and CC O
13 CD O
of IN O
exon NN O
1 CD O
, , O
which WDT O
are VBP O
responsible JJ O
for IN O
90 CD O
% NN O
activating JJ O
mutations NNS O
in IN O
the DT O
of IN O
the DT O
K-ras NNP B-NP
gene NN O
[8] NN O
. . O

According VBG O
to TO O
the DT O
paradigm NN O
for IN O
colorectal NN O
cancer NN O
development NN O
, , O
mutations NNS O
in IN O
the DT O
APC NNP B-NP
and CC O
K-ras NNP B-NP
are VBP O
thought VBN O
to TO O
contribute VB O
to TO O
the DT O
early JJ O
developmental JJ O
stages NNS O
of IN O
colorectal NN O
cancer NN O
[3] NN O
. . O

However RB O
, , O
a DT O
recent JJ O
study NN O
based VBN O
on IN O
the DT O
analysis NN O
of IN O
APC NNP B-NP
, , O
K-ras NNP B-NP
and CC O
TP53 NNP B-NP
genes NNS O
concluded VBD O
that IN O
simultaneous JJ O
occurrence NN O
of IN O
all DT O
three CD O
genetic JJ O
alterations NNS O
is VBZ O
rare JJ O
and CC O
that DT O
multiple JJ O
genetic JJ O
pathways NNS O
may MD O
be VB O
relevant JJ O
to TO O
colorectal JJ O
cancer NN O
[9] NN O
. . O

Genetic JJ O
instability NN O
is VBZ O
seen VBN O
in IN O
most JJS O
types NNS O
of IN O
cancer NN O
[10] NN O
. . O

Two CD O
distinct JJ O
types NNS O
of IN O
genetic JJ O
instability NN O
appear VBP O
to TO O
occur VB O
in IN O
colorectal NN O
cancer NN O
[11] VBP O
: : O
chromosomal NN O
and CC O
microsatellite NN O
instability NN O
. . O

Chromosomal NNP O
instability NN O
results NNS O
in IN O
gains NNS O
or CC O
losses NNS O
of IN O
entire JJ O
chromosomes NNS O
or CC O
parts NNS O
of IN O
them PRP O
, , O
and CC O
gives VBZ O
rise NN O
to TO O
aneuploid JJ O
tumours NNS O
and CC O
occurs VBZ O
in IN O
the DT O
majority NN O
of IN O
cancers NNS O
. . O

A DT O
smaller JJR O
proportion NN O
of IN O
colorectal NN O
cancers NNS O
displays NNS O
microsatellite JJ O
instability NN O
, , O
represented VBN O
by IN O
diploid JJ O
cells NNS O
acquiring VBG O
high JJ O
mutation NN O
rates NNS O
, , O
and CC O
was VBD O
found VBN O
to TO O
be VB O
associated VBN O
with IN O
defective JJ O
mismatch NN O
repair NN O
[12] NN O
. . O

These DT O
tumours NNS O
are VBP O
less RBR O
likely JJ O
to TO O
harbour PRP$ O
mutations NNS O
in IN O
genes NNS O
associated VBN O
with IN O
chromosomally RB O
instable JJ O
and CC O
generally RB O
aneuploid JJ O
tumours NNS O
, , O
such JJ O
as IN O
APC NNP B-NP
, , O
K-ras NNP B-NP
and CC O
TP53 NNP B-NP
[13-21] NNP O
, , O
suggesting VBG O
that IN O
these DT O
tumours NNS O
form VBP O
a DT O
distinct JJ O
group NN O
. . O

Moreover RB O
, , O
microsatellite JJ O
instable JJ O
tumours NNS O
are VBP O
found VBN O
predominantly RB O
in IN O
the DT O
proximal JJ O
colon NN O
[22,23] NNS O
, , O
are VBP O
more RBR O
likely JJ O
to TO O
occur VB O
in IN O
patients NNS O
with IN O
a DT O
positive JJ O
family NN O
history NN O
of IN O
colorectal JJ O
cancer NN O
[22,23] NN O
, , O
are VBP O
often RB O
less RBR O
differentiated JJ O
than IN O
microsatellite NN O
stable JJ O
tumours NNS O
[22] JJ O
, , O
and CC O
occur VBP O
more RBR O
frequently RB O
in IN O
women NNS B-NP
[24] JJ O
and CC O
at IN O
older JJR O
age NN O
[25] CD O
. . O

Moreover RB O
, , O
in IN O
tumours NNS O
displaying VBG O
microsatellite JJ O
instability NN O
, , O
mutations NNS O
the DT O
CTNNB1 NNP B-NP
gene NN O
were VBD O
more RBR O
frequent JJ O
[26] NN O
. . O

-DOCSTART- X X O

Methods NNS O

Study VB O
population NN O

The DT O
prospective JJ O
Netherlands NNP O
Cohort NNP O
Study NNP O
on IN O
diet NN O
and CC O
cancer NN O
was VBD O
initiated VBN O
in IN O
September NNP O
1986 CD O
. . O

The DT O
study NN O
design NN O
has VBZ O
been VBN O
described VBN O
in IN O
detail NN O
elsewhere RB O
[29] VBD O
. . O

The DT O
study NN O
population NN O
originated VBD O
from IN O
204 CD O
municipal JJ O
population NN O
registries NNS O
throughout IN O
the DT O
Netherlands NNP O
, , O
and CC O
included VBD O
a DT O
total NN O
of IN O
58,279 CD O
men NNS O
and CC O
62,573 CD O
women NNS O
between IN O
the DT O
ages NNS O
of IN O
55 CD O
and CC O
69 CD O
years NNS O
at IN O
baseline NN O
. . O

Incident NNP O
cancer NN O
cases NNS O
are VBP O
identified VBN O
by IN O
monitoring NN O
of IN O
the DT O
entire JJ O
cohort NN O
for IN O
cancer NN O
occurrence NN O
through IN O
annual JJ O
record NN O
linkage NN O
to TO O
the DT O
Netherlands NNP O
Cancer NNP O
Registry NNP O
, , O
i IN O
.e NN O
. . O
nine CD O
regional JJ O
cancer NN O
registries NNS O
throughout IN O
the DT O
Netherlands NNP O
, , O
and CC O
to TO O
PALGA NNP O
, , O
a DT O
nationwide JJ O
network NN O
and CC O
registry NN O
of IN O
histo NN O
- : O
and CC O
cytopathology NN O
[30] NN O
. . O

Together RB O
, , O
the DT O
NCR NNP O
and CC O
PALGA NNP O
provide VBP O
a DT O
near JJ O
100 CD O
% NN O
coverage NN O
of IN O
the DT O
municipalities NNS O
included VBD O
in IN O
the DT O
NLCS. NNP O

The DT O
first JJ O
2.3 CD O
years NNS O
of IN O
follow VBP O
up RP O
were VBD O
excluded VBN O
because IN O
of IN O
possible JJ O
pre-clinical JJ O
disease NN O
affecting VBG O
exposure NN O
status NN O
and CC O
because IN O
of IN O
incomplete JJ O
nationwide JJ O
coverage NN O
of IN O
PALGA NNP O
in IN O
some DT O
of IN O
the DT O
municipalities NNS O
included VBD O
in IN O
the DT O
NLCS NNP O
in IN O
that DT O
period NN O
. . O

From IN O
1989 CD O
until IN O
1994 CD O
, , O
929 CD O
incident NN O
cases NNS O
with IN O
histologically RB O
confirmed VBN O
colorectal NN O
cancer NN O
were VBD O
identified VBN O
within IN O
the DT O
cohort JJ O
, , O
of IN O
whom WP O
819 PRP O
could MD O
also RB O
be VB O
linked VBN O
to TO O
a DT O
PALGA NNP O
report NN O
of IN O
the DT O
lesion NN O
. . O

The DT O
PALGA NNP O
reports NNS O
were VBD O
used VBN O
to TO O
identify VB O
and CC O
locate VB O
tumour JJ O
tissue NN O
from IN O
eligible JJ O
colorectal JJ O
cancer NN O
patients NNS O
in IN O
Dutch NNP O
pathology NN O
laboratories NNS O
. . O

Colon NNP O
and CC O
rectal JJ O
cancer NN O
were VBD O
classified VBN O
according VBG O
to TO O
site NN O
as IN O
follows VBZ O
, , O
colon NN O
: : O
cecum NN O
through IN O
sigmoid JJ O
colon NN O
( -LRB- O
ICD-O JJ O
codes NNS O
153.0, IN O
153.1 CD O
, , O
153.2 CD O
, , O
153.3 CD O
, , O
153.4 CD O
, , O

153.5 CD O
, , O
153.6 CD O
, , O
153.7 CD O
) -RRB- O
, , O
rectosigmoid JJ O
( -LRB- O
ICD-O NN O
code NN O
154.0) CD O
, , O
and CC O
rectum NN O
( -LRB- O
ICD-O NNP O
code NN O
154.1 CD O
) -RRB- O
. . O

Tissue NN O
samples NNS O

Tumour NNP O
material NN O
of IN O
colorectal JJ O
cancer NN O
patients NNS O
was VBD O
collected VBN O
after IN O
approval NN O
by IN O
the DT O
Ethical NNP O
Review NNP O
Board NNP O
of IN O
Maastricht NNP O
University NNP O
, , O
PALGA NNP O
and CC O
the DT O
NCR. NNP O

Tissue NN O
samples NNS O
from IN O
819 CD O
colorectal JJ O
cancer NN O
patients NNS O
were VBD O
localized VBN O
in IN O
54 CD O
pathology NN O
laboratories NNS O
throughout IN O
the DT O
Netherlands NNP O
. . O

Forty-four CD O
( -LRB- O
5 CD O
% NN O
) -RRB- O
tumour JJ O
tissue NN O
samples NNS O
could MD O
not RB O
be VB O
retrieved VBN O
from IN O
the DT O
pathology NN O
archives NNS O
. . O

Of IN O
775 CD O
available JJ O
tissue NN O
samples NNS O
, , O
737 CD O
( -LRB- O
95 CD O
% NN O
) -RRB- O
contained VBN O
sufficient JJ O
tumour VBG O
material NN O
for IN O
molecular JJ O
analyses NNS O
. . O

Tissue NN O
sections NNS O
were VBD O
cut VBN O
from IN O
each DT O
sample NN O
, , O
which WDT O
were VBD O
used VBN O
for IN O
DNA NNP O
isolation NN O
and CC O
immunohistochemical JJ O
analysis NN O
. . O

DNA NN O
isolation NN O

DNA NNP O
isolation NN O
was VBD O
described VBN O
in IN O
detail NN O
elsewhere RB O
[27] VBD O
. . O

Briefly RB O
, , O
a DT O
4 CD O
μm NN O
section NN O
, , O
cut NN O
from IN O
each DT O
paraffin-embedded JJ O
tumour JJ O
tissue NN O
block NN O
, , O
was VBD O
stained VBN O
with IN O
haematoxylin NN O
and CC O
eosin NN O
( -LRB- O
HE PRP O
) -RRB- O
for IN O
histopathological JJ O
examination NN O
by IN O
a DT O
pathologist NN O
. . O

Five CD O
20 CD O
μm JJ O
sections NNS O
of IN O
tumour JJ O
tissue NN O
were VBD O
cut VBN O
from IN O
each DT O
sample NN O
for IN O
DNA NNP O
isolation NN O
. . O

Tumour NNP O
tissue NN O
was VBD O
separated VBN O
from IN O
normal JJ O
colon NN O
epithelium NN O
using VBG O
the DT O
HE NN O
section NN O
as IN O
a DT O
reference NN O
. . O

Genomic JJ O
DNA NNP O
was VBD O
extracted VBN O
from IN O
macrodissected JJ O
tumour JJ O
tissue NN O
using VBG O
proteinase NN O
K NNP O
( -LRB- O
Qiagen NNP O
, , O
St NNP O
. . O
Louis NNP O
, , O
MO VBZ O
, , O
USA NNP O
) -RRB- O
and CC O
the DT O
Puregene NNP O
DNA NNP O
isolation NN O
kit NN O
( -LRB- O
Gentra NNP O
Systems NNPS O
, , O
Minneapolis NNP O
, , O
MN NNP O
, , O
USA NNP O
) -RRB- O
. . O

DNA NNP O
concentration NN O
and CC O
purity NN O
was VBD O
measured VBN O
at IN O
260 CD O
and CC O
280 CD O
nm NN O
. . O

-DOCSTART- X X O

Conclusion NN O

In IN O
conclusion NN O
, , O
this DT O
study NN O
shows VBZ O
that IN O
mutations NNS O
in IN O
the DT O
CTNNB1 NNP B-NP
gene NN O
are VBP O
presumably RB O
of IN O
minor JJ O
importance NN O
in IN O
sporadic JJ O
colorectal NN O
cancer NN O
. . O

Although IN O
APC NNP B-NP
and CC O
K-ras NNP B-NP
mutations NNS O
are VBP O
often RB O
observed VBN O
seperately RB O
in IN O
a DT O
tumour NN O
, , O
these DT O
mutations NNS O
seem VBP O
to TO O
also RB O
occur VB O
in IN O
a DT O
co-dependent JJ O
manner NN O
. . O

Tumours NNS O
that IN O
display NN O
mismatch NN O
repair NN O
deficiency NN O
, , O
may MD O
form VB O
a DT O
distinct JJ O
sub-group NN O
as IN O
they PRP O
differ VBP O
from IN O
tumours NNS O
with IN O
APC NNP B-NP
and/or CC O
K-ras NNP B-NP
mutations NNS O
with IN O
regard NN O
to TO O
age NN O
, , O
sex NN O
, , O
tumour NN O
sub-localisation NN O
and CC O
differentiation NN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Background CC O

BRAF NN B-NP
is VBZ O
a DT O
member NN O
of IN O
the DT O
RAF NNP B-NP
family NN O
of IN O
kinases NNS O
that WDT O
acts VBZ O
upstream RB O
of IN O
the DT O
MEK1/2 NNP B-NP
kinases NNS O
in IN O
response NN O
to TO O
RAS NNP B-NP
signals NNS O
. . O

Activating VBG O
mutations NNS O
in IN O
BRAF NNP B-NP
have VBP O
been VBN O
reported VBN O
in IN O
5–15 CD O
% NN O
of IN O
colorectal JJ O
carcinomas NNS O
( -LRB- O
CRC NNP O
) -RRB- O
, , O
with IN O
by IN O
far RB O
the DT O
most RBS O
common JJ O
mutation NN O
being VBG O
a DT O
1796T JJ O
to TO O
A DT O
transversion NN O
leading VBG O
to TO O
a DT O
V600E NNP O
substitution NN O
[1-3] NN O
. . O

The DT O
BRAF NNP B-NP
V600E NNP O
hotspot NN O
mutation NN O
is VBZ O
strongly RB O
associated VBN O
with IN O
the DT O
microsatellite NN O
instability NN O
( -LRB- O
MSI+ NNP O
) -RRB- O
phenotype NN O
but CC O
is VBZ O
mutually RB O
exclusive JJ O
with IN O
KRAS NNP B-NP
mutations NNS O
[4-7] JJ O
. . O

Interestingly RB O
, , O
BRAF NNP B-NP
mutations NNS O
are VBP O
found VBN O
only RB O
in IN O
MSI+ NNP O
sporadic JJ O
tumors NNS O
that IN O
result NN O
from IN O
aberrant JJ O
MLH1 NNP B-NP
promoter NN O
methylation NN O
and CC O
do VBP O
not RB O
occur VB O
in IN O
MSI+ NNP O
tumors NNS O
from IN O
hereditary PRP O
non-polyposis . O
colorectal NN O
cancer NN O
( -LRB- O
HNPCC NNP O
) -RRB- O
patients NNS O
[5,8-10] JJ O
, , O
thus RB O
providing VBG O
a DT O
convenient JJ O
discriminator NN O
between IN O
sporadic JJ O
and CC O
familial JJ O
cases NNS O
. . O

The DT O
majority NN O
of IN O
MSI+ NNP O
sporadic JJ O
tumors NNS O
belong VBP O
to TO O
a DT O
larger JJR O
CRC NNP O
group NN O
referred VBD O
to TO O
as IN O
the DT O
CpG NNP O
island NN O
methylator NN O
phenotype NN O
( -LRB- O
CIMP+ NNP O
) -RRB- O
that WDT O
is VBZ O
characterised VBN O
by IN O
widespread JJ O
hypermethylation NN O
of IN O
CpG JJ O
islands NNS O
located VBN O
with IN O
gene NN O
promoter NN O
regions NNS O
[11] VBD O
. . O

Both DT O
MSI+ NNP O
and CC O
CIMP+ NNP O
tumors NNS O
are VBP O
thought VBN O
to TO O
arise VB O
from IN O
large JJ O
hyperplastic JJ O
polyps NNS O
and CC O
serrated JJ O
adenomas NNS O
[12,13] . O
and CC O
recent JJ O
work NN O
has VBZ O
demonstrated VBN O
a DT O
high JJ O
frequency NN O
of IN O
BRAF NNP B-NP
mutations NNS O
in IN O
these DT O
lesions NNS O
[7,14,15] VBP O
. . O

Although IN O
the DT O
positive JJ O
association NN O
with IN O
MSI+ NNP O
and CC O
inverse JJ O
association NN O
with IN O
KRAS NNP B-NP
mutation NN O
have VBP O
been VBN O
well RB O
documented VBN O
, , O
little RB O
is VBZ O
known VBN O
about IN O
the DT O
other JJ O
properties NNS O
of IN O
tumors NNS O
with IN O
BRAF NNP B-NP
mutation NN O
. . O

In IN O
the DT O
present JJ O
study NN O
we PRP O
analysed VBD O
for IN O
BRAF NNP B-NP
V600E NNP O
mutations NNS O
in IN O
a DT O
consecutive JJ O
series NN O
of IN O
275 CD O
CRCs NNS O
that WDT O
were VBD O
well RB O
characterised VBN O
for IN O
the DT O
major JJ O
pathological JJ O
and CC O
molecular JJ O
features NNS O
of IN O
this DT O
disease NN O
. . O

Our PRP$ O
results NNS O
demonstrate VBP O
that IN O
oncogenic JJ O
BRAF NN B-NP
mutation NN O
occurs VBZ O
preferentially RB O
within IN O
a DT O
subgroup NN O
of IN O
CRCs NNP O
that WDT O
have VBP O
distinctive JJ O
features NNS O
. . O

It PRP O
could MD O
therefore RB O
be VB O
used VBN O
as IN O
a DT O
convenient JJ O
marker NN O
for IN O
the DT O
further JJ O
characterisation NN O
of IN O
these DT O
tumors NNS O
, , O
particularly RB O
in IN O
relation NN O
to TO O
their PRP$ O
prognosis NN O
and CC O
response NN O
to TO O
adjuvant JJ O
chemotherapy NN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Results NNS O

Figure NN O
1A IN O
shows NNS O
representative JJ O
Fluorescent-SSCP JJ O
results NNS O
for IN O
the DT O
screening NN O
of IN O
BRAF NNP B-NP
mutations NNS O
in IN O
this DT O
CRC NNP O
series NN O
, , O
while IN O
Figure NN O
1B IN O
shows NNS O
DNA NNP O
sequencing NN O
confirmation NN O
of IN O
the DT O
1799T JJ O
to TO O
A DT O
transversion NN O
resulting VBG O
in IN O
the DT O
V600E NNP O
mutation NN O
. . O

The DT O
overall JJ O
frequency NN O
of IN O
BRAF NNP B-NP
mutation NN O
was VBD O
8.4 CD O
% NN O
( -LRB- O
23/275 CD O
) -RRB- O
, , O
comparing VBG O
favourably RB O
with IN O
frequencies NNS O
of IN O
9–11 CD O
% NN O
reported VBN O
for IN O
other JJ O
large JJ O
studies NNS O
of IN O
this DT O
tumor NN O
type NN O
[6,16,17] NN O
. . O

The DT O
mean JJ O
age NN O
of IN O
patients NNS O
with IN O
and CC O
without IN O
BRAF NNP B-NP
mutation NN O
was VBD O
identical JJ O
( -LRB- O
Table NN O
1 CD O
) -RRB- O
. . O

Strong JJ O
associations NNS O
were VBD O
observed VBN O
between IN O
BRAF NNP B-NP
mutation NN O
and CC O
tumor NN O
origin NN O
in IN O
the DT O
proximal JJ O
side NN O
of IN O
the DT O
large JJ O
bowel NN O
, , O
poor JJ O
histological JJ O
grade NN O
, , O
mucinous JJ O
appearance NN O
and CC O
the DT O
presence NN O
of IN O
infiltrating JJ O
lymphocytes NNS O
. . O

Higher JJR O
frequencies NNS O
of IN O
BRAF NNP B-NP
mutation NN O
were VBD O
also RB O
observed VBN O
in IN O
females NNS O
and CC O
in IN O
node NN O
negative JJ O
tumors NNS O
but CC O
these DT O
did VBD O
not RB O
reach VB O
significance NN O
. . O

( -LRB- O
A DT O
) -RRB- O
Representative NNP O
F-SSCP NNP O
gel NNP O
used VBD O
to TO O
detect VB O
BRAF NN B-NP
mutationsin NN O
colorectal NN O
cancer NN O
. . O

WT NNP O
, , O
wild-type JJ O
; : O
M NNP O
, , O
mutation NN O
. . O

( -LRB- O
B NN O
) -RRB- O
DNA NN O
sequencing NN O
gel NN O
resultconfirms VBZ O
the DT O
presence NN O
of IN O
a DT O
1799T JJ O
to TO O
A DT O
mutation NN O
giving VBG O
rise NN O
to TO O
the DT O
V600E NNP O
mutation NN O
. . O

Associations NNP O
between IN O
BRAF NNP B-NP
mutation NN O
and CC O
clinicopathological JJ O
features NNS O
of IN O
colorectal JJ O
cancer NN O
. . O

a DT O
Data NNP O
was VBD O
unavailable JJ O
for IN O
gender NN O
in IN O
43 CD O
cases NNS O
, , O
infiltrating VBG O
lymphocytes NNS O
in IN O
55 CD O
cases NNS O
, , O
nodal JJ O
involvement NN O
in IN O
77 CD O
cases NNS O
, , O
tumor NN O
site NN O
in IN O
56 CD O
cases NNS O
, , O
grade NN O
in IN O
106 CD O
cases NNS O
and CC O
mucinous JJ O
appearance NN O
in IN O
89 CD O
cases NNS O
. . O

BRAF NN B-NP
mutations NNS O
showed VBD O
no DT O
association NN O
with IN O
TP53 DT B-NP
mutations NNS O
and CC O
were VBD O
mutually RB O
exclusive JJ O
with IN O
the DT O
presence NN O
of IN O
KRAS NNP B-NP
mutations NNS O
( -LRB- O
Table NN O
2 CD O
) -RRB- O
. . O

In IN O
contrast NN O
, , O
BRAF NNP B-NP
mutations NNS O
were VBD O
approximately RB O
10-fold JJ O
more RBR O
frequent JJ O
in IN O
MSI+ NNP O
and CC O
CIMP+ NNP O
tumors NNS O
compared VBN O
to TO O
tumors NNS O
without IN O
these DT O
phenotypes NNS O
. . O

A DT O
strong JJ O
association NN O
was VBD O
also RB O
seen VBN O
with IN O
methylation NN O
of IN O
the DT O
MLH1 NNP B-NP
gene NN O
promoter NN O
and CC O
in IN O
particular JJ O
with IN O
methylation NN O
of IN O
its PRP$ O
proximal JJ O
region NN O
. . O

We PRP O
have VBP O
previously RB O
examined VBN O
the DT O
methylation NN O
status NN O
of IN O
7 CD O
different JJ O
CpG NN O
islands NNS O
in IN O
this DT O
CRC NNP O
series NN O
[18] NNP O
. . O

The DT O
mean JJ O
number NN O
of IN O
these DT O
methylated VBN O
sites NNS O
was VBD O
3-fold JJ O
higher JJR O
in IN O
tumors NNS O
with IN O
BRAF NNP B-NP
mutation NN O
compared VBN O
to TO O
those DT O
without IN O
( -LRB- O
2.6 CD O
± RB O
1.7 CD O
vs JJ O
0.8 CD O
± NN O
1.0 CD O
; : O
P NNP O
< NNP O
0.001 CD O
) -RRB- O
. . O

Multivariate VB O
analysis NN O
revealed VBN O
that IN O
MSI+ NNP O
was VBD O
the DT O
only RB O
significant JJ O
independent JJ O
predictor NN O
of IN O
BRAF NN B-NP
mutation NN O
( -LRB- O
RR NNP O
= SYM O
6.3 CD O
, , O
95 CD O
%C NN O
I PRP O
[1.2–32.3] VBP O
; : O

P NNP O
= SYM O
0.028 CD O
) -RRB- O
in IN O
a DT O
model NN O
that WDT O
included VBD O
CIMP+ NNP O
, , O
tumor NN O
site NN O
, , O
histological JJ O
grade NN O
, , O
presence NN O
of IN O
infiltrating JJ O
lymphocytes NNS O
and CC O
mucinous JJ O
appearance NN O
. . O

Associations NNP O
between IN O
BRAF NNP B-NP
mutation NN O
and CC O
molecular JJ O
features NNS O
of IN O
colorectal JJ O
cancer NN O
. . O

a DT O
Data NNP O
was VBD O
unavailable JJ O
for IN O
MSI JJ O
status NN O
in IN O
40 CD O
cases NNS O
, , O
methylation NN O
status NN O
in IN O
83 CD O
cases NNS O
, , O
KRAS NNP B-NP
mutation NN O
in IN O
26 CD O
cases NNS O
and CC O
TP53 DT B-NP
mutation NN O
in IN O
26 CD O
cases NNS O

We PRP O
next JJ O
examined VBN O
whether IN O
the DT O
characteristic JJ O
features NNS O
of IN O
tumors NNS O
with IN O
BRAF NNP B-NP
mutation NN O
were VBD O
still RB O
apparent JJ O
following VBG O
stratification NN O
into IN O
MSI NNP O
and CC O
CIMP NNP O
phenotypes NNS O
. . O

Although IN O
the DT O
statistical JJ O
power NN O
of IN O
this DT O
subgroup NN O
analysis NN O
was VBD O
limited VBN O
, , O
the DT O
morphological JJ O
features NNS O
of IN O
infiltrating NN O
lymphocytes NNS O
, , O
poor JJ O
histological JJ O
grade NN O
and CC O
mucinous JJ O
appearance NN O
were VBD O
clearly RB O
associated VBN O
with IN O
BRAF NNP B-NP
mutation NN O
regardless RB O
of IN O
tumor NN O
MSI NN O
status NN O
( -LRB- O
Table NN O
3 CD O
) -RRB- O
. . O

Similarly RB O
, , O
these DT O
features NNS O
were VBD O
each DT O
more RBR O
common JJ O
in IN O
tumors NNS O
with IN O
BRAF NNP B-NP
mutation NN O
in IN O
both DT O
the DT O
CIMP- NNP O
and CC O
CIMP+ NNP O
subgroups NNS O
( -LRB- O
Table NN O
4) CD O
. . O

Similar JJ O
to TO O
previous JJ O
observations NNS O
in IN O
a DT O
separate JJ O
CRC NNP O
cohort NN O
[20] NN O
, , O
the DT O
frequency NN O
of IN O
KRAS NNP B-NP
mutation NN O
was VBD O
lower JJR O
in IN O
MSI+ NNP O
compared VBN O
to TO O
MSI- NNP O
tumors NNS O
( -LRB- O
P NNP O
= SYM O
0.034 CD O
; : O
Table NN O
3 CD O
) -RRB- O
, , O
while IN O
the DT O
frequency NN O
of IN O
TP53 DT B-NP
mutation NN O
was VBD O
also RB O
considerably RB O
lower JJR O
in IN O
MSI+ NNP O
tumors NNS O
with IN O
wildtype JJ O
BRAF NN B-NP
than IN O
in IN O
MSI- NNP O
tumors NNS O
with IN O
wildtype JJ O
BRAF NN B-NP
( -LRB- O
P NNP O
= SYM O
0.014 CD O
) -RRB- O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Mismatch NNP O
repair NN O
and CC O
treatment NN O
resistance NN O
in IN O
ovarian JJ O
cancer NN O

Abstract NN O

Background CC O

The DT O
treatment NN O
of IN O
ovarian JJ O
cancer NN O
is VBZ O
hindered VBN O
by IN O
intrinsic JJ O
or CC O
acquired VBN O
resistance NN O
to TO O
platinum-based JJ O
chemotherapy NN O
. . O

The DT O
aim NN O
of IN O
this DT O
study NN O
is VBZ O
to TO O
determine VB O
the DT O
frequency NN O
of IN O
mismatch NN O
repair NN O
( -LRB- O
MMR NNP B-NP
) -RRB- O
inactivation NN O
in IN O
ovarian JJ O
cancer NN O
and CC O
its PRP$ O
association NN O
with IN O
resistance NN O
to TO O
platinum-based JJ O
chemotherapy NN O
. . O

Methods NNS O

We PRP O
determined VBD O
, , O
microsatellite JJ O
instability NN O
( -LRB- O
MSI) NNP O
as IN O
a DT O
marker NN O
for IN O
MMR NNP B-NP
inactivation NN O
( -LRB- O
analysis NN O
of IN O
BAT25 NNP O
and CC O
BAT26 NNP O
) -RRB- O
, , O
MLH1 NNP B-NP
promoter NN O
methylation NN O
status NN O
( -LRB- O
methylation NN O
specific JJ O
PCR NN O
on IN O
bisulfite JJ O
treated VBN O
DNA NN O
) -RRB- O
and CC O
mRNA JJ O
expression NN O
of IN O
MLH1 NNP B-NP
, , O
MSH2 NNP B-NP
, , O
MSH3 NNP B-NP
, , O
MSH6 NNP B-NP
and CC O
PMS2 NNP B-NP
(quantitative JJ O
RT-PCR NN O
) -RRB- O
in IN O
75 CD O
ovarian JJ O
carcinomas NNS O
and CC O
eight CD O
ovarian JJ O
cancer NN O
cell NN O
lines NNS O

Results NNS O

MSI NNP O
was VBD O
detected VBN O
in IN O
three CD O
of IN O
the DT O
eight CD O
cell NN O
lines NNS O
i IN O
.e NN O
. . O

A2780 NN O
( -LRB- O
no DT O
MLH1 NNP B-NP
mRNA NN O
expression NN O
due JJ O
to TO O
promoter NN O
methylation NN O
) -RRB- O
, , O
SKOV3 FW O
( -LRB- O
no DT O
MLH1 NNP B-NP
mRNA JJ O
expression NN O
) -RRB- O
and CC O
2774 CD O
( -LRB- O
no DT O
altered JJ O
expression NN O
of IN O
MMR JJ B-NP
genes NNS O
) -RRB- O
. . O

Overall RB O
, , O
there EX O
was VBD O
no DT O
association NN O
between IN O
cisplatin JJ O
response NN O
and CC O
MMR NNP B-NP
status NN O
in IN O
these DT O
eight CD O
cell NN O
lines NNS O
. . O

Seven CD O
of IN O
the DT O
75 CD O
ovarian JJ O
carcinomas NNS O
showed VBD O
MLH1 IN B-NP
promoter NN O
methylation NN O
, , O
however RB O
, , O
none NN O
of IN O
these DT O
showed VBD O
MSI. . O

Forty-six CD O
of IN O
these DT O
patients NNS O
received VBD O
platinum-based JJ O
chemotherapy NN O
( -LRB- O
11 CD O
non-responders NNS O
, , O
34 CD O
responders NNS O
, , O
one CD O
unknown JJ O
response NN O
) -RRB- O
. . O

The DT O
resistance NN O
seen VBN O
in IN O
the DT O
eleven CD O
non-responders NNS O
was VBD O
not RB O
related VBN O
to TO O
MSI NNP O
and CC O
therefore RB O
also RB O
not RB O
to TO O
MMR NNP B-NP
inactivation NN O
. . O

Conclusion NN O

No DT O
MMR NNP B-NP
inactivation NN O
was VBD O
detected VBN O
in IN O
75 CD O
ovarian JJ O
carcinoma NN O
specimens NNS O
and CC O
no DT O
association NN O
was VBD O
seen VBN O
between IN O
MMR NNP B-NP
inactivation NN O
and CC O
resistance NN O
in IN O
the DT O
ovarian JJ O
cancer NN O
cell NN O
lines NNS O
as RB O
well RB O
as IN O
the DT O
ovarian JJ O
carcinomas NNS O
. . O

In IN O
the DT O
discussion NN O
, , O
the DT O
results NNS O
were VBD O
compared VBN O
to TO O
that DT O
of IN O
twenty CD O
similar JJ O
studies NNS O
in IN O
the DT O
literature NN O
including VBG O
in IN O
total JJ O
1315 CD O
ovarian JJ O
cancer NN O
patients NNS O
. . O

Although IN O
no DT O
association NN O
between IN O
response NN O
and CC O
MMR NNP B-NP
status NN O
was VBD O
seen VBN O
in IN O
the DT O
primary JJ O
tumor NN O
the DT O
possible JJ O
role NN O
of IN O
MMR NNP B-NP
inactivation NN O
in IN O
acquired VBN O
resistance NN O
deserves VBZ O
further JJ O
investigation NN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Interestingly RB O
, , O
a DT O
number NN O
of IN O
in IN O
vitro NN O
studies NNS O
have VBP O
suggested VBN O
a DT O
relationship NN O
between IN O
MMR NNP B-NP
deficiency NN O
and CC O
platinum-drug NN O
resistance NN O
. . O

Several JJ O
resistant JJ O
sublines NNS O
of IN O
ovarian JJ O
and CC O
melanoma NN O
cell NN O
lines NNS O
generated VBN O
by IN O
cisplatin NN O
selection NN O
, , O
appeared VBD O
to TO O
be VB O
MMR NNP O
deficient JJ O
[11-15] NN O
. . O

In IN O
addition NN O
, , O
a DT O
colon NN O
( -LRB- O
HCT116 CD O
) -RRB- O
and CC O
an DT O
endometrioid JJ O
cell NN O
line NN O
( -LRB- O
HEC59 PRP O
) -RRB- O
, , O
deficient JJ O
for IN O
MLH1 NNP B-NP
and CC O
MSH2 NNP B-NP
respectively RB O
, , O
were VBD O
2.1 CD O
and CC O
1.8 CD O
fold NN O
resistant JJ O
to TO O
cisplatin NN O
compared VBN O
to TO O
cell NN O
lines NNS O
complemented VBN O
with IN O
chromosome NN O
3 CD O
, , O
containing VBG O
MLH1 NNP B-NP
, , O
or CC O
chromosome NN O
2 CD O
, , O
containing VBG O
MSH2 NNP B-NP
[15-17] NNP O
. . O

These DT O
in IN O
vitro NN O
studies NNS O
suggest VBP O
that IN O
inactivation NN O
of IN O
proteins NNS O
involved VBN O
in IN O
the DT O
initiation NN O
of IN O
MMR NNP B-NP
might MD O
cause VB O
cisplatin JJ O
resistance NN O
. . O

It PRP O
is VBZ O
thought VBN O
that IN O
the DT O
DNA NN O
damage NN O
caused VBN O
by IN O
platin-drugs NNS O
is VBZ O
recognized VBN O
by IN O
MMR. NNP O

The DT O
cell NN O
will MD O
then RB O
undergo VB O
several JJ O
unsuccessful JJ O
repair NN O
cycles NNS O
, , O
finally RB O
resulting VBG O
in IN O
the DT O
induction NN O
of IN O
apoptosis NN O
. . O

When WRB O
MMR NNP O
is VBZ O
inactive JJ O
the DT O
DNA NN O
damage NN O
caused VBN O
by IN O
platin-drugs NNS O
will MD O
not RB O
be VB O
picked VBN O
up RP O
and CC O
will MD O
therefore RB O
not RB O
result VB O
in IN O
apoptosis NN O
rendering VBG O
the DT O
cells NNS O
resistant JJ O
to TO O
platin-drugs NNS O
. . O

Several JJ O
studies NNS O
have VBP O
determined VBN O
the DT O
frequency NN O
of IN O
MMR NNP B-NP
inactivation NN O
in IN O
ovarian JJ O
cancer NN O
using VBG O
MSI NNP O
as IN O
a DT O
marker NN O
[18-37] NN O
. . O

However RB O
, , O
there EX O
was VBD O
a DT O
wide JJ O
range NN O
observed VBD O
( -LRB- O
0 CD O
% NN O
–39 CD O
% NN O
) -RRB- O
and CC O
so RB O
far RB O
only RB O
a DT O
few JJ O
studies NNS O
have VBP O
linked VBN O
MMR NNP B-NP
inactivation NN O
to TO O
platinum-based JJ O
chemotherapy NN O
resistance NN O
. . O

Thus RB O
, , O
there EX O
is VBZ O
still RB O
no DT O
general JJ O
agreement NN O
about IN O
the DT O
frequency NN O
of IN O
MMR NNP B-NP
inactivation NN O
and CC O
its PRP$ O
possible JJ O
involvement NN O
in IN O
the DT O
platinum-based JJ O
chemotherapy NN O
resistance NN O
seen VBN O
in IN O
ovarian JJ O
cancer NN O
patients NNS O
. . O

The DT O
aim NN O
of IN O
this DT O
study NN O
is VBZ O
to TO O
determine VB O
the DT O
frequency NN O
of IN O
mismatch NN O
repair NN O
( -LRB- O
MMR NNP B-NP
) -RRB- O
inactivation NN O
in IN O
ovarian JJ O
cancer NN O
and CC O
whether IN O
it PRP O
is VBZ O
associated VBN O
with IN O
platinum-based JJ O
chemotherapy NN O
resistance NN O
. . O

To TO O
this DT O
purpose NN O
we PRP O
analyzed VBD O
seventy-five CD O
ovarian JJ O
carcinomas NNS O
and CC O
eight CD O
ovarian JJ O
cancer NN O
cell NN O
lines NNS O
. . O

In IN O
the DT O
discussion NN O
, , O
the DT O
results NNS O
were VBD O
compared VBN O
to TO O
that DT O
of IN O
twenty CD O
similar JJ O
studies NNS O
in IN O
the DT O
literature NN O
including VBG O
in IN O
total JJ O
1315 CD O
ovarian JJ O
cancer NN O
patients NNS O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Another DT O
difference NN O
between IN O
the DT O
studies NNS O
is VBZ O
the DT O
distribution NN O
of IN O
the DT O
various JJ O
histological JJ O
types NNS O
of IN O
the DT O
ovarian JJ O
carcinoma NN O
tissues NNS O
analyzed VBD O
( -LRB- O
Table NN O
2 CD O
) -RRB- O
. . O

This DT O
difference NN O
in IN O
the DT O
distribution NN O
could MD O
be VB O
a DT O
cause NN O
for IN O
the DT O
wide JJ O
range NN O
in IN O
the DT O
MSI NNP O
frequency NN O
especially RB O
since IN O
it PRP O
has VBZ O
been VBN O
suggested VBN O
that IN O
certain JJ O
histological JJ O
types NNS O
have VBP O
a DT O
higher JJR O
frequency NN O
of IN O
MSI. NNP O

To TO O
determine VB O
whether IN O
there EX O
is VBZ O
a DT O
relation NN O
between IN O
histology NN O
and CC O
MSI NNP O
within IN O
these DT O
studies NNS O
, , O
we PRP O
looked VBD O
at IN O
the DT O
frequency NN O
of IN O
MSI NNP O
per IN O
histological JJ O
type NN O
for IN O
the DT O
628 CD O
patients NNS O
with IN O
known JJ O
histology NN O
( -LRB- O
Table NN O
2 CD O
) -RRB- O
. . O

The DT O
summary NN O
of IN O
these DT O
studies NNS O
suggests VBZ O
that IN O
the DT O
frequency NN O
of IN O
MSI NNP O
is VBZ O
higher JJR O
in IN O
the DT O
mucinous JJ O
and CC O
endometrioid JJ O
adenocarcinoma NN O
compared VBN O
to TO O
clear JJ O
cell NN O
and CC O
serous JJ O
adenocarcinoma NN O
( -LRB- O
the DT O
overall JJ O
frequencies NNS O
of IN O
MSI NNP O
were VBD O
22 CD O
% NN O
, , O
16 CD O
% NN O
, , O
9 CD O
% NN O
and CC O
8 CD O
% NN O
, , O
respectively RB O
) -RRB- O
( -LRB- O
Table NN O
2 CD O
) -RRB- O
. . O

We PRP O
hypothesize VBP O
that IN O
mucinous JJ O
and CC O
endometrioid JJ O
histology NN O
might MD O
be VB O
prone JJ O
to TO O
a DT O
higher JJR O
MSI JJ O
frequency NN O
since IN O
sporadic JJ O
endometrial NN O
carcinoma NN O
, , O
which WDT O
is VBZ O
closely RB O
related VBN O
to TO O
endometrioid VB O
ovarian JJ O
cancer NN O
, , O
has VBZ O
a DT O
MSI JJ O
frequency NN O
of IN O
20–30 CD O
% NN O
[49-51] JJ O
and CC O
MSI NNP O
is VBZ O
almost RB O
universal JJ O
present NN O
in IN O
the DT O
colorectal JJ O
tumors NNS O
of IN O
the DT O
hereditary JJ O
nonpolyposis NN O
colon NN O
cancer NN O
( -LRB- O
HNPCC NNP O
) -RRB- O
syndrome NN O
which WDT O
all DT O
have VBP O
a DT O
mucinous JJ O
histological JJ O
type NN O
. . O

Therefore RB O
, , O
the DT O
different JJ O
histology NN O
's POS O
of IN O
the DT O
ovarian JJ O
carcinomas NNS O
included VBD O
in IN O
the DT O
several JJ O
studies NNS O
seems VBZ O
to TO O
be VB O
a DT O
plausible JJ O
cause NN O
for IN O
the DT O
wide JJ O
range NN O
in IN O
MSI NNP O
frequency NN O
reported VBD O
in IN O
these DT O
studies NNS O
. . O

Next JJ O
we PRP O
addressed VBD O
the DT O
second JJ O
part NN O
of IN O
the DT O
aim NN O
of IN O
this DT O
study NN O
, , O
is VBZ O
MMR NNP B-NP
inactivation NN O
associated VBN O
with IN O
resistance NN O
to TO O
platinum-based JJ O
chemotherapy NN O
in IN O
ovarian JJ O
cancer NN O
. . O

Forty-six CD O
of IN O
the DT O
75 CD O
ovarian JJ O
carcinomas NNS O
we PRP O
analyzed VBD O
had VBD O
been VBN O
treated VBN O
with IN O
platinum-based JJ O
chemotherapy NN O
, , O
eleven CD O
did VBD O
not RB O
respond VB O
and CC O
34 CD O
did VBD O
. . O

For IN O
one CD O
patient NN O
the DT O
response NN O
was VBD O
not RB O
known VBN O
. . O

Methylation NNP O
of IN O
the DT O
MLH1 NNP B-NP
promoter NN O
was VBD O
detected VBN O
in IN O
two CD O
of IN O
the DT O
eleven CD O
non-responders NNS O
( -LRB- O
18 CD O
% NN O
) -RRB- O
and CC O
four CD O
of IN O
the DT O
34 CD O
responders NNS O
( -LRB- O
12 CD O
% NN O
) -RRB- O
and CC O
this DT O
was VBD O
not RB O
significantly RB O
different JJ O
( -LRB- O
p NN O
= SYM O
0.664 CD O
) -RRB- O
. . O

Since IN O
we PRP O
did VBD O
not RB O
detect VB O
any DT O
MSI NNP O
, , O
the DT O
resistance NN O
seen VBN O
in IN O
the DT O
eleven CD O
patients NNS O
could MD O
not RB O
be VB O
associated VBN O
with IN O
MSI NNP O
and CC O
MMR NNP B-NP
inactivation NN O
. . O

The DT O
relation NN O
between IN O
MMR NNP B-NP
deficiency NN O
and CC O
platinum-drug NN O
resistance NN O
has VBZ O
been VBN O
investigated VBN O
in IN O
only RB O
a DT O
few JJ O
in IN O
vivo JJ O
studies NNS O
. . O

Similarly RB O
to TO O
our PRP$ O
result NN O
, , O
no DT O
MSI NNP O
was VBD O
detected VBN O
by IN O
Mesquita NNP O
et NNP O
al NN O
. . O
[18] '' O
who WP O
studied VBD O
34 CD O
ovarian JJ O
carcinomas NNS O
of IN O
which WDT O
seven CD O
did VBD O
not RB O
respond VB O
to TO O
cisplatin/paclitaxel VB O
therapy NN O
. . O

So RB O
the DT O
resistance NN O
seen VBN O
in IN O
these DT O
seven CD O
nonresponding JJ O
patients NNS O
was VBD O
also RB O
not RB O
associated VBN O
with IN O
MMR NNP B-NP
inactivation NN O
. . O

In IN O
contrast NN O
, , O
Samimi NNP O
et NNP O
al NN O
. . O
[52] WDT O
found VBD O
an DT O
inverse JJ O
relation NN O
between IN O
MLH1 NNP B-NP
protein NN O
expression NN O
and CC O
the DT O
response NN O
to TO O
platinum-based JJ O
chemotherapy NN O
in IN O
54 CD O
ovarian JJ O
carcinomas NNS O
. . O

Again RB O
, , O
the DT O
number NN O
of IN O
ovarian JJ O
carcinomas NNS O
included VBD O
in IN O
these DT O
studies NNS O
is VBZ O
small JJ O
and CC O
no DT O
further JJ O
conclusion NN O
can MD O
be VB O
drawn VBN O
from IN O
these DT O
results NNS O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Since IN O
platinum-drug NN O
resistance NN O
is VBZ O
thought VBN O
to TO O
be VB O
multifactorial JJ O
the DT O
involvement NN O
of IN O
other JJ O
resistance NN O
mechanisms NNS O
could MD O
have VB O
overruled VBN O
the DT O
possible JJ O
contribution NN O
of IN O
MMR NN O
status NN O
. . O

However RB O
, , O
platinum NN O
treatment NN O
does VBZ O
seem VB O
to TO O
select VB O
for IN O
MMR NNP O
deficient NN O
cells NNS O
since IN O
in IN O
vitro NN O
enrichment NN O
for IN O
MLH1 NNP B-NP
deficient JJ O
colon NN O
cancer NN O
HCT116 IN O
cells NNS O
in IN O
a DT O
mixed JJ O
cell NN O
population NN O
was VBD O
seen VBN O
after IN O
cisplatin VBG O
treatment NN O
[53] NN O
. . O

In IN O
addition NN O
, , O
several JJ O
in IN O
vivo JJ O
studies NNS O
found VBD O
an DT O
increase NN O
in IN O
the DT O
percentage NN O
of IN O
MSI NNP O
and CC O
MLH1 NNP B-NP
methylation NN O
after IN O
platinum-based JJ O
chemotherapy NN O
as RB O
well RB O
as IN O
a DT O
decrease NN O
in IN O
the DT O
percentage NN O
of IN O
cells NNS O
positive JJ O
for IN O
MLH1 NNP B-NP
and CC O
MSH2 NNP B-NP
[14,19,25,52] NNP O
. . O

Moreover RB O
, , O
an DT O
increase NN O
in IN O
MLH1 NNP B-NP
methylation NN O
after IN O
platinum-based JJ O
chemotherapy NN O
was VBD O
associated VBN O
with IN O
poor JJ O
survival NN O
in IN O
ovarian JJ O
cancer NN O
patients NNS O
[19] VBP O
. . O

These DT O
results NNS O
as RB O
well RB O
as IN O
the DT O
in IN O
vitro NN O
studies NNS O
mentioned VBN O
in IN O
the DT O
introduction NN O
, , O
suggest VBP O
that IN O
MMR NNP B-NP
inactivation NN O
causes VBZ O
a DT O
low JJ O
level NN O
resistance NN O
to TO O
platinum-based DT O
chemotherapy NN O
which WDT O
does VBZ O
not RB O
play VB O
a DT O
significant JJ O
role NN O
in IN O
intrinsic JJ O
resistance NN O
. . O

However RB O
, , O
due JJ O
to TO O
selection NN O
during IN O
chemotherapy NN O
MMR NNP B-NP
inactivation NN O
might MD O
play VB O
a DT O
greater JJR O
role NN O
in IN O
the DT O
acquired VBN O
resistance NN O
. . O

We PRP O
therefore RB O
propose VBP O
that IN O
the DT O
role NN O
of IN O
MMR NNP B-NP
inactivation NN O
in IN O
acquired VBN O
resistance NN O
in IN O
ovarian JJ O
cancer NN O
should MD O
be VB O
further JJ O
investigated VBN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Whole-chromosome JJ O
plots NNS O
of IN O
running VBG O
average NN O
of IN O
fractions NNS O
of IN O
samples NNS O
showing VBG O
up-/down-regulation NN O
in IN O
tumor NN O
versus IN O
normal JJ O
samples NNS O
( -LRB- O
Chromosome DT O
17,18,19,20,21,22,X,Y) CD O
. . O

For IN O
each DT O
chromosome NN O
you PRP O
see VBP O
a DT O
separate JJ O
figure NN O
. . O

Gray NNP O
dots NNS O
denote VBP O
the DT O
number NN O
of IN O
patients NNS O
with IN O
up IN O
- : O
or CC O
down-regulation NN O
for IN O
a DT O
single JJ O
gene NN O
. . O

Orange/green NNP O
lines NNS O
represent VBP O
a DT O
running VBG O
average NN O
of IN O
these DT O
values NNS O
. . O

The DT O
plots NNS O
are VBP O
made VBN O
to TO O
be VB O
easily RB O
comparable JJ O
with IN O
whole-genome JJ O
CGH NNP O
plots NNS O
( -LRB- O
like IN O
e.g NN O
. . O

those DT O
in IN O
Knösel NNP O
et NNP O
al NN O
. . O
[21] '' O
) -RRB- O
Further JJ O
details NNS O
of IN O
plot NN O
construction NN O
are VBP O
described VBN O
in IN O
the DT O
methods NNS O
section NN O
. . O

Individual JJ O
chromosomal NN O
islands NNS O
of IN O
up IN O
- : O
or CC O
down-regulation NN O
. . O

These DT O
are VBP O
condensed JJ O
results NNS O
of IN O
the DT O
ChARM NNP O
analyses NNS O
: : O
overlapping VBG O
regions NNS O
with IN O
evidence NN O
for IN O
up IN O
- : O
or CC O
down-regulation NN O
from IN O
various JJ O
analyses NNS O
of IN O
different JJ O
cross-correlation NN O
window NN O
sizes NNS O
have VBP O
been VBN O
fused VBN O
into IN O
single JJ O
regions NNS O
. . O

The DT O
original JJ O
ChARM NN O
output NN O
including VBG O
p NN O
values NNS O
for IN O
each DT O
region NN O
and CC O
additional JJ O
annotation NN O
can MD O
be VB O
found VBN O
in IN O
Additional JJ O
file NN O
1 CD O
. . O
Hereditary IN O
colorectal JJ O
cancer NN O
syndromes NNS O
are VBP O
indicated VBN O
along IN O
with IN O
their PRP$ O
OMIM NNP O
ID. . O

Gene NNP O
symbols NNS O
are VBP O
official JJ O
or CC O
provisional JJ O
HUGO NNP O
symbols NNS O
if IN O
available JJ O
, , O
otherwise RB O
names NNS O
of IN O
Unigene NNP O
clusters NNS O
. . O

Information NN O
about IN O
known VBN O
tumor NN O
genes NNS O
in IN O
misregulated JJ O
regions NNS O
were VBD O
extracted VBN O
from IN O
the DT O
literature NN O
. . O

Tumor-associated JJ O
genes NNS O
are VBP O
located VBN O
within IN O
expression NN O
islands NNS O
or CC O
in IN O
near JJ O
vicinity NN O
. . O

Statistics NNS O
on IN O
expression NN O
imbalances NNS O
across IN O
human JJ O
chromosomes NNS O
. . O

Here RB O
, , O
estimates NNS O
of IN O
portions NNS O
of IN O
chromosomes NNS O
that WDT O
are VBP O
affected VBN O
by IN O
regional JJ O
regulation NN O
of IN O
expression NN O
are VBP O
given VBN O
. . O

The DT O
second JJ O
column NN O
gives VBZ O
the DT O
number NN O
of IN O
genes NNS O
on IN O
a DT O
particular JJ O
chromosome NN O
that WDT O
were VBD O
included VBN O
in IN O
our PRP$ O
analysis NN O
. . O

The DT O
following JJ O
columns NNS O
contain VBP O
the DT O
numbers NNS O
of IN O
genes NNS O
that WDT O
are VBP O
located VBN O
in IN O
deregulated JJ O
expression NN O
islands NNS O
(up/down IN O
) -RRB- O
. . O

Individual JJ O
chromosomal NN O
islands NNS O
with IN O
gain NN O
of IN O
expression NN O

8q11.23-q21.13 CD O

Gain NNP O
of IN O
expression NN O
in IN O
region NN O
8q11.23-q21.13 CD O
is VBZ O
strongest JJS O
in IN O
a DT O
small JJ O
interval NN O
( -LRB- O
8q12.1 CD O
) -RRB- O

that IN O
spans NNS O
genes NNS O
from IN O
TCEA1 NNP B-NP
to TO O
PLAG1 VB B-NP
( -LRB- O
see VB O
Figures NNS O
6 CD O
, , O
7 CD O
, , O
8 CD O
) -RRB- O
. . O

There EX O
have VBP O
been VBN O
numerous JJ O
reports NNS O
of IN O
copy NN O
number NN O
gains NNS O
of IN O
chromosome NN O
8q CD O
in IN O
CRC NNP O
[18,21,23,25 CD O
] SYM O
which WDT O
suggests VBZ O
a DT O
possible JJ O
mechanism NN O
leading VBG O
to TO O
over-expression NN O
in IN O
our PRP$ O
patients NNS O
. . O

The DT O
known VBN O
blood NN O
cell NN O
oncogene IN O
LYN NNP B-NP
is VBZ O
located VBN O
in IN O
this DT O
interval NN O
and CC O
it PRP O
is VBZ O
up-regulated JJ O
in IN O
several JJ O
of IN O
our PRP$ O
tumor NN O
samples NNS O
. . O

It PRP O
has VBZ O
been VBN O
reported VBN O
before IN O
that DT O
LYN NNP B-NP
is VBZ O
expressed VBN O
in IN O
colorectal NN O
tumors NNS O
[26] VBP O
. . O

The DT O
concerted JJ O
up-regulation NN O
of IN O
LYN NNP B-NP
along IN O
with IN O
other JJ O
genes NNS O
in IN O
this DT O
region NN O
suggests VBZ O
a DT O
role NN O
for IN O
LYN NNP B-NP
in IN O
CRC. NNP O

Another DT O
interesting JJ O
gene NN O
in IN O
this DT O
interval NN O
is VBZ O
PLAG1 DT B-NP
( -LRB- O
pleomorphic JJ B-NP
adenoma NN I-NP
gene NN I-NP
1 CD I-NP
) -RRB- O
for IN O
which WDT O
chromosomal NN O
aberrations NNS O
have VBP O
been VBN O
described VBN O
that IN O
lead NN O
to TO O
over-expression NN O
in IN O
salivary JJ O
gland NN O
tumors NNS O
[27,28] VBP O
. . O

No DT O
informative JJ O
expression NN O
measures NNS O
were VBD O
obtained VBN O
for IN O
the DT O
MOS NNP B-NP
protein NN O
kinase NN O
gene NN O
which WDT O
is VBZ O
located VBN O
between IN O
RPS20 NNP B-NP
and CC O
PLAG1 NNP B-NP
, , O
although IN O
this DT O
may MD O
be VB O
due JJ O
to TO O
technical JJ O
limitations NNS O
. . O

Genes NNP O
encoding VBG O
components NNS O
of IN O
the DT O
translation NN O
machinery NN O
, , O
the DT O
mitochondrial JJ O
ribosomal JJ O
protein NN O
MRPL15 . B-NP
and CC O
cytosolic JJ O
ribosomal JJ O
proteins NNS O
RPL7 . B-NP
and CC O
RPS20 JJ B-NP
, , O
are VBP O
located VBN O
in IN O
this DT O
region NN O
, , O
highlighting VBG O
the DT O
need NN O
for IN O
enhanced JJ O
translation NN O
in IN O
cancer NN O
cells NNS O
. . O

The DT O
concomitant JJ O
down-regulation NN O
of IN O
the DT O
TOX NNP B-NP
and CC O
ANKTM1 NNP B-NP
genes NNS O
in IN O
many JJ O
patients NNS O
in IN O
an DT O
environment NN O
of IN O
transcriptional JJ O
activation NN O
is VBZ O
remarkable JJ O
, , O
but CC O
the DT O
functional JJ O
significance NN O
remains VBZ O
unclear JJ O
. . O

Buffart NNP O
et NNP O
al NN O
. . O
have VBP O
reported VBN O
amplifications NNS O
of IN O
8q11-q24 CD O
in IN O
metastasizing VBG O
CRC NNP O
[29] CD O
, , O
highlighting VBG O
a DT O
possible JJ O
mechanism NN O
for IN O
gain NN O
of IN O
expression NN O
in IN O
this DT O
region NN O
. . O

In IN O
summary NN O
, , O
our PRP$ O
analysis NN O
suggests VBZ O
that IN O
chromosomal NN O
region NN O
8q12.1 CD O
is VBZ O
a DT O
candidate NN O
target NN O
region NN O
for IN O
genetic JJ O
alterations NNS O
that WDT O
lead VBP O
to TO O
over-expression NNP O
in IN O
CRC. NNP O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Up-regulation NN O
of IN O
mRNA JJ O
expression NN O
in IN O
human JJ O
chromosomal NN O
region NN O
8q11.23-q21.13 . O

( -LRB- O
T/N NN O
relative JJ O
expression NN O
heat NN O
map NN O
) -RRB- O
. . O

Heat NN O
map NN O
of IN O
fold NN O
change NN O
of IN O
tumor-versus-normal JJ O
expression NN O
. . O

Genes NNP O
are VBP O
given VBN O
in IN O
chromosomal NN O
order NN O
on IN O
the DT O
horizontal JJ O
axis NN O
. . O

Patient JJ O
codes NNS O
are VBP O
given VBN O
on IN O
the DT O
vertical JJ O
axis NN O
. . O

The DT O
legend NN O
depicts VBZ O
which WDT O
colors NNS O
code NN O
for IN O
which WDT O
expression NN O
changes NNS O
on IN O
a DT O
loge NN O
scale NN O
( -LRB- O
green JJ O
: : O
down RP O
in IN O
tumor NN O
; : O
red JJ O
: : O
up RP O
in IN O
tumor NN O
) -RRB- O
. . O

View NN O
in IN O
conjunction NN O
with IN O
Figures NNS O
7 CD O
and CC O
8. CD O

Up-regulation NN O
of IN O
mRNA JJ O
expression NN O
in IN O
human JJ O
chromosomal NN O
region NN O
8q11.23-q21.13 . O

( -LRB- O
patient NN O
counts VBZ O
with IN O
coordinate VB O
up-regulation JJ O
) -RRB- O
. . O

Grayscale NNP O
plot NN O
of IN O
cross-comparison NN O
of IN O
up-regulation NN O
patterns NNS O
across IN O
patients NNS O
for IN O
gene NN O
pairs NNS O
in IN O
a DT O
particular JJ O
region NN O
. . O

Both DT O
, , O
horizontal JJ O
and CC O
vertical JJ O
axes NNS O
comprise VBP O
the DT O
same JJ O
genes NNS O
in IN O
chromosomal NN O
order NN O
. . O

In IN O
each DT O
square JJ O
total NN O
counts NNS O
of IN O
patients NNS O
with IN O
consistent JJ O
up-regulation NN O
in IN O
two CD O
genes NNS O
are VBP O
coded VBN O
by IN O
different JJ O
shades NNS O
of IN O
gray JJ O
. . O

Dark JJ O
squared JJ O
regions NNS O
along IN O
the DT O
diagonal JJ O
indicate VBP O
coordinated VBN O
regulation NN O
in IN O
patient NN O
subgroups NNS O
. . O

Note VB O
, , O
that IN O
many JJ O
more JJR O
patients NNS O
show VBP O
up-regulation RP O
as IN O
indicated VBN O
by IN O
dark JJ O
spots NNS O
in IN O
this DT O
figure NN O
than IN O
down-regulation NN O
as IN O
indicated JJ O
by IN O
dark JJ O
spots NNS O
in IN O
Figure NN O
8. . O

The DT O
left JJ O
region NN O
of IN O
exceptionally RB O
strong JJ O
up-regulation NN O
spans VBZ O
TCEA1 NNP B-NP
, , O
LYPLA1 NNP B-NP
, , O
MRPL15 NNP B-NP
, , O
the DT O
known VBN O
tumor NN O
gene NN O
LYN NNP B-NP
, , O
and CC O
PLAG1 NNP B-NP
. . O

Note VB O
that IN O
TOX NNP B-NP
and CC O
ANKTM1 NNP B-NP
are VBP O
down-regulated JJ O
in IN O
approximately RB O
half NN O
of IN O
the DT O
tumor NN O
samples NNS O
. . O

Up-regulation NN O
of IN O
mRNA JJ O
expression NN O
in IN O
human JJ O
chromosomal NN O
region NN O
8q11.23-q21.13 . O

( -LRB- O
patient NN O
counts VBZ O
with IN O
coordinate VB O
down-regulation NN O
) -RRB- O
. . O

Grayscale NNP O
plot NN O
of IN O
cross-comparison NN O
of IN O
down-regulation NN O
patterns NNS O
across IN O
patients NNS O
for IN O
gene NN O
pairs NNS O
in IN O
a DT O
particular JJ O
region NN O
. . O

Both DT O
, , O
horizontal JJ O
and CC O
vertical JJ O
axes NNS O
comprise VBP O
the DT O
same JJ O
genes NNS O
in IN O
chromosomal NN O
order NN O
. . O

In IN O
each DT O
square JJ O
total NN O
counts NNS O
of IN O
patients NNS O
with IN O
consistent JJ O
down-regulation NN O
in IN O
two CD O
genes NNS O
are VBP O
coded VBN O
by IN O
different JJ O
shades NNS O
of IN O
gray JJ O
. . O

Dark JJ O
squared JJ O
regions NNS O
along IN O
the DT O
diagonal JJ O
indicate VBP O
coordinated VBN O
regulation NN O
in IN O
patient NN O
subgroups NNS O
. . O

View NN O
in IN O
conjunction NN O
with IN O
Figures NNS O
6 CD O
and CC O
7. CD O

20q11.22-q11.23 CD O

The DT O
region NN O
20q11.22-q11.23 CD O
was VBD O
among IN O
the DT O
most RBS O
frequently RB O
up-regulated JJ O
regions NNS O
( -LRB- O
see VB O
Figures NNS O
12 CD O
, , O
13 CD O
, , O
14 CD O
) -RRB- O
. . O

Amplifications NNS O
of IN O
regions NNS O
on IN O
chromosome NN O
20q CD O
have VBP O
been VBN O
identified VBN O
independently RB O
by IN O
several JJ O
groups NNS O
in IN O
CRCs NNP O
[19,21,23,24] NNP O
. . O

The DT O
interval NN O
comprises VBZ O
the DT O
known VBN O
tumor NN O
gene NN O
SRC JJ B-NP
( -LRB- O
located VBN O
between IN O
MANBAL NNP B-NP
and CC O
BLCAP NNP B-NP
in IN O
Figures NNS O
12 CD O
, , O
13 CD O
, , O
14 CD O
) -RRB- O
for IN O
which WDT O
no DT O
informative JJ O
expression NN O
measures NNS O
were VBD O
obtained VBN O
. . O

We PRP B-NP
note VBP O
that IN O
it PRP O
is VBZ O
possible JJ O
that IN O
the DT O
SRC NNP B-NP
gene NN O
is VBZ O
the DT O
primary JJ O
target NN O
of IN O
up-regulation NN O
in IN O
our PRP$ O
CRC NNP O
patients NNS O
, , O
the DT O
up-regulation NN O
of IN O
other JJ O
genes NNS O
being VBG O
just RB O
piggy-back JJ O
effects NNS O
. . O

However RB O
, , O
also RB O
the DT O
up-regulation NN O
of IN O
the DT O
CTNN1L1 NNP B-NP
transcript NN O
could MD O
be VB O
of IN O
potential JJ O
functional JJ O
significance NN O
for IN O
CRC NNP O
development NN O
. . O

CTNN1L1 PRP B-NP
shows VBZ O
partial JJ O
homology NN O
to TO O
the DT O
known VBN O
colorectal NN O
cancer NN O
gene NN O
beta-catenin NN O
in IN O
the DT O
armadillo NN O
repeat NN O
region NN O
and CC O
has VBZ O
a DT O
nuclear JJ O
localization NN O
signal NN O
, , O
suggesting VBG O
that IN O
it PRP O
could MD O
play VB O
an DT O
important JJ O
role NN O
in IN O
signal NN O
transduction NN O
to TO O
the DT O
nucleus NN O
in IN O
CRC. NNP O

Also RB O
up-regulation JJ O
of IN O
the DT O
E3 NNP O
ubiquitin NNP O
ligase NN O
Itchy NNP O
( -LRB- O
ITCH) NN B-NP
could MD O
be VB O
of IN O
potential JJ O
importance NN O
as IN O
selective JJ O
ubiquitin-tagging NN O
of IN O
signaling VBG O
proteins NNS O
for IN O
destruction NN O
is VBZ O
an DT O
emerging VBG O
mechanism NN O
in IN O
cancer NN O
biology NN O
. . O

The DT O
need NN O
for IN O
accelerated JJ O
protein NN O
synthesis NN O
in IN O
cancer NN O
cells NNS O
is VBZ O
reflected VBN O
by IN O
the DT O
up-regulation NN O
of IN O
the DT O
translation NN O
initiation NN O
factor NN O
EIF2S2 NNP B-NP
. . O

Remarkably RB O
, , O
we PRP O
found VBD O
dramatic JJ O
down-regulation NN O
against IN O
the DT O
regional JJ O
trend NN O
of IN O
C20orf110 DT O
alias NNS O
p53-inducible JJ B-NP
protein NN O
2 CD O
( -LRB- O
TP53INP2 NN B-NP
) -RRB- O
whose WP$ O
expression NN O
is VBZ O
usually RB O
positively RB O
controlled VBN O
by IN O
the DT O
p53 NN B-NP
protein NN O
. . O

For IN O
unknown JJ O
reasons NNS O
p53 NN B-NP
seems VBZ O
to TO O
be VB O
unable JJ O
to TO O
induce VB O
TP53INP2 DT B-NP
expression NN O
in IN O
the DT O
majority NN O
of IN O
CRCs NNP O
studied VBD O
here RB O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Down-regulation NN O
of IN O
mRNA JJ O
expression NN O
in IN O
human JJ O
chromosomal NN O
region NN O
14q24.1-14q24.3 . O

– IN O
the DT O
FOS JJ B-NP
region NN O
( -LRB- O
patient NN O
counts NNS O
with IN O
coordinate VB O
up-regulation JJ O
) -RRB- O
. . O

Grayscale NNP O
cross-comparison NN O
plot NN O
of IN O
up-regulation NN O
patterns NNS O
across IN O
patients NNS O
( -LRB- O
analogous JJ O
to TO O
Figures NNS O
7 CD O
, , O
10 CD O
, , O
13 CD O
) -RRB- O
. . O

View NN O
this DT O
plot NN O
in IN O
conjunction NN O
with IN O
Figures NNS O
30 CD O
and CC O
32 CD O
. . O

Down-regulation NN O
of IN O
mRNA JJ O
expression NN O
in IN O
human JJ O
chromosomal NN O
region NN O
14q24.1-14q24.3 . O

– IN O
the DT O
FOS JJ B-NP
region NN O
( -LRB- O
patient NN O
counts NNS O
with IN O
coordinate VB O
down-regulation NN O
) -RRB- O
. . O

Grayscale NNP O
cross-comparison NN O
plot NN O
of IN O
down-regulation NN O
patterns NNS O
across IN O
patients NNS O
( -LRB- O
analogous JJ O
to TO O
Figures NNS O
8 CD O
, , O
11 CD O
, , O
14 CD O
) -RRB- O
. . O

View NN O
this DT O
plot NN O
in IN O
conjunction NN O
with IN O
Figures NNS O
30 CD O
and CC O
31 CD O
. . O

Note VB O
, , O
that IN O
many JJ O
more JJR O
patients NNS O
show VBP O
down-regulation JJ O
as IN O
indicated VBN O
by IN O
dark JJ O
spots NNS O
in IN O
this DT O
plot NN O
than IN O
up-regulation JJ O
as IN O
indicated VBN O
by IN O
dark JJ O
spots NNS O
in IN O
Figure NN O
31 CD O
. . O

This DT O
region NN O
has VBZ O
been VBN O
reported VBN O
in IN O
other JJ O
studies NNS O
to TO O
be VB O
frequently RB O
deleted VBN O
in IN O
colon NN O
cancer NN O
metastases NNS O
( -LRB- O
see VB O
Table NN O
1 CD O
) -RRB- O
. . O

The DT O
FOS NNP B-NP
oncogene NNP O
is VBZ O
the DT O
5th JJ O
gene NN O
from IN O
the DT O
right NN O
and CC O
is VBZ O
one CD O
of IN O
the DT O
most RBS O
strongly RB O
down-regulated JJ O
genes NNS O
in IN O
this DT O
region NN O
. . O

Note VB O
the DT O
expression NN O
of IN O
MLH3 NNP B-NP
, , O
KIAA0317 NNP B-NP
, , O
KIAA0440/SIPA1L1 NNP O
, , O
NUMB NNP B-NP
, , O
SYNJ2BP NNP B-NP
and CC O
PSEN1 NNP B-NP
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Discussion NN O

Global JJ O
analysis NN O
of IN O
chromosomal NN O
regions NNS O
with IN O
expression NN O
gain NN O
or CC O
loss NN O

We PRP O
found VBD O
that IN O
25 CD O
% NN O
of IN O
the DT O
genes NNS O
lie VBP O
in IN O
regions NNS O
that WDT O
are VBP O
affected VBN O
by IN O
expression NN O
imbalance NN O
in IN O
colon NN O
cancer NN O
. . O

This DT O
does VBZ O
not RB O
mean VB O
that IN O
25 CD O
% NN O
of IN O
the DT O
genes NNS O
are VBP O
misregulated VBN O
as IN O
many JJ O
genes NNS O
that WDT O
fall VBP O
into IN O
these DT O
regions NNS O
are VBP O
not RB O
expressed VBN O
at IN O
all DT O
in IN O
tumors NNS O
and CC O
in IN O
normal JJ O
epithelium NN O
of IN O
the DT O
colon NN O
. . O

Additionally RB O
, , O
we PRP O
note VBP O
that IN O
these DT O
numbers NNS O
are VBP O
probably RB O
an DT O
upper JJ O
limit NN O
because IN O
the DT O
sliding VBG O
window NN O
approach NN O
probably RB O
included VBD O
several JJ O
genes NNS O
in IN O
close JJ O
proximity NN O
to TO O
the DT O
boundaries NNS O
of IN O
misexpressed JJ O
regions NNS O
. . O

Nevertheless RB O
, , O
the DT O
number NN O
of IN O
regions NNS O
of IN O
imbalanced JJ O
expression NN O
is VBZ O
remarkable JJ O
and CC O
suggest VBP O
that IN O
there EX O
is VBZ O
extensive JJ O
regulation NN O
in IN O
CRC NNP O
at IN O
the DT O
genomic JJ O
level NN O
. . O

Recently RB O
, , O
Nakao NNP O
et NNP O
al NN O
. . O
estimated VBN O
from IN O
genome-wide JJ O
array NN O
CGH NNP O
data NNS O
that IN O
~17 CD O
% NN O
of IN O
the DT O
human JJ O
genome NN O
is VBZ O
affected VBN O
by IN O
DNA NNP O
copy NN O
number NN O
changes NNS O
in IN O
CRC NNP O
[23] NNP O
. . O

Prior RB O
to TO O
a DT O
more RBR O
detailed JJ O
analysis NN O
of IN O
individual JJ O
regions NNS O
in IN O
this DT O
study NN O
, , O
this DT O
suggested VBD O
that IN O
not RB O
all DT O
regional JJ O
expression NN O
changes NNS O
in IN O
CRC NNP O
will MD O
be VB O
explainable JJ O
by IN O
DNA NNP O
copy NN O
number NN O
aberrations NNS O
. . O

There EX O
are VBP O
only RB O
slightly RB O
more RBR O
genes NNS O
with IN O
expression NN O
loss NN O
than IN O
regions NNS O
with IN O
expression NN O
gain NN O
. . O

One NN O
can MD O
argue VB O
that IN O
a DT O
tumor NN O
ought MD O
to TO O
show VB O
a DT O
higher JJR O
frequency NN O
of IN O
expression NN O
loss NN O
than IN O
expression NN O
gain NN O
. . O

Reasons NNS O
are VBP O
that IN O
there EX O
should MD O
be VB O
a DT O
tendency NN O
to TO O
lose VB O
tumor NN O
suppressor NN O
genes NNS O
selectively RB O
and CC O
to TO O
lose VB O
non-essential JJ O
genes NNS O
( -LRB- O
genomic JJ O
ballast NN O
) -RRB- O
as IN O
a DT O
side NN O
effect NN O
. . O

If IN O
transcription NN O
would MD O
be VB O
a DT O
process NN O
that WDT O
is VBZ O
predominantly RB O
driven VBN O
by IN O
positive JJ O
regulation NN O
of IN O
transcriptional JJ O
activators NNS O
, , O
one CD O
would MD O
assume VB O
that IN O
any DT O
partial JJ O
genome NN O
loss NN O
results NNS O
in IN O
a DT O
slow JJ O
down IN O
of IN O
transcription NN O
. . O

In IN O
the DT O
light NN O
of IN O
these DT O
considerations NNS O
, , O
an DT O
equally RB O
high JJ O
number NN O
of IN O
regions NNS O
with IN O
expression NN O
gain NN O
can MD O
be VB O
interpreted VBN O
in IN O
two CD O
ways NNS O
. . O

Either CC O
positive JJ O
selection NN O
drives NNS O
expression NN O
gain NN O
of IN O
some DT O
regions NNS O
in IN O
cancer NN O
cells NNS O
, , O
or CC O
a DT O
default NN O
phenotype NN O
of IN O
transcription NN O
suppression NN O
dominates VBZ O
in IN O
normal JJ O
cells NNS O
which WDT O
is VBZ O
relaxed VBN O
during IN O
tumor NN O
cell NN O
development NN O
. . O

Gene NNP O
expression NN O
in IN O
chromosomal NN O
regions NNS O
with IN O
frequent JJ O
DNA NNP O
copy NN O
number NN O
changes NNS O
in IN O
CRC NNP O

Most JJS O
studies NNS O
reported VBD O
frequent JJ O
gains NNS O
of IN O
chromosome NN O
7 CD O
, , O
8q CD O
, , O
13q CD O
, , O
20q CD O
and CC O
losses NNS O
of IN O
4 CD O
and CC O
18q CD O
in IN O
CRC NNP O
[18,19,21-25] NNP O
. . O

These DT O
broadly-defined JJ O
alterations NNS O
are VBP O
in IN O
perfect JJ O
agreement NN O
with IN O
chromosome-specific JJ O
trends NNS O
in IN O
our PRP$ O
expression NN O
data NNS O
, , O
especially RB O
the DT O
exclusive JJ O
presence NN O
of IN O
domains NNS O
of IN O
expression NN O
gain NN O
on IN O
8 CD O
, , O
13 CD O
and CC O
20 CD O
and CC O
the DT O
exclusive JJ O
presence NN O
of IN O
domains NNS O
of IN O
expression NN O
loss NN O
on IN O
chromosome NN O
4 CD O
and CC O
18 CD O
( -LRB- O
see VBP O
Table NN O
2 CD O
and CC O
Figures NNS O
21 CD O
, , O
22 CD O
, , O
23 CD O
, , O
24 CD O
, , O
25 CD O
, , O
26 CD O
) -RRB- O
. . O

There EX O
is VBZ O
a DT O
single JJ O
discrepancy NN O
for IN O
chromosome NN O
7 CD O
: : O
region NN O
7q11-7q12 CD O
has VBZ O
been VBN O
reported VBN O
as IN O
amplified JJ O
in IN O
CRC NNP O
, , O
but CC O
its PRP$ O
expression NN O
is VBZ O
significantly RB O
down-regulated JJ O
in IN O
our PRP$ O
tumor NN O
samples NNS O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Conclusion NN O

Roughly RB O
a DT O
quarter NN O
of IN O
all DT O
human JJ O
genes NNS O
is VBZ O
located VBN O
in IN O
islands NNS O
of IN O
misregulated VBN O
gene NN O
expression NN O
in IN O
colorectal JJ O
cancer NN O
. . O

There EX O
are VBP O
only RB O
slightly RB O
more RBR O
down-regulated JJ O
than IN O
up-regulated JJ O
genes NNS O
. . O

Chromosomal JJ O
regions NNS O
that WDT O
are VBP O
linked VBN O
to TO O
hereditary PRP$ O
colorectal NN O
cancer NN O
often RB O
exhibit VBP O
deregulated VBN O
expression NN O
, , O
suggesting VBG O
that IN O
they PRP O
are VBP O
implicated VBN O
in IN O
spontaneous JJ O
CRC NNP O
not RB O
only RB O
through IN O
collection NN O
of IN O
mutations NNS O
. . O

Thus RB O
, , O
genes NNS O
in IN O
these DT O
chromosomal NN O
hotspots NNS O
may MD O
be VB O
systematically RB O
tested VBN O
in IN O
patients NNS O
with IN O
sporadic JJ O
CRC NNP O
for IN O
molecular JJ O
lesions NNS O
and CC O
for IN O
transcriptional JJ O
silencing NN O
. . O

Chromosomal JJ O
regions NNS O
that WDT O
are VBP O
frequently RB O
deleted VBN O
in IN O
CRC NNP O
very RB O
often RB O
comprise VB O
islands NNS O
in IN O
which WDT O
we PRP O
found VBD O
reduced VBN O
expression NN O
. . O

Although IN O
many JJ O
regions NNS O
that WDT O
are VBP O
known VBN O
to TO O
be VB O
amplified VBN O
in IN O
colorectal NN O
tumors NNS O
show VBP O
a DT O
gain NN O
of IN O
expression NN O
, , O
there EX O
are VBP O
also RB O
a DT O
considerable JJ O
number NN O
of IN O
amplified JJ O
islands NNS O
that WDT O
show VBP O
no DT O
alterations NNS O
or CC O
even RB O
down-regulation NN O
. . O

Comparison NNP O
of IN O
published VBN O
CGH NNP O
studies NNS O
with IN O
our PRP$ O
expression NN O
data NNS O
suggests VBZ O
that IN O
amplified JJ O
or CC O
deleted VBN O
chromosomal NN O
regions NNS O
are VBP O
responsible JJ O
for IN O
many JJ O
islands NNS O
with IN O
aberrant JJ O
expression NN O
. . O

However RB O
, , O
we PRP O
suggest VBP O
that IN O
it PRP O
is VBZ O
necessary JJ O
to TO O
invoke VB O
other JJ O
mechanism NN O
like IN O
epigenetic JJ O
regulation NN O
of IN O
chromatin NN O
or CC O
disruption NN O
of IN O
enhancer NN O
actions NNS O
to TO O
explain VB O
the DT O
remaining JJ O
expression NN O
imbalances NNS O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Non-dysplastic JJ O
serrated JJ O
polyps NNS O
: : O
HP NNP O
and CC O
SSA NNP O

Non-dysplastic JJ O
serrated JJ O
polyps NNS O
comprise VBP O
conventional JJ O
HPs NNS O
and CC O
the DT O
variant JJ O
lesion NN O
which WDT O
has VBZ O
been VBN O
described VBN O
as IN O
SSA NNP O
. . O

In IN O
this DT O
study NN O
, , O
SSAs NNP O
accounted VBD O
for IN O
approximately RB O
3 CD O
% NN O
of IN O
the DT O
overall JJ O
series NN O
of IN O
polyps NNS O
and CC O
were VBD O
more JJR O
age-related JJ O
than IN O
HPs NNS O
. . O

Importantly RB O
, , O
SSAs NNP O
have VBP O
been VBN O
linked VBN O
with IN O
the DT O
subset NN O
of IN O
colorectal JJ O
cancer NN O
with IN O
BRAF NNP B-NP
mutation NN O
, , O
DNA NNP O
methylation NN O
, , O
MSI NNP O
and CC O
serrated VBD O
architecture NN O
.14,18,37 . O

In IN O
this DT O
study NN O
there EX O
was VBD O
a DT O
high JJ O
frequency NN O
of IN O
BRAF NNP B-NP
mutation NN O
in IN O
conventional JJ O
HPs NNS O
( -LRB- O
67 CD O
% NN O
) -RRB- O
as RB O
well RB O
as IN O
in IN O
SSAs NNP O
( -LRB- O
81 CD O
% NN O
) -RRB- O
. . O

Previous JJ O
reports NNS O
have VBP O
shown VBN O
very RB O
similar JJ O
results NNS O
for IN O
BRAF NNP B-NP
mutation NN O
in IN O
SSA NNP O
,16 CD O
but CC O
higher JJR O
frequencies NNS O
of IN O
KRAS NNP B-NP
mutation NN O
and CC O
lower JJR O
frequencies NNS O
of IN O
BRAF NNP B-NP
mutation NN O
in IN O
HPs.12,16,38 CD O

As IN O
mentioned VBN O
in IN O
Materials NNS O
and CC O
methods NNS O
, , O
there EX O
had VBD O
been VBN O
selection NN O
of IN O
larger JJR O
HPs NNS O
in IN O
an DT O
earlier JJR O
cell NN O
kinetic NN O
study NN O
involving VBG O
the DT O
same JJ O
material NN O
. . O

Large JJ O
HPs NNS O
are VBP O
more RBR O
likely JJ O
to TO O
include VB O
the DT O
subset NN O
described VBD O
as IN O
‘microvesicular’ JJ O
, , O
in IN O
which WDT O
the DT O
columnar NN O
cells NNS O
contain VBP O
apical JJ O
mucin NN O
droplets NNS O
within IN O
small JJ O
vesicles NNS O
while IN O
goblet NN O
cells NNS O
are VBP O
rendered VBN O
inconspicuous JJ O
.25BRAF . O

mutation NN O
occurs VBZ O
more RBR O
frequently RB O
in IN O
the DT O
microvesicular JJ O
variant NN O
of IN O
HP.16 CD O

By IN O
contrast NN O
, , O
KRAS NNP B-NP
mutation NN O
occurs VBZ O
much RB O
more RBR O
commonly RB O
in IN O
the DT O
goblet NN O
cell NN O
variant NN O
of IN O
HP NNP O
, , O
which WDT O
is VBZ O
usually RB O
small JJ O
, , O
located VBN O
in IN O
the DT O
left JJ O
colon NN O
or CC O
rectum NN O
and CC O
deviates NNS O
minimally RB O
from IN O
normal JJ O
colorectal NN O
mucosa NN O
in IN O
terms NNS O
of IN O
differentiation NN O
and CC O
architecture NN O
.16,25 . O

The DT O
latter NN O
were VBD O
under-represented JJ O
in IN O
this DT O
series NN O
( -LRB- O
details NNS O
not RB O
shown VBN O
) -RRB- O
. . O

dysplastic JJ O
serrated JJ O
polyps NNS O
: : O
MP NNP O
and CC O
SA NNP O

Serrated JJ O
polyps NNS O
with IN O
dysplasia NN O
, , O
i IN O
.e NN O
. . O

MPs NNS O
and CC O
SAs NNP O
, , O
together RB O
comprised VBN O
only RB O
2 CD O
% NN O
of IN O
the DT O
overall JJ O
consecutive JJ O
series NN O
of IN O
1250 CD O
polyps NNS O
. . O

While IN O
mutation NN O
of IN O
KRAS NNP B-NP
and CC O
BRAF NNP B-NP
was VBD O
associated VBN O
with IN O
conventional JJ O
adenoma NN O
and CC O
SSA NNP O
, , O
respectively RB O
( -LRB- O
see VBP O
above IN O
) -RRB- O
, , O
BRAF NNP B-NP
and CC O
KRAS NNP B-NP
mutation NN O
occurred VBD O
with IN O
similar JJ O
frequency NN O
in IN O
both DT O
MPs NNS O
( -LRB- O
40 CD O
% NN O
and CC O
50 CD O
% NN O
, , O
respectively RB O
) -RRB- O
and CC O
SAs NNP O
( -LRB- O
33 CD O
% NN O
and CC O
27 CD O
% NN O
, , O
respectively RB O
) -RRB- O
. . O

In IN O
the DT O
literature NN O
, , O
the DT O
frequency NN O
of IN O
BRAF NNP B-NP
and CC O
KRAS NNP B-NP
mutation NN O
in IN O
MP NNP O
or CC O
SA NNP O
has VBZ O
ranged VBN O
from IN O
36 CD O
to TO O
100 CD O
% NN O
and CC O
from IN O
0 CD O
% NN O
to TO O
60 CD O
% NN O
, , O
respectively RB O
.12,16,39–42 CD O

These DT O
findings NNS O
indicate VBP O
that IN O
this DT O
subset NN O
of IN O
colorectal JJ O
polyps NNS O
is VBZ O
likely JJ O
to TO O
be VB O
heterogeneous JJ O
in IN O
terms NNS O
of IN O
its PRP$ O
molecular JJ O
origins NNS O
. . O

These DT O
polyps NNS O
were VBD O
therefore RB O
reclassified JJ O
according VBG O
to TO O
their PRP$ O
resemblance NN O
to TO O
HP NNP O
or CC O
SSA NNP O
( -LRB- O
Group NNP O
A) NNP O
( -LRB- O
Figure NN O
1A,B,E,F) JJ O
or CC O
to TO O
conventional JJ O
adenoma NN O
( -LRB- O
Group NNP O
B) NNP O
( -LRB- O
Figure NN O
1C,D) CD O
. . O

Particular JJ O
histological JJ O
features NNS O
among IN O
the DT O
Group NNP O
A DT O
polyps NNS O
were VBD O
: : O
marked VBN O
serration NN O
, , O
a DT O
papillary NN O
or CC O
villous JJ O
architecture NN O
, , O
a DT O
relatively RB O
abundant JJ O
eosinophilic JJ O
cytoplasm NN O
, , O
columnar NN O
cells NNS O
with IN O
apical JJ O
mucin NN O
droplets NNS O
, , O
nuclei NNS O
that WDT O
were VBD O
enlarged VBN O
, , O
ovoid JJ O
, , O
vesicular JJ O
and CC O
contained VBD O
a DT O
prominent JJ O
nucleolus JJ O
, , O
and CC O
adjacent JJ O
non-dysplastic JJ O
serrated JJ O
polyp NN O
. . O

Particular JJ O
histological JJ O
features NNS O
among IN O
the DT O
Group NNP O
B NNP O
polyps NNS O
were VBD O
: : O
some DT O
glandular JJ O
serration NN O
, , O
frequent JJ O
villous JJ O
change NN O
and CC O
epithelial NN O
dysplasia NN O
that WDT O
appeared VBD O
adenomatous JJ O
( -LRB- O
cytoplasmic JJ O
basophilia NNS O
and CC O
nuclei NNS O
that WDT O
were VBD O
elongated VBN O
, , O
pseudostratified VBN O
and CC O
hyperchromatic JJ O
without IN O
a DT O
prominent JJ O
nucleolus JJ O
) -RRB- O
. . O

Importantly RB O
, , O
BRAF NNP B-NP
mutation NN O
occurred VBD O
more RBR O
frequently RB O
among IN O
Group NNP O
A DT O
polyps NNS O
( -LRB- O
P NNP O
< JJ O
0.03 CD O
) -RRB- O
, , O
whereas IN O
there EX O
was VBD O
a DT O
trend NN O
for IN O
KRAS NNP B-NP
to TO O
be VB O
more RBR O
frequent JJ O
among IN O
Group NNP O
B NNP O
polyps NNS O
( -LRB- O
P NNP O
= SYM O
0.06 CD O
) -RRB- O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

In IN O
summary NN O
, , O
MPs NNP O
and CC O
SAs NNP O
account NN O
for IN O
only RB O
about IN O
2 CD O
% NN O
of IN O
colorectal JJ O
polyps NNS O
. . O

Nevertheless RB O
, , O
those DT O
serrated JJ O
polyps NNS O
with IN O
dysplasia NN O
show NN O
frequent JJ O
mutation NN O
of IN O
either DT O
KRAS NNP B-NP
or CC O
BRAF NNP B-NP
and CC O
frequent JJ O
loss NN O
of IN O
expression NN O
of IN O
MGMT NNP B-NP
( -LRB- O
particularly RB O
MP NNP O
) -RRB- O
. . O

Additionally RB O
, , O
four CD O
of IN O
25 CD O
( -LRB- O
16 CD O
% NN O
) -RRB- O
showed VBD O
high-grade JJ O
dysplasia NN O
and CC O
in IN O
three CD O
of IN O
these DT O
there EX O
was VBD O
concordant NN O
aberrant JJ O
nuclear JJ O
expression NN O
of IN O
p53 NN B-NP
. . O

Along IN O
with IN O
SSAs NNP O
, , O
these DT O
rare JJ O
polyps NNS O
may MD O
serve VB O
as IN O
the DT O
precursors NNS O
of IN O
sporadic JJ O
CRCs NNS O
with IN O
BRAF NNP B-NP
mutation NN O
and CC O
DNA NN O
methylation NN O
( -LRB- O
with IN O
and CC O
without IN O
DNA NNP O
MSI) NNP O
and CC O
a DT O
subset NN O
of IN O
CRCs NNP O
with IN O
KRAS NNP B-NP
mutation NN O
. . O

Their PRP$ O
malignant JJ O
potential NN O
is VBZ O
explained VBN O
by IN O
the DT O
accumulation NN O
of IN O
genetic JJ O
alterations NNS O
that WDT O
may MD O
in IN O
turn NN O
depend VBP O
upon IN O
the DT O
inactivation NN O
of IN O
the DT O
DNA NNP O
repair NN O
gene NN O
MGMT.28 . B-NP

The DT O
importance NN O
of IN O
these DT O
‘fusion NN O
’ VBD O
polyps NNS O
as IN O
cancer NN O
precursors NNS O
may MD O
be VB O
under-appreciated JJ O
because IN O
critical JJ O
rate-limiting NN O
changes NNS O
governing VBG O
malignant JJ O
transition NN O
, , O
particularly RB O
in IN O
association NN O
with IN O
loss NN O
of IN O
function NN O
of IN O
MLH1 NNP B-NP
of IN O
p53 NN B-NP
, , O
occur VBP O
rapidly RB O
and CC O
can MD O
rarely RB O
be VB O
‘caught VBN O
in IN O
the DT O
act’ NN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Methods NNS O

Patients NNS O

A DT O
large JJ O
colorectal NN O
cancer NN O
family NN O
( -LRB- O
Figure NN O
1 CD O
) -RRB- O
with IN O
a DT O
recently RB O
identified VBN O
mutation NN O
in IN O
the DT O
MLH1 NNP B-NP
gene NN O
( -LRB- O
c.1046dupT CD O
, , O

p.Pro350fs NNS O
) -RRB- O
was VBD O
studied VBN O
. . O

Nine CD O
family NN O
members NNS O
are VBP O
affected VBN O
with IN O
colorectal JJ O
cancer NN O
. . O

Another DT O
two CD O
family NN O
members NNS O
are VBP O
affected VBN O
with IN O
polyps NNS O
and CC O
three CD O
cases NNS O
with IN O
skin NN O
cancer NN O
( -LRB- O
non-specified JJ O
) -RRB- O
and CC O
one CD O
case NN O
with IN O
endometrium NN O
cancer NN O
( -LRB- O
non-specified JJ O
) -RRB- O
are VBP O
seen VBN O
as RB O
well RB O
. . O

Peripheral JJ O
blood NN O
lymphocytes NNS O
were VBD O
collected VBN O
from IN O
the DT O
family NN O
members NNS O
. . O

DNA NN O
was VBD O
extracted VBN O
using VBG O
standard JJ O
procedures NNS O
. . O

A DT O
total NN O
of IN O
thirteen CD O
family NN O
members NNS O
were VBD O
genotyped VBN O
on IN O
Affymetrix NNP O
GeneChip NNP O
Human NNP O
Mapping NNP O
10K . O
2.0 CD O
SNP NNP O
arrays NNS O
. . O

The DT O
arrays NNS O
were VBD O
processed VBN O
according VBG O
to TO O
the DT O
instructions NNS O
of IN O
the DT O
manufacturer NN O
. . O

The DT O
mean JJ O
SNP JJ O
call NN O
rate NN O
was VBD O
96.3 CD O
% NN O
(89.0%-98.5 CD O
% NN O
) -RRB- O
. . O

The DT O
study NN O
was VBD O
approved VBN O
by IN O
the DT O
Medical NNP O
Ethical NNP O
Committee NNP O
of IN O
the DT O
LUMC NNP O
( -LRB- O
protocol NN O
P01-019 JJ O
) -RRB- O
. . O

Workflow NN O

We PRP O
processed VBD O
the DT O
data NNS O
according VBG O
to TO O
the DT O
following VBG O
workflow NN O
: : O
1 CD O
) -RRB- O
First RB O
, , O
the DT O
genotype NN O
data NNS O
were VBD O
generated VBN O
by IN O
GeneChip NNP O
DNA NNP O
Analysis NNP O
Software NNP O
( -LRB- O
GDAS NNP O
) -RRB- O
from IN O
Affymetrix NNP O
. . O
2 CD O
) -RRB- O
These DT O
genotype NN O
data NNS O
were VBD O
combined VBN O
with IN O
the DT O
pedigree NN O
and CC O
the DT O
marker NN O
information NN O
in IN O
Alohomora NNP O
. . O

3 LS O
) -RRB- O
In IN O
this DT O
program NN O
the DT O
uninformative JJ O
SNPs NNS O
were VBD O
removed VBN O
as RB O
well RB O
. . O

4 CD O
) -RRB- O
To TO O
be VB O
able JJ O
to TO O
perform VB O
linkage NN O
analysis NN O
in IN O
the DT O
desired VBN O
program NN O
, , O
the DT O
output NN O
files NNS O
( -LRB- O
in IN O
Merlin-format NNP O
) -RRB- O
of IN O
Alohomora NNP O
were VBD O
by IN O
Mega2 NNP O
converted VBD O
to TO O
the DT O
proper JJ O
format NN O
. . O

5 CD O
) -RRB- O
Mega2 NNP O
also RB O
removed VBD O
the DT O
Mendelian NNP O
inconsistent JJ O
errors NNS O
. . O

6 CD O
) -RRB- O
The DT O
files NNS O
were VBD O
then RB O
ready JJ O
to TO O
perform VB O
parametric JJ O
linkage NN O
analysis NN O
using VBG O
2 CD O
flanking NN O
markers NNS O
in IN O
MENDEL NNP O
; : O
affected-only JJ O
analysis NN O
as RB O
well RB O
as IN O
parametric JJ O
linkage NN O
analysis NN O
using VBG O
liability NN O
classes NNS O
was VBD O
performed VBN O
. . O

7 CD O
) -RRB- O
Based VBN O
on IN O
the DT O
second JJ O
analysis NN O
, , O
regions NNS O
of IN O
interest NN O
were VBD O
defined VBN O
that IN O
were VBD O
further RB O
tested VBN O
for IN O
Mendelian NNP O
consistent JJ O
errors NNS O
and CC O
8 CD O
) -RRB- O
possible JJ O
linkage NN O
disequilibrium NN O
was VBD O
removed VBN O
in IN O
SNPLINK. NNP O

9 CD O
) -RRB- O
Multipoint VB O
parametric JJ O
linkage NN O
analysis NN O
using VBG O
the DT O
liability NN O
classes NNS O
was VBD O
then RB O
performed VBN O
in IN O
Simwalk2 NNP O
for IN O
the DT O
ROIs NNP O
and CC O
10 CD O
) -RRB- O
finally RB O
, , O
the DT O
haplotypes NNS O
were VBD O
inferred VBN O
in IN O
Simwalk2 NNP O
. . O

Data NNP O
formatting NN O
and CC O
quality NN O
control NN O

Genotype NNP O
data NNS O
of IN O
the DT O
individual JJ O
family NN O
members NNS O
were VBD O
generated VBN O
using VBG O
GeneChip NNP O
DNA NNP O
Analysis NNP O
Software NNP O
( -LRB- O
GDAS NNP O
) -RRB- O
from IN O
Affymetrix NNP O
. . O

In IN O
the DT O
Alohomora NNP O
program NN O
[32 NN O
] SYM O
the DT O
pedigree NN O
information NN O
, , O
allele DT O
frequencies NNS O
and CC O
map NN O
position NN O
of IN O
the DT O
SNPs NNS O
were VBD O
combined VBN O
with IN O
the DT O
genotype NN O
data NNS O
generated VBN O
by IN O
GDAS. NNP O

The DT O
uninformative JJ O
SNPs NNS O
in IN O
this DT O
pedigree NN O
, , O
that WDT O
show VBP O
either DT O
only RB O
A DT O
alleles NNS O
and CC O
No DT O
Calls NNS O
or CC O
only RB O
B NNP O
alleles NNS O
and CC O
No DT O
Calls NNS O
, , O
were VBD O
removed VBN O
from IN O
further JJ O
analysis NN O
by IN O
Alohomora NNP O
. . O

The DT O
data NNS O
files NNS O
were VBD O
exported VBN O
in IN O
Merlin NNP O
format NN O
. . O

Subsequently RB O
, , O
in IN O
Mega2 NNP O
[33] IN O
these DT O
Alohomora NNP O
files NNS O
were VBD O
converted VBN O
into IN O
the DT O
appropriate JJ O
format NN O
for IN O
the DT O
programs NNS O
used VBN O
for IN O
linkage NN O
analysis NN O
, , O
i IN O
.e NN O
. . O
either CC O
the DT O
Mendel NNP O
5 CD O
format NN O
or CC O
the DT O
SimWalk2 NNP O
format NN O
. . O

Mendelian NNP O
inconsistent JJ O
errors NNS O
were VBD O
removed VBN O
from IN O
analysis NN O
with IN O
Mega2 NNP O
by IN O
setting VBG O
all DT O
genotypes NNS O
of IN O
these DT O
SNPs NNS O
to TO O
unknown JJ O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Results NNS O

HLA NNP B-NP
class NN I-NP
I PRP I-NP
, , O
β2m NNP B-NP
and CC O
APM NNP B-NP
component NN I-NP
expression NN O

In IN O
order NN O
to TO O
compare VB O
the DT O
expression NN O
of IN O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
in IN O
sporadic JJ O
MSI-H NNP O
and CC O
MSS RB O
right JJ O
sided JJ O
tumors NNS O
( -LRB- O
RS NNS O
T NNP O
) -RRB- O
and CC O
HNPCC NNP O
MSI-H NNP O
cases NNS O
, , O
we PRP O
used VBD O
an DT O
antibody NN O
panel NN O
recognizing VBG O
monomorphic JJ O
determinants NNS O
expressed VBN O
on IN O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
heavy JJ O
chains NNS O
, , O
β2m NNP B-NP
and CC O
APM NNP B-NP
components NNS I-NP
( -LRB- O
Figure NN O
1 CD O
) -RRB- O
. . O

In IN O
total JJ O
, , O
we PRP O
identified VBD O
loss NN O
of IN O
HLA NNP O
class NN O
I PRP O
expression NN O
in IN O
about IN O
34.6 CD O
% NN O
of IN O
the DT O
RST NNP O
and CC O
42.7 CD O
% NN O
of IN O
the DT O
HNPCC NNP O
cases NNS O
. . O

The DT O
frequency NN O
of IN O
alterations NNS O
differed VBD O
significantly RB O
between IN O
the DT O
sporadic JJ O
MSS NNP O
and CC O
MSI-H NNP O
RST. . O

The DT O
lack NN O
of IN O
HLA NNP O
class NN O
I PRP O
expression NN O
was VBD O
more RBR O
frequent JJ O
in IN O
MSI-H NNP O
sporadic JJ O
cases NNS O
than IN O
in IN O
MSS NNP O
cases NNS O
( -LRB- O
p NN O
< JJ O
0.0001 CD O
) -RRB- O
, , O
as IN O
it PRP O
was VBD O
16.7 CD O
% NN O
in IN O
the DT O
latter JJ O
group NN O
, , O
but CC O
60.6 CD O
% NN O
in IN O
the DT O
former JJ O
( -LRB- O
Table NN O
2 CD O
) -RRB- O
. . O

Subsequently RB O
, , O
we PRP O
have VBP O
investigated VBN O
the DT O
frequency NN O
of IN O
a DT O
concomitant JJ O
loss NN O
of IN O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
expression NN O
with IN O
that DT O
of IN O
either CC O
the DT O
β2m NN O
molecule NN O
or CC O
of IN O
any DT O
APM NNP B-NP
component NN I-NP
. . O

In IN O
the DT O
sporadic JJ O
subset NN O
, , O
loss NN O
of IN O
HLA NNP O
class NN O
I PRP O
expression NN O
was VBD O
more RBR O
often RB O
associated VBN O
with IN O
that DT O
of IN O
one CD O
of IN O
the DT O
APM NNP O
components NNS O
, , O
occurring VBG O
in IN O
about IN O
37 CD O
% NN O
of IN O
HLA-negative JJ O
tumors NNS O
regardless RB O
of IN O
their PRP$ O
mismatch NN O
repair NN O
status NN O
( -LRB- O
Table NN O
2 CD O
) -RRB- O
. . O

β2m JJ O
loss NN O
was VBD O
only RB O
found VBN O
in IN O
one CD O
HLA NNP O
class NN O
I PRP O
negative JJ O
MSI-H JJ O
sporadic JJ O
tumor NN O
( -LRB- O
case NN O
65 CD O
) -RRB- O
that WDT O
interestingly RB O
also RB O
presented VBN O
loss NN O
of IN O
the DT O
APM NNP O
molecules NNS O
TAP2 NNP O
, , O
Calreticulin NNP O
and CC O
Tapasin NNP O
( -LRB- O
Figure NN O
2 CD O
) -RRB- O
. . O

In IN O
contrast NN O
, , O
loss NN O
of IN O
HLA NNP O
class NN O
I PRP O
expression NN O
in IN O
HNPCC NNP O
cases NNS O
was VBD O
more RBR O
frequently RB O
associated VBN O
with IN O
that DT O
of IN O
β2m NN B-NP
( -LRB- O
Table NN O
2 CD O
) -RRB- O
, , O
as IN O
it PRP O
was VBD O
found VBN O
in IN O
46.9 CD O
% NN O
of IN O
the DT O
HLA NNP O
class NN O
I-negative JJ O
tumors NNS O
. . O

In IN O
contrast NN O
loss NN O
of IN O
any DT O
APM NNP O
component NN O
was VBD O
observed VBN O
in IN O
only RB O
6 CD O
% NN O
of IN O
these DT O
cases NNS O
( -LRB- O
h38 NNS O
, , O
h49 . O
) -RRB- O
which WDT O
also RB O
showed VBD O
loss NN O
of IN O
β2m JJ O
expression NN O
. . O

In IN O
sporadic JJ O
RST NN O
, , O
the DT O
simultaneous JJ O
loss NN O
of IN O
more JJR O
than IN O
one CD O
APM NNP B-NP
molecule NN O
per IN O
case NN O
was VBD O
frequent JJ O
( -LRB- O
Figure NN O
2 CD O
) -RRB- O
. . O

Only RB O
3 CD O
out IN O
of IN O
10 CD O
cases NNS O
lost VBD O
a DT O
single JJ O
APM NNP B-NP
component NN O
. . O

The DT O
TAP2 JJ B-NP
molecule NN O
was VBD O
most RBS O
frequently RB O
lost VBN O
( -LRB- O
6 CD O
cases NNS O
) -RRB- O
, , O
followed VBN O
by IN O
TAP1 NNP B-NP
, , O
Tapasin NNP B-NP
and CC O
LMP2 NNP B-NP
( -LRB- O
5 CD O
cases NNS O
) -RRB- O
, , O
Calreticulin NNP B-NP
( -LRB- O
4 CD O
cases NNS O
) -RRB- O
, , O
LMP7 FW B-NP
( -LRB- O
2 CD O
cases NNS O
) -RRB- O
, , O
and CC O
Calnexin NNP B-NP
and CC O
ERp57 NNP B-NP
( -LRB- O
1 CD O
case NN O
) -RRB- O
. . O

Loss NN O
of IN O
the DT O
LPM10 JJ B-NP
protein NN O
was VBD O
detected VBN O
in IN O
neither DT O
sporadic JJ O
RST NNP O
nor CC O
HNPCC NNP O
tumors NNS O
. . O

The DT O
HNPCC NNP O
cases NNS O
h38 VBP O
and CC O
h49 VBP O
lost VBN O
the DT O
expression NN O
of IN O
TAP2 NNP B-NP
and CC O
LMP7 NNP B-NP
respectively RB O
. . O

LOH NNP O
and CC O
frameshift NN O
analysis NN O

Polymorphic JJ O
markers NNS O
around IN O
the DT O
classical JJ O
HLA NNP B-NP
genes NNS I-NP
( -LRB- I-NP
A DT I-NP
, , I-NP
B NNP I-NP
and CC I-NP
C) NNP I-NP
, , O
TAP NNP B-NP
1 CD I-NP
and CC O
TAP2 JJ B-NP
genes NNS O
were VBD O
used VBN O
to TO O
study VB O
LOH NNP O
and CC O
reveal VB O
possible JJ O
chromosomal NN O
aberrations NNS O
that WDT O
could MD O
relate VB O
to TO O
loss NN O
of IN O
HLA NNP O
class NN O
I PRP O
expression NN O
( -LRB- O
Figure NN O
5A JJ O
) -RRB- O
. . O

In IN O
HNPCC NNP O
cases NNS O
, , O
LOH NNP O
analysis NN O
was VBD O
only RB O
performed VBN O
around IN O
the DT O
HLA NNP B-NP
genes NNS O
since IN O
loss NN O
of IN O
the DT O
TAP1 JJ B-NP
and CC O
TAP2 JJ B-NP
proteins NNS O
was VBD O
rarely RB O
associated VBN O
with IN O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
loss NN O
. . O

LOH NNP O
was VBD O
more RBR O
frequent JJ O
in IN O
the DT O
MSS NNP O
tumors NNS O
( -LRB- O
50 CD O
% NN O
) -RRB- O
than IN O
in IN O
the DT O
MSI-H NNP O
sporadic JJ O
( -LRB- O
20 CD O
% NN O
) -RRB- O
and CC O
HNPCC NNP O
( -LRB- O
6 CD O
% NN O
) -RRB- O
tumors NNS O
with IN O
loss NN O
of IN O
HLA NNP O
class NN O
I PRP O
expression NN O
( -LRB- O
P NNP O
< NN O
0.05 CD O
) -RRB- O
( -LRB- O
Figure NN O
3 CD O
, , O
4) CD O
. . O

Furthermore RB O
, , O
the DT O
patterns NNS O
of IN O
LOH NNP O
in IN O
the DT O
MSS NNP O
cases NNS O
might MD O
indicate VB O
loss NN O
of IN O
the DT O
entire JJ O
6p21.3 CD O

region NN O
, , O
in IN O
contrast NN O
to TO O
the DT O
MSI-H JJ O
cases NNS O
( -LRB- O
hereditary NN O
and CC O
sporadic JJ O
forms NNS O
) -RRB- O
where WRB O
LOH NNP O
seems VBZ O
to TO O
be VB O
limited VBN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Discussion NN O

Abnormalities NNS O
in IN O
HLA NNP O
class NN O
I PRP O
cell NN O
surface NN O
expression NN O
are VBP O
commonly RB O
observed VBN O
in IN O
tumors NNS O
and CC O
are VBP O
interpreted VBN O
as IN O
a DT O
mechanism NN O
by IN O
which WDT O
tumor NN O
cells NNS O
evade VB O
the DT O
host NN O
immune JJ O
system NN O
[1] NN O
. . O

In IN O
colorectal JJ O
cancer NN O
, , O
especially RB O
in IN O
MSI-H NNP O
tumors NNS O
, , O
the DT O
high JJ O
degree NN O
of IN O
lymphocytic JJ O
infiltrate NN O
in IN O
some DT O
cases NNS O
may MD O
suggest VB O
an DT O
active JJ O
immune JJ O
response NN O
during IN O
tumor NN O
development NN O
[41,42] NN O
. . O

Moreover RB O
, , O
MSI-H NNP O
tumors NNS O
might MD O
cause VB O
increased VBN O
immune JJ O
reactivity NN O
as IN O
a DT O
consequence NN O
of IN O
the DT O
high JJ O
amounts NNS O
of IN O
aberrant JJ O
frameshift NN O
peptides NNS O
they PRP O
generate VBP O
[8,18] NN O
. . O

A DT O
selective JJ O
pressure NN O
by IN O
CTLs NNS O
upon IN O
these DT O
tumors NNS O
would MD O
favor VB O
the DT O
outgrowth NN O
of IN O
tumor NN O
cells NNS O
that WDT O
lost VBD O
HLA NNP O
class NN O
I PRP O
expression NN O
at IN O
the DT O
cell NN O
surface NN O
allowing VBG O
them PRP O
to TO O
surpass VB O
the DT O
action NN O
of IN O
the DT O
immune JJ O
system NN O
. . O

Applying VBG O
immunohistochemistry NN O
on IN O
tissue NN O
arrays NNS O
, , O
we PRP O
compared VBD O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
expression NN O
in IN O
both DT O
sporadic JJ O
RST NN O
( -LRB- O
MSI-H NNP O
and CC O
MSS NNP O
sub-groups NNS O
) -RRB- O
and CC O
HNPCC NNP O
tumors NNS O
. . O

RST NNP O
were VBD O
chosen VBN O
because IN O
of IN O
the DT O
high JJ O
percentage NN O
of IN O
MSI-H JJ O
cases NNS O
in IN O
this DT O
specific JJ O
tumor NN O
type NN O
[43] NN O
. . O

Indeed RB O
, , O
immunohistochemical JJ O
staining NN O
with IN O
mAb NN O
showed VBD O
that IN O
HLA NNP O
class NN O
I PRP O
loss NN O
was VBD O
frequent JJ O
in IN O
the DT O
MSI-H NNP O
cases NNS O
analyzed VBD O
when WRB O
compared VBN O
to TO O
their PRP$ O
MSS NNP O
counterpart NN O
. . O

This DT O
finding NN O
supports VBZ O
the DT O
hypothesis NN O
that IN O
MSI-H NNP O
tumors NNS O
face VBP O
greater JJR O
selective JJ O
pressure NN O
to TO O
lose VB O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
expression NN O
, , O
as IN O
described VBN O
by IN O
Kloor NNP O
et NNP O
al[8] NN O
. . O

However RB O
, , O
we PRP O
have VBP O
shown VBN O
for IN O
the DT O
first JJ O
time NN O
that IN O
distinct JJ O
molecular JJ O
mechanisms NNS O
underlie VBP O
HLA NNP O
class NN O
I PRP O
loss NN O
in IN O
sporadic JJ O
MSI-H NNP O
and CC O
HNPCC NNP O
colon NN O
cancers NNS O
. . O

In IN O
the DT O
latter NN O
, , O
HLA NNP O
class NN O
I PRP O
loss NN O
was VBD O
preferentially RB O
associated VBN O
with IN O
that DT O
of IN O
β2m JJ B-NP
, , O
while IN O
in IN O
the DT O
former JJ O
HLA NNP O
class NN O
I PRP O
loss NN O
was VBD O
associated VBN O
with IN O
that DT O
of IN O
one CD O
or CC O
more JJR O
APM NNP O
components NNS O
( -LRB- O
p NN O
< JJ O
0.0001 CD O
) -RRB- O
. . O

We PRP O
investigated VBD O
the DT O
genetic JJ O
abnormalities NNS O
underlying VBG O
the DT O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
loss NN O
of IN O
expression NN O
. . O

They PRP O
included VBD O
LOH NNP O
on IN O
chromosome NN O
region NN O
6p21.3 CD O

( -LRB- O
encompassing VBG O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
and CC O
TAP JJ B-NP
genes NNS O
) -RRB- O
, , O
mutations NNS O
in IN O
APM NNP B-NP
components NNS I-NP
and CC O
mutations NNS O
in IN O
β2m NN B-NP
. . O

Loss NN O
of IN O
heterozygosity NN O
at IN O
6p21.3 CD O
was VBD O
most RBS O
prevalent JJ O
in IN O
MSS NNP O
tumors NNS O
. . O

This DT O
is VBZ O
consistent JJ O
with IN O
the DT O
observation NN O
that IN O
these DT O
tumors NNS O
frequently RB O
possess VBP O
gross JJ O
chromosomal JJ O
aberrations NNS O
and CC O
are VBP O
often RB O
aneuploid JJ O
[13] NN O
. . O

Moreover RB O
, , O
since IN O
LOH NNP O
events NNS O
in IN O
MSS NNP O
tumors NNS O
normally RB O
comprise VBP O
large JJ O
areas NNS O
of IN O
a DT O
chromosome NN O
, , O
LOH NNP O
on IN O
6p21 PRP O
might MD O
not RB O
be VB O
a DT O
direct JJ O
consequence NN O
of IN O
selective JJ O
pressure NN O
directed VBN O
to TO O
the DT O
loss NN O
of IN O
HLA NNP O
expression NN O
but CC O
instead RB O
to TO O
other JJ O
genes NNS O
within IN O
the DT O
same JJ O
chromosomal NN O
region NN O
. . O

The DT O
general JJ O
absence NN O
of IN O
LOH NNP O
in IN O
MSI-H NNP O
tumors NNS O
suggests VBZ O
that IN O
this DT O
is VBZ O
not RB O
the DT O
major JJ O
mechanism NN O
by IN O
which WDT O
the DT O
cells NNS O
abrogate IN O
HLA NNP O
class NN O
I PRP O
expression NN O
. . O

The DT O
genome NN O
's POS O
coding NN O
regions NNS O
contain VBP O
multiple JJ O
microsatellite NN O
repeats NNS O
, , O
which WDT O
are VBP O
considered VBN O
hotspots NNS O
for IN O
mutations NNS O
in IN O
mismatch NN O
repair-deficient NN O
tumors NNS O
[43] VBP O
. . O

Such JJ O
repeats NNS O
are VBP O
also RB O
present JJ O
within IN O
the DT O
exons NNS O
of IN O
the DT O
APM NNP B-NP
components NNS I-NP
, , O
β2m JJ B-NP
, , O
HLA-A NNP B-NP
and CC O
HLA-B NNP B-NP
genes NNS O
. . O

In IN O
about IN O
half NN O
of IN O
the DT O
MSI-H NNP O
cases NNS O
, , O
loss NN O
of IN O
expression NN O
of IN O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
was VBD O
concordant JJ O
with IN O
the DT O
detection NN O
of IN O
one CD O
or CC O
more JJR O
mutations NNS O
in IN O
these DT O
genes NNS O
. . O

We PRP O
have VBP O
discovered VBN O
novel NN O
mutations NNS O
in IN O
the DT O
antigen NN O
presenting VBG O
machinery NN O
genes NNS O
; : O
Tapasin NNP B-NP
, , O
Erp57 NNP B-NP
, , O
Calreticulin NNP B-NP
and CC O
Calnexin NNP B-NP
in IN O
colorectal JJ O
cancer NN O
. . O

Previous JJ O
reports NNS O
associated VBN O
the DT O
loss NN O
of IN O
HLA NNP O
class NN O
I PRP O
expression NN O
in IN O
MSI-H NNP O
tumors NNS O
with IN O
defects NNS O
on IN O
β2m NNP O
molecule NN O
[7,9] NN O
. . O

However RB O
, , O
the DT O
authors NNS O
did VBD O
not RB O
distinguish VB O
the DT O
sporadic/hereditary JJ O
nature NN O
of IN O
the DT O
tumors NNS O
that WDT O
were VBD O
studied VBN O
. . O

We PRP O
cannot MD O
exclude VB O
that IN O
the DT O
MSI-H JJ O
cases NNS O
included VBD O
in IN O
these DT O
studies NNS O
were VBD O
mainly RB O
HNPCC NNP O
tumors NNS O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Dietary NNP O
fat JJ O
and CC O
risk NN O
of IN O
colon NN O
and CC O
rectal JJ O
cancer NN O
with IN O
aberrant JJ O
MLH1 NNP B-NP
expression NN O
, , O
or CC O
genes NNS O

Abstract NN O

Objective JJ O

To TO O
investigate VB O
baseline NN O
fat JJ O
intake NN O
and CC O
the DT O
risk NN O
of IN O
colon NN O
and CC O
rectal JJ O
tumors NNS O
lacking VBG O
MLH1 FW B-NP
( -LRB- O
mutL NN O
homolog NN O
1 CD O
, , O
colon NN O
cancer NN O
, , O
nonpolyposis NN O
type NN O
2 CD O
) -RRB- O
repair NN O
gene NN O
expression NN O
and CC O
harboring NN O
mutations NNS O
in IN O
the DT O
APC NNP B-NP
(adenomatous NNP O
polyposis NN B-NP
coli NNS I-NP
) -RRB- O
tumor NN O
suppressor NN O
gene NN O
and CC O
in IN O
the DT O
KRAS NNP B-NP
(v-Ki-ras2 NNP O
Kirsten NNP B-NP
rat NN I-NP
sarcoma NN I-NP
viral NN I-NP
oncogene NN I-NP
homolog NN I-NP
) -RRB- O
oncogene NN O
. . O

Methods NNS O

After IN O
7.3 CD O
years NNS O
of IN O
follow-up NN O
of IN O
the DT O
Netherlands NNP O
Cohort NNP O
Study NNP O
( -LRB- O
n NN O
= SYM O
120,852 CD O
) -RRB- O
, , O
adjusted VBN O
incidence NN O
rate NN O
ratios NNS O
( -LRB- O
RR NN O
) -RRB- O
and CC O
95 CD O
% NN O
confidence NN O
intervals NNS O
( -LRB- O
CI) NNS O
were VBD O
computed VBN O
, , O
based VBN O
on IN O
401 CD O
colon NN O
and CC O
130 CD O
rectal JJ O
cancer NN O
patients NNS O
. . O

Results NNS O

Total JJ O
, , O
saturated VBD O
and CC O
monounsaturated VBD O
fat JJ O
were VBD O
not RB O
associated VBN O
with IN O
the DT O
risk NN O
of IN O
colon NN O
or CC O
rectal JJ O
cancer NN O
, , O
or CC O
different JJ O
molecular JJ O
subgroups NNS O
. . O

There EX O
was VBD O
also RB O
no DT O
association NN O
between IN O
polyunsaturated JJ O
fat NN O
and CC O
the DT O
risk NN O
of IN O
overall JJ O
or CC O
subgroups NNS O
of IN O
rectal JJ O
cancer NN O
. . O

Linoleic NNP O
acid NN O
, , O
the DT O
most RBS O
abundant JJ O
polyunsaturated JJ O
fatty JJ O
acid NN O
in IN O
the DT O
diet NN O
, , O
was VBD O
associated VBN O
with IN O
increased VBN O
risk NN O
of IN O
colon NN O
tumors NNS O
with IN O
only RB O
a DT O
KRAS NNP B-NP
mutation NN O
and CC O
no DT O
additional JJ O
truncating NN O
APC NNP B-NP
mutation NN O
or CC O
lack NN O
of IN O
MLH1 JJ B-NP
expression NN O
( -LRB- O
RR NNP O
= SYM O
1.41 CD O
, , O
95 CD O
% NN O
CI NNP O
1.18–1.69 CD O

for IN O
one CD O
standard JJ O
deviation NN O
( -LRB- O
i NN O
.e NN O
. . O
, , O
7.5 CD O
g/day NN O
) -RRB- O
increase NN O
in IN O
intake NN O
, , O
p-trend NN O
over IN O
the DT O
quartiles NNS O
of IN O
intake JJ O
<0.001 CD O
) -RRB- O
. . O

Linoleic NNP O
acid NN O
intake NN O
was VBD O
not RB O
associated VBN O
with IN O
risk NN O
of IN O
colon NN O
tumors NNS O
without IN O
any DT O
of IN O
the DT O
gene NN O
defects NNS O
, , O
or CC O
with IN O
tumors NNS O
harboring VBG O
aberrations NNS O
in IN O
either DT O
MLH1 NNP B-NP
or CC O
APC. NNP B-NP

Conclusion NN O

Linoleic NNP O
acid NN O
intake NN O
is VBZ O
associated VBN O
with IN O
colon NN O
tumors NNS O
with IN O
an DT O
aberrant JJ O
KRAS NNP B-NP
gene NN O
, , O
but CC O
an DT O
intact JJ O
APC NNP B-NP
gene NN O
and CC O
MLH1 CD B-NP
expression NN O
, , O
suggesting VBG O
a DT O
unique JJ O
etiology NN O
of IN O
tumors NNS O
with IN O
specific JJ O
genetic JJ O
aberrations NNS O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

These DT O
observations NNS O
and CC O
hypotheses NNS O
prompted VBD O
us PRP O
to TO O
investigate VB O
the DT O
associations NNS O
between IN O
the DT O
intake NN O
of IN O
total JJ O
fat JJ O
and CC O
different JJ O
types NNS O
of IN O
fat JJ O
and CC O
the DT O
risk NN O
of IN O
colon NN O
and CC O
rectal JJ O
tumors NNS O
lacking VBG O
MLH1 JJ B-NP
expression NN O
and CC O
with IN O
and CC O
without IN O
APC NNP B-NP
gene NN O
mutations NNS O
, , O
two CD O
early JJ O
events NNS O
in IN O
colorectal JJ O
tumorigenesis NN O
, , O
independent JJ O
of IN O
tumors NNS O
harboring VBG O
KRAS NNP B-NP
gene NN O
mutations NNS O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Materials NNS O
and CC O
methods NNS O

Study VB O
population NN O

The DT O
prospective JJ O
NLCS NNP O
was VBD O
initiated VBN O
in IN O
The DT O
Netherlands NNP O
in IN O
September NNP O
1986 CD O
. . O

The DT O
study NN O
design NN O
has VBZ O
been VBN O
described VBN O
in IN O
detail NN O
elsewhere RB O
[23] VBD O
. . O

Briefly RB O
, , O
at IN O
baseline NN O
a DT O
total NN O
of IN O
58,279 CD O
men NNS O
and CC O
62,573 CD O
women NNS O
, , O
between IN O
the DT O
ages NNS O
of IN O
55 CD O
and CC O
69 CD O
years NNS O
, , O
completed VBD O
a DT O
self-administered JJ O
food NN O
frequency NN O
and CC O
lifestyle NN O
questionnaire NN O
. . O

Incident NNP O
cancer NN O
cases NNS O
are VBP O
identified VBN O
by IN O
monitoring NN O
of IN O
the DT O
entire JJ O
cohort NN O
for IN O
cancer NN O
occurrence NN O
through IN O
annual JJ O
record NN O
linkage NN O
to TO O
the DT O
National NNP O
Cancer NNP O
Registry NNP O
(NCR NN O
) -RRB- O
, , O
consisting VBG O
of IN O
nine CD O
regional JJ O
cancer NN O
registries NNS O
throughout IN O
The DT O
Netherlands NNP O
, , O
and CC O
to TO O
PALGA NNP O
, , O
a DT O
nationwide JJ O
network NN O
and CC O
registry NN O
of IN O
histo NN O
- : O
and CC O
cytopathology NN O
[24] NN O
. . O

The DT O
NCR NNP O
and CC O
PALGA NNP O
together RB O
provide VBP O
a DT O
near JJ O
100 CD O
% NN O
coverage NN O
of IN O
the DT O
204 NNS O
municipalities NNS O
included VBD O
in IN O
the DT O
NLCS. NNP O

Accumulation NNP O
of IN O
person-time NN O
in IN O
the DT O
cohort NN O
was VBD O
estimated VBN O
through IN O
biennial JJ O
vital JJ O
status NN O
follow-up NN O
of IN O
a DT O
subcohort NN O
of IN O
3,500 CD O
men NNS O
and CC O
women NNS O
who WP O
were VBD O
randomly RB O
selected VBN O
after IN O
baseline NN O
exposure NN O
measurement NN O
[24] NN O
. . O

Cases NNS O
with IN O
prevalent JJ O
cancer NN O
other JJ O
than IN O
non-melanoma JJ O
skin NN O
cancer NN O
were VBD O
excluded VBN O
from IN O
the DT O
subcohort NN O
, , O
which WDT O
left VBD O
3,346 CD O
men NNS O
and CC O
women NNS O
for IN O
analysis NN O
next JJ O
to TO O
all DT O
colorectal JJ O
cancer NN O
cases NNS O
from IN O
the DT O
entire JJ O
cohort NN O
. . O

No DT O
subcohort NN O
members NNS O
were VBD O
lost VBN O
to TO O
follow-up JJ O
. . O

A DT O
flow NN O
diagram NN O
of IN O
subcohort NN O
members NNS O
and CC O
patients NNS O
on IN O
whom WP O
the DT O
analyses NNS O
are VBP O
based VBN O
is VBZ O
given VBN O
in IN O
Fig NNP O
. . O
1 CD O
. . O

Fig VB O
. . O
1Flow VB O
diagram NN O
of IN O
the DT O
number NN O
of IN O
subjects NNS O
on IN O
whom WP O
the DT O
final JJ O
statistical JJ O
analyses NNS O
were VBD O
based VBN O
. . O

aNetherlands NNS O
Cancer NNP O
Registry NNP O
. . O

bPathologisch JJ O
Anatomisch NNP O
Landelijk NNP O
Geautomatiseerd NNP O
Archief NNP O
. . O

cPatients NNS O
with IN O
rectosigmoid JJ O
tumors NNS O
were VBD O
not RB O
included VBN O
in IN O
the DT O
analyses NNS O
. . O

dmutL JJ O
homolog NN B-NP
1 CD I-NP
, , O
colon NN O
cancer NN O
, , O
nonpolyposis NN O
type NN O
2. VBZ O
eAdenomatous JJ O
polyposis NN B-NP
coli NNS I-NP
. . O

fMutation NN O
cluster NN O
region NN O
. . O

gv-Ki-ras2 JJ O
Kirsten NNP B-NP
rat NN I-NP
sarcoma NN I-NP
viral NN I-NP
oncogene IN I-NP
homolog NN I-NP
. . O

hPatients NNS O
with IN O
rectal JJ O
tumors NNS O
were VBD O
not RB O
included VBN O
in IN O
the DT O
analysis NN O
according VBG O
to TO O
MLH1 NNP B-NP
expression NN O

Flow JJ O
diagram NN O
of IN O
the DT O
number NN O
of IN O
subjects NNS O
on IN O
whom WP O
the DT O
final JJ O
statistical JJ O
analyses NNS O
were VBD O
based VBN O
. . O

aNetherlands NNS O
Cancer NNP O
Registry NNP O
. . O

bPathologisch JJ O
Anatomisch NNP O
Landelijk NNP O
Geautomatiseerd NNP O
Archief NNP O
. . O

cPatients NNS O
with IN O
rectosigmoid JJ O
tumors NNS O
were VBD O
not RB O
included VBN O
in IN O
the DT O
analyses NNS O
. . O

dmutL JJ O
homolog NN B-NP
1 CD I-NP
, , O
colon NN O
cancer NN O
, , O
nonpolyposis NN O
type NN O
2. VBZ O
eAdenomatous JJ O
polyposis NN B-NP
coli NNS I-NP
. . O

fMutation NN O
cluster NN O
region NN O
. . O

gv-Ki-ras2 JJ O
Kirsten NNP B-NP
rat NN I-NP
sarcoma NN I-NP
viral NN I-NP
oncogene IN I-NP
homolog NN I-NP
. . O

hPatients NNS O
with IN O
rectal JJ O
tumors NNS O
were VBD O
not RB O
included VBN O
in IN O
the DT O
analysis NN O
according VBG O
to TO O
MLH1 NNP B-NP
expression NN O

The DT O
first JJ O
2.3 CD O
years NNS O
of IN O
follow VBP O
up RP O
were VBD O
excluded VBN O
because IN O
of IN O
possible JJ O
preclinical JJ O
disease NN O
affecting VBG O
exposure NN O
status NN O
and CC O
because IN O
of IN O
incomplete JJ O
nationwide JJ O
coverage NN O
of IN O
PALGA NNP O
alone RB O
( -LRB- O
i FW O
.e FW O
. . O
, , O
not RB O
in IN O
combination NN O
with IN O
the DT O
NCR NN O
) -RRB- O
in IN O
some DT O
of IN O
the DT O
municipalities NNS O
included VBD O
in IN O
the DT O
NLCS. NNP O

Within IN O
this DT O
period NN O
, , O
83 CD O
subcohort NN O
members NNS O
deceased JJ O
or CC O
were VBD O
diagnosed VBN O
with IN O
cancer NN O
other JJ O
than IN O
non-melanoma JJ O
skin NN O
cancer NN O
, , O
leaving VBG O
3,263 CD O
subcohort NN O
members NNS O
for IN O
analysis NN O
. . O

From IN O
1989 CD O
to TO O
1994 CD O
, , O
929 CD O
incident NN O
cases NNS O
with IN O
histologically RB O
confirmed VBN O
colorectal NN O
cancer NN O
were VBD O
identified VBN O
within IN O
the DT O
entire JJ O
cohort JJ O
, , O
of IN O
whom WP O
819 PRP O
could MD O
also RB O
be VB O
linked VBN O
to TO O
a DT O
PALGA NNP O
report NN O
of IN O
the DT O
lesion NN O
. . O

The DT O
PALGA NNP O
reports NNS O
were VBD O
used VBN O
to TO O
identify VB O
and CC O
locate VB O
tumor NN O
tissues NNS O
from IN O
eligible JJ O
colorectal JJ O
cancer NN O
patients NNS O
in IN O
54 CD O
pathology NN O
laboratories NNS O
throughout IN O
the DT O
Netherlands NNP O
. . O

Cancers NNS O
were VBD O
classified VBN O
according VBG O
to TO O
site NN O
as IN O
follows VBZ O
, , O
colon NN O
: : O
cecum NN O
through IN O
sigmoid JJ O
colon NN O
( -LRB- O
ICD-O JJ O
codes NNS O
153:0 VBP O
, , O
153.1 CD O
, , O
153.2 CD O
, , O
153.3 CD O
, , O
153.4 CD O
, , O

153.5 CD O
, , O
153.6 CD O
, , O
153.7 CD O
) -RRB- O
, , O
proximal JJ O
colon NN O
( -LRB- O
ICD-O JJ O
codes NNS O
153.0, IN O
153.1 CD O
, , O
153.4 CD O
, , O

153.5 CD O
, , O
153.6) CD O
, , O
distal JJ O
colon NN O
( -LRB- O
ICD-O NN O
codes NNS O
153.2 CD O
, , O
153,3 CD O
, , O
`53.7 CD O
) -RRB- O
, , O
rectosigmoid JJ O
( -LRB- O
ICD-O NN O
code NN O
154.0) CD O
, , O
and CC O
rectum NN O
( -LRB- O
ICD-O NNP O
code NN O
154.1 CD O
) -RRB- O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

This DT O
still RB O
does VBZ O
not RB O
satisfy VB O
our PRP$ O
third JJ O
query NN O
, , O
i IN O
.e NN O
. . O
, , O
why WRB O
are VBP O
the DT O
associations NNS O
specifically RB O
confined VBN O
to TO O
this DT O
subgroup NN O
of IN O
colon NN O
cancer NN O
patients NNS O
whose WP$ O
tumors NNS O
are VBP O
characterized VBN O
by IN O
activating VBG O
KRAS NNP B-NP
mutations NNS O
, , O
and CC O
not RB O
truncating VBG O
APC NNP B-NP
mutations NNS O
or CC O
lack NN O
of IN O
MLH1 NNP B-NP
expression NN O
? . O

It PRP O
is VBZ O
speculative JJ O
, , O
but CC O
plausible JJ O
, , O
that IN O
when WRB O
KRAS NNP B-NP
is VBZ O
the DT O
only JJ O
one CD O
of IN O
the DT O
three CD O
genes NNS O
affected VBN O
, , O
the DT O
mutation NN O
may MD O
more RBR O
likely RB O
be VB O
the DT O
result NN O
of IN O
exogenous JJ O
exposure NN O
, , O
for IN O
example NN O
a DT O
relatively RB O
high JJ O
linoleic JJ O
acid NN O
intake NN O
. . O

In IN O
contrast NN O
, , O
when WRB O
a DT O
KRAS NNP B-NP
mutation NN O
co-occurs VBZ O
with IN O
a DT O
mutation NN O
in IN O
APC NNP B-NP
or CC O
, , O
although IN O
more RBR O
rarely RB O
, , O
in IN O
addition NN O
to TO O
a DT O
defective JJ O
MLH1 NN B-NP
, , O
these DT O
other JJ O
early JJ O
gene NN O
defects NNS O
also RB O
had VBD O
a DT O
role NN O
in IN O
tumor NN O
formation NN O
and CC O
may MD O
have VB O
resulted VBN O
in IN O
a DT O
mutator NN O
phenotype NN O
leading VBG O
to TO O
mutations NNS O
in IN O
other JJ O
genes NNS O
( -LRB- O
such JJ O
as IN O
the DT O
KRAS NNP B-NP
gene NN O
) -RRB- O
irrespective NN O
of IN O
exogenous JJ O
factors NNS O
. . O

Since IN O
there EX O
is VBZ O
no DT O
information NN O
on IN O
the DT O
timing NN O
of IN O
genetic JJ O
aberrations NNS O
in IN O
this DT O
type NN O
of IN O
human JJ O
studies NNS O
, , O
we PRP O
cannot MD O
verify VB O
this DT O
with IN O
our PRP$ O
data NNS O
. . O

Aberrations NNPS O
in IN O
other JJ O
genes NNS O
, , O
not RB O
available JJ O
for IN O
this DT O
study NN O
, , O
but CC O
possibly RB O
involved VBN O
in IN O
early JJ O
tumorigenesis NN O
of IN O
colorectal JJ O
cancer NN O
, , O
could MD O
not RB O
be VB O
accounted VBN O
for IN O
in IN O
analyses NNS O
and CC O
may MD O
have VB O
influenced VBN O
results NNS O
. . O

However RB O
, , O
a DT O
recent JJ O
systematic JJ O
sequence NN O
analysis NN O
of IN O
13,023 CD O
exons NNS O
in IN O
individual JJ O
colorectal NN O
cancers NNS O
showed VBD O
that IN O
the DT O
prevalence NN O
of IN O
mutations NNS O
other JJ O
than IN O
in IN O
APC NNP B-NP
, , O
KRAS NNP B-NP
and CC O
TP53 NNP B-NP
is VBZ O
rather RB O
low JJ O
[44] VB O
, , O
and CC O
mutations NNS O
in IN O
TP53 NNP B-NP
is VBZ O
not RB O
an DT O
early JJ O
event NN O
in IN O
colorectal JJ O
carcinogenesis NN O
. . O

Finally RB O
, , O
results NNS O
are VBP O
based VBN O
on IN O
relatively RB O
small JJ O
numbers NNS O
of IN O
patients NNS O
, , O
especially RB O
in IN O
the DT O
reference NN O
group NN O
of IN O
polyunsaturated VBN O
fat JJ O
or CC O
linoleic JJ O
acid NN O
intake NN O
( -LRB- O
four CD O
patients NNS O
, , O
see VBP O
Table NN O
4) NNS O
, , O
and CC O
point NN O
estimates NNS O
of IN O
RRs NNS O
for IN O
quartiles NNS O
of IN O
intake NN O
of IN O
polyunstaturated VBN O
fat JJ O
or CC O
linoleic JJ O
acid NN O
should MD O
therefore RB O
, , O
be VB O
interpreted VBN O
cautiously RB O
. . O

Nevertheless RB O
, , O
as IN O
discussed VBN O
previously RB O
, , O
the DT O
association NN O
appears VBZ O
to TO O
be VB O
robust JJ O
when WRB O
regarding VBG O
the DT O
results NNS O
for IN O
one CD O
standard JJ O
deviation NN O
increase NN O
in IN O
linoleic JJ O
acid NN O
intake NN O
( -LRB- O
based VBN O
on IN O
a DT O
total NN O
of IN O
65 CD O
patients NNS O
) -RRB- O
. . O

Therefore RB O
, , O
Breivik NNP O
and CC O
Glaudernack’s NNP O
hypothesis NN O
for IN O
distinct JJ O
carcinogens NNS O
to TO O
exert VB O
their PRP$ O
effect NN O
on IN O
two CD O
proposed JJ O
types NNS O
of IN O
genetic JJ O
instability NN O
, , O
i IN O
.e NN O
. . O
, , O
microsatellite JJ O
instability NN O
and CC O
chromosomal NN O
instability NN O
[16] NN O
, , O
may MD O
be VB O
extended VBN O
to TO O
the DT O
potential JJ O
effect NN O
of IN O
carcinogens NNS O
on IN O
more JJR O
specific JJ O
genetic JJ O
pathways NNS O
to TO O
colorectal JJ O
tumorigenesis NN O
, , O
as IN O
for IN O
example NN O
the DT O
KRAS NNP B-NP
mutated VBD O
pathway NN O
. . O

The DT O
data NNS O
from IN O
this DT O
large JJ O
prospective JJ O
cohort JJ O
study NN O
suggest VBP O
that IN O
linoleic JJ O
acid NN O
intake NN O
is VBZ O
strongly RB O
associated VBN O
with IN O
colon NN O
tumors NNS O
with IN O
an DT O
aberrant JJ O
KRAS NNP B-NP
gene NN O
, , O
but CC O
an DT O
intact JJ O
APC NNP B-NP
gene NN O
and CC O
MLH1 CD B-NP
expression NN O
. . O

Verification NNP O
in IN O
other JJ O
studies NNS O
is VBZ O
warranted VBN O
. . O

Possibly RB O
, , O
tumors NNS O
revealing VBG O
the DT O
involvement NN O
of IN O
distinct JJ O
genetic JJ O
pathways NNS O
on IN O
the DT O
basis NN O
of IN O
specific JJ O
genetic JJ O
aberrations NNS O
, , O
may MD O
have VB O
a DT O
unique JJ O
etiology NN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Discussion NN O

We PRP O
report VBP O
the DT O
analysis NN O
of IN O
the DT O
combined VBN O
miRNA/mRNA NN O
expression NN O
for IN O
the DT O
discrimination NN O
of IN O
MSI-H NNP O
versus IN O
MSS NNP O
human JJ O
colon NN O
cancer NN O
. . O

Because IN O
colorectal JJ O
tumors NNS O
characterized VBN O
by IN O
MSI NNP O
are VBP O
distinct JJ O
from IN O
MSS NNP O
tumors NNS O
in IN O
many JJ O
molecular JJ O
aspects NNS O
, , O
such JJ O
the DT O
association NN O
with IN O
the DT O
methylator NN O
phenotype NN O
, , O
which WDT O
is VBZ O
responsible JJ O
for IN O
MLH1 NNP B-NP
methylation NN O
, , O
the DT O
higher JJR O
frequency NN O
of IN O
BRAF NNP B-NP
mutations NNS O
and CC O
the DT O
lower JJR O
frequencies NNS O
of IN O
KRAS NNP B-NP
, , O
APC NNP B-NP
and CC O
TP53 NNP B-NP
mutations NNS O
, , O
MSI NNP O
and CC O
MSS NNP O
colon NN O
cancers NNS O
represent VBP O
tumors NNS O
with IN O
a DT O
different JJ O
molecular JJ O
background NN O
. . O

Thus RB O
, , O
it PRP O
is VBZ O
reasonable JJ O
that IN O
their PRP$ O
overall JJ O
gene NN O
expression NN O
pattern NN O
( -LRB- O
including VBG O
both DT O
mRNAs NNS O
and CC O
microRNAs NNS O
) -RRB- O
might MD O
be VB O
affected VBN O
by IN O
any DT O
of IN O
the DT O
above JJ O
mentioned VBN O
mechanisms NNS O
. . O

Indeed RB O
, , O
our PRP$ O
analyses NNS O
identified VBN O
14 CD O
miRNAs NNS O
and CC O
451 CD O
mRNAs NNS O
differentially RB O
expressed VBN O
between IN O
the DT O
two CD O
genetically RB O
distinct JJ O
colon NN O
cancer NN O
classes NNS O
. . O

These DT O
results NNS O
not RB O
only RB O
indicate VB O
the DT O
existence NN O
of IN O
a DT O
mRNA/miRNA NN O
gene NN O
expression NN O
profile NN O
able JJ O
to TO O
distinguish VB O
MSS NNP O
versus IN O
MSI NNP O
colon NN O
cancers NNS O
, , O
but CC O
also RB O
indicate VBP O
that IN O
the DT O
combination NN O
of IN O
miRNA/mRNA NN O
gene NN O
expression NN O
data NNS O
can MD O
distinguish VB O
microsatellite JJ O
instability NN O
status NN O
of IN O
human JJ O
colorectal NN O
cancers NNS O
better RB O
than IN O
each DT O
RNA NNP O
class NN O
independently RB O
, , O
suggesting VBG O
that IN O
the DT O
combination NN O
of IN O
mRNA NN O
and CC O
miRNA JJ O
expression NN O
may MD O
potentially RB O
represent VB O
a DT O
general JJ O
approach NN O
for IN O
improving VBG O
characterization NN O
and CC O
classification NN O
of IN O
bio-molecular JJ O
and CC O
possibly RB O
clinical JJ O
traits NNS O
associated VBN O
with IN O
human JJ O
cancer NN O
. . O

We PRP O
also RB O
examined VBD O
the DT O
prediction NN O
power NN O
of IN O
published VBN O
lists NNS O
of IN O
genes NNS O
differentially RB O
expressed VBD O
between IN O
MSI-H NNP O
and CC O
MSS NNP O
colorectal NN O
cancers NNS O
[34-36] . O
against IN O
our PRP$ O
data NNS O
set VBN O
. . O

Two CD O
published VBD O
lists NNS O
describe VBP O
differentially RB O
expressed VBN O
genes NNS O
( -LRB- O
100 CD O
genes NNS O
in IN O
the DT O
report NN O
from IN O
Di NNP O
Pietro NNP O
et NNP O
al NN O
. . O
2005 CD O
[36] NN O
and CC O
542 CD O
genes NNS O
from IN O
Banerjea NNP O
et NNP O
al NN O
. . O
2004 CD O
[35] NN O
) -RRB- O
and CC O
one CD O
is VBZ O
a DT O
short JJ O
list NN O
of IN O
predictors NNS O
( -LRB- O
9 CD O
genes NNS O
in IN O
Kruhoffer NNP O
et NNP O
al NN O
. . O
2005 CD O
[34] NN O
) -RRB- O
. . O

Although IN O
these DT O
studies NNS O
were VBD O
all DT O
performed VBN O
on IN O
Affymetrix NNP O
platforms NNS O
, , O
they PRP O
generated VBD O
only RB O
partially RB O
overlapping JJ O
results NNS O
. . O

The DT O
list NN O
of IN O
genes NNS O
from IN O
Di NNP O
Pietro NNP O
et NNP O
al NN O
. . O
[36] '' O
was VBD O
the DT O
one NN O
that WDT O
better RB O
correlated VBN O
with IN O
our PRP$ O
results NNS O
. . O

Twenty CD O
two CD O
of IN O
their PRP$ O
100 CD O
genes NNS O
were VBD O
present JJ O
in IN O
our PRP$ O
list NN O
of IN O
differentially RB O
expressed VBN O
genes NNS O
and CC O
, , O
for IN O
all PDT O
the DT O
remaining VBG O
genes NNS O
, , O
expression NN O
tendency NN O
completely RB O
matched VBD O
our PRP$ O
data NNS O
. . O

A DT O
cluster NN O
analysis NN O
of IN O
our PRP$ O
data NNS O
set VBN O
using VBG O
the DT O
100 CD O
genes NNS O
from IN O
the DT O
Di NNP O
Pietro NNP O
's POS O
paper NN O
could MD O
generate VB O
a DT O
good JJ O
, , O
although IN O
not RB O
perfect JJ O
, , O
separation NN O
between IN O
MSS NNP O
versus CC O
MSI-H NNP O
tumors NNS O
and CC O
performed VBN O
well RB O
in IN O
the DT O
prediction NN O
of IN O
our PRP$ O
samples NNS O
( -LRB- O
36 CD O
of IN O
39 CD O
samples NNS O
were VBD O
correctly RB O
classified VBN O
using VBG O
the DT O
SVM NN O
prediction NN O
) -RRB- O
( -LRB- O
data NNS O
not RB O
shown VBN O
) -RRB- O
. . O

These DT O
results NNS O
indicate VBP O
that IN O
a DT O
similar JJ O
set NN O
of IN O
genes NNS O
emerged VBD O
as IN O
differentially RB O
expressed VBN O
between IN O
MSS NNP O
and CC O
MSI-H NNP O
colon NN O
cancers NNS O
in IN O
the DT O
Di NNP O
Pietro NNP O
's POS O
and CC O
our PRP$ O
studies NNS O
, , O
with IN O
discrepancies NNS O
possibly RB O
due JJ O
to TO O
small JJ O
statistical JJ O
differences NNS O
. . O

Discrepancies NNS O
between IN O
results NNS O
obtained VBN O
with IN O
different JJ O
microarray NN O
platforms NNS O
are VBP O
not RB O
uncommon JJ O
and CC O
are VBP O
mainly RB O
determined VBN O
by IN O
differences NNS O
in IN O
microarray NN O
probe NN O
sequences NNS O
used VBD O
to TO O
detect VB O
mRNA NN O
transcripts NNS O
[37] JJ O
and CC O
in IN O
algorithms NNS O
used VBN O
for IN O
predictor NN O
genes NNS O
identification NN O
. . O

Hence RB O
, , O
the DT O
parallel NN O
between IN O
Di NNP O
Pietro NNP O
's POS O
and CC O
our PRP$ O
results NNS O
is VBZ O
significant JJ O
given VBN O
that IN O
data NNS O
were VBD O
generated VBN O
using VBG O
a DT O
different JJ O
set NN O
of IN O
samples NNS O
and CC O
a DT O
different JJ O
microarray NN O
platform NN O
, , O
and CC O
suggests VBZ O
that IN O
the DT O
commonly RB O
identified VBN O
set VBN O
of IN O
genes NNS O
may MD O
represent VB O
the DT O
most RBS O
significant JJ O
differences NNS O
between IN O
MSI-H NNP O
and CC O
MSS NNP O
colon NN O
cancers NNS O
( -LRB- O
Additional JJ O
file NN O
6 CD O
) -RRB- O
. . O

Unfortunately RB O
, , O
data NNS O
sets NNS O
from IN O
published VBN O
reports NNS O
were VBD O
not RB O
available JJ O
for IN O
cross JJ O
confirmation NN O
of IN O
our PRP$ O
list NN O
of IN O
predictive JJ O
genes NNS O
on IN O
published VBN O
microarray NN O
data NNS O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Conclusion NN O

This DT O
report NN O
provides VBZ O
the DT O
first JJ O
study NN O
on IN O
microRNA JJ O
expression NN O
in IN O
MSI NNP O
versus IN O
MSS NNP O
colon NN O
cancer NN O
. . O

We PRP O
identified VBD O
microRNAs NNS O
that WDT O
are VBP O
differentially RB O
expressed VBN O
between IN O
these DT O
two CD O
classes NNS O
of IN O
tumors NNS O
; : O
moreover RB O
, , O
the DT O
addition NN O
of IN O
microRNAs NNS O
in IN O
the DT O
molecular JJ O
classifier NN O
improves VBZ O
the DT O
separation NN O
between IN O
MSI NNP O
and CC O
MSS NNP O
cancer NN O
samples NNS O
, , O
suggesting VBG O
that IN O
the DT O
mRNA/miRNA NN O
combination NN O
could MD O
provide VB O
an DT O
improved JJ O
stratification NN O
of IN O
tumor-associated JJ O
characters NNS O
. . O

Interestingly RB O
, , O
the DT O
most RBS O
prominent JJ O
class NN O
of IN O
differentially RB O
expressed VBN O
miRNAs NN O
includes VBZ O
various JJ O
members NNS O
of IN O
the DT O
oncogenic JJ O
miR-17-92 JJ O
family NN O
, , O
suggesting VBG O
that IN O
these DT O
microRNAs NNS O
have VBP O
a DT O
role NN O
in IN O
bio-pathologic JJ O
characteristics NNS O
that IN O
distinguish VB O
MSS NNP O
versus IN O
MSI NNP O
colon NN O
cancers NNS O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Introduction NN O

Over IN O
the DT O
past JJ O
ten CD O
years NNS O
, , O
aberrant JJ O
DNA NNP O
methylation NN O
has VBZ O
been VBN O
recognized VBN O
as IN O
one CD O
of IN O
the DT O
most RBS O
common JJ O
molecular JJ O
abnormalities NNS O
in IN O
breast NN O
cancer NN O
[1,2] VBP O
. . O

A DT O
large JJ O
body NN O
of IN O
evidence NN O
implicates VBZ O
potential JJ O
hypermethylation NN O
of IN O
CpG NNP O
islands NNS O
in IN O
the DT O
loss NN O
of IN O
expression NN O
of IN O
a DT O
variety NN O
of IN O
crucial JJ O
genes NNS O
. . O

Tumor-suppressor NNP O
genes NNS O
with IN O
aberrant JJ O
methylation NN O
in IN O
breast NN O
cancers NNS O
include VBP O
ARHI NNP B-NP
[3,4] NNP O
, , O
RASSF1A NNP B-NP
[5] VBD O
, , O
HIN-1 PRP$ B-NP
[6] NN O
, , O
the DT O
retinoic JJ B-NP
acid NN I-NP
receptor NN I-NP
II NNP I-NP
gene NN O
(RARβ2 NNS O
) -RRB- O
[7] VBP O
, , O
hMLH1 JJ B-NP
[8] NN O
, , O
14-3-3 JJ B-NP
σ NN I-NP
[9] NN O
, , O
RIZ1 NNP B-NP
[10] NNP O
, , O
p16 DT B-NP
[11] NN O
, , O
the DT B-NP
E-cadherin NNP I-NP
gene NN O
[12] VBD O
, , O
PTEN NNP B-NP
[13] NNP O
, , O
and CC O
BRCA1 NNP B-NP
[14] NNP O
. . O

Methylation NNP O
in IN O
breast NN O
cancer NN O
has VBZ O
been VBN O
related VBN O
to TO O
clinical JJ O
and CC O
pathologic NN O
characteristics NNS O
evident JJ O
at IN O
presentation NN O
and CC O
clinical JJ O
outcomes NNS O
. . O

A DT O
higher JJR O
prevalence NN O
of IN O
HIN-1 NN B-NP
and CC O
RAR NN B-NP
β2 IN I-NP
methylation NN O
was VBD O
found VBN O
in IN O
the DT O
lymph NN O
nodes VBZ O
, , O
bone NN O
, , O
brain NN O
, , O
and CC O
lung NN O
metastases NNS O
than IN O
the DT O
primary JJ O
tumor NN O
[15] VBD O
. . O

Widschwendter NN O
and CC O
colleagues NNS O
[16] VBP O
reported VBN O
that IN O
the DT O
methylation NN O
of IN O
certain JJ O
genes NNS O
was VBD O
associated VBN O
with IN O
hormone NN O
receptor NN O
( -LRB- O
HR NNP B-NP
) -RRB- O
status NN O
, , O
in IN O
addition NN O
to TO O
the DT O
response NN O
to TO O
treatment NN O
with IN O
tamoxifen NNS O
. . O

A DT O
high JJ O
prevalence NN O
of IN O
PGR NNP B-NP
, , O
HSD17B4 NNP B-NP
, , O
and CC O
CDH13 NNP B-NP
methylation NN O
has VBZ O
been VBN O
associated VBN O
with IN O
HER-2/neu-positive JJ B-NP
breast NN O
cancer NN O
[17] VBP O
. . O

Methylation-specific JJ O
PCR NN O
( -LRB- O
MSP) NNP O
is VBZ O
a DT O
sensitive JJ O
assay NN O
used VBN O
to TO O
detect VB O
methylation NN O
and CC O
analyze VB O
the DT O
methylation NN O
status NN O
of IN O
genes NNS O
of IN O
interest NN O
. . O

However RB O
, , O
problems NNS O
inherent JJ O
to TO O
this DT O
assay NN O
( -LRB- O
such JJ O
as IN O
those DT O
caused VBN O
by IN O
the DT O
use NN O
of IN O
different JJ O
primers NNS O
for IN O
the DT O
methylated JJ O
or CC O
unmethylated JJ O
alleles NNS O
, , O
the DT O
gel-based JJ O
data NNS O
analysis NN O
system NN O
used VBN O
, , O
and CC O
difficulties NNS O
in IN O
quantitation NN O
) -RRB- O
have VBP O
caused VBN O
frequent JJ O
false-positive JJ O
results NNS O
in IN O
tissue-sample JJ O
analyses NNS O
. . O

A DT O
new JJ O
technique NN O
, , O
pyrosequencing VBG O
, , O
has VBZ O
been VBN O
adapted VBN O
for IN O
use NN O
in IN O
highly RB O
sensitive JJ O
and CC O
quantitative JJ O
methylation NN O
analyses NNS O
[18,19] VBP O
. . O

Pyrosequencing VBG O
methylation NN O
analysis NN O
is VBZ O
a DT O
modification NN O
of IN O
the DT O
combined VBN O
bisulfite NN O
restriction NN O
analysis NN O
( -LRB- O
COBRA NN O
) -RRB- O
that WDT O
compares VBZ O
favorably RB O
with IN O
COBRA NNP O
in IN O
sensitivity NN O
, , O
specificity NN O
, , O
and CC O
robustness NN O
[18] NN O
. . O

Tost NNP O
and CC O
colleagues NNS O
also RB O
confirmed VBD O
that IN O
the DT O
pyrosequencing NN O
technique NN O
is VBZ O
quantitative JJ O
, , O
amenable JJ O
to TO O
the DT O
analysis NN O
of IN O
bisulfite-treated JJ O
DNA NN O
derived VBN O
from IN O
paraffin-embedded JJ O
tissue NN O
samples NNS O
, , O
highly RB O
reproducible JJ O
, , O
and CC O
accurate JJ O
[19] NN O
. . O

Bisulfite NNP O
pyrosequencing NN O
has VBZ O
been VBN O
used VBN O
in IN O
clinical JJ O
trials NNS O
of IN O
hypomethylating VBG O
drug NN O
treatment NN O
and CC O
provides VBZ O
accurate JJ O
and CC O
reliable JJ O
results NNS O
[20] VBP O
. . O

To TO O
investigate VB O
methylation NN O
profiles NNS O
in IN O
breast NN O
cancer NN O
cells NNS O
, , O
we PRP O
used VBD O
bisulfite JJ O
pyrosequencing VBG O
to TO O
screen VB O
12 CD O
known VBN O
tumor-suppressor JJ O
genes NNS O
in IN O
90 CD O
pairs NNS O
of IN O
breast NN O
cancers NNS O
and CC O
normal JJ O
tissues NNS O
. . O

Although IN O
all DT O
12 CD O
genes NNS O
had VBD O
been VBN O
reported VBN O
to TO O
exhibit VB O
hypermethylation NN O
in IN O
a DT O
fraction NN O
of IN O
breast NN O
cancer NN O
cases NNS O
, , O
our PRP$ O
assays WDT O
provided VBD O
a DT O
comprehensive JJ O
survey NN O
of IN O
their PRP$ O
methylation NN O
status NN O
and CC O
confirmed VBD O
that IN O
five CD O
genes NNS O
could MD O
be VB O
useful JJ O
in IN O
defining VBG O
a DT O
methylation NN O
profile NN O
in IN O
breast NN O
cancer NN O
cells NNS O
. . O

Our PRP$ O
findings NNS O
also RB O
suggest VBP O
that IN O
two CD O
panels NNS O
of IN O
methylation NN O
profiles NNS O
correlated VBN O
, , O
either CC O
positively RB O
or CC O
negatively RB O
, , O
to TO O
HR VB B-NP
status NN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Statistical JJ O
methods NNS O
and CC O
analysis NN O

In IN O
the DT O
studied VBN O
cohort NN O
, , O
adjacent JJ O
normal JJ O
breast NN O
tissue NN O
was VBD O
taken VBN O
from IN O
each DT O
of IN O
90 CD O
patients NNS O
during IN O
surgery NN O
. . O

Taking VBG O
advantage NN O
of IN O
paired JJ O
normal/tumor NN O
samples NNS O
in IN O
this DT O
study NN O
, , O
we PRP O
chose VBD O
the DT O
value NN O
of IN O
normal JJ O
samples NNS O
as IN O
the DT O
reference NN O
. . O

If IN O
using VBG O
the DT O
sample NN O
mean NN O
plus CC O
two CD O
times NNS O
the DT O
standard JJ O
deviation NN O
of IN O
the DT O
pooled JJ O
normal JJ O
samples NNS O
( -LRB- O
and CC O
a DT O
minimum NN O
of IN O
10 CD O
% NN O
methylation NN O
) -RRB- O
as IN O
a DT O
cut-off JJ O
point NN O
, , O
there EX O
is VBZ O
> RB O
97 CD O
% NN O
probability NN O
that IN O
the DT O
methylation NN O
level NN O
for IN O
a DT O
normal JJ O
tissue NN O
will MD O
be VB O
lower JJR O
than IN O
the DT O
cut-off JJ O
point NN O
. . O

It PRP O
is VBZ O
reasonable JJ O
to TO O
assume VB O
that IN O
a DT O
value NN O
larger JJR O
than IN O
the DT O
cut-off JJ O
point NN O
is VBZ O
likely JJ O
to TO O
be VB O
abnormal JJ O
( -LRB- O
or CC O
positive JJ O
) -RRB- O
. . O

Panels NNS O
of IN O
genes NNS O
, , O
that WDT O
is VBZ O
to TO O
say VB O
, , O
HIN-1/RASSF1A NNP B-NP
and CC O
RIL/CDH13 NNP B-NP
were VBD O
considered VBN O
positive JJ O
if IN O
both DT O
markers NNS O
in IN O
each DT O
panel NN O
were VBD O
positive JJ O
. . O

Descriptive NNP O
analyses NNS O
were VBD O
performed VBN O
first RB O
for IN O
exploratory JJ O
purposes NNS O
. . O

Pair-wise NN O
scatter NN O
plots NNS O
are VBP O
presented VBN O
to TO O
show VB O
the DT O
correlations NNS O
among IN O
the DT O
genes NNS O
methylated VBD O
. . O

Heat NN O
maps NNS O
were VBD O
plotted VBN O
to TO O
show VB O
levels NNS O
of IN O
gene NN O
expression NN O
or CC O
methylation NN O
using VBG O
hierarchical JJ O
clustering NN O
to TO O
visually RB O
represent VB O
the DT O
association NN O
of IN O
different JJ O
genes NNS O
or CC O
samples NNS O
by IN O
histopathologic NN O
tumor NN O
characteristics NNS O
( -LRB- O
ERs NNS B-NP
, , O
PRs NNS B-NP
, , O
and CC O
HER-2/neu NNP B-NP
) -RRB- O
. . O

Chi-square NN O
or CC O
Fisher NNP O
's POS O
exact JJ O
test NN O
were VBD O
used VBN O
to TO O
assess VB O
the DT O
dependence NN O
between IN O
two CD O
categorical JJ O
variables NNS O
. . O

Pearson NNP O
's POS O
correlation NN O
coefficient NN O
was VBD O
used VBN O
to TO O
assess VB O
the DT O
relationship NN O
between IN O
two CD O
continuous JJ O
variables NNS O
. . O

The DT O
Wilcoxon NNP O
rank-sum NN O
test NN O
was VBD O
used VBN O
to TO O
compare VB O
either DT O
continuous JJ O
or CC O
categorical JJ O
variables NNS O
between IN O
two CD O
groups NNS O
. . O

Analysis NN O
of IN O
variance NN O
( -LRB- O
ANOVA NNP O
) -RRB- O
was VBD O
applied VBN O
to TO O
compare VB O
the DT O
values NNS O
of IN O
gene NN O
methylation NN O
with IN O
tumor NN O
characteristics NNS O
. . O

Multivariate VB O
logistic JJ O
regression NN O
was VBD O
used VBN O
to TO O
assess VB O
the DT O
ability NN O
of IN O
various JJ O
levels NNS O
of IN O
gene NN O
methylation NN O
to TO O
predict VB O
the DT O
ER NNP B-NP
, , O
PR NNP B-NP
, , O
HR NNP B-NP
, , O
or CC O
HER-2/neu NNP B-NP
status NN O
. . O

All DT O
reported VBN O
p NN O
values NNS O
are VBP O
two-sided JJ O
and CC O
considered VBN O
statistically RB O
significant JJ O
if IN O
p NN O
< RB O
0.05 CD O
. . O

Analyses NNS O
were VBD O
performed VBN O
using VBG O
S-PLUS NNP O
2000 CD O
software NN O
( -LRB- O
Insightful NNP O
Corp. NNP O
, , O
Seattle NNP O
, , O
WA NNP O
, , O
USA NNP O
) -RRB- O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Discussion NN O

Although IN O
a DT O
large JJ O
body NN O
of IN O
evidence NN O
has VBZ O
demonstrated VBN O
that IN O
aberrant JJ O
DNA NNP O
methylation NN O
has VBZ O
an DT O
important JJ O
role NN O
in IN O
breast NN O
carcinogenesis NN O
, , O
variation NN O
in IN O
the DT O
data NNS O
is VBZ O
still RB O
a DT O
problem NN O
. . O

In IN O
this DT O
study NN O
, , O
we PRP O
used VBD O
bisulfite JJ O
pyrosequencing VBG O
to TO O
quantitate VB O
the DT O
methylation NN O
of IN O
12 CD O
known VBN O
tumor-suppressor JJ O
genes NNS O
in IN O
breast NN O
cancers NNS O
. . O

To TO O
avoid VB O
contamination NN O
with IN O
normal JJ O
tissues NNS O
, , O
we PRP O
isolated VBD O
breast NN O
cancer NN O
cells NNS O
by IN O
microdissection NN O
and CC O
compared VBN O
levels NNS O
of IN O
methylation NN O
with IN O
those DT O
in IN O
normal JJ O
breast NN O
epithelial NN O
cells NNS O
from IN O
the DT O
same JJ O
patients NNS O
. . O

Bisulfite NNP O
pyrosequencing VBG O
provided VBN O
sensitive JJ O
and CC O
reproducible JJ O
measurements NNS O
. . O

The DT O
variation NN O
between IN O
the DT O
different JJ O
assays . O
was VBD O
< RB O
6 CD O
% NN O
. . O

Our PRP$ O
data NNS O
confirmed VBD O
that IN O
RIL NNP B-NP
, , O
HIN-1 NNP B-NP
, , O
RASSF1A NNP B-NP
, , O
CDH13 NNP B-NP
, , O
and CC O
RARβ2 NNP B-NP
were VBD O
frequently RB O
methylated VBN O
in IN O
breast NN O
cancers NNS O
but CC O
not RB O
in IN O
normal JJ O
breast NN O
tissues NNS O
. . O

The DT O
other JJ O
six CD O
genes NNS O
were VBD O
not RB O
highly RB O
methylated VBN O
in IN O
breast NN O
cancers NNS O
or CC O
methylated VBN O
in IN O
either DT O
malignant JJ O
and CC O
normal JJ O
breast NN O
tissues NNS O
; : O
ARHI NN B-NP
, , O
as IN O
an DT O
imprinted JJ O
gene NN O
, , O
has VBZ O
a DT O
different JJ O
methylation NN O
status NN O
. . O

All PDT O
the DT O
inconsistencies NNS O
indicate VBP O
that IN O
these DT O
seven CD O
genes NNS O
are VBP O
unsuitable JJ O
for IN O
methylation NN O
profile NN O
studies NNS O
. . O

In IN O
the DT O
past NN O
, , O
methylation NN O
data NNS O
have VBP O
been VBN O
correlated VBN O
to TO O
clinical JJ O
pathologic NN O
parameters NNS O
, , O
to TO O
clarify VB O
the DT O
role NN O
of IN O
methylation NN O
in IN O
breast NN O
carcinogenesis NN O
. . O

Our PRP$ O
most RBS O
interesting JJ O
finding NN O
was VBD O
a DT O
correlation NN O
between IN O
gene NN O
methylation NN O
and CC O
the DT O
HR NN O
status NN O
. . O

Methylation NNP O
in IN O
breast NN O
cancer NN O
has VBZ O
already RB O
been VBN O
connected VBN O
to TO O
hormone NN O
regulation NN O
, , O
but CC O
the DT O
correlation NN O
is VBZ O
not RB O
clear JJ O
yet RB O
. . O

Campan NNP O
and CC O
colleagues NNS O
[26] VBP O
reviewed VBN O
the DT O
DNA NNP O
methylation NN O
profiles NNS O
of IN O
breast NN O
, , O
endometrial JJ O
, , O
ovarian JJ O
, , O
and CC O
proximal JJ O
colon NN O
cancers NNS O
but CC O
did VBD O
not RB O
find VB O
evidence NN O
for IN O
global JJ O
hormone-specific JJ O
DNA NN O
methylation NN O
alterations NNS O
. . O

Widschwendter NN O
and CC O
colleagues NNS O
[16] VBP O
reported VBN O
significant JJ O
differences NNS O
in IN O
the DT O
HR NN O
status NN O
between IN O
clusters NNS O
of IN O
DNA NNP O
methylation NN O
profiles NNS O
. . O

Their PRP$ O
results NNS O
suggested VBD O
the DT O
existence NN O
of IN O
an DT O
interaction NN O
between IN O
DNA NNP O
methylation NN O
and CC O
HR NNP O
biology NN O
in IN O
breast NN O
cancer NN O
cells NNS O
. . O

In IN O
our PRP$ O
own JJ O
study NN O
, , O
we PRP O
found VBD O
that IN O
the DT O
ER NN B-NP
status NN O
was VBD O
positively RB O
associated VBN O
with IN O
the DT O
methylation NN O
of IN O
HIN-1 NNP B-NP
and CC O
RASSF1A NNP B-NP
but CC O
negatively RB O
correlated VBN O
to TO O
the DT O
methylation NN O
of IN O
RIL. NNP B-NP

In IN O
addition NN O
, , O
the DT O
PR NN B-NP
status NN O
was VBD O
positively RB O
associated VBN O
with IN O
the DT O
methylation NN O
of IN O
HIN-1 NN B-NP
and CC O
negatively RB O
associated VBN O
with IN O
the DT O
methylation NN O
of IN O
CDH13 NNP B-NP
. . O

Moreover RB O
, , O
if IN O
data NNS O
from IN O
the DT O
methylation NN O
of IN O
individual JJ O
genes NNS O
were VBD O
combined VBN O
into IN O
two CD O
panels NNS O
, , O
methylation NN O
of IN O
the DT O
HIN-1/RASSF1A JJ B-NP
panel NN O
strongly RB O
predicted VBD O
the DT O
expression NN O
of IN O
ERs NNS B-NP
, , O
PRs NNS B-NP
, , O
and CC O
HRs NNP B-NP
and CC O
methylation NN O
of IN O
the DT O
RIL/CDH13 JJ B-NP
panel NN O
strongly RB O
predicted VBD O
the DT O
negative JJ O
expression NN O
of IN O
ERs NNS B-NP
, , O
PRs NNS B-NP
, , O
and CC O
HRs NNP B-NP
. . O

The DT O
status NN O
of IN O
ERs NNS B-NP
, , O
PRs NNS B-NP
, , O
and CC O
HRs NNP B-NP
has VBZ O
been VBN O
recognized VBN O
as IN O
an DT O
important JJ O
prognostic JJ O
factor NN O
in IN O
patients NNS O
with IN O
breast NN O
cancer NN O
, , O
in IN O
addition NN O
to TO O
a DT O
predictive JJ O
marker NN O
for IN O
the DT O
response NN O
to TO O
treatment NN O
with IN O
endocrine JJ O
therapy NN O
. . O

The DT O
presence NN O
of IN O
ERs NNS B-NP
and/or CC O
PRs NNS B-NP
is VBZ O
predictive JJ O
of IN O
the DT O
response NN O
to TO O
treatment NN O
with IN O
the DT O
antiestrogen NN O
tamoxifen JJ O
[27] NN O
. . O

ER NNP B-NP
and CC O
PR NNP B-NP
expression NN O
patterns NNS O
are VBP O
heavily RB O
influenced VBN O
by IN O
changes NNS O
in IN O
the DT O
chromatin NN O
structure NN O
during IN O
transcription NN O
. . O

Indeed RB O
, , O
both CC O
the DT O
predominant JJ O
mammalian JJ O
DNA NN O
methyltransferase NN O
and CC O
histone NN O
deacetylases NNS O
have VBP O
crucial JJ O
roles NNS O
in IN O
maintaining VBG O
transcriptionally RB O
repressive JJ O
chromatin NN O
by IN O
forming VBG O
suppressive JJ O
complexes NNS O
at IN O
replication NN O
foci NNS O
[28] VBP O
. . O

Our PRP$ O
current JJ O
studies NNS O
provide VBP O
evidence NN O
that IN O
epigenetic JJ O
changes NNS O
are VBP O
tightly RB O
connected VBN O
with IN O
HR NNP B-NP
regulation NN O
in IN O
breast NN O
cancer NN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Tumors NNS O
negatively RB O
stained VBN O
for IN O
HCA2 NNP O
and/or CC O
HC10 PRP O
were VBD O
stained VBN O
for IN O
mismatch NN O
repair NN O
proteins VBZ O
MLH1 NNP B-NP
and CC O
PMS2 NNP B-NP
. . O

MLH1 NNP B-NP
and CC O
PMS2 NNP B-NP
are VBP O
deficient JJ O
in IN O
sporadic JJ O
MSI NNP O
tumors NNS O
. . O

Therefore RB O
, , O
the DT O
expression NN O
of IN O
these DT O
proteins NNS O
was VBD O
used VBN O
to TO O
differentiate JJ O
MSI NNP O
and CC O
MSS NNP O
rectal NN O
cancers NNS O
. . O

Tissue NNP O
stromal JJ O
cells NNS O
, , O
normal JJ O
epithelium NN O
or CC O
lymph NN O
follicles NNS O
served VBD O
as IN O
positive JJ O
internal JJ O
controls NNS O
when WRB O
analyzing VBG O
MLH1 NNP B-NP
, , O
PMS2 NNP B-NP
expression NN O
. . O

The DT O
expression NN O
of IN O
MLH1 NNP B-NP
and CC O
PMS2 NNP B-NP
was VBD O
scored VBN O
positive JJ O
if IN O
tumor NN O
cells NNS O
showed VBD O
expression NN O
, , O
and CC O
negative JJ O
if IN O
tumor NN O
cells NNS O
showed VBD O
no DT O
expression NN O
of IN O
either DT O
MLH1 NNP B-NP
or CC O
PMS2 NNP B-NP
, , O
provided VBD O
that IN O
and CC O
tissue NN O
stromal JJ O
cells NNS O
did VBD O
show VB O
expression NN O
, , O
indicating VBG O
microsatellite NN O
stable NN O
( -LRB- O
MSS) NNP O
and CC O
microsatellite JJ O
instable JJ O
( -LRB- O
MSI) NN O
tumors NNS O
, , O
respectively RB O
[7] CD O
. . O

Statistical NNP O
analyses NNS O

All DT O
analyses NNS O
were VBD O
performed VBN O
with IN O
SPSS NNP O
statistical JJ O
software NN O
(version NN O
12.0 CD O
for IN O
Windows NNP O
, , O
SPSS NNP O
Inc NNP O
, , O
Chicago NNP O
, , O
USA NNP O
) -RRB- O
. . O

Mann– NNP O
Whitney NNP O
U, NNP O
t NN O
test NN O
and CC O
χ2-tests NNS O
were VBD O
used VBN O
to TO O
compare VB O
variables NNS O
. . O

Kaplan–Meier NNP O
analyses NNS O
were VBD O
performed VBN O
to TO O
analyze VB O
patient NN O
survival NN O
. . O

The DT O
entry NN O
date NN O
for IN O
the DT O
survival NN O
analyses NNS O
was VBD O
the DT O
time NN O
of IN O
surgery NN O
of IN O
the DT O
primary JJ O
tumor NN O
. . O

Events NNS O
for IN O
time NN O
to TO O
local JJ O
recurrence NN O
, , O
distant JJ O
recurrence NN O
, , O
cancer-specific JJ O
survival NN O
, , O
disease-free JJ O
and CC O
overall JJ O
survival NN O
were VBD O
defined VBN O
as IN O
follows VBZ O
: : O
from IN O
time NN O
of IN O
surgery NN O
to TO O
time NN O
of IN O
local JJ O
disease NN O
relapse NN O
( -LRB- O
for IN O
local JJ O
recurrence NN O
) -RRB- O
, , O
time NN O
of IN O
distant JJ O
disease NN O
relapse NN O
( -LRB- O
for IN O
distant JJ O
recurrence NN O
) -RRB- O
, , O
time NN O
of IN O
disease NN O
relapse NN O
or CC O
death NN O
by IN O
disease NN O
( -LRB- O
for IN O
cancer NN O
specific JJ O
survival NN O
) -RRB- O
, , O
time NN O
of IN O
disease NN O
relapse NN O
or CC O
death NN O
( -LRB- O
for IN O
disease NN O
free JJ O
survival NN O
) -RRB- O
and CC O
time NN O
of IN O
death NN O
, , O
respectively RB O
( -LRB- O
for IN O
overall JJ O
survival NN O
) -RRB- O
. . O

Non-irradiated JJ O
and CC O
irradiated JJ O
patients NNS O
were VBD O
first JJ O
separately RB O
analyzed VBN O
in IN O
univariate JJ O
analysis NN O
and CC O
second JJ O
, , O
variables NNS O
with IN O
a DT O
P NNP O
value NN O
of IN O
<0.10 CD O
in IN O
the DT O
univariate JJ O
analyses NNS O
were VBD O
subjected VBN O
to TO O
a DT O
multivariate JJ O
analysis NN O
. . O

Multivariate JJ O
analysis NN O
was VBD O
performed VBN O
on IN O
the DT O
whole JJ O
group NN O
of IN O
irradiated JJ O
and CC O
non-irradiated JJ O
patients NNS O
with IN O
the DT O
following JJ O
variables NNS O
: : O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
, , O
randomization NN O
for IN O
radiotherapy NN O
, , O
TNM NNP O
and CC O
circumferential JJ O
margin NN O
. . O

Cox NNP O
’ , O
regression NN O
analyses NNS O
were VBD O
used VBN O
to TO O
calculate VB O
hazard NN O
ratios NNS O
( -LRB- O
HR NN O
) -RRB- O
with IN O
95 CD O
% NN O
confidence NN O
intervals NNS O
( -LRB- O
CI) NNP O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Most JJS O
rectal JJ O
tumors NNS O
have VBP O
high JJ O
numbers NNS O
of IN O
tumor NN O
cells NNS O
positive JJ O
for IN O
HCA2 NNP O
or CC O
HC10 CD O

Numbers NNS O
( -LRB- O
N NNP O
) -RRB- O
of IN O
patients NNS O
are VBP O
indicated VBN O
with IN O
percentages NNS O
shown VBN O
in IN O
parentheses NNS O
, , O
showing VBG O
: : O
expression NN O
of IN O
HCA2 NNP O
and CC O
HC10 CD O
in IN O
more JJR O
than IN O
50 CD O
% NN O
of IN O
the DT O
tumor NN O
cells NNS O
( -LRB- O
high JJ O
) -RRB- O
, , O
expression NN O
in IN O
less JJR O
than IN O
50 CD O
% NN O
of IN O
the DT O
tumor NN O
cells NNS O
( -LRB- O
low JJ O
) -RRB- O
and CC O
total JJ O
absence NN O
( -LRB- O
absence NN O
) -RRB- O

Examples NNS O
of IN O
HCA2 NNP O
and CC O
HC10 NNP O
immunohistochemical JJ O
staining NN O
of IN O
rectal JJ O
tumors NNS O
; : O
a–c VBN O
HCA2 NNP O
, , O
d–f NN O
HC10 IN O
expression NN O
. . O

a DT O
, , O
d VBN O
Expression NNP O
of IN O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
in IN O
>50 CD O
% NN O
tumor NN O
cells NNS O
; : O
b NN O
, , O
e NN O
expression NN O
of IN O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
in IN O
<50 CD O
% NN O
tumor NN O
cells NNS O
; : O
c NNS O
, , O
f NN O
epithelial NN O
cells NNS O
show VBP O
total JJ O
absence NN O
for IN O
HCA2 CD O
or CC O
HC10 CD O
and CC O
only RB O
stromal JJ O
and CC O
infiltrative JJ O
cells NNS O
show VBP O
positive JJ O
staining NN O
for IN O
HCA2 CD O
or CC O
HC10 CD O
; : O
Original NNP O
magnification NN O
×20 . O

Analysis NN O
of IN O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
expression NN O
in IN O
rectal NN O
tumors NNS O

Together RB O
, , O
the DT O
results NNS O
obtained VBN O
with IN O
HCA2 NNP O
and CC O
HC10 NNP O
are VBP O
expected VBN O
to TO O
reflect VB O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
expression NN O
in IN O
rectal JJ O
cancer NN O
. . O

In IN O
a DT O
group NN O
of IN O
64 CD O
tumors NNS O
it PRP O
was VBD O
studied VBN O
whether IN O
an DT O
additional JJ O
staining NN O
for IN O
β2 CD O
m NN O
would MD O
better RB O
define VB O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
expression NN O
. . O

The DT O
results NNS O
of IN O
the DT O
addition NN O
of IN O
β2 DT O
m NN O
to TO O
HCA2 NNP O
and CC O
HC10 PRP O
were VBD O
comparable JJ O
to TO O
those DT O
obtained VBN O
with IN O
HCA2 NNP O
and CC O
HC10 NNP O
, , O
i IN O
.e NN O
. . O

only RB O
1 CD O
of IN O
64 CD O
tumors NNS O
was VBD O
differently RB O
classified VBN O
. . O

Therefore RB O
, , O
β2 DT O
m NN O
was VBD O
not RB O
scored VBN O
in IN O
the DT O
whole JJ O
cohort NN O
and CC O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
expression NN O
was VBD O
assessed VBN O
by IN O
combining VBG O
HCA2 NNP O
and CC O
HC10 NNP O
. . O

A DT O
total NN O
of IN O
406 CD O
( -LRB- O
85 CD O
% NN O
) -RRB- O
irradiated VBN O
and CC O
445 CD O
( -LRB- O
84 CD O
% NN O
) -RRB- O
non-irradiated JJ O
tumors NNS O
exhibited JJ O
expression NN O
of IN O
at IN O
least JJS O
one CD O
of IN O
the DT O
two CD O
markers NNS O
showing VBG O
>50 CD O
% NN O
positive JJ O
staining NN O
of IN O
all DT O
tumor NN O
cells NNS O
( -LRB- O
further RB O
referred VBN O
to TO O
as IN O
‘the DT O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
high JJ O
expression NN O
group NN O
’ NN O
) -RRB- O
. . O

A DT O
total NN O
of IN O
70 CD O
( -LRB- O
15 CD O
% NN O
) -RRB- O
irradiated VBN O
and CC O
87 CD O
( -LRB- O
16 CD O
% NN O
) -RRB- O
non-irradiated JJ O
tumors NNS O
showed VBD O
reduced VBN O
numbers NNS O
( -LRB- O
≤50 CD O
% NN O
) -RRB- O
of IN O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
positive JJ O
tumor NN O
cells NNS O
. . O

Only RB O
3 CD O
( -LRB- O
0.6 CD O
% NN O
) -RRB- O
irradiated VBN O
tumors NNS O
and CC O
8 CD O
( -LRB- O
1.5 CD O
% NN O
) -RRB- O
non-irradiated JJ O
tumors NNS O
showed VBD O
total JJ O
loss NN O
of IN O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
( -LRB- O
negative JJ O
for IN O
both DT O
HCA2 NNP O
and CC O
HC10 NNP O
) -RRB- O
. . O

Survival JJ O
results NNS O
of IN O
patients NNS O
with IN O
total JJ O
absence NN O
of IN O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
on IN O
tumor NN O
cells NNS O
did VBD O
not RB O
show VB O
significant JJ O
difference NN O
from IN O
patients NNS O
with IN O
reduced JJ O
numbers NNS O
of IN O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
positive JJ O
tumor NN O
cells NNS O
. . O

Therefore RB O
, , O
these DT O
groups NNS O
were VBD O
combined VBN O
and CC O
will MD O
be VB O
further RB O
referred VBN O
to TO O
as IN O
‘the DT O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
low-expression NN O
group’ NN O
. . O

The DT O
complete JJ O
results NNS O
are VBP O
shown VBN O
in IN O
Table NN O
2. . O

The DT O
number NN O
of IN O
patients NNS O
in IN O
the DT O
group NN O
of IN O
the DT O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
high-expression PRP$ O
group NN O
and CC O
the DT O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
low-expression NN O
group NN O
was VBD O
equally RB O
distributed VBN O
between IN O
irradiated JJ O
and CC O
non-irradiated JJ O
tumors NNS O
( -LRB- O
χ2 CD O
= SYM O
0.519 CD O
, , O
P NNP O
= SYM O
0.471 CD O
) -RRB- O
, , O
indicating VBG O
that IN O
irradiation NN O
had VBD O
no DT O
effect NN O
on IN O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
expression NN O
in IN O
these DT O
patients NNS O
. . O

Table NN O
2Expression CD O
of IN O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
in IN O
rectal JJ O
cancer NN O
using VBG O
HCA2 NNP O
and CC O
HC10 CD O
antibodiesHCA2HC10HLA JJ O
class NN O
IHigh IN O
( -LRB- O
N)Low NN O
+ NN O
absence NN O
( -LRB- O
N)N FW O
( -LRB- O
%)IrradiatedHigh NN O
( -LRB- O
N)27037406 FW O
( -LRB- O
85 CD O
% NN O
)Low JJ O
+ NN O
absence NN O
( -LRB- O
N)997070 FW O
( -LRB- O
15 CD O
% NN O
) -RRB- O
Non-irradiatedHigh FW O
( -LRB- O
N)27732445 NN O
( -LRB- O
84 CD O
% NN O
)Low IN O
+ JJ O
absence NN O
( -LRB- O
N)1368787 FW O
( -LRB- O
16 CD O
% NN O
)Expression NN O
of IN O
results NNS O
of IN O
HCA2 NNP O
and CC O
HC10 CD O
staining NN O
in IN O
a DT O
cross NN O
table NN O
for IN O
numbers NNS O
( -LRB- O
N NNP O
) -RRB- O
of IN O
irradiated JJ O
and CC O
non-irradiated JJ O
patients NNS O
; : O
expression NN O
of IN O
HCA2 NNP O
and CC O
HC10 CD O
in IN O
more JJR O
than IN O
50 CD O
% NN O
of IN O
the DT O
tumor NN O
cells NNS O
( -LRB- O
high JJ O
) -RRB- O
versus JJ O
expression NN O
in IN O
less JJR O
than IN O
50 CD O
% NN O
of IN O
the DT O
tumor NN O
cells NNS O
( -LRB- O
low JJ O
) -RRB- O
is VBZ O
shown VBN O
. . O

A DT O
significant JJ O
correlation NN O
was VBD O
noted VBN O
between IN O
HCA2 NNP O
and CC O
HC10 NNP O
staining NN O
for IN O
both DT O
irradiated JJ O
( -LRB- O
χ2 CD O
= SYM O
53.947 CD O
, , O

P NNP O
< JJ O
0.001 CD O
) -RRB- O
and CC O
non-irradiated JJ O
patients NNS O
( -LRB- O
χ2 NNP O
= SYM O
61.257 CD O
, , O

P NNP O
< JJ O
0.001 CD O
) -RRB- O
. . O

The DT O
right JJ O
side NN O
of IN O
the DT O
table NN O
displays VBZ O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
expression NN O
estimated VBN O
on IN O
HCA2 NNP O
and CC O
HC10 NNP O
expression NN O
. . O

A DT O
total NN O
of IN O
406 CD O
( -LRB- O
85 CD O
% NN O
) -RRB- O
irradiated VBN O
and CC O
445 CD O
( -LRB- O
84 CD O
% NN O
) -RRB- O
non-irradiated JJ O
tumors NNS O
exhibited JJ O
expression NN O
of IN O
at IN O
least JJS O
one CD O
of IN O
the DT O
two CD O
markers NNS O
showing VBG O
>50 CD O
% NN O
positive JJ O
staining NN O
of IN O
all DT O
tumor NN O
cells NNS O
. . O

A DT O
total NN O
of IN O
70 CD O
( -LRB- O
15 CD O
% NN O
) -RRB- O
irradiated VBN O
and CC O
88 CD O
( -LRB- O
16 CD O
% NN O
) -RRB- O
non-irradiated JJ O
tumors NNS O
showed VBD O
reduced VBN O
numbers NNS O
( -LRB- O
≤50 CD O
% NN O
) -RRB- O
of IN O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
positive JJ O
tumor NN O
cells NNS O
. . O

The DT O
number NN O
of IN O
patients NNS O
in IN O
the DT O
group NN O
of IN O
the DT O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
high JJ O
expression NN O
group NN O
and CC O
the DT O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
low JJ O
expression NN O
group NN O
was VBD O
equally RB O
distributed VBN O
between IN O
irradiated JJ O
and CC O
non-irradiated JJ O
tumors NNS O
( -LRB- O
χ2 CD O
= SYM O
0.519 CD O
, , O
P NNP O
= SYM O
0.471 CD O
) -RRB- O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Examples NNS O
of IN O
Kaplan–Meier NNP O
curves NNS O
showing VBG O
overall JJ O
survival NN O
and CC O
cancer NN O
specific JJ O
survival NN O
for IN O
irradiated JJ O
and CC O
non-irradiated JJ O
patients NNS O
( -LRB- O
a–d JJ O
) -RRB- O
. . O

Kaplan–Meier NNP O
curves NNS O
for IN O
overall JJ O
survival NN O
( -LRB- O
a DT O
, , O
b NN O
) -RRB- O
and CC O
cancer NN O
specific JJ O
survival NN O
( -LRB- O
c NN O
, , O
d VBN O
) -RRB- O
; : O
curves NNS O
show VBP O
prognosis NN O
for IN O
non-irradiated JJ O
( -LRB- O
a DT O
, , O
c NN O
) -RRB- O
and CC O
irradiated JJ O
patients NNS O
( -LRB- O
b NN O
, , O
d VBN O
) -RRB- O
for IN O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
expression NN O
in IN O
more JJR O
than IN O
50 CD O
% NN O
of IN O
the DT O
tumor NN O
cells NNS O
( -LRB- O
high JJ O
) -RRB- O
versus JJ O
expression NN O
in IN O
less JJR O
than IN O
50 CD O
% NN O
of IN O
the DT O
tumor NN O
cells NNS O
( -LRB- O
low JJ O
) -RRB- O
. . O

P NNP O
value NN O
is VBZ O
based VBN O
on IN O
univariate JJ O
log NN O
rank NN O
analyses NNS O

Both DT O
irradiated JJ O
and CC O
non-irradiated JJ O
patients NNS O
with IN O
high JJ O
expression NN O
of IN O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
have VBP O
a DT O
better JJR O
overall JJ O
, , O
and CC O
disease NN O
free JJ O
survival NN O

Survival NNP O
and CC O
recurrence NN O
rates NNS O
indicated VBD O
in IN O
percentages NNS O
after IN O
5-years NNS O
of IN O
follow-up JJ O
for IN O
non-irradiated JJ O
and CC O
irradiated JJ O
patients NNS O
for IN O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
expression NN O
in IN O
more JJR O
than IN O
50 CD O
% NN O
of IN O
the DT O
tumor NN O
cells NNS O
( -LRB- O
high JJ O
) -RRB- O
versus JJ O
expression NN O
in IN O
less JJR O
than IN O
50 CD O
% NN O
of IN O
the DT O
tumor NN O
cells NNS O
( -LRB- O
low JJ O
) -RRB- O
. . O

P NNP O
value NN O
is VBZ O
based VBN O
on IN O
univariate JJ O
log NN O
rank NN O
analyses NNS O
for IN O
overall JJ O
survival NN O
, , O
disease NN O
free JJ O
survival NN O
, , O
cancer NN O
specific JJ O
survival NN O
, , O
local JJ O
recurrence NN O
and CC O
distant JJ O
recurrence VBG O

* NN O
Statistical NNP O
significant JJ O
P NNP O
values NNS O
are VBP O
in IN O
bold JJ O

Multivariate VB O
analysis NN O

Multivariate JJ O
analysis NN O
was VBD O
performed VBN O
to TO O
identify VB O
factors NNS O
with IN O
independent JJ O
prognostic JJ O
significance NN O
and CC O
to TO O
calculate VB O
hazard NN O
ratios NNS O
( -LRB- O
HR NN O
) -RRB- O
. . O

Analyses NNS O
included VBD O
TNM NNP O
, , O
circumferential JJ O
margin NN O
, , O
randomization NN O
for IN O
preoperative JJ O
radiotherapy NN O
and CC O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
expression NN O
( -LRB- O
low JJ O
vs. FW O
high JJ O
HLA NNP B-NP
class NN I-NP
I PRP I-NP
positive JJ O
tumor NN O
cells NNS O
) -RRB- O
( -LRB- O
Table NN O
5 CD O
) -RRB- O
. . O

Advanced NNP O
pathological JJ O
( -LRB- O
TNM) NNP O
stage NN O
and CC O
tumor-positive JJ O
circumferential JJ O
resection NN O
margins NNS O
retained VBN O
their PRP$ O
strength NN O
as IN O
independent JJ O
prognostic JJ O
factors NNS O
in IN O
these DT O
survival NN O
analyses NNS O
. . O

HLA NNP B-NP
class NN I-NP
I PRP I-NP
expression NN O
showed VBD O
independent JJ O
prognostic JJ O
value NN O
for IN O
overall JJ O
survival NN O
and CC O
disease-free JJ O
survival NN O
( -LRB- O
HR NNP O
: : O
1.3 CD O
, , O
P NNP O
= SYM O
0.042 CD O
and CC O
HR NNP O
: : O
1.4 CD O
, , O
P NNP O
= SYM O
0.006 CD O
, , O
respectively RB O
) -RRB- O
, , O
but CC O
not RB O
for IN O
cancer-specific JJ O
survival NN O
. . O

Table NN O
5Multivariate JJ O
analysis NN O
confirms VBZ O
independent JJ O
better JJR O
overall JJ O
, , O
and CC O
disease NN O
free JJ O
survival NN O
for IN O
rectal JJ O
cancer NN O
patients NNS O
with IN O
high JJ O
expression NN O
of IN O
HLA NNP B-NP
class NN I-NP
IOverall NN I-NP
survivalDisease NN O
free JJ O
survivalCancer NN O
specific JJ O
survivalHR VBG O
(95 CD O
% NN O
CI) NNP O
P NNP O
valueHR NN O
(95 CD O
% NN O
CI) NNP O
P NNP O
valueHR NN O
(95 CD O
% NN O
CI) NNP O
P NNP O
valueHLA NN O
High10.04210.00610.653 . O

Low1.3 . O

( -LRB- O
1.0–1.6)1.4 CD O
( -LRB- O
1.1–1.8)1.1 CD O
( -LRB- O
0.8–1.5)Randomization NN O
TME10.63210.21410.282 CD O

TME NNP O
+ NN O
RT1 NNP O
( -LRB- O
0.8–1.2)0.9 CD O
( -LRB- O
0.7–1.1)1.1 CD O
( -LRB- O
0.9–1.5)TNM CD O
I111 NN O
II2.2 NN O
( -LRB- O
1.7–3.0)<0.0012.1 FW O
( -LRB- O
1.6–2.8 CD O
)<0.0013.5 CD O
( -LRB- O
2.0–6.1 CD O
)<0.001 CD O

III3.1 NNP O
( -LRB- O
2.4–4.1 CD O
)<0.0013.1 CD O
( -LRB- O
2.3–4.0)<0.0019.0 CD O

( -LRB- O
5.4–14.9 CD O
)<0.001 CD O

IV11.8 . O

( -LRB- O
8.1–17.1 CD O
)<0.001––50.3 CD O

( -LRB- O
28.5–89.1 CD O
)<0.001CRM NN O

Negative1<0.0011<0.0011<0.001 . O

Positive1.3 NNP O
( -LRB- O
1.1–1.5)1.8 FW O
( -LRB- O
1.4–2.2)1.3 CD O
( -LRB- O
1.1–1.5)Multivariate CD O

analysis NN O
for IN O
cancer NN O
specific JJ O
, , O
overall JJ O
and CC O
disease NN O
free JJ O
survival NN O
was VBD O
performed VBN O
to TO O
identify VB O
factors NNS O
with IN O
independent JJ O
prognostic JJ O
significance NN O
and CC O
to TO O
calculate VB O
hazard NN O
ratios NNS O
( -LRB- O
HR NN O
) -RRB- O
with IN O
95 CD O
% NN O
confidence NN O
intervals NNS O
( -LRB- O
CI) NNP O
shown VBN O
in IN O
parentheses NNS O
. . O

HLA NNP B-NP
class NN I-NP
I PRP I-NP
expression NN O
in IN O
more JJR O
than IN O
50 CD O
% NN O
of IN O
the DT O
tumor NN O
cells NNS O
( -LRB- O
high JJ O
) -RRB- O
versus JJ O
expression NN O
in IN O
less JJR O
than IN O
50 CD O
% NN O
of IN O
the DT O
tumor NN O
cells NNS O
( -LRB- O
low JJ O
) -RRB- O
, , O
total JJ O
mesorectal NN O
excision NN O
( -LRB- O
TME) NNP O
, , O
Radiotherapy NNP O
(RT NNP O
) -RRB- O
; : O
circumferential JJ O
margin NN O
( -LRB- O
CRM NNP O
) -RRB- O
; : O
P NNP O
value NN O
is VBZ O
based VBN O
on IN O
Cox NNP O
’ NNP O
regression NN O
analyses* NN O
Statistical NNP O
significant JJ O
P NNP O
values NNS O
and CC O
HR NNP O
are VBP O
in IN O
bold JJ O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Case NNP O
presentation NN O

In IN O
November NNP O
2006 CD O
, , O
a DT O
56-year JJ O
old JJ O
woman NN O
( -LRB- O
III-1 NN O
in IN O
pedigree NN O
, , O
Figure NN O
1 CD O
) -RRB- O
visited VBD O
our PRP$ O
clinic NN O
for IN O
genetic JJ O
counseling NN O
because IN O
she PRP O
was VBD O
worried VBN O
about IN O
the DT O
many JJ O
cases NNS O
of IN O
cancer NN O
that WDT O
had VBD O
occurred VBN O
in IN O
her PRP$ O
family NN O
. . O

The DT O
direct JJ O
reason NN O
for IN O
her PRP$ O
visit NN O
was VBD O
the DT O
recent JJ O
death NN O
of IN O
her PRP$ O
39-year JJ O
old JJ O
son NN O
( -LRB- O
IV-1 NN O
) -RRB- O
with IN O
a DT O
symptomatic JJ O
, , O
and CC O
already RB O
metastasized VBN O
, , O
rectal JJ O
adenocarcinoma NN O
. . O

The DT O
counselee NN O
had VBD O
been VBN O
diagnosed VBN O
with IN O
an DT O
endometrial NN O
and CC O
a DT O
sigmoid JJ O
carcinoma NN O
at IN O
age NN O
53- CD O
and CC O
54-years NNS O
old JJ O
, , O
respectively RB O
. . O

She PRP O
reported VBD O
her PRP$ O
overwhelming JJ O
family NN O
history NN O
, , O
which WDT O
easily RB O
fulfilled VBN O
the DT O
criteria NNS O
that WDT O
enable VBP O
selection NN O
of IN O
families NNS O
that WDT O
are VBP O
at IN O
risk NN O
for IN O
Lynch NNP O
syndrome NN O
( -LRB- O
Table NN O
1 CD O
) -RRB- O
. . O

Subsequent JJ O
IHC-analysis NN O
on IN O
archival NN O
tumor NN O
material NN O
of IN O
her PRP$ O
sigmoid JJ O
carcinoma NN O
demonstrated VBD O
abrogation RB O
of IN O
the DT O
MSH2 NNP B-NP
and CC O
MSH6 NNP B-NP
proteins NNS O
, , O
which WDT O
is VBZ O
typically RB O
associated VBN O
with IN O
a DT O
germline NN O
MSH2 IN B-NP
mutation NN O
. . O

Multiplex NNP O
ligation-dependent NN O
probe NN O
amplification NN O
( -LRB- O
MLPA NNP O
) -RRB- O
, , O
in IN O
DNA NNP O
extracted VBD O
from IN O
peripheral JJ O
lymphocytes NNS O
, , O
identified VBD O
an DT O
entire JJ O
MSH2 JJ B-NP
gene NN O
deletion NN O
( -LRB- O
exons VBD O
1–16 CD O
) -RRB- O
and CC O
confirmed VBD O
the DT O
diagnosis NN O
of IN O
Lynch NNP O
syndrome NN O
. . O

Pedigree NNP O
of IN O
a DT O
Lynch NNP O
syndrome NN O
family NN O
, , O
showing VBG O
organ NN O
systems NNS O
and CC O
age NN O
of IN O
diagnosis NN O
, , O
see VBP O
legend NN O
. . O

Year NN O
, , O
year NN O
of IN O
diagnosis/diagnoses NNS O
; : O
asterisk NN O
, , O
anamnestically RB O
obtained VBN O
information NN O
; : O
urinary JJ O
tract NN O
, , O
urothelial JJ O
carcinoma NN O
of IN O
renal JJ O
pelvis NNS O
or CC O
ureter NN O
; : O
skin NN O
, , O
keratoacanthoma NN O
; : O
asc. NN O
, , O
ascending VBG O
colon NN O
; : O
transv. NN O
, , O
transverse JJ O
colon NN O
; : O
desc. NN O
, , O
descending VBG O
colon NN O
. . O

In IN O
retrospect NN O
, , O
some DT O
doctors NNS O
had VBD O
indeed RB O
signaled VBN O
noteworthy JJ O
features NNS O
in IN O
this DT O
family NN O
. . O

First RB O
, , O
in IN O
1979 CD O
, , O
a DT O
gynecologist NN O
who WP O
was VBD O
treating VBG O
patient NN O
II-6 NN O
consulted VBD O
a DT O
colleague NN O
about IN O
the DT O
very RB O
early JJ O
onset NN O
of IN O
endometrial JJ O
carcinoma NN O
. . O

His PRP$ O
colleague NN O
reassured VBD O
him PRP O
at IN O
that DT O
time NN O
that IN O
the DT O
age NN O
at IN O
presentation NN O
, , O
41 CD O
years NNS O
old JJ O
, , O
was VBD O
not RB O
in IN O
fact NN O
very RB O
rare JJ O
. . O

Second JJ O
, , O
in IN O
2005 CD O
, , O
a DT O
gastroenterologist NN O
spoke VBD O
of IN O
possible JJ O
HNPCC NNP O
in IN O
patient NN O
III-2 NN O
, , O
who WP O
was VBD O
diagnosed VBN O
with IN O
carcinoma NN O
of IN O
the DT O
papilla NN O
of IN O
Vater NNP O
after IN O
she PRP O
had VBD O
developed VBN O
three CD O
separate JJ O
colon NN O
carcinomas NNS O
, , O
but CC O
no DT O
further JJ O
action NN O
was VBD O
taken VBN O
. . O

Third NNP O
, , O
in IN O
2006 CD O
, , O
an DT O
oncologist JJ O
treating VBG O
patient NN O
IV-1 NN O
suggested VBN O
MSI NNP O
testing NN O
on IN O
tumor NN O
material NN O
after IN O
his PRP$ O
mother NN O
( -LRB- O
III-1 NN O
) -RRB- O
had VBD O
expressed VBN O
her PRP$ O
concern NN O
about IN O
the DT O
family NN O
history NN O
, , O
but CC O
did VBD O
not RB O
proceed VB O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Discussion NN O

This DT O
family NN O
is VBZ O
a DT O
fine JJ O
example NN O
of IN O
the DT O
plethora NN O
of IN O
tumors NNS O
that WDT O
may MD O
occur VB O
in IN O
Lynch NNP O
syndrome NN O
and CC O
demonstrates VBZ O
why WRB O
the DT O
term NN O
Lynch NNP O
syndrome NN O
is VBZ O
preferred VBN O
nowadays RB O
over IN O
HNPCC NNP O
( -LRB- O
hereditary RB O
non-polyposis NN O
colorectal JJ O
cancer NN O
) -RRB- O
, , O
which WDT O
only RB O
refers VBZ O
to TO O
CRC. . O

The DT O
organ NN O
involvement NN O
in IN O
this DT O
family NN O
included VBD O
seven CD O
organ NN O
systems NNS O
: : O
colon NN O
, , O
uterus NN O
, , O
skin NN O
, , O
stomach NN O
, , O
urinary JJ O
tract NN O
, , O
pancreas NNS O
and CC O
hepatobiliary NN O
system NN O
. . O

The DT O
manifestation NN O
of IN O
keratoacanthoma NN O
in IN O
this DT O
family NN O
enabled VBD O
a DT O
sub-classification NN O
to TO O
Muir NNP O
Torre NNP O
syndrome NN O
( -LRB- O
MTS NNS O
) -RRB- O
. . O

MTS NNS O
is VBZ O
a DT O
variant NN O
of IN O
Lynch NNP O
syndrome NN O
and CC O
germline NN O
mutations NNS O
in IN O
the DT O
three CD O
main JJ O
Lynch NNP O
syndrome NN O
genes NNS O
( -LRB- O
MLH1 NNP B-NP
, , O
MSH2 NNP B-NP
and CC O
MSH6 NNP B-NP
) -RRB- O
have VBP O
been VBN O
identified VBN O
in IN O
MTS NNS O
families NNS O
[7,8] VBD O
. . O

Keratoacanthoma NNP O
should MD O
be VB O
regarded VBN O
as IN O
one CD O
of IN O
the DT O
tumors NNS O
that IN O
lie NN O
in IN O
the DT O
constellation NN O
of IN O
Lynch NNP O
syndrome NN O
but CC O
their PRP$ O
manifestation NN O
could MD O
depend VB O
on IN O
modifier NN O
genes NNS O
and/or CC O
environmental JJ O
factors NNS O
. . O

This DT O
case NN O
report NN O
shows VBZ O
a DT O
considerable JJ O
delay NN O
in IN O
diagnosing VBG O
Lynch NNP O
syndrome NN O
which WDT O
negatively RB O
influenced VBD O
the DT O
management NN O
of IN O
many JJ O
family NN O
members NNS O
. . O

None NN O
of IN O
the DT O
family NN O
members NNS O
underwent IN O
presymptomatic JJ O
screening NN O
on IN O
the DT O
basis NN O
of IN O
the DT O
family NN O
history NN O
, , O
while IN O
clinical JJ O
surveillance NN O
has VBZ O
been VBN O
shown VBN O
to TO O
decrease VB O
mortality NN O
in IN O
Lynch NNP O
syndrome NN O
families NNS O
[9] VBD O
. . O

Remarkably RB O
, , O
in IN O
none NN O
of IN O
the DT O
medical JJ O
reports NNS O
we PRP O
obtained VBD O
was VBD O
a DT O
family NN O
history NN O
reported VBD O
extending VBG O
further RBR O
than IN O
first-degree JJ O
relatives NNS O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Conclusion NN O

This DT O
family NN O
clearly RB O
illustrates VBZ O
a DT O
lack NN O
of IN O
awareness NN O
about IN O
a DT O
hereditary JJ O
tumor NN O
syndrome NN O
among IN O
doctors NNS O
as RB O
well RB O
as IN O
patients NNS O
. . O

In IN O
general JJ O
, , O
it PRP O
is VBZ O
prudent JJ O
to TO O
be VB O
aware JJ O
of IN O
classic JJ O
hereditary NN O
features NNS O
, , O
like IN O
young JJ O
age NN O
at IN O
diagnosis NN O
, , O
multiple JJ O
tumors NNS O
in IN O
multiple JJ O
organs NNS O
and CC O
a DT O
positive JJ O
family NN O
history NN O
, , O
and CC O
to TO O
refer VB O
suspected VBN O
cases NNS O
for IN O
genetic JJ O
counseling NN O
. . O

More RBR O
specifically RB O
, , O
these DT O
features NNS O
can MD O
be VB O
found VBN O
in IN O
the DT O
Amsterdam NNP O
and CC O
Bethesda NNP O
criteria NNS O
( -LRB- O
Table NN O
1 CD O
) -RRB- O
. . O

Subsequently RB O
, , O
the DT O
identification NN O
of IN O
at-risk JJ O
persons NNS O
will MD O
optimize VB O
the DT O
timing NN O
and CC O
efficiency NN O
that IN O
surveillance NN O
and CC O
treatment NN O
are VBP O
carried VBN O
out RP O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

The DT O
DNA NNP O
sequence NN O
of IN O
each DT O
microsatellite NN O
in IN O
the DT O
tumor NN O
was VBD O
compared VBN O
with IN O
that DT O
of IN O
the DT O
matched VBN O
normal JJ O
mucosa NN O
. . O

It PRP O
was VBD O
considered VBN O
as IN O
unstable JJ O
if IN O
there EX O
was VBD O
an DT O
absence NN O
, , O
shortening VBG O
or CC O
prolongation NN O
of IN O
the DT O
DNA NNP O
sequence NN O
. . O

MSI-L NNP O
was VBD O
defined VBN O
as IN O
1 CD O
unstable JJ O
microsatellite NN O
out IN O
of IN O
5 CD O
, , O
while IN O
MSI-H NNP O
was VBD O
defined VBN O
as IN O
more JJR O
than IN O
1 CD O
unstable JJ O
microsatellite NN O
out IN O
of IN O
5 CD O
. . O

If IN O
the DT O
tumor NN O
microsatellites NNS O
were VBD O
identical JJ O
to TO O
those DT O
of IN O
the DT O
normal JJ O
tissue NN O
, , O
the DT O
microsatellite NN O
was VBD O
considered VBN O
as IN O
stable JJ O
( -LRB- O
MSS) NN O
. . O

For IN O
the DT O
MSI-L JJ O
CRCs NNP O
, , O
BAT-40 NNP O
and CC O
MYCL NNP O
were VBD O
detected VBN O
. . O

If IN O
either DT O
of IN O
these DT O
two CD O
markers NNS O
was VBD O
unstable JJ O
, , O
this DT O
colorectal JJ O
sample NN O
was VBD O
considered VBN O
as IN O
MSI-H. . O

Immunohistochemical NNP O
staining NN O
for IN O
MSH2 NNP B-NP
, , O
MSH6 NNP B-NP
and CC O
MLH1 NNP B-NP
on IN O
TMAs NNP O

The DT O
CRC NNP O
microarray NN O
was VBD O
constructed VBN O
as IN O
previously RB O
described VBN O
[8,9] JJ O
. . O

Briefly RB O
, , O
formalin-fixed JJ O
paraffin-embedded JJ O
tissue NN O
blocks NNS O
of IN O
CRC NNP O
resections NNS O
were VBD O
cut VBN O
from IN O
the DT O
donor NN O
block NN O
and CC O
stained VBN O
with IN O
hematoxylin-eosin NN O
( -LRB- O
HE) NNP O
. . O

These DT O
slides NNS O
were VBD O
used VBN O
to TO O
guide VB O
the DT O
sampling NN O
from IN O
morphologically RB O
representative JJ O
regions NNS O
of IN O
the DT O
tissues NNS O
. . O

A DT O
tissue NN O
array NN O
instrument NN O
( -LRB- O
Beecher NNP O
Instruments NNP O
, , O
Silver NNP O
Spring NNP O
, , O
MD) NNP O
was VBD O
used VBN O
to TO O
create VB O
holes NNS O
in IN O
a DT O
recipient NN O
paraffin NN O
block NN O
and CC O
to TO O
acquire VB O
tissue NN O
cores NNS O
from IN O
the DT O
donor NN O
block NN O
by IN O
a DT O
thin-walled JJ O
needle NN O
with IN O
an DT O
inner JJ O
diameter NN O
of IN O
1.0 CD O
mm CD O
, , O
held VBN O
in IN O
an DT O
X-Y JJ O
precision NN O
guide NN O
. . O

The DT O
cylindrical JJ O
samples NNS O
were VBD O
retrieved VBN O
from IN O
the DT O
selected VBN O
regions NNS O
in IN O
the DT O
donors NNS O
and CC O
extruded VBD O
directly RB O
into IN O
the DT O
recipient NN O
blocks NNS O
with IN O
defined VBN O
array NN O
coordinates NNS O
. . O

Three CD O
cores NNS O
were VBD O
obtained VBN O
from IN O
each DT O
sample NN O
. . O

After IN O
the DT O
construction NN O
of IN O
the DT O
array NN O
block NN O
, , O
multiple JJ O
4-mm JJ O
thick JJ O
sections NNS O
were VBD O
cut VBN O
with IN O
a DT O
microtome NN O
using VBG O
an DT O
adhesive-coated JJ O
tape NN O
sectioning NN O
system NN O
( -LRB- O
Instrumedics NNP O
, , O
Hackensack NNP O
, , O
NJ) NNP O
. . O

In IN O
our PRP$ O
analysis NN O
the DT O
rates NNS O
of IN O
lost VBN O
cases NNS O
attributable JJ O
to TO O
tissue NN O
damage NN O
were VBD O
less JJR O
than IN O
5 CD O
% NN O
for IN O
the DT O
different JJ O
markers NNS O
. . O

TMA DT O
slides NNS O
were VBD O
stained VBN O
with IN O
MLH1 NNP B-NP
antibodies NNS O
( -LRB- O
1:50 CD O
dilution NN O
, , O
No. NN O
sc-494 NN O
, , O
Santa NNP O
Cruz NNP O
, , O
Biotrade NNP O
Ltd NNP O
, , O
Shanghai NNP O
, , O
China NNP O
) -RRB- O
and CC O
MSH2 NNP B-NP
( -LRB- O
1:100 CD O
dilution NN O
, , O
No. NN O
sc-581 JJ O
, , O
Santa NNP O
Cruz NNP O
, , O
Biotrade NNP O
Ltd NNP O
, , O
Shanghai NNP O
, , O
China NNP O
) -RRB- O
. . O

IHC NNP O
staining NN O
for IN O
samples NNS O
on IN O
the DT O
tissue NN O
microarray NN O
was VBD O
carried VBN O
out RP O
using VBG O
Envision NNP O
ready-to-use NN O
methods NNS O
( -LRB- O
Dako NNP O
Diagnostics NNP O
, , O
Zug NNP O
, , O
Switzerland NNP O
) -RRB- O
. . O

Slides NNS O
were VBD O
deparaffinized VBN O
in IN O
xylene NN O
and CC O
rehydrated VBD O
through IN O
graded JJ O
concentrations NNS O
of IN O
ethanol NN O
to TO O
distilled JJ O
water NN O
, , O
and CC O
endogenous JJ O
peroxidase NN O
activity NN O
was VBD O
blocked VBN O
by IN O
incubation NN O
with IN O
30 CD O
mL/L JJ O
H2O2 NN O
in IN O
methanol NN O
for IN O
10 CD O
min NN O
at IN O
room NN O
temperature NN O
. . O

Then RB O
sections NNS O
were VBD O
submitted VBN O
to TO O
antigen JJ O
retrieval NN O
in IN O
a DT O
pressure NN O
cooker NN O
containing VBG O
0.01 CD O
mmol/L JJ O
natrium NN O
citricium NN O
buffer NN O
for IN O
10 CD O
min NN O
. . O

Slides NNS O
were VBD O
subsequently RB O
incubated VBN O
in IN O
100 CD O
mL/L JJ O
normal JJ O
goat NN O
serum NN O
for IN O
20 CD O
min NN O
at IN O
room NN O
temperature NN O
. . O

Sections NNS O
were VBD O
permeabilized VBN O
in IN O
PBS-Triton NNP O
and CC O
incubated VBN O
overnight JJ O
with IN O
primary JJ O
antibody NN O
at IN O
4°C. VBG O

The DT O
pathologist NN O
and CC O
technician NN O
who WP O
reviewed VBN O
the DT O
immunostaining NN O
of IN O
the DT O
tissue NN O
samples NNS O
were VBD O
blinded VBN O
to TO O
the DT O
patient NN O
's POS O
information NN O
. . O

Stained VBN O
slides NNS O
and CC O
individual JJ O
cores NNS O
were VBD O
scored VBN O
as IN O
either DT O
positive JJ O
( -LRB- O
showing VBG O
nuclear JJ O
staining NN O
in IN O
at IN O
least JJS O
some DT O
tumor NN O
cells NNS O
) -RRB- O
or CC O
negative JJ O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Regarding VBG O
the DT O
location NN O
of IN O
gene NN O
mutations NNS O
, , O
we PRP O
found VBD O
that IN O
3 CD O
patients NNS O
bore VBD O
mutations NNS O
in IN O
exon NN O
7 CD O
of IN O
MSH2 NNP B-NP
, , O
2 CD O
had VBD O
mutations NNS O
in IN O
exon JJ O
12 CD O
of IN O
MSH2 NNP B-NP
, , O
1 CD O
had VBD O
a DT O
mutation NN O
in IN O
exon NN O
2 CD O
of IN O
MSH6 CD B-NP
, , O
and CC O
2 CD O
had VBD O
mutations NNS O
in IN O
exon NN O
5 CD O
of IN O
MSH6 NNP B-NP
. . O

No DT O
MLH1 NNP B-NP
mutations NNS O
were VBD O
found VBN O
in IN O
our PRP$ O
cohort NN O
. . O

All DT O
8 CD O
mutations NNS O
were VBD O
considered VBN O
pathogenic JJ O
mutations NNS O
. . O

The DT O
mutation NN O
of IN O
C1886 NNP O
A DT O
> JJ O
G NNP O
, , O
C1668 DT O
C NNP O
> NNP O
T NNP O
was VBD O
reported VBN O
as IN O
a DT O
pathogenic JJ O
mutation NN O
previously RB O
[22-25] JJ O
. . O

However RB O
, , O
the DT O
other JJ O
six CD O
mutations NNS O
have VBP O
not RB O
been VBN O
reported VBN O
in IN O
other JJ O
publications NNS O
and CC O
are VBP O
likely JJ O
to TO O
be VB O
novel JJ O
mutations NNS O
. . O

We PRP O
also RB O
attempted VBD O
to TO O
screen VB O
for IN O
the DT O
presence NN O
of IN O
all DT O
these DT O
mutations NNS O
in IN O
50 CD O
randomly RB O
selected VBN O
patients NNS O
in IN O
the DT O
MSS NNP O
group NN O
and CC O
in IN O
50 CD O
normal JJ O
people NNS O
. . O

The DT O
result NN O
of IN O
this DT O
screen NN O
was VBD O
negative JJ O
, , O
and CC O
all PDT O
these DT O
CRCs NNS O
with IN O
mutations NNS O
stained VBN O
negatively RB O
for IN O
MSH2 NNP B-NP
or/and CC O
MSH6 NNP B-NP
, , O
indicating VBG O
that IN O
these DT O
6 CD O
mutations NNS O
may MD O
be VB O
pathogenic JJ O
mutations NNS O
but CC O
not RB O
polymorphisms NNS O
. . O

In IN O
terms NNS O
of IN O
the DT O
clinical JJ O
features NNS O
of IN O
the DT O
8 CD O
cases NNS O
with IN O
mutations NNS O
, , O
only RB O
1 CD O
conformed JJ O
to TO O
the DT O
Amsterdam NNP O
criteria NNS O
II NNP O
; : O
all PDT O
the DT O
others NNS O
did VBD O
not RB O
have VB O
any DT O
family NN O
history NN O
of IN O
malignancy NN O
. . O

Moreover RB O
, , O
the DT O
median JJ O
age NN O
was VBD O
59 CD O
with IN O
4 CD O
patients NNS O
that WDT O
were VBD O
older JJR O
than IN O
60 CD O
years NNS O
old JJ O
. . O

One CD O
limitation NN O
of IN O
this DT O
study NN O
is VBZ O
that IN O
it PRP O
is VBZ O
a DT O
single-center JJ O
study NN O
with IN O
a DT O
relatively RB O
small JJ O
sample NN O
size NN O
. . O

Therefore RB O
, , O
the DT O
results NNS O
of IN O
this DT O
study NN O
need NN O
to TO O
be VB O
confirmed VBN O
by IN O
a DT O
well RB O
designed VBN O
multi-center JJ O
study NN O
, , O
which WDT O
is VBZ O
one CD O
of IN O
our PRP$ O
ongoing JJ O
studies NNS O
in IN O
China NNP O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Background CC O

The DT O
colon NN O
is VBZ O
composed VBN O
of IN O
a DT O
dynamic JJ O
and CC O
self-renewing JJ O
epithelium NN O
that WDT O
turns VBZ O
over IN O
every DT O
three CD O
to TO O
five CD O
days NNS O
. . O

It PRP O
is VBZ O
generally RB O
accepted VBN O
that IN O
at IN O
the DT O
base NN O
of IN O
the DT O
crypt NN O
, , O
variable JJ O
numbers NNS O
( -LRB- O
between IN O
1 CD O
and CC O
16 CD O
) -RRB- O
of IN O
slowly RB O
dividing JJ O
, , O
stationary JJ O
, , O
pluripotent JJ O
stem NN O
cells NNS O
give VBP O
rise VB O
to TO O
more RBR O
rapidly RB O
proliferating VBG O
, , O
transient JJ O
amplifying JJ O
cells NNS O
. . O

These DT O
cells NNS O
differentiate JJ O
chiefly RB O
into IN O
post-mitotic JJ O
columnar NN O
colonocytes NNS O
, , O
mucin-secreting JJ O
goblet NN O
cells NNS O
, , O
and CC O
enteroendocrine NN O
cells NNS O
as IN O
they PRP O
migrate VBP O
from IN O
the DT O
crypt NN O
base NN O
to TO O
the DT O
surface NN O
where WRB O
they PRP O
are VBP O
sloughed VBN O
into IN O
the DT O
lumen NN O
[1] NN O
. . O

Several JJ O
signaling VBG O
pathways NNS O
, , O
notably RB O
Wnt NNP B-NP
, , O
Tgfβ NNP O
, , O
Bmp NNP O
, , O
Hedgehog NNP O
and CC O
Notch NNP O
, , O
play NN O
pivotal NN O
roles NNS O
in IN O
the DT O
control NN O
of IN O
proliferation NN O
and CC O
differentiation NN O
of IN O
the DT O
developing VBG O
and CC O
adult NN O
colon NN O
[2] NNS O
. . O

Their PRP$ O
perturbation NN O
, , O
via IN O
mutation NN O
or CC O
epigenetic JJ O
modification NN O
, , O
occurs VBZ O
in IN O
human JJ O
colorectal NN O
cancer NN O
( -LRB- O
CRC NNP O
) -RRB- O
and CC O
the DT O
instillation NN O
of IN O
these DT O
changes NNS O
via IN O
genetic JJ O
engineering NN O
in IN O
mice NNS O
confers VBZ O
a DT O
correspondingly RB O
high JJ O
risk NN O
for IN O
neoplasia NN O
in IN O
the DT O
mouse NN O
models NNS O
. . O

Moreover RB O
, , O
tumor NN O
cell NN O
de-differentiation NN O
correlates VBZ O
with IN O
key JJ O
tumor NN O
features NNS O
, , O
such JJ O
as IN O
tumor NN O
progression NN O
rates NNS O
, , O
invasiveness NN O
, , O
drug NN O
resistance NN O
and CC O
metastatic JJ O
potential JJ O
[3-5] NN O
. . O

A DT O
variety NN O
of IN O
scientific JJ O
and CC O
organizational JJ O
obstacles NNS O
make VBP O
it PRP O
a DT O
challenging JJ O
proposition NN O
to TO O
undertake VB O
large-scale JJ O
comparisons NNS O
of IN O
human JJ O
cancer NN O
to TO O
the DT O
wide JJ O
range NN O
of IN O
genetically RB O
engineered VBN O
mouse NN O
models NNS O
. . O

To TO O
evaluate VB O
the DT O
potential NN O
of IN O
this DT O
approach NN O
to TO O
provide VB O
integrated JJ O
views NNS O
of IN O
the DT O
molecular JJ O
basis NN O
of IN O
cancer NN O
risk NN O
, , O
tumor NN O
development NN O
and CC O
malignant JJ O
progression NN O
, , O
we PRP O
have VBP O
undertaken VBN O
a DT O
comparative JJ O
analysis NN O
of IN O
a DT O
variety NN O
of IN O
individually RB O
developed VBN O
mouse NN O
colon NN O
tumor NN O
models NNS O
( -LRB- O
reviewed VBN O
in IN O
[6,7] NN O
) -RRB- O
to TO O
human JJ O
CRC. NNP O

The DT O
ApcMin/+ NNP B-NP
( -LRB- O
multiple NN O
intestinal JJ O
neoplasia NN O
) -RRB- O
mouse NN O
model NN O
harbors VBZ O
a DT O
germline NN O
mutation NN O
in IN O
the DT O
Apc NNP B-NP
tumor NN O
suppressor NN O
gene NN O
and CC O
exhibits NNS O
multiple JJ O
tumors NNS O
in IN O
the DT O
small JJ O
intestine NN O
and CC O
colon NN O
[8] NNS O
. . O

A DT O
major JJ O
function NN O
of IN O
APC NNP B-NP
is VBZ O
to TO O
regulate VB O
the DT O
canonical NN O
WNT NNP O
signaling VBG O
pathway NN O
as IN O
part NN O
of IN O
a DT O
β-catenin JJ O
degradation NN O
complex NN O
. . O

Loss NN O
of IN O
APC NNP B-NP
results NNS O
in IN O
a DT O
failure NN O
to TO O
degrade VB O
β-catenin NN O
, , O
which WDT O
instead RB O
enters VBZ O
the DT O
nucleus JJ O
to TO O
act VB O
as IN O
a DT O
transcriptional JJ O
co-activator NN O
with IN O
the DT O
lymphoid JJ O
enhancer NN O
factor/T-cell NN O
factor NN O
( -LRB- O
LEF/TCF NN B-NP
) -RRB- O
family NN O
of IN O
transcription NN O
factors NNS O
[9] VBD O
. . O

The DT O
localization NN O
of IN O
β-catenin NN O
within IN O
the DT O
nucleus NN O
indicates VBZ O
activated VBN O
canonical JJ O
WNT NNP O
signaling NN O
. . O

In IN O
addition NN O
to TO O
germline VB O
APC NNP B-NP
mutations NNS O
that WDT O
occur VBP O
in IN O
persons NNS O
with IN O
familial JJ O
adenomatous JJ O
polyposis NN O
coli NNS O
( -LRB- O
FAP NNP O
) -RRB- O
and CC O
ApcMin/+ NNP B-NP
mice NNS O
, , O
loss NN O
of IN O
functional JJ O
APC NNP B-NP
and CC O
activation NN O
of IN O
canonical JJ O
WNT NNP O
signaling NN O
occurs VBZ O
in IN O
more JJR O
than IN O
80 CD O
% NN O
of IN O
human JJ O
sporadic JJ O
CRCs NNP O
[10] NNP O
. . O

Similar JJ O
to TO O
the DT O
ApcMin/+ NNP B-NP
model NN O
, , O
tumors NNS O
in IN O
the DT O
azoxymethane NN O
( -LRB- O
AOM) NNP O
carcinogen NN O
model NN O
, , O
which WDT O
occur VBP O
predominantly RB O
in IN O
the DT O
colon NN O
[11] NN O
, , O
have VBP O
signaling VBG O
alterations NNS O
marked VBN O
by IN O
activated JJ O
canonical JJ O
WNT NNP O
signaling NN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Results NNS O

Strategy NN O
for IN O
cross-species NNS O
analysis NN O

Our PRP$ O
strategy NN O
for IN O
the DT O
characterization NN O
of IN O
mouse NN O
models NNS O
of IN O
human JJ O
CRC NNP O
( -LRB- O
Figure NN O
1 CD O
) -RRB- O
relies VBZ O
on IN O
gene NN O
expression NN O
differences NNS O
and CC O
relative JJ O
patterning NN O
across IN O
a DT O
range NN O
of IN O
mouse NN O
CRC NNP O
models NNS O
, , O
normal JJ O
mouse NN O
colon NN O
developmental JJ O
stages NNS O
, , O
and CC O
human JJ O
CRCs NNS O
. . O

Achieving VBG O
this DT O
comparison NN O
was VBD O
facilitated VBN O
by IN O
the DT O
use NN O
of IN O
reference NN O
RNAs NNS O
from IN O
whole-mouse NN O
and CC O
normal JJ O
adult NN O
colon NN O
reference NN O
RNAs IN O
for IN O
both DT O
mouse NN O
and CC O
human JJ O
measurements NNS O
. . O

Mouse NN O
tumor NN O
samples NNS O
were VBD O
profiled VBN O
on IN O
cDNA NN O
microarrays NNS O
using VBG O
the DT O
embryonic JJ O
day NN O
( -LRB- O
E)17.5 CD O
whole JJ O
mouse NN O
reference NN O
RNA IN O
identical JJ O
to TO O
that DT O
used VBN O
previously RB O
[15 CD O
] NNS O
to TO O
examine VB O
embryonic JJ O
mouse NN O
colon NN O
gene NN O
expression NN O
dynamics NNS O
from IN O
E13.5 CD O
to TO O
E18.5 CD O
, , O
during IN O
which WDT O
time NN O
the DT O
primitive JJ O
, , O
undifferentiated JJ O
, , O
pseudo-stratified JJ O
colonic JJ O
endoderm NN O
becomes VBZ O
a DT O
differentiated JJ O
, , O
single-layered JJ O
epithelium NN O
. . O

This DT O
strategy NN O
allowed VBD O
us PRP O
to TO O
construct VB O
a DT O
gene NN O
expression NN O
database NN O
of IN O
mouse NN O
colon NN O
tumors NNS O
in IN O
which WDT O
gene NN O
expression NN O
levels NNS O
of IN O
the DT O
tumors NNS O
could MD O
be VB O
referenced VBN O
, , O
ranked VBD O
, , O
and CC O
statistically RB O
compared VBN O
to TO O
an DT O
average JJ O
value NN O
among IN O
the DT O
tumors NNS O
or CC O
to TO O
embryonic JJ O
or CC O
adult JJ O
colon NN O
gene NN O
expression NN O
levels NNS O
on IN O
a DT O
per-gene JJ O
basis NN O
. . O

First RB O
, , O
we PRP O
compared VBD O
the DT O
four CD O
models NNS O
with IN O
each DT O
other JJ O
, , O
then RB O
to TO O
mouse NN O
colon NN O
development NN O
, , O
and CC O
finally RB O
to TO O
human JJ O
CRCs NNS O
using VBG O
gene NN O
ortholog NN O
mapping NN O
( -LRB- O
Figure NN O
1 CD O
) -RRB- O
. . O

Stratification NNP O
of IN O
murine NN O
colon NN O
tumor NN O
models NNS O
by IN O
localization NN O
of IN O
β-catenin NN O
and CC O
plan NN O
for IN O
analysis NN O
. . O

Colon NN O
tumors NNS O
from IN O
four CD O
etiologically RB O
distinct JJ O
mouse NN O
models NNS O
of IN O
CRC NNP O
were VBD O
subjected VBN O
to TO O
microarray JJ O
gene NN O
expression NN O
profiling NN O
. . O

The DT O
gene NN O
expression NN O
profiles NNS O
from IN O
the DT O
different JJ O
mouse NN O
model NN O
tumors NNS O
were VBD O
compared VBN O
and CC O
contrasted VBN O
to TO O
each DT O
other JJ O
, , O
as RB O
well RB O
as IN O
to TO O
those DT O
from IN O
embryonic JJ O
mouse NN O
colon NN O
development NN O
and CC O
100 CD O
human JJ O
CRCs NNS O
. . O

Mouse NN O
colon NN O
tumors NNS O
partition NN O
into IN O
classes NNS O
reflecting VBG O
differential JJ O
canonical JJ O
WNT NNP O
signaling NN O
activity NN O

To TO O
discover VB O
gene NN O
expression NN O
programs NNS O
underlying VBG O
differences NNS O
between IN O
etiologically RB O
distinct JJ O
mouse NN O
models NNS O
of IN O
CRC NNP O
, , O
gene NN O
expression NN O
level NN O
values NNS O
for IN O
each DT O
transcript NN O
in IN O
each DT O
tumor NN O
sample NN O
was VBD O
set VBN O
to TO O
its PRP$ O
ratio NN O
relative JJ O
to TO O
its PRP$ O
median NN O
across IN O
the DT O
series NN O
of IN O
tumor NN O
models NNS O
. . O

Using VBG O
non-parametric JJ O
statistical JJ O
analyses NNS O
, , O
1,798 CD O
cDNA NN O
transcripts NNS O
were VBD O
identified VBN O
as IN O
differentially RB O
expressed VBN O
among IN O
the DT O
four CD O
mouse NN O
models NNS O
of IN O
CRC. NNP O

Five CD O
major JJ O
gene NN O
patterns NNS O
were VBD O
identified VBN O
using VBG O
K-means NNP O
clustering NN O
( -LRB- O
clusters NNS O
C1-C5 : O
; : O
Figure NN O
2a CD O
, , O
top NN O
) -RRB- O
. . O

Genes NNP O
belonging VBG O
to TO O
these DT O
clusters NNS O
were VBD O
strongly RB O
associated VBN O
with IN O
annotated JJ O
gene NN O
function NN O
categories NNS O
( -LRB- O
see VB O
Table NN O
1 CD O
for IN O
detailed JJ O
biological JJ O
descriptions NNS O
and CC O
associations NNS O
) -RRB- O
. . O

For IN O
example NN O
, , O
cluster NN O
C1 NNP O
, , O
composed VBN O
of IN O
transcripts NNS O
that WDT O
exhibited VBD O
lower JJR O
expression NN O
in IN O
Smad3-/- NNP B-NP
tumors NNS O
and CC O
higher JJR O
expression NN O
in IN O
AOM NNP O
, , O
ApcMin/+ NNP B-NP
and CC O
Tgfb1-/-; JJ B-NP
Rag2-/- NNP B-NP
tumors NNS O
, , O
contains VBZ O
391 CD O
transcripts NNS O
, , O
including VBG O
Cdk4 NNP B-NP
, , O
Ctnnb1 NNP B-NP
, , O
Myc NNP B-NP
, , O
Ezh2 NNP B-NP
, , O
Mcm2 NNP B-NP
and CC O
Tcf3 NNP B-NP
. . O

Gene NNP O
list NN O
over-representation NN O
analysis NN O
using VBG O
Ingenuity NNP O
Pathway NNP O
Analysis NNP O
applications NNS O
demonstrated VBD O
highly RB O
significant JJ O
associations NNS O
to TO O
cell NN O
cycle NN O
progression NN O
, , O
replication NN O
, , O
post-transcriptional JJ O
control NN O
and CC O
cancer NN O
. . O

Similarly RB O
, , O
cluster NN O
C2 NNP O
, , O
composed VBN O
of IN O
663 CD O
transcripts NNS O
that IN O
exhibited JJ O
high JJ O
expression NN O
in IN O
AOM NNP O
and CC O
ApcMin/+ NNP B-NP
tumors NNS O
, , O
but CC O
low JJ O
in IN O
Smad3-/- NNP B-NP
and CC O
Tgfb1-/-; JJ B-NP
Rag2-/- NNP B-NP
tumors NNS O
, , O
included VBN O
transcripts NNS O
for IN O
contact NN O
growth NN O
inhibition NN O
( -LRB- O
Metap1 NNP B-NP
, , O
Pcyox1 NNP B-NP
) -RRB- O
, , O
mitosis NN O
( -LRB- O
Mif NNP B-NP
, , O
Pik1 NNP B-NP
) -RRB- O
, , O
cell NN O
cycle NN O
progression NN O
and CC O
checkpoint NN O
control NN O
( -LRB- O
Id2 NNP B-NP
, , O
Ptp4A2 NNP B-NP
, , O
Tp53 CD B-NP
) -RRB- O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Detailed VBN O
cluster NN O
analysis NN O
: : O
differential JJ O
and CC O
statistically RB O
significant JJ O
biological JJ O
functions NNS O
in IN O
clusters NNS O
C11-C17 . O

PS NNP O
, , O
ProbeSets NNP O
. . O

Human JJ O
CRCs NNP O
exhibit NN O
gene NN O
expression NN O
profile VB O
complexity NN O
consistent JJ O
with IN O
significant JJ O
tumor NN O
subclasses NNS O
. . O

Genes NNP O
potentially RB O
able JJ O
to TO O
distinguish VB O
cancer NN O
subtypes NNS O
were VBD O
identified VBN O
from IN O
Affymetrix NNP O
HG-U133 CD O
plus2 CC O
Genechip NNP O
expression NN O
profiles NNS O
by IN O
filtering VBG O
for IN O
3,285 CD O
probe NN O
sets NNS O
that WDT O
were VBD O
top-ranked JJ O
by IN O
raw JJ O
expression NN O
and CC O
their PRP$ O
differential JJ O
regulation NN O
in IN O
at IN O
least JJS O
10 CD O
out IN O
of IN O
100 CD O
human JJ O
colorectal NN O
cancer NN O
tumors NNS O
. . O

Coordinately NNP O
regulated VBD O
transcripts NNS O
and CC O
similarly RB O
behaving VBG O
samples NNS O
were VBD O
identified VBN O
via IN O
hierarchical JJ O
tree NN O
clustering NN O
. . O

Seven CD O
different JJ O
gene NN O
clusters NNS O
( -LRB- O
C11-17 NN O
) -RRB- O
were VBD O
identified VBN O
that IN O
distinguished VBN O
ten CD O
or CC O
more JJR O
tumors NNS O
from IN O
the DT O
other JJ O
tumors NNS O
. . O

Gene NNP O
clusters NNS O
were VBD O
found VBN O
to TO O
be VB O
highly RB O
enriched VBN O
for IN O
gene NN O
functions NNS O
listed VBN O
in IN O
Table NN O
3. NNP O
Data NNP O
were VBD O
processed VBN O
using VBG O
Robust NNP O
Microarray NNP O
Analysis NNP O
( -LRB- O
RMA NN O
) -RRB- O
with IN O
expression NN O
value NN O
ratios NNS O
depicted VBN O
as IN O
the DT O
relative JJ O
expression NN O
per IN O
probe NN O
set VBN O
in IN O
each DT O
sample NN O
relative NN O
to TO O
the DT O
median NN O
of IN O
its PRP$ O
expression NN O
across IN O
the DT O
100 CD O
CRCs NNP O
. . O

A DT O
striking JJ O
heterogeneity NN O
of IN O
gene NN O
expression NN O
was VBD O
observed VBN O
, , O
including VBG O
metallothionein NN O
genes NNS O
in IN O
cluster NN O
C15 IN O
previously RB O
shown VBN O
to TO O
be VB O
predictive JJ O
of IN O
microsatellite NN O
instability NN O
( -LRB- O
indicated VBN O
by IN O
asterisk NN O
) -RRB- O
, , O
and CC O
C17 DT O
represented VBN O
by IN O
734 CD O
probesets NNS O
rich JJ O
in IN O
genes NNS O
associated VBN O
with IN O
extracellular JJ O
matrix NN O
and CC O
connective JJ O
tissue NN O
, , O
tumor NN O
invasion NN O
and CC O
malignancy NN O
. . O

Tissue NN O
groups NNS O
: : O
AC NNP O
, , O
adult NN O
colon NN O
; : O
CRC NNP O
, , O
human JJ O
CRC. NNP O

Staging VBG O
: : O
nAC RB O
, , O
normal JJ O
colon NN O
; : O
Dukes NNP O
A-D NNP O
, , O
human JJ O
tumors NNS O
obtained VBN O
from IN O
individuals NNS O
. . O

Clusters NNS O
C11-C17 CC O
labeled VBN O
to TO O
the DT O
right NN O
of IN O
the DT O
heatmap NN O
correspond NN O
to TO O
the DT O
K-means NNP O
functional JJ O
clusters NNS O
listed VBN O
in IN O
Table NN O
3. . O

To TO O
evaluate VB O
if IN O
similar JJ O
sets NNS O
of IN O
genes NNS O
are VBP O
systematically RB O
activated VBN O
or CC O
repressed VBN O
in IN O
human JJ O
CRC NNP O
, , O
as IN O
in IN O
the DT O
mouse NN O
colon NN O
tumors NNS O
, , O
we PRP O
undertook VBP O
two CD O
procedures NNS O
to TO O
align VB O
the DT O
data NNS O
. . O

First RB O
, , O
gene NN O
expression NN O
values NNS O
for IN O
the DT O
mouse NN O
and CC O
human JJ O
tumors NNS O
were VBD O
separately RB O
normalized JJ O
and CC O
referenced JJ O
relative JJ O
to TO O
their PRP$ O
respective JJ O
normal JJ O
adult NN O
colon NN O
controls NNS O
; : O
second JJ O
, , O
mouse NN O
and CC O
human JJ O
gene NN O
identifiers NNS O
were VBD O
reduced VBN O
to TO O
a DT O
single JJ O
ortholog NN O
gene NN O
identifier NN O
. . O

The DT O
latter NN O
is VBZ O
a DT O
somewhat RB O
complex JJ O
procedure NN O
that WDT O
requires VBZ O
identifying VBG O
microarray NN O
probes NNS O
from IN O
each DT O
platform NN O
that WDT O
can MD O
be VB O
mapped VBN O
to TO O
a DT O
single JJ O
gene NN O
ortholog NN O
and CC O
undertaking VBG O
a DT O
procedure NN O
to TO O
aggregate VB O
redundant NN O
probes NNS O
within IN O
a DT O
platform NN O
( -LRB- O
see VB O
Materials NNS O
and CC O
methods NNS O
) -RRB- O
. . O

This DT O
approach NN O
allowed VBD O
the DT O
identification NN O
of IN O
8,621 CD O
gene NN O
transcripts NNS O
on IN O
the DT O
HG-U133 JJ O
plus2 NN O
and CC O
Vanderbilt NNP O
NIA NNP O
20 CD O
K NNP O
cDNA NN O
arrays NNS O
for IN O
which WDT O
relative JJ O
expression NN O
values NNS O
could MD O
be VB O
mapped VBN O
for IN O
nearly RB O
all DT O
mouse NN O
and CC O
human JJ O
samples NNS O
. . O

A DT O
clustering-based JJ O
assessment NN O
of IN O
expression NN O
across IN O
the DT O
whole JJ O
mouse-human NN O
ortholog NN O
gene NN O
set VBN O
identified VBN O
a DT O
large JJ O
number NN O
of IN O
transcripts NNS O
behaving VBG O
similarly RB O
across IN O
colon NN O
tumors NNS O
, , O
many JJ O
irrespective JJ O
, , O
but CC O
some DT O
respective JJ O
of IN O
species NNS O
. . O

Notably RB O
, , O
the DT O
great JJ O
majority NN O
of IN O
genes NNS O
over-expressed JJ O
in IN O
all DT O
tumors NNS O
were VBD O
also RB O
over-expressed JJ O
during IN O
colon NN O
development NN O
( -LRB- O
Figure NN O
6a CD O
) -RRB- O
. . O

To TO O
evaluate VB O
the DT O
statistical JJ O
significance NN O
of IN O
this DT O
pattern NN O
, , O
we PRP O
used VBD O
a DT O
Venn NNP O
overlap IN O
filtering VBG O
strategy NN O
and CC O
Fisher NNP O
's POS O
exact JJ O
test NN O
analysis NN O
. . O

Approximately RB O
50 CD O
% NN O
of IN O
the DT O
2,212 CD O
ortholog NN O
genes NNS O
over-expressed JJ O
in IN O
at IN O
least JJS O
10 CD O
% NN O
of IN O
the DT O
human JJ O
cancers NNS O
relative JJ O
to TO O
adult NN O
colon NN O
were VBD O
also RB O
over-expressed JJ O
in IN O
developing VBG O
colon NN O
. . O

If IN O
there EX O
was VBD O
not RB O
a DT O
selection NN O
for IN O
developmental JJ O
genes NNS O
among IN O
those DT O
over-expressed JJ O
in IN O
tumors NNS O
, , O
the DT O
expected VBN O
overlap NN O
would MD O
be VB O
( -LRB- O
2,718/8 CD O
,621 NN O
) -RRB- O
× VBZ O
2,212 CD O
= SYM O
697 CD O
transcripts NNS O
. . O

Using VBG O
Fisher NNP O
's POS O
exact JJ O
test NN O
for IN O
the DT O
significance NN O
of IN O
the DT O
increased VBN O
overlap NN O
of IN O
1,080 CD O
versus NN O
697 CD O
transcripts NNS O
is VBZ O
p JJ O
< IN O
1e-300 CD O
. . O

Similarly RB O
, , O
genes NNS O
under-expressed JJ O
in IN O
mouse NN O
colon NN O
development NN O
and CC O
human JJ O
CRCs NNS O
also RB O
strongly RB O
overlapped VBN O
( -LRB- O
Figure NN O
6b NN O
; : O
431 CD O
of IN O
737 CD O
, , O
p NN O
< NN O
1e-76 CD O
) -RRB- O
. . O

This DT O
result NN O
is VBZ O
significantly RB O
greater JJR O
than IN O
the DT O
8-19 CD O
% NN O
of IN O
genes NNS O
that WDT O
were VBD O
estimated VBN O
to TO O
be VB O
over-expressed JJ O
in IN O
human JJ O
colon NN O
tumors NNS O
and CC O
fetal NN O
gut NN O
morphogenesis NN O
based VBN O
upon IN O
a DT O
computational JJ O
extrapolation NN O
of IN O
SAGE NNP O
data NNS O
[27] VBP O
. . O

Thus RB O
, , O
our PRP$ O
findings NNS O
not RB O
only RB O
confirm VB O
but CC O
also RB O
significantly RB O
expand VB O
and CC O
experimentally RB O
validate VB O
the DT O
previously RB O
suggested VBN O
recapitulation NN O
of IN O
embryonic JJ O
signatures NNS O
by IN O
human JJ O
CRCs NNP O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

All DT O
overlaps NNS O
between IN O
tumor NN O
expression NN O
and CC O
development NN O
were VBD O
pooled VBN O
to TO O
form VB O
a DT O
set NN O
of IN O
2,116 CD O
ortholog NN O
gene NN O
transcripts NNS O
. . O

This DT O
was VBD O
subjected VBN O
to TO O
hierarchical JJ O
tree NN O
and CC O
K-means NNP O
clustering NN O
to TO O
define VB O
six CD O
expression NN O
clusters NNS O
, , O
C18-C23 DT O
( -LRB- O
Figure NN O
6c NN O
; : O
Table NN O
4) CD O
. . O

These DT O
clusters NNS O
provide VBP O
an DT O
impressive JJ O
partitioning NN O
of IN O
groups NNS O
of IN O
genes NNS O
associated VBN O
with IN O
different JJ O
biological JJ O
functions NNS O
critical JJ O
for IN O
colon NN O
development NN O
, , O
maturation NN O
and CC O
oncogenesis NN O
. . O

Cluster NNP O
C22 IN O
(860 CD O
transcripts NNS O
of IN O
genes NNS O
strongly RB O
expressed VBD O
both DT O
developmentally RB O
and CC O
across IN O
all DT O
tumors NNS O
) -RRB- O
is VBZ O
highly RB O
enriched VBN O
with IN O
genes NNS O
associated VBN O
with IN O
cell NN O
cycle NN O
progression NN O
, , O
replication NN O
, , O
cancer NN O
, , O
tumor NN O
morphology NN O
and CC O
cellular JJ O
movement NN O
. . O

Cluster NN O
C18 NNS O
( -LRB- O
258 CD O
transcripts NNS O
down-regulated JJ O
in IN O
mouse NN O
and CC O
human JJ O
tumors NNS O
, , O
as RB O
well RB O
as IN O
in IN O
development NN O
) -RRB- O
is VBZ O
highly RB O
enriched VBN O
in IN O
genes NNS O
associated VBN O
with IN O
digestive JJ O
tract NN O
function NN O
, , O
biochemical JJ O
and CC O
lipid JJ O
metabolism NN O
. . O

This DT O
cluster NN O
is VBZ O
clearly RB O
composed VBN O
of IN O
genes NNS O
associated VBN O
with IN O
the DT O
mature JJ O
GI NNP O
tract NN O
. . O

Thus RB O
, , O
as IN O
opposed VBN O
to TO O
recapitulating VBG O
developmental JJ O
gene NN O
activation NN O
, , O
the DT O
cluster NN O
C18 IN O
pattern NN O
indicates VBZ O
a DT O
corresponding JJ O
arrest NN O
of IN O
differentiation NN O
in IN O
both DT O
mouse NN O
and CC O
human JJ O
tumors NNS O
. . O

Cluster NN O
C23 NNS O
( -LRB- O
142 CD O
transcripts NNS O
over-expressed JJ O
in IN O
all DT O
mouse NN O
models NNS O
and CC O
human JJ O
CRC NNP O
, , O
but CC O
with IN O
low JJ O
expression NN O
in IN O
development NN O
) -RRB- O
maps NNS O
to TO O
genes NNS O
highly RB O
associated VBN O
with IN O
the DT O
disruption NN O
of IN O
basement NN O
membranes NNS O
, , O
invasion NN O
and CC O
cell NN O
cycle NN O
progression NN O
, , O
as RB O
well RB O
as IN O
altered VBN O
transcriptional JJ O
control NN O
. . O

Cluster NNP O
C21 NNP O
( -LRB- O
313 CD O
transcripts NNS O
in IN O
which WDT O
human JJ O
tumors NNS O
somewhat RB O
variably RB O
express VB O
a DT O
set NN O
of IN O
genes NNS O
that WDT O
are VBP O
rarely RB O
expressed VBN O
by IN O
the DT O
mouse NN O
tumors NNS O
) -RRB- O
is VBZ O
remarkable JJ O
for IN O
its PRP$ O
composition NN O
of IN O
genes NNS O
associated VBN O
with IN O
cell NN O
cycle NN O
proliferation NN O
, , O
tissue NN O
disruption NN O
and CC O
angiogenesis NN O
. . O

Thus RB O
, , O
while IN O
categorically RB O
quite RB O
similar JJ O
to TO O
cluster NN O
C23 NNS O
, , O
the DT O
genes NNS O
in IN O
cluster NN O
C21 NNP O
represent VBP O
a DT O
separately RB O
regulated JJ O
module NN O
that WDT O
is VBZ O
enriched VBN O
for IN O
genes NNS O
associated VBN O
with IN O
invasion NN O
. . O

Clusters NNS O
C21 NNP O
and CC O
C23 NNP O
reveal VBP O
sets NNS O
of IN O
genes NNS O
likely JJ O
involved VBN O
in IN O
tumor NN O
progression NN O
. . O

Cluster NN O
C22 NN O
( -LRB- O
with IN O
genes NNS O
over-expressed JJ O
in IN O
all DT O
mouse NN O
and CC O
human JJ O
tumors NNS O
and CC O
strongly RB O
expressed VBN O
in IN O
embryonic JJ O
colon NN O
) -RRB- O
represents VBZ O
a DT O
group NN O
of IN O
genes NNS O
highly RB O
correlated VBN O
with IN O
transformation NN O
. . O

The DT O
top-ranked JJ O
transcription NN O
factor NN O
present NN O
in IN O
this DT O
cluster NN O
, , O
with IN O
regulation NN O
independent JJ O
of IN O
β-catenin JJ O
localization NN O
, , O
is VBZ O
Myc/MYC NNP B-NP
( -LRB- O
Figure NN O
7b JJ O
) -RRB- O
. . O

Although IN O
Myc NNP B-NP
was VBD O
lower JJR O
in IN O
expression NN O
in IN O
the DT O
Smad3-/- NNP B-NP
tumors NNS O
compared VBN O
to TO O
tumors NNS O
from IN O
the DT O
other JJ O
three CD O
models NNS O
, , O
it PRP O
was VBD O
elevated VBN O
in IN O
all DT O
four CD O
models NNS O
relative JJ O
to TO O
normal JJ O
adult NN O
colon NN O
. . O

Myc/MYC NNP B-NP
was VBD O
over-expressed JJ O
in IN O
all DT O
mouse NN O
and CC O
human JJ O
tumors NNS O
as RB O
well RB O
as IN O
in IN O
development NN O
. . O

This DT O
contrasts VBZ O
with IN O
Sox4 NNP B-NP
, , O
which WDT O
is VBZ O
unaltered JJ O
in IN O
expression NN O
in IN O
the DT O
Smad3-/- NNP B-NP
and CC O
Tgfb1-/-; DT B-NP
Rag2-/- NNP B-NP
tumors NNS O
but CC O
is VBZ O
up-regulated JJ O
in IN O
AOM NNP B-NP
and CC O
ApcMin/+ NNP B-NP
tumors NNS O
relative JJ O
to TO O
normal JJ O
adult NN O
colon NN O
( -LRB- O
Figure NN O
7b JJ O
) -RRB- O
. . O

Myc/MYC NNP B-NP
over-expression NN O
may MD O
be VB O
independent JJ O
of IN O
nuclear JJ O
β-catenin NN O
status NN O
. . O

Increased VBN O
Myc/MYC NNP B-NP
expression NN O
may MD O
reflect VB O
both DT O
activation NN O
of IN O
canonical JJ O
Wnt JJ O
signaling NN O
, , O
as IN O
it PRP O
is VBZ O
a DT O
target NN O
of IN O
nuclear JJ O
β-catenin/TCF NN O
[28] NN O
, , O
and CC O
deregulation NN O
of IN O
TGFβ JJ O
signaling NN O
, , O
as IN O
TGFβ1 NNP B-NP
is VBZ O
known VBN O
to TO O
repress VB O
Myc/MYC NNP B-NP
[29-31] NNP O
. . O

These DT O
observations NNS O
suggest VBP O
a DT O
fundamental JJ O
role NN O
for IN O
Myc/MYC NNP B-NP
in IN O
colonic JJ O
neoplasia NN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

As IN O
shown VBN O
in IN O
Figure NN O
2a CD O
, , O
the DT O
microarray NN O
patterns NNS O
of IN O
gene NN O
expression NN O
for IN O
AOM NNP B-NP
and CC O
ApcMin/+ NNP B-NP
tumors NNS O
are VBP O
mirror NN O
images NNS O
of IN O
those DT O
for IN O
Tgfb1-/-; JJ B-NP
Rag2-/- NNP B-NP
tumors NNS O
. . O

It PRP O
is VBZ O
perhaps RB O
not RB O
surprising JJ O
that IN O
combining VBG O
these DT O
two CD O
transcriptional JJ O
programs NNS O
results NNS O
in IN O
increased JJ O
number NN O
and CC O
invasiveness NN O
of IN O
colonic JJ O
tumors NNS O
as IN O
recently RB O
reported VBN O
for IN O
ApcMin/+ NNP B-NP
mice NNS O
crossed VBD O
to TO O
Smad3-/- NNP B-NP
mice NNS O
[45] VBD O
. . O

Moreover RB O
, , O
combined VBN O
activation NN O
of IN O
canonical JJ O
WNT NNP O
signaling NN O
and CC O
inhibition NN O
of IN O
TGFβ NNP O
signaling VBG O
also RB O
results NNS O
in IN O
more JJR O
advanced JJ O
intestinal NN O
tumors NNS O
in IN O
Apcdelta716/+ NNP B-NP
; : O
Smad4+/ JJ B-NP
- : O
mice NNS O
[46] VBP O
, , O
and CC O
intestine-specific JJ O
deletion NN O
of IN O
the DT O
type NN B-NP
II NNP I-NP
TGFβ NN I-NP
receptor NN I-NP
in IN O
Apc1638N/wt NNP O
mice NNS O
[47] VBD O
. . O

The DT O
findings NNS O
that WDT O
shared VBD O
over-expressed JJ O
signatures NNS O
are VBP O
identifiable JJ O
in IN O
all DT O
four CD O
mouse NN O
models NNS O
of IN O
CRC NNP O
, , O
which WDT O
are VBP O
also RB O
representative JJ O
of IN O
the DT O
majority NN O
of IN O
embryonic JJ O
colonic JJ O
over-expressed JJ O
signatures NNS O
, , O
and CC O
that IN O
these DT O
signatures NNS O
are VBP O
also RB O
present JJ O
in IN O
all DT O
human JJ O
CRCs NNP O
, , O
suggest VBP O
that IN O
colon NN O
tumors NNS O
may MD O
arise VB O
independently RB O
of IN O
canonical NN O
WNT NNP O
signaling VBG O
status NN O
. . O

A DT O
likely JJ O
candidate NN O
to TO O
impart VB O
this DT O
oncogenic JJ O
signaling NN O
is VBZ O
Myc NNP B-NP
, , O
which WDT O
is VBZ O
an DT O
embryonic JJ O
up-regulated JJ O
transcript NN O
that WDT O
is VBZ O
also RB O
upregulated VBN O
in IN O
all DT O
human JJ O
CRCs NNP O
and CC O
mouse NN O
tumor NN O
models NNS O
independently RB O
of IN O
nuclear JJ O
β-catenin NN O
status NN O
. . O

Embryology NNP O
provides VBZ O
insight NN O
into IN O
the DT O
biology NN O
of IN O
mouse NN O
and CC O
human JJ O
colon NN O
tumors NNS O

It PRP O
has VBZ O
long RB O
been VBN O
suggested VBN O
that IN O
cancer NN O
represents VBZ O
a DT O
reversion NN O
to TO O
an DT O
embryonic JJ O
state NN O
, , O
partly RB O
based VBN O
upon IN O
the DT O
observation NN O
that IN O
several JJ O
oncofetal JJ O
antigens NNS O
are VBP O
diagnostic JJ O
for IN O
some DT O
tumors NNS O
[48,49] VBP O
. . O

To TO O
assess VB O
the DT O
embryology-related JJ O
aspects NNS O
of IN O
tumorigenesis NN O
and CC O
tumor NN O
progression NN O
in IN O
CRC NNP O
, , O
we PRP O
analyzed VBD O
and CC O
compared VBD O
the DT O
transcriptomes NNS O
of IN O
normal JJ O
mouse NN O
colon NN O
development NN O
and CC O
models NNS O
of IN O
CRC. NNP O

Our PRP$ O
data NNS O
show VBP O
that IN O
developmentally RB O
regulated VBN O
genes NNS O
represent VBP O
approximately RB O
56 CD O
% NN O
of IN O
mouse NN O
tumor NN O
signatures NNS O
, , O
and CC O
that IN O
the DT O
tumor NN O
signatures NNS O
from IN O
the DT O
four CD O
mouse NN O
models NNS O
recapitulate VBP O
approximately RB O
85 CD O
% NN O
of IN O
developmentally RB O
regulated VBN O
genes NNS O
. . O

There EX O
are VBP O
at IN O
least JJS O
two CD O
regulatory JJ O
programs NNS O
that WDT O
determine VBP O
the DT O
expression NN O
of IN O
developmental JJ O
genes NNS O
by IN O
mouse NN O
tumors NNS O
( -LRB- O
Figures NNS O
2 CD O
, , O
4 CD O
, , O
and CC O
8 CD O
) -RRB- O
. . O

The DT O
simpler JJR O
program NN O
is VBZ O
evident JJ O
by IN O
the DT O
over-expression NN O
of IN O
the DT O
earliest JJS O
genes NNS O
of IN O
colon NN O
development NN O
by IN O
the DT O
nuclear JJ O
β-catenin-positive JJ O
models NNS O
. . O

The DT O
more RBR O
subtle JJ O
program NN O
could MD O
be VB O
detected VBN O
only RB O
in IN O
reference NN O
to TO O
adult NN O
colon NN O
and CC O
is VBZ O
highly RB O
shared VBN O
by IN O
nuclear JJ O
β-catenin-negative JJ O
models NNS O
. . O

This DT O
program NN O
, , O
though IN O
modified VBN O
by IN O
nuclear JJ O
β-catenin NN O
status NN O
, , O
is VBZ O
represented VBN O
by IN O
a DT O
large JJ O
scale NN O
over-expression NN O
of IN O
developmentally VBG O
expressed VBN O
genes NNS O
in IN O
tumors NNS O
that WDT O
are VBP O
both DT O
positive JJ O
and CC O
negative JJ O
for IN O
canonical JJ O
WNT NNP O
signaling NN O
. . O

Genes NNP O
found VBD O
within IN O
this DT O
signature NN O
have VBP O
a DT O
large JJ O
overlap NN O
with IN O
those DT O
present JJ O
in IN O
the DT O
colon NN O
at IN O
later RB O
developmental JJ O
stages NNS O
( -LRB- O
E16.5-E18.5 CD O
) -RRB- O
. . O

An DT O
integrated JJ O
view NN O
of IN O
colon NN O
cancer NN O
transcriptional JJ O
programs NNS O
provides VBZ O
novel JJ O
insight NN O
into IN O
neoplasia NN O
. . O

Murine NNP O
colon NN O
tumor NN O
adenomas NNS O
and CC O
human JJ O
CRCs NNS O
both DT O
show NN O
adoption NN O
and CC O
dysregulation NN O
of IN O
signatures NNS O
tightly RB O
controlled VBN O
during IN O
embryonic JJ O
mouse NN O
colon NN O
development NN O
. . O

The DT O
use NN O
of IN O
etiologically RB O
distinct JJ O
mouse NN O
models NNS O
of IN O
colon NN O
cancer NN O
allows VBZ O
for IN O
the DT O
identification NN O
of IN O
models NNS O
that IN O
resemble VBP O
different JJ O
stages NNS O
of IN O
embryonic VBG O
mouse NN O
colon NN O
development NN O
and CC O
that DT O
are VBP O
recapitulated VBN O
by IN O
specific JJ O
tumor NN O
types NNS O
. . O

( -LRB- O
a DT O
) -RRB- O
All DT O
tumors NNS O
exhibit VBP O
large-scale JJ O
activation NN O
of IN O
developmental JJ O
patterns NNS O
. . O

Nuclear NNP O
β-catenin-positive JJ O
( -LRB- O
ApcMin/+ NNP B-NP
and CC O
AOM) NNP B-NP
tumors NNS O
map VBP O
more RBR O
strongly RB O
to TO O
early JJ O
development NN O
stages NNS O
during IN O
( -LRB- O
more RBR O
proliferative JJ O
, , O
less RBR O
differentiated JJ O
) -RRB- O
, , O
whereas IN O
nuclear JJ O
β-catenin-negative JJ O
( -LRB- O
Tgfb1-/-; JJ B-NP
Rag2-/- : B-NP
and CC O
Smad3-/-) JJ B-NP
tumors NNS O
map VBP O
more RBR O
strongly RB O
to TO O
later RB O
stages VBZ O
consistent JJ O
with IN O
increased VBN O
epithelial NN O
differentiation NN O
. . O

( -LRB- O
b NN O
) -RRB- O
Overall JJ O
representation NN O
of IN O
the DT O
relationship NN O
of IN O
mouse NN O
colon NN O
tumor NN O
models NNS O
and CC O
human JJ O
CRC NNP O
to TO O
development NN O
and CC O
non-developmental JJ O
expression NN O
patterns NNS O
. . O

Gene NNP O
expression NN O
clusters NNS O
mapped VBN O
to TO O
the DT O
progression NN O
of IN O
adenomatous JJ O
and CC O
carcinomatous JJ O
transformation NN O
identified VBN O
in IN O
Figures NNS O
5 CD O
and CC O
6 CD O
are VBP O
shown VBN O
as IN O
the DT O
clusters NNS O
of IN O
genes NNS O
whose WP$ O
expression NN O
is VBZ O
either DT O
gained VBN O
or CC O
lost VBN O
associated VBN O
with IN O
the DT O
stage NN O
of IN O
progression NN O
. . O

For IN O
example NN O
normal JJ O
development NN O
could MD O
be VB O
considered VBN O
as IN O
'subverted JJ O
' '' O
if IN O
there EX O
is VBZ O
an DT O
absence NN O
of IN O
expression NN O
of IN O
genes NNS O
normally RB O
expressed VBN O
at IN O
high JJ O
level NN O
in IN O
the DT O
developing VBG O
colon NN O
that WDT O
fail VBP O
to TO O
be VB O
expressed VBN O
in IN O
tumors NNS O
( -LRB- O
for IN O
example NN O
, , O
C18 PRP O
, , O
C19 NNP O
) -RRB- O
, , O
or CC O
that DT O
are VBP O
activated VBN O
in IN O
tumor NN O
but CC O
not RB O
normally RB O
expressed VBN O
in IN O
development NN O
( -LRB- O
C20 NNP O
) -RRB- O
. . O

Upregulated VBN O
clusters NNS O
are VBP O
enriched VBN O
for IN O
genes NNS O
with IN O
known VBN O
oncogenic JJ O
functions NNS O
and CC O
down-regulated JJ O
clusters NNS O
for IN O
genes NNS O
associated VBN O
with IN O
tumor NN O
suppression NN O
. . O

Both DT O
mouse NN O
colon NN O
tumor NN O
models NNS O
and CC O
human JJ O
CRC NNP O
share NN O
in IN O
the DT O
activation NN O
of IN O
embryonic JJ O
colon NN O
expression NN O
( -LRB- O
C22 NN O
) -RRB- O
, , O
or CC O
partially RB O
overlap JJ O
( -LRB- O
C23 NN O
, , O
dotted JJ O
lines NNS O
) -RRB- O
the DT O
loss NN O
or CC O
repression NN O
of IN O
adult NN O
differentiation-associated JJ O
genes NNS O
( -LRB- O
C19 CC O
) -RRB- O
, , O
and CC O
the DT O
loss NN O
of IN O
tumor NN O
suppressor NN O
genes NNS O
( -LRB- O
C18 NNS O
) -RRB- O
. . O

Many JJ O
human JJ O
CRCs NNS O
also RB O
lack VBP O
the DT O
expression NN O
of IN O
additional JJ O
tumor NN O
suppressor NN O
programs NNS O
and CC O
gain VB O
the DT O
expression NN O
of IN O
oncogenes NNS O
that WDT O
are VBP O
not RB O
over-expressed JJ O
during IN O
normal JJ O
developmental JJ O
morphogenesis NN O
( -LRB- O
C21 NNP O
) -RRB- O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

How WRB O
do VBP O
genes NNS O
tightly RB O
regulated VBN O
during IN O
mouse NN O
colon NN O
development NN O
become VBP O
activated VBN O
in IN O
colon NN O
tumors NNS O
? . O

While IN O
activated JJ O
canonical JJ O
WNT NNP O
signaling VBG O
imparts NNS O
a DT O
strong JJ O
influence NN O
, , O
its PRP$ O
absence NN O
in IN O
Tgfb1-/-; JJ B-NP
Rag2-/- NNP B-NP
and CC O
Smad3-/- NNP B-NP
tumors NNS O
, , O
as IN O
determined VBN O
by IN O
the DT O
absence NN O
of IN O
nuclear JJ O
β-catenin NN O
, , O
did VBD O
not RB O
prevent VB O
the DT O
large JJ O
scale NN O
activation NN O
of IN O
developmental/embryonic JJ O
gene NN O
expression NN O
. . O

One CD O
mechanism NN O
may MD O
be VB O
through IN O
epigenetic JJ O
alterations NNS O
. . O

In IN O
human JJ O
CRCs NNS O
, , O
these DT O
types NNS O
of IN O
alterations NNS O
in IN O
gene NN O
expression NN O
programs NNS O
[50] MD O
suggest VB O
a DT O
link NN O
between IN O
cellular JJ O
homeostasis NN O
and CC O
tumorigenesis NN O
. . O

The DT O
recruitment NN O
of IN O
histone NN O
acetyltransferases NNS O
and CC O
histone NN O
deacetylases NNS O
( -LRB- O
HDACs NNS O
) -RRB- O
are VBP O
key JJ O
steps NNS O
in IN O
the DT O
regulation NN O
of IN O
cell NN O
proliferation NN O
and CC O
differentiation NN O
during IN O
normal JJ O
development NN O
and CC O
carcinogenesis NN O
[51] NN O
. . O

Induction NN O
of IN O
Hdac2 NNP B-NP
expression NN O
occurs VBZ O
in IN O
82 CD O
% NN O
of IN O
human JJ O
CRCs NNS O
as RB O
well RB O
as IN O
in IN O
tumors NNS O
from IN O
ApcMin/+ NNP B-NP
mice NNS O
[19] VBD O
. . O

Alternatively RB O
, , O
common JJ O
regulatory JJ O
controls NNS O
may MD O
operate VB O
in IN O
parallel JJ O
growth NN O
and CC O
differentiation/anti-diifferentiation NN O
pathways NNS O
such JJ O
that IN O
a DT O
single JJ O
or CC O
small JJ O
subset NN O
of IN O
regulators NNS O
, , O
such JJ O
as IN O
MYC NNP B-NP
or CC O
one CD O
or CC O
more JJR O
micro JJ O
RNAs NNS O
, , O
may MD O
be VB O
responsible JJ O
for IN O
the DT O
control NN O
of IN O
multiple JJ O
pathways NNS O
. . O

Indeed RB O
, , O
consistent JJ O
with IN O
our PRP$ O
observation NN O
of IN O
nuclear JJ O
β-catenin-independent JJ O
activation NN O
of IN O
Myc NNP B-NP
in IN O
all DT O
mouse NN O
models NNS O
and CC O
across IN O
the DT O
board NN O
for IN O
human JJ O
CRC NNP O
, , O
deletion NN O
of IN O
Myc NNP B-NP
has VBZ O
recently RB O
been VBN O
demonstrated VBN O
to TO O
completely RB O
abrogate JJ O
nuclear JJ O
β-catenin-driven JJ O
small JJ O
bowel NN O
oncogenesis NN O
in IN O
mouse NN O
models NNS O
[52] VBP O
. . O

Comparative JJ O
analysis NN O
reveals VBZ O
underlying VBG O
development-related JJ O
signatures NNS O
in IN O
human JJ O
CRCs NNS O

As IN O
shown VBN O
in IN O
Figure NN O
5 CD O
, , O
considerable JJ O
and CC O
intriguing JJ O
heterogeneity NN O
of IN O
human JJ O
CRC NNP O
is VBZ O
observed VBN O
among IN O
genes NNS O
highly RB O
relevant JJ O
for IN O
differential JJ O
malignant JJ O
behavior NN O
. . O

However RB O
, , O
employing VBG O
between-tumors NNS O
normalization RB O
and CC O
referencing VBG O
strategies NNS O
prevents VBZ O
the DT O
detection NN O
of IN O
gene NN O
expression NN O
patterns NNS O
that WDT O
are VBP O
shared VBN O
between IN O
tumors NNS O
. . O

Using VBG O
the DT O
adult NN O
normal JJ O
colon NN O
as IN O
a DT O
reference NN O
, , O
as IN O
shown VBN O
in IN O
Figure NN O
6 CD O
, , O
a DT O
large JJ O
fraction NN O
of IN O
differential JJ O
gene NN O
expression NN O
relative JJ O
to TO O
adult NN O
colon NN O
could MD O
be VB O
demonstrated VBN O
that IN O
recapitulated VBN O
developmental JJ O
gene NN O
expression NN O
by IN O
virtue NN O
of IN O
both DT O
activating VBG O
embryonic JJ O
colon NN O
gene NN O
expression NN O
and CC O
failing VBG O
to TO O
express VB O
genes NNS O
associated VBN O
with IN O
normal JJ O
colon NN O
maturation NN O
. . O

Within IN O
these DT O
developmentally VBG O
regulated JJ O
gene NN O
sets NNS O
, , O
our PRP$ O
analyses NNS O
revealed VBD O
little JJ O
evidence NN O
of IN O
CRC NNP O
subsets NNS O
, , O
including VBG O
those DT O
suggestive JJ O
of IN O
nuclear JJ O
β-catenin NN O
negative JJ O
tumors NNS O
that WDT O
might MD O
approximate JJ O
the DT O
Smad3-/- NNP B-NP
and CC O
Tgfb1-/-; NNP B-NP
Rag2-/- NNP B-NP
signature NN O
. . O

Our PRP$ O
inability NN O
to TO O
identify VB O
distinct JJ O
subclasses NNS O
with IN O
respect NN O
to TO O
developmental JJ O
genes NNS O
in IN O
the DT O
human JJ O
CRCs NNP O
is VBZ O
perhaps RB O
not RB O
surprising JJ O
in IN O
that DT O
over IN O
80 CD O
% NN O
of IN O
microsatellite-unstable JJ O
( -LRB- O
MSI+ NN O
) -RRB- O
CRCs NNPS O
from IN O
HNPCC NNP O
families NNS O
exhibit VBP O
nuclear JJ B-NP
β-catenin NN I-NP
[53] NN O
. . O

In IN O
addition NN O
, , O
within IN O
the DT O
developmental JJ O
genes NNS O
, , O
little JJ O
evidence NN O
was VBD O
apparent JJ O
for IN O
signatures NNS O
related VBN O
to TO O
MSI+ NNP O
tumors NNS O
, , O
often RB O
associated VBN O
with IN O
HNPCC NNP O
, , O
although IN O
some DT O
of IN O
this DT O
type NN O
of IN O
signature NN O
was VBD O
perhaps RB O
apparent JJ O
in IN O
the DT O
median JJ O
normalized JJ O
depiction NN O
of IN O
the DT O
tumors NNS O
as IN O
highlighted VBN O
in IN O
Figure NN O
5 CD O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Inter-organism NNP O
gene NN O
ortholog NN O
and CC O
inter-platform NN O
comparison NN O
strategy NN O

Pairs NNS O
of IN O
human JJ O
and CC O
mouse NN O
ortholog NN O
genes NNS O
( -LRB- O
12,693 CD O
) -RRB- O
were VBD O
curated VBN O
using VBG O
the DT O
Mouse NN O
Genome NN O
Informatics NNP O
( -LRB- O
MGI NNP O
; : O
The DT O
Jackson NNP O
Laboratory NNP O
) -RRB- O
[61] CD O
and CC O
National NNP O
Center NNP O
for IN O
Biotechnology NNP O
Information NN O
(NCBI NN O
) -RRB- O
Homologene NN O
[62] JJ O
databases NNS O
. . O

Individual JJ O
microarray NN O
elements NNS O
or CC O
features NNS O
were VBD O
mapped VBN O
to TO O
these DT O
. . O

The DT O
concatenated JJ O
human NN O
and CC O
mouse NN O
RefSeq NNP O
IDs NNP O
was VBD O
used VBN O
as IN O
the DT O
composite JJ O
ID NN O
for IN O
the DT O
orthologous JJ O
gene NN O
pair NN O
in IN O
the DT O
ortholog NN O
genome JJ O
definition NN O
. . O

NIA/Research NNP O
Genetics NNP O
mouse NN O
cDNAs NNS O
were VBD O
mapped VBN O
to TO O
human JJ O
orthologs NNS O
using VBG O
a DT O
variety NN O
of IN O
resources NNS O
, , O
usually RB O
via IN O
the DT O
Stanford NNP O
Online NNP O
Universal NNP O
Reference NNP O
resource NN O
[63] NN O
. . O

Gene NNP O
transcript NN O
assignments NNS O
were VBD O
made VBN O
unique JJ O
by IN O
choosing VBG O
the DT O
longest JJS O
corresponding JJ O
transcript NN O
. . O

To TO O
map NN O
the DT O
Affymetrix NNP O
human NN O
and CC O
mouse NN O
array NN O
data NNS O
into IN O
the DT O
ortholog NN O
genome NN O
, , O
we PRP O
used VBD O
a DT O
sequence NN O
matching VBG O
approach NN O
. . O

First RB O
, , O
we PRP O
obtained VBD O
human JJ O
and CC O
mouse NN O
transcript NN O
sequences NNS O
from IN O
RefSeq NNP O
[64] NNP O
and CC O
probe NN O
sequences NNS O
from IN O
the DT O
manufacturer NN O
's POS O
website JJ O
[65] NN O
. . O

Next JJ O
, , O
we PRP O
computed VBD O
all DT O
perfect JJ O
probe-transcript NN O
pairs NNS O
. . O

We PRP O
excluded VBN O
probes NNS O
that WDT O
matched VBD O
multiple JJ O
gene NN O
symbols NNS O
but CC O
accepted VBD O
probes NNS O
that IN O
matched VBN O
multiple JJ O
transcripts NNS O
. . O

Probe NNP O
sets NNS O
were VBD O
assigned VBN O
to TO O
represent VB O
a DT O
given VBN O
transcript NN O
if IN O
at IN O
least JJS O
50 CD O
% NN O
of IN O
the DT O
perfect JJ O
match NN O
probes NNS O
of IN O
the DT O
probe NN O
set VBD O
matched VBN O
to TO O
that DT O
transcript NN O
. . O

The DT O
newly RB O
assigned VBN O
transcript NN O
identifiers NNS O
were VBD O
then RB O
used VBN O
to TO O
map NN O
probe NN O
sets VBZ O
to TO O
ortholog VB O
genes NNS O
. . O

Since IN O
some DT O
transcripts NNS O
have VBP O
multiple JJ O
probe-set JJ O
representations NNS O
on IN O
both DT O
the DT O
Affymetrix NNP O
and CC O
cDNA DT O
microarrays NNS O
to TO O
one CD O
ortholog NN O
identifier NN O
, , O
we PRP O
employed VBD O
an DT O
ad NN O
hoc NN O
strategy NN O
to TO O
use VB O
the DT O
average NN O
of IN O
those DT O
probe NN O
sets NNS O
or CC O
cDNAs NNS O
that IN O
exhibited VBN O
consistent JJ O
regulation NN O
across IN O
a DT O
sample NN O
series NN O
. . O

In IN O
such JJ O
cases NNS O
, , O
the DT O
signals NNS O
of IN O
the DT O
regulated JJ O
probe NN O
sets NNS O
that WDT O
were VBD O
interpreted VBN O
as IN O
being VBG O
in IN O
agreement NN O
were VBD O
averaged VBN O
and CC O
assigned VBN O
to TO O
the DT O
corresponding JJ O
ortholog NN O
. . O

We PRP O
excluded VBN O
probe NN O
sets NNS O
or CC O
cDNAs NNS O
that IN O
we PRP O
were VBD O
aware JJ O
corresponded JJ O
to TO O
non-transcript JJ O
genomic JJ O
sequence NN O
as IN O
tested VBN O
using VBG O
BLAT NN O
at IN O
the DT O
UCSC NNP O
Goldenpath NNP O
website NN O
[66] NN O
. . O

Mouse-human NNP O
RefSeq NNP O
gene NN O
ortholog NN O
assignments NNS O
can MD O
be VB O
found VBN O
at IN O
GenomeTrafac NNP O
[67,68] NNP O
. . O

All DT O
ortholog NN O
assignments NNS O
and CC O
cross-species NNS O
mapping NN O
annotations NNS O
were VBD O
incorporated VBN O
into IN O
annotations NNS O
associated VBN O
with IN O
the DT O
Affymetrix NNP O
HG-U133 NNP O
plus2.0 CC O

genome NN O
. . O

Gene NNP O
expression NN O
ratios NNS O
obtained VBN O
for IN O
the DT O
mouse NN O
samples NNS O
were VBD O
then RB O
represented VBN O
as IN O
expression NN O
values NNS O
within IN O
the DT O
human JJ O
platform NN O
for IN O
all DT O
of IN O
the DT O
probe NN O
sets VBZ O
that DT O
mapped VBN O
to TO O
the DT O
corresponding JJ O
mouse NN O
gene NN O
ortholog NN O
. . O

Data NNP O
for IN O
the DT O
primary JJ O
human JJ O
sample NN O
series NN O
, , O
as RB O
well RB O
as IN O
the DT O
combined VBN O
mouse-human NN O
data NNS O
sets NNS O
, , O
are VBP O
available JJ O
in IN O
the DT O
Cincinnati NNP O
Children NNP O
's POS O
Hospital NNP O
Medical NNP O
Center NNP O
microarray NN O
data NNS O
server NN O
[69] NN O
in IN O
the DT O
HG-U133 JJ O
genome NN O
under IN O
the DT O
KaiserEtAl_2006 NNP O
folders NNS O
( -LRB- O
'guest JJS O
' POS O
login NN O
; : O
all DT O
cross-platform NN O
ortholog NN O
gene NN O
identifiers NNS O
are VBP O
contained VBN O
as IN O
annotation NN O
fields NNS O
within IN O
the DT O
HG-U133 JJ O
genome JJ O
table NN O
) -RRB- O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Statistical NNP O
and CC O
data NNS O
visualization NN O
approaches NNS O

Most JJS O
normalization NN O
, , O
expression-level JJ O
referencing NN O
, , O
statistical JJ O
comparisons NNS O
, , O
and CC O
data NNS O
visualization NN O
were VBD O
performed VBN O
using VBG O
GeneSpring NNP O
v7.0 CD O
( -LRB- O
Silicon NNP O
Genetics-Agilent NNP O
( -LRB- O
part NN O
of IN O
Agilent JJ O
Technologies NNP O
) -RRB- O
. . O

Fisher NNP O
's POS O
exact JJ O
test NN O
was VBD O
performed VBN O
online RB O
at IN O
the DT O
MATFORSK NNP O
Fisher NNP O
's POS O
Exact NNP O
Test NNP O
server NN O
[70] NN O
. . O

To TO O
identify VB O
differentially RB O
expressed VBN O
features NNS O
between IN O
two CD O
or CC O
more JJR O
classes NNS O
, , O
we PRP O
applied VBD O
GeneSpring NNP O
's POS O
Wilcoxon-Mann-Whitney NNP O
or CC O
the DT O
Kruskal-Wallis NNP O
test NN O
, , O
respectively RB O
. . O

For IN O
three CD O
or CC O
more JJR O
classes NNS O
, , O
the DT O
initial JJ O
non-parametric JJ O
test NN O
was VBD O
followed VBN O
by IN O
the DT O
Student-Newman-Keuls NNP O
post-hoc JJ O
test NN O
. . O

Results NNS O
from IN O
the DT O
primary JJ O
analyses NNS O
were VBD O
corrected VBN O
for IN O
multiple JJ O
testing NN O
effects NNS O
by IN O
applying VBG O
Benjamini NNP O
and CC O
Hochberg NNP O
false JJ O
discovery NN O
rate NN O
( -LRB- O
FDR) JJ O
correction NN O
[71] NN O
. . O

In IN O
general JJ O
, , O
due JJ O
to TO O
the DT O
referencing VBG O
strategies NNS O
, , O
good JJ O
platform NN O
technical JJ O
performances NNS O
, , O
and CC O
moderately RB O
low JJ O
within-group , O
biological JJ O
variation NN O
of IN O
gene NN O
expression NN O
, , O
stringent JJ O
cutoffs NNS O
could MD O
be VB O
used VBN O
, , O
that DT O
is VBZ O
, , O
the DT O
FDR NNP O
level NN O
of IN O
significance NN O
was VBD O
set VBN O
between IN O
FDR NNP O
< NNP O
5.10-5 CD O
and CC O
FDR NNP O
< NNP O
5.10-4. . O

K-means NNP O
clustering NN O
was VBD O
performed VBN O
using VBG O
the DT O
GeneSpring NNP O
K-means NNP O
tool NN O
and CC O
the DT O
Pearson NNP O
correlation NN O
similarity NN O
measure NN O
. . O

Ontology-based JJ O
analysis NN O
of IN O
gene NN O
cluster-associated JJ O
functional JJ O
correlates NNS O

Gene NNP O
expression NN O
clusters NNS O
were VBD O
analyzed VBN O
for IN O
the DT O
occurrence NN O
of IN O
multiple JJ O
genes NNS O
involved VBN O
in IN O
related VBN O
gene NN O
function NN O
categories NNS O
by IN O
comparing VBG O
each DT O
list NN O
of IN O
coordinately RB O
regulated VBN O
clustered VBN O
genes NNS O
to TO O
categories NNS O
within IN O
Gene NNP O
Ontology NNP O
, , O
pathways NNS O
, , O
or CC O
literature-based JJ O
gene NN O
associations NNS O
using VBG O
GATACA NNP O
[72] NNP O
, , O
Ontoexpress NNP O
[73] NNP O
, , O
and CC O
Ingenuity NNP O
Pathway NNP O
Analysis NNP O
, , O
version NN O
3 CD O
( -LRB- O
IPA NN O
, , O
Ingenuity NNP O
Systems NNPS O
, , O
Redwood NNP O
City NNP O
, , O
CA NNP O
, , O
USA NNP O
) -RRB- O
[74] VBD O
. . O

To TO O
do VB O
this DT O
, , O
each DT O
cluster NN O
indicated VBD O
in IN O
Figures NNS O
2 CD O
, , O
4 CD O
, , O
5 CD O
, , O
6 CD O
and CC O
8 CD O
was VBD O
converted VBN O
to TO O
a DT O
list NN O
of IN O
gene NN O
identifiers NNS O
, , O
uploaded VBN O
to TO O
the DT O
application NN O
, , O
and CC O
examined VBD O
for IN O
over-representation NN O
of IN O
multiple JJ O
genes NNS O
from IN O
one CD O
or CC O
more JJR O
molecular JJ O
networks NNS O
, , O
or CC O
functional JJ O
or CC O
disease NN O
associations NNS O
as IN O
developed VBN O
from IN O
literature NN O
mining NN O
. . O

Networks NNS O
of IN O
these DT O
focus NN O
genes NNS O
were VBD O
algorithmically RB O
generated VBN O
based VBN O
on IN O
the DT O
relationships NNS O
of IN O
individual JJ O
genes NNS O
as IN O
derived VBN O
from IN O
literature NN O
review NN O
and CC O
used VBD O
to TO O
identify VB O
the DT O
biological JJ O
functions NNS O
and/or CC O
associated JJ O
pathological JJ O
processes NNS O
most RBS O
significant JJ O
for IN O
each DT O
gene NN O
cluster NN O
. . O

Fisher NNP O
's POS O
exact JJ O
test NN O
was VBD O
used VBN O
to TO O
calculate VB O
a DT O
p NN O
value NN O
estimating VBG O
the DT O
probability NN O
that IN O
a DT O
particular JJ O
functional JJ O
classification NN O
or CC O
category NN O
of IN O
genes NNS O
is VBZ O
associated VBN O
with IN O
a DT O
particular JJ O
pattern NN O
or CC O
cluster NN O
of IN O
gene NN O
expression NN O
more JJR O
than IN O
would MD O
be VB O
expected VBN O
by IN O
chance NN O
. . O

For IN O
each DT O
cluster NN O
, , O
only RB O
the DT O
top JJ O
significant JJ O
functional JJ O
classes NNS O
and CC O
canonical JJ O
pathways NNS O
are VBP O
shown VBN O
. . O

Figure NN O
7a CD O
shows VBZ O
a DT O
diagram NN O
of IN O
the DT O
canonical JJ O
WNT NNP O
signaling VBG O
pathway NN O
and CC O
an DT O
associated-gene NN O
network NN O
that WDT O
was VBD O
a DT O
top-ranked JJ O
association NN O
of IN O
the DT O
clusters NNS O
that IN O
exhibited JJ O
significant JJ O
over-expression NN O
in IN O
AOM NNP O
and CC O
ApcMin/+ NNP B-NP
versus IN O
Smad3-/- NNP B-NP
and CC O
Tgfb1-/-; DT B-NP
Rag2-/- NNP B-NP
mouse NN O
models NNS O
. . O

Genes NNP O
or CC O
gene NN O
products NNS O
are VBP O
represented VBN O
as IN O
nodes NNS O
, , O
and CC O
biological JJ O
relationships NNS O
between IN O
nodes NNS O
are VBP O
represented VBN O
as IN O
edges NNS O
( -LRB- O
lines NNS O
) -RRB- O
. . O

All DT O
edges NNS O
are VBP O
supported VBN O
by IN O
at IN O
least JJS O
one CD O
literature NN O
reference NN O
from IN O
a DT O
manuscript NN O
, , O
or CC O
from IN O
canonical JJ O
information NN O
stored VBN O
in IN O
the DT O
Ingenuity NNP O
Pathways NNP O
Knowledge NN O
Base NN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

promoter NN O
methylation NN O
in IN O
peripheral JJ O
blood NN O
DNA NN O
of IN O
mutation NN O
negative JJ O
familial JJ O
breast NN O
cancer NN O
patients NNS O
with IN O
a DT O
tumour NN O
phenotype NN O

Abstract NN O

Introduction NN O

Individuals NNS O
with IN O
germline NN O
mutations NNS O
in IN O
the DT O
BRCA1 NNP B-NP
gene NN O
have VBP O
an DT O
elevated JJ O
risk NN O
of IN O
developing VBG O
breast NN O
cancer NN O
, , O
and CC O
often RB O
display VB O
characteristic JJ O
clinicopathological JJ O
features NNS O
. . O

We PRP O
hypothesised VBD O
that IN O
inactivation NN O
of IN O
BRCA1 NN B-NP
by IN O
promoter NN O
methylation NN O
could MD O
occur VB O
as IN O
a DT O
germline NN O
or CC O
an DT O
early JJ O
somatic JJ O
event NN O
that IN O
predisposes NNS O
to TO O
breast NN O
cancer NN O
with IN O
the DT O
phenotype NN O
normally RB O
associated VBN O
with IN O
BRCA1 NNP B-NP
germline NN O
mutation NN O
. . O

Methods NNS O

We PRP O
examined VBD O
seven CD O
cases NNS O
from IN O
breast-ovarian NN O
cancer NN O
families NNS O
with IN O
tumours NNS O
that WDT O
showed VBD O
BRCA1-like JJ B-NP
pathology NN O
but CC O
did VBD O
not RB O
have VB O
detectable JJ O
BRCA1 NN B-NP
or CC O
BRCA2 NN B-NP
germline NN O
mutations NNS O
present JJ O
. . O

Methylation NN O
levels NNS O
were VBD O
tested VBN O
by IN O
several JJ O
quantitative JJ O
techniques NNS O
including VBG O
Methy NNP O
Light NNP O
, , O
methylation-sensitive JJ O
high JJ O
resolution NN O
melting VBG O
( -LRB- O
MS-HRM JJ O
) -RRB- O
and CC O
a DT O
newly RB O
developed VBN O
digital JJ O
MS-HRM JJ O
assay NN O
. . O

Results NNS O

In IN O
one CD O
patient NN O
, , O
methylation NN O
of IN O
10 CD O
% NN O
of IN O
the DT O
BRCA1 NNP B-NP
alleles NNS O
was VBD O
detected VBN O
in IN O
the DT O
peripheral JJ O
blood NN O
DNA NN O
, , O
consistent JJ O
with IN O
20 CD O
% NN O
of IN O
cells NNS O
having VBG O
one CD O
methylated JJ O
allele NN O
. . O

Buccal NNP O
mucosa NN O
DNA NN O
from IN O
this DT O
individual JJ O
displayed VBD O
approximately RB O
5 CD O
% NN O
BRCA1 NN B-NP
methylation NN O
. . O

In IN O
two CD O
other JJ O
patients NNS O
, , O
methylation NN O
of IN O
BRCA1 NNP B-NP
was VBD O
detected VBN O
in IN O
the DT O
peripheral JJ O
blood NN O
at IN O
significantly RB O
lower JJR O
but CC O
still RB O
readily RB O
detectable JJ O
levels NNS O
( -LRB- O
approximately RB O
1 CD O
% NN O
) -RRB- O
. . O

Tumour NNP O
DNAs NNP O
from IN O
these DT O
three CD O
patients NNS O
were VBD O
heavily RB O
methylated VBN O
at IN O
BRCA1 NNP B-NP
. . O

The DT O
other JJ O
patients NNS O
had VBD O
no DT O
detectable JJ O
BRCA1 NN B-NP
methylation NN O
in IN O
their PRP$ O
peripheral JJ O
blood NN O
. . O

One CD O
of IN O
seven CD O
age-matched JJ O
controls NNS O
showed VBD O
extremely RB O
low JJ O
levels NNS O
of IN O
methylation NN O
in IN O
their PRP$ O
peripheral JJ O
blood NN O
( -LRB- O
approximately RB O
0.1 CD O
% NN O
) -RRB- O
. . O

Conclusion NN O

These DT O
results NNS O
demonstrate VBP O
that IN O
in IN O
some DT O
cases NNS O
of IN O
breast NN O
cancer NN O
, , O
low-level JJ O
promoter NN O
methylation NN O
of IN O
BRCA1 NNP B-NP
occurs VBZ O
in IN O
normal JJ O
tissues NNS O
of IN O
the DT O
body NN O
and CC O
is VBZ O
associated VBN O
with IN O
the DT O
development NN O
of IN O
BRCA1-like JJ B-NP
breast NN O
cancer NN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Introduction NN O

In IN O
1994 CD O
, , O
BRCA1 NNP B-NP
was VBD O
identified VBN O
as IN O
the DT O
first JJ O
major JJ O
gene NN O
associated VBN O
with IN O
familial JJ O
breast NN O
cancer NN O
predisposition NN O
[1] NN O
. . O

Since IN O
then RB O
many JJ O
inactivating JJ O
mutations NNS O
in IN O
BRCA1 NNP B-NP
have VBP O
been VBN O
identified VBN O
as IN O
breast NN O
cancer NN O
predisposition NN O
alleles NNS O
. . O

Breast NNP O
cancers NNS O
associated VBN O
with IN O
BRCA1 NN B-NP
mutations NNS O
often RB O
show VBP O
characteristic JJ O
histological JJ O
features NNS O
including VBG O
high JJ O
grade NN O
, , O
high JJ O
mitotic JJ O
count NN O
, , O
solid JJ O
architecture NN O
and CC O
prominent JJ O
lymphocytic JJ O
infiltrates NNS O
, , O
all DT O
features NNS O
resembling VBG O
so-called JJ O
medullary NN O
cancer NN O
[2-4] NN O
. . O

BRCA1-associated JJ B-NP
tumours NNS O
are VBP O
usually RB O
negative JJ O
by IN O
immunohistochemistry NN O
for IN O
the DT O
oestrogen NN O
receptor NN O
( -LRB- O
ER NNP B-NP
) -RRB- O
, , O
the DT O
progesterone NN O
receptor NN O
( -LRB- O
PR NN B-NP
) -RRB- O
and CC O
HER2 NNP B-NP
[5-7] NNP O
. . O

However RB O
, , O
the DT O
majority NN O
of IN O
breast NN O
cancers NNS O
that IN O
exhibit NN O
a DT O
BRCA1-like JJ B-NP
phenotype NN O
do VBP O
not RB O
harbour RB O
detectable JJ O
germline NN O
mutations NNS O
in IN O
BRCA1 NNP B-NP
. . O

Some DT O
of IN O
this DT O
discordance NN O
may MD O
be VB O
due JJ O
to TO O
epigenetic JJ O
defects NNS O
in IN O
breast NN O
cancer NN O
susceptibility NN O
genes NNS O
such JJ O
as IN O
BRCA1 NNP B-NP
contributing VBG O
to TO O
breast NN O
cancer NN O
predisposition NN O
. . O

Recent JJ O
reports NNS O
of IN O
somatic JJ O
methylation NN O
( -LRB- O
or CC O
epimutations NNS O
) -RRB- O
affecting VBG O
an DT O
allele NN O
of IN O
the DT O
MLH1 NNP B-NP
gene NN O
in IN O
patients NNS O
with IN O
hereditary JJ O
non-polyposis NN O
colorectal NN O
cancer NN O
indicate VBP O
inactivation NN O
of IN O
tumour NN O
suppressor NN O
genes NNS O
by IN O
promoter NN O
methylation NN O
can MD O
occur VB O
early RB O
in IN O
development NN O
or CC O
possibly RB O
in IN O
the DT O
germline NN O
[8-10] NN O
. . O

Allelic NNP O
methylation NN O
is VBZ O
functionally RB O
equivalent JJ O
to TO O
a DT O
mutation NN O
in IN O
that DT O
loss NN O
of IN O
activity NN O
of IN O
the DT O
second JJ O
allele NN O
arising VBG O
from IN O
a DT O
mutation NN O
, , O
loss NN O
of IN O
heterozygosity NN O
or CC O
a DT O
second JJ O
methylation NN O
event NN O
will MD O
inactivate VB O
the DT O
gene NN O
. . O

Methylation NNP O
of IN O
the DT O
BRCA1 NN B-NP
promoter NN O
has VBZ O
been VBN O
shown VBN O
to TO O
occur VB O
in IN O
approximately RB O
20 CD O
% NN O
of IN O
breast NN O
cancer NN O
patients NNS O
[11-14] JJ O
. . O

Sporadic JJ O
tumours NNS O
with IN O
BRCA1 NNP B-NP
promoter NN O
methylation NN O
have VBP O
been VBN O
reported VBN O
to TO O
be VB O
ER NNP B-NP
and CC O
PR NNP B-NP
negative JJ O
[13,14] NN O
, , O
or CC O
to TO O
display VB O
similar JJ O
pathological JJ O
features NNS O
to TO O
those DT O
of IN O
BRCA1-mutated JJ B-NP
hereditary JJ O
breast NN O
cancers NNS O
[15] VBP O
. . O

Furthermore RB O
, , O
tumours NNS O
with IN O
BRCA1 NNP B-NP
methylation NN O
appear VBP O
to TO O
have VB O
similar JJ O
global JJ O
gene NN O
expression NN O
profiles NNS O
to TO O
BRCA1 NNP B-NP
mutated VBD O
tumours NNS O
[16] VB O
and CC O
similar JJ O
genomic JJ O
copy NN O
number NN O
profiles NNS O
[17] VBP O
. . O

Other JJ O
authors NNS O
have VBP O
claimed VBN O
that IN O
BRCA1 NNP B-NP
methylated VBD O
tumours NNS O
have VBP O
distinct JJ O
pathologies NNS O
to TO O
those DT O
seen VBN O
in IN O
BRCA1 NNP B-NP
mutated VBD O
tumours NNS O
[18] VBD O
. . O

The DT O
discrepancy NN O
may MD O
at IN O
least JJS O
in IN O
part NN O
be VB O
resolved VBN O
by IN O
the DT O
hypothesis NN O
that IN O
the DT O
timing NN O
of IN O
BRCA1 NNP B-NP
methylation NN O
will MD O
influence VB O
tumour NN O
phenotype NN O
; : O
the DT O
earlier RBR O
in IN O
tumorigenesis NN O
methylation NN O
occurs VBZ O
, , O
the DT O
greater JJR O
the DT O
similarity NN O
to TO O
tumours NNS O
arising VBG O
from IN O
germline NN O
BRCA1 NN B-NP
mutations NNS O
. . O

It PRP O
must MD O
also RB O
be VB O
taken VBN O
into IN O
consideration NN O
that IN O
while IN O
most JJS O
tumours NNS O
arising VBG O
in IN O
BRCA1 JJ B-NP
mutation NN O
carriers NNS O
have VBP O
typical JJ O
pathology NN O
, , O
a DT O
sizeable JJ O
minority NN O
do VBP O
not RB O
. . O

We PRP O
hypothesised VBD O
that IN O
some DT O
individuals NNS O
are VBP O
predisposed VBN O
to TO O
develop VB O
breast NN O
cancer NN O
with IN O
the DT O
features NNS O
associated VBN O
with IN O
BRCA1 NNP B-NP
mutations NNS O
because IN O
they PRP O
carry VBP O
a DT O
methylated JJ O
BRCA1 NN B-NP
allele NN O
in IN O
their PRP$ O
somatic JJ O
tissues NNS O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

In IN O
digital JJ O
MS-HRM JJ O
, , O
bisulfite JJ O
modified JJ O
DNA NN O
is VBZ O
diluted VBN O
to TO O
the DT O
point NN O
where WRB O
the DT O
individual JJ O
PCR NNP O
reactions NNS O
contained VBD O
0, CD O
1 CD O
or CC O
occasionally RB O
2 CD O
amplifiable JJ O
templates NNS O
. . O

This DT O
eliminates VBZ O
the DT O
problem NN O
of IN O
PCR NN O
bias NN O
where WRB O
unmethylated JJ O
or CC O
methylated JJ O
templates NNS O
have VBP O
different JJ O
amplification NN O
efficiencies NNS O
, , O
hence RB O
skewing VBG O
the DT O
actual JJ O
methylated JJ O
to TO O
unmethylated JJ O
ratios NNS O
. . O

Multiple JJ O
replicates NNS O
of IN O
the DT O
diluted JJ O
sample NN O
are VBP O
amplified VBN O
by IN O
PCR NNP O
where WRB O
it PRP O
is VBZ O
expected VBN O
that IN O
many JJ O
reactions NNS O
will MD O
not RB O
amplify VB O
because IN O
of IN O
the DT O
absence NN O
of IN O
template JJ O
. . O

The DT O
melting VBG O
profile NN O
of IN O
each DT O
reaction NN O
or CC O
'clone JJ O
' '' O
is VBZ O
then RB O
used VBN O
to TO O
determine VB O
its PRP$ O
methylation NN O
status NN O
. . O

The DT O
proportion NN O
of IN O
methylation NN O
in IN O
a DT O
sample NN O
can MD O
be VB O
readily RB O
estimated VBN O
by IN O
comparing VBG O
the DT O
number NN O
of IN O
reactions NNS O
with IN O
a DT O
peak NN O
with IN O
elevated JJ O
melting NN O
temperature NN O
characteristic NN O
of IN O
methylation NN O
, , O
over IN O
those DT O
with IN O
an DT O
lower JJR O
melting NN O
temperature NN O
unmethylated JJ O
peak NN O
. . O

Digital NNP O
MS-HRM NNP O
was VBD O
performed VBN O
on IN O
peripheral JJ O
blood NN O
and CC O
buccal JJ O
mucosal NN O
DNA NN O
from IN O
KCF3 NN O
. . O

For IN O
the DT O
peripheral JJ O
blood NN O
DNA NN O
, , O
13 CD O
of IN O
the DT O
107 CD O
clones NNS O
had VBD O
a DT O
methylated JJ O
peak NN O
on IN O
melting VBG O
analysis NN O
( -LRB- O
Figure NN O
3 CD O
) -RRB- O
, , O
equating VBG O
to TO O
12 CD O
% NN O
BRCA1 NN B-NP
methylation NN O
in IN O
the DT O
peripheral JJ O
blood NN O
. . O

In IN O
the DT O
buccal JJ O
mucosa NN O
, , O
4 CD O
of IN O
the DT O
69 CD O
clones NNS O
were VBD O
methylated VBN O
, , O
equating VBG O
to TO O
6 CD O
% NN O
methylation NN O
. . O

These DT O
results NNS O
confirmed VBD O
the DT O
level NN O
of IN O
BRCA1 NNP B-NP
methylation NN O
estimated VBN O
by IN O
both DT O
MethyLight NNP O
and CC O
MS-HRM NNP O
. . O

When WRB O
considered VBN O
at IN O
a DT O
cellular JJ O
rather RB O
than IN O
an DT O
allelic JJ O
level NN O
, , O
we PRP O
estimate VBP O
that IN O
the DT O
peripheral JJ O
blood NN O
contains VBZ O
approximately RB O
25 CD O
% NN O
of IN O
cells NNS O
with IN O
one CD O
methylated VBN O
BRCA1 NN B-NP
allele NN O
and CC O
that IN O
the DT O
buccal JJ O
mucosa NN O
contains VBZ O
approximately RB O
10 CD O
% NN O
methylated JJ O
cells NNS O
. . O

Digital NNP O
methylation-sensitive JJ O
high JJ O
resolution NN O
melting VBG O
( -LRB- O
MS-HRM JJ O
) -RRB- O
and CC O
sequencing VBG O
for IN O
KCF3 NNS O
peripheral JJ O
blood NN O
DNA NN O
. . O

The DT O
blue JJ O
curve NN O
indicates VBZ O
the DT O
unmethylated JJ O
control NN O
. . O

The DT O
black JJ O
curve NN O
indicates VBZ O
the DT O
methylated JJ O
control NN O
. . O

The DT O
green JJ O
curves NNS O
indicate VBP O
unmethylated JJ O
amplicons NNS O
. . O

The DT O
red JJ O
curves NNS O
indicate VBP O
methylated VBN O
amplicons NNS O
. . O

Sequencing VBG O
for IN O
the DT O
unmethylated JJ O
and CC O
methylated JJ O
controls NNS O
are VBP O
shown VBN O
above IN O
the DT O
digital JJ O
MS-HRM JJ O
results NNS O
. . O

Sequences NNS O
of IN O
the DT O
indicated VBN O
red JJ O
amplicons NNS O
( -LRB- O
lettered VBN O
) -RRB- O
are VBP O
shown VBN O
to TO O
right NN O
of IN O
the DT O
figure NN O
where WRB O
the DT O
letter NN O
to TO O
the DT O
right NN O
of IN O
the DT O
chromatograph NN O
corresponds NNS O
to TO O
the DT O
curve NN O
shown VBN O
. . O

Representative NNP O
methylated VBD O
and CC O
unmethylated VBD O
clones NNS O
from IN O
the DT O
digital JJ O
MS-HRM JJ O
experiments NNS O
were VBD O
sequenced VBN O
to TO O
confirm VB O
the DT O
methylation NN O
status NN O
( -LRB- O
Figure NN O
3 CD O
) -RRB- O
. . O

A DT O
stretch NN O
of IN O
22 CD O
bases NNS O
containing VBG O
four CD O
CpG NNP O
sites NNS O
was VBD O
analysed VBN O
. . O

For IN O
the DT O
peripheral JJ O
blood NN O
DNA NN O
of IN O
KCF3 NN O
( -LRB- O
Figure NN O
3 CD O
) -RRB- O
, , O
four CD O
of IN O
the DT O
six CD O
methylated VBN O
clones NNS O
had VBD O
a DT O
cytosine NN O
present NN O
at IN O
all DT O
four CD O
CpGs NNS O
, , O
confirming VBG O
the DT O
methylation NN O
seen VBN O
by IN O
other JJ O
methodologies NNS O
. . O

One CD O
clone NN O
had VBD O
cytosines NNS O
present VB O
at IN O
all DT O
CpGs NNP O
sites NNS O
but CC O
also RB O
had VBD O
an DT O
additional JJ O
cytosine NN O
present NN O
at IN O
a DT O
conversion NN O
site NN O
where WRB O
a DT O
thymine NN O
would MD O
be VB O
expected VBN O
, , O
preceding VBG O
a DT O
CpG NNP O
site NN O
. . O

The DT O
other JJ O
non-CpG JJ O
cytosines NNS O
were VBD O
converted VBN O
indicating VBG O
that IN O
this DT O
corresponded VBN O
to TO O
a DT O
methylated JJ O
allele NN O
. . O

For IN O
one CD O
other JJ O
clone NN O
only RB O
two CD O
of IN O
the DT O
CpGs NNP O
were VBD O
methylated VBN O
but CC O
this DT O
may MD O
have VB O
been VBN O
due JJ O
to TO O
incomplete JJ O
conversion NN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

The DT O
assay NN O
conditions NNS O
used VBN O
in IN O
this DT O
study NN O
could MD O
not RB O
distinguish VB O
between IN O
samples NNS O
with IN O
pathogenic JJ O
BRCA1 NN B-NP
mutations NNS O
and CC O
those DT O
with IN O
pathogenic JJ O
BRCA2 NN B-NP
mutations NNS O
. . O

Ionising NNP O
radiation NN O
has VBZ O
previously RB O
been VBN O
show NN O
to TO O
separate JJ O
fibroblast NN O
cells NNS O
which WDT O
carry VBP O
BRCA1 NNP B-NP
or CC O
BRCA2 NNP B-NP
mutations NNS O
from IN O
sporadic JJ O
cases NNS O
with IN O
100 CD O
% NN O
accuracy NN O
[31] NN O
, , O
but CC O
our PRP$ O
experiment NN O
differs NNS O
in IN O
several JJ O
respects NNS O
. . O

We PRP O
compared VBN O
BRCA1 NN B-NP
and CC O
BRCA2 NN B-NP
cases NNS O
to TO O
familial JJ O
BRCAX NN B-NP
cases NNS O
as IN O
an DT O
appropriate JJ O
reference NN O
group NN O
for IN O
familial JJ O
breast NN O
cases NNS O
likely JJ O
to TO O
be VB O
identified VBN O
as IN O
carriers NNS O
of IN O
BRCA1/2 NNP B-NP
mutations NNS O
or CC O
unclassified JJ O
variants NNS O
, , O
we PRP O
used VBD O
LCLs NNS O
instead RB O
of IN O
fibroblasts NNS O
, , O
we PRP O
selected VBD O
a DT O
lower JJR O
IR NN O
exposure NN O
( -LRB- O
10Gy JJ O
vs JJ O
15Gy JJ O
) -RRB- O
, , O
and CC O
we PRP O
chose VBD O
a DT O
relatively RB O
early JJ O
time NN O
point NN O
of IN O
30 CD O
mins NNS O
after IN O
exposure NN O
to TO O
IR NNP O
in IN O
order NN O
to TO O
gain VB O
a DT O
better JJR O
understanding NN O
of IN O
the DT O
functional JJ O
differences NNS O
in IN O
response NN O
to TO O
IR NNP O
between IN O
the DT O
BRCA1 NNP B-NP
, , O
BRCA2 NNP B-NP
and CC O
BRCAX NNP O
cell NN O
lines NNS O
. . O

Some DT O
or CC O
all DT O
of IN O
these DT O
factors NNS O
may MD O
explain VB O
the DT O
difference NN O
in IN O
the DT O
ability NN O
of IN O
this DT O
study NN O
to TO O
distinguish VB O
BRCA1 NN B-NP
from IN O
BRCA2 NN B-NP
, , O
both DT O
of IN O
which WDT O
are VBP O
involved VBN O
in IN O
DNA NNP O
damage NN O
repair NN O
. . O

However RB O
, , O
differences NNS O
in IN O
post-irradiation JJ O
response NN O
between IN O
BRCAX NNP B-NP
individuals NNS O
and CC O
BRCA1/2 NN B-NP
mutation NN O
carriers NNS O
are VBP O
supported VBN O
by IN O
alternative JJ O
analysis NN O
we PRP O
have VBP O
conducted VBN O
of IN O
the DT O
subset NN O
of IN O
genes NNS O
reported VBN O
to TO O
be VB O
involved VBN O
in IN O
post-irradiation JJ O
response NN O
, , O
comparing VBG O
mutation-negative JJ O
normal JJ O
female NN O
controls NNS O
to TO O
BRCAX NNP B-NP
individuals NNS O
without IN O
an DT O
LCS NNP O
variant NN O
, , O
or CC O
to TO O
BRCA1 NNP B-NP
or CC O
BRCA2 NNP B-NP
truncating NN O
mutation NN O
carriers NNS O
. . O

Our PRP$ O
results NNS O
indicate VBP O
substantial JJ O
differences NNS O
in IN O
radiation NN O
response NN O
between IN O
normal JJ O
controls NNS O
and CC O
the DT O
patient NN O
groups NNS O
, , O
and CC O
also RB O
considerable JJ O
differences NNS O
between IN O
the DT O
BRCAX NNP B-NP
group NN O
and CC O
BRCA1 NN B-NP
and CC O
BRCA2 NN B-NP
carriers NNS O
[37] VBP O
. . O

Alternative JJ O
IR NNP O
exposures NNS O
and/or CC O
post-IR JJ O
timepoints NNS O
, , O
and CC O
possibly RB O
different JJ O
DNA NN O
damaging VBG O
agents NNS O
, , O
should MD O
be VB O
considered VBN O
for IN O
future JJ O
experiments NNS O
. . O

The DT O
ultimate JJ O
aim NN O
of IN O
this DT O
experiment NN O
was VBD O
to TO O
identify VB O
array NN O
profiles NNS O
that WDT O
would MD O
be VB O
useful JJ O
for IN O
the DT O
classification NN O
of IN O
unclassified JJ O
sequence NN O
variants NNS O
of IN O
BRCA1 NN B-NP
or CC O
BRCA2 NN B-NP
. . O

In IN O
the DT O
clinical JJ O
setting NN O
, , O
individuals NNS O
generally RB O
present VB O
with IN O
full JJ O
sequencing NN O
of IN O
both DT O
genes NNS O
, , O
and CC O
presence NN O
of IN O
a DT O
variant NN O
in IN O
one CD O
gene NN O
or CC O
the DT O
other JJ O
. . O

We PRP O
thus RB O
assessed VBD O
the DT O
ability NN O
to TO O
distinguish VB O
BRCA1 NN B-NP
or CC O
BRCA2 NN B-NP
, , O
separately RB O
, , O
from IN O
BRCAX NNP B-NP
individuals NNS O
. . O

Importantly RB O
, , O
since IN O
most JJS O
unclassified JJ O
variants NNS O
are VBP O
predicted VBN O
to TO O
cause VB O
amino IN O
acid NN O
substitutions NNS O
, , O
we PRP O
also RB O
assessed VBD O
the DT O
relevance NN O
of IN O
mutation NN O
effect NN O
for IN O
expression NN O
profiles NNS O
. . O

We PRP O
found VBD O
that IN O
the DT O
genes NNS O
which WDT O
significantly RB O
differed VBD O
between IN O
BRCA1 NNP B-NP
or CC O
BRCA2 NNP B-NP
and CC O
BRCAX NNP O
LCLs NNP O
were VBD O
dependent JJ O
on IN O
mutation JJ O
effect NN O
. . O

Accordingly RB O
, , O
the DT O
SVM NNP O
prediction NN O
for IN O
each DT O
mutation NN O
effect NN O
was VBD O
best JJS O
if IN O
the DT O
appropriate JJ O
gene NN O
list NN O
was VBD O
used VBN O
, , O
in IN O
terms NNS O
of IN O
both DT O
accuracy NN O
of IN O
prediction NN O
( -LRB- O
BRCA1 NN B-NP
or CC O
BRCA2 NN B-NP
vs JJ O
BRCAX NN O
) -RRB- O
and CC O
confidence NN O
in IN O
the DT O
classification NN O
as IN O
determined VBN O
by IN O
the DT O
distance NN O
of IN O
the DT O
prediction NN O
from IN O
the DT O
SVM NNP O
plane NN O
. . O

Thus RB O
we PRP O
strongly RB O
urge VB O
that IN O
mutation NN O
effect NN O
is VBZ O
taken VBN O
into IN O
account NN O
if IN O
this DT O
type NN O
of IN O
assay NN O
is VBZ O
to TO O
be VB O
developed VBN O
for IN O
use NN O
in IN O
predicting VBG O
the DT O
clinical JJ O
significance NN O
of IN O
BRCA1/2 NNP B-NP
variants NNS O
. . O

The DT O
current JJ O
challenge NN O
is VBZ O
that IN O
few JJ O
missense NN O
variants NNS O
have VBP O
been VBN O
classified VBN O
with IN O
respect NN O
to TO O
their PRP$ O
clinical JJ O
significance NN O
, , O
with IN O
the DT O
only RB O
23 CD O
individual NN O
missense NN O
variants VBZ O
termed VBN O
clinically RB O
important JJ O
by IN O
BIC NNP O
, , O
17 CD O
in IN O
BRCA1 NNP B-NP
and CC O
six CD O
in IN O
BRCA2 NNP B-NP
. . O

Moreover RB O
, , O
these DT O
are VBP O
restricted VBN O
in IN O
terms NNS O
of IN O
the DT O
domains/regions NNS O
in IN O
which WDT O
they PRP O
occur VBP O
, , O
residing VBG O
in IN O
the DT O
BRCA1 NNP B-NP
start NN O
site NN O
( -LRB- O
n RB O
= SYM O
2 CD O
) -RRB- O
, , O
ring NN O
finger NN O
( -LRB- O
n NN O
= SYM O
4 CD O
) -RRB- O
or CC O
transactivation NN O
domains NNS O
( -LRB- O
n RB O
= SYM O
11 CD O
) -RRB- O
, , O
and CC O
the DT O
BRCA2 NN B-NP
CDK2 IN O
phosphorylation NN O
site NN O
( -LRB- O
n RB O
= SYM O
3 CD O
) -RRB- O
or CC O
at IN O
one CD O
codon NN O
( -LRB- O
2336 CD O
, , O
n RB O
= SYM O
3 CD O
) -RRB- O
in IN O
a DT O
region NN O
of IN O
unknown JJ O
function NN O
. . O

It PRP O
will MD O
thus RB O
be VB O
difficult JJ O
to TO O
accrue VB O
a DT O
panel NN O
of IN O
known VBN O
pathogenic NN O
missense NN O
variants VBZ O
for IN O
use NN O
in IN O
such JJ O
predictive JJ O
assays NNS O
, , O
and CC O
will MD O
require VB O
a DT O
concerted JJ O
collaborative JJ O
effort NN O
. . O

Assuming VBG O
sufficient JJ O
pathogenic JJ O
variants NNS O
are VBP O
identified VBN O
, , O
the DT O
successful JJ O
execution NN O
of IN O
such JJ O
a DT O
study NN O
may MD O
eventually RB O
distinguish VB O
missense-associated JJ O
gene NN O
expression NN O
patterns NNS O
that WDT O
are VBP O
generic JJ O
to TO O
missense VB O
mutations NNS O
, , O
and/or CC O
those DT O
that WDT O
are VBP O
specific JJ O
to TO O
the DT O
domain NN O
location NN O
of IN O
missense NN O
mutations NNS O
. . O

In IN O
addition NN O
, , O
a DT O
possibly RB O
greater JJR O
challenge NN O
will MD O
be VB O
identifying VBG O
assay NN O
conditions NNS O
(cell VBP O
type NN O
, , O
perturbation NN O
, , O
time-point NN O
etc NN O
) -RRB- O
that WDT O
can MD O
also RB O
identify VB O
gene NN O
expression NN O
differences NNS O
between IN O
patients NNS O
with IN O
rare JJ O
variants NNS O
of IN O
low JJ O
clinical JJ O
significance NN O
in IN O
BRCA1 NNP B-NP
and/or CC O
BRCA2 NNP B-NP
and CC O
those DT O
with IN O
truly RB O
high-risk JJ O
pathogenic JJ O
mutations NNS O
( -LRB- O
truncating NN O
or CC O
missense NN O
) -RRB- O
in IN O
these DT O
genes NNS O
. . O

Our PRP$ O
study NN O
, , O
using VBG O
conditions NNS O
that WDT O
were VBD O
not RB O
optimal JJ O
for IN O
separating VBG O
BRCA1 NNP B-NP
and CC O
BRCA2 NNP B-NP
mutations NNS O
nevertheless RB O
identified VBN O
gene NN O
expression NN O
differences NNS O
between IN O
BRCA1/2 NN B-NP
pathogenic JJ O
mutations NNS O
and CC O
LCS NNP O
variants NNS O
, , O
suggesting VBG O
that IN O
larger JJR O
sample NN O
sizes NNS O
and CC O
further JJ O
experimentation NN O
may MD O
identify VB O
a DT O
more JJR O
robust JJ O
gene NN O
list NN O
to TO O
separate JJ O
pathogenic JJ O
mutations NNS O
, , O
variants NNS O
of IN O
low JJ O
clinical JJ O
significance NN O
, , O
and CC O
individuals NNS O
with IN O
no DT O
sequence NN O
alterations NNS O
in IN O
BRCA1/2 NNP B-NP
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

27 CD O
LCLs NNS O
from IN O
women NNS O
from IN O
breast NN O
cancer NN O
families NNS O
that WDT O
have VBP O
tested VBN O
negative JJ O
for IN O
pathogenic JJ O
mutations NNS O
in IN O
BRCA1 NN B-NP
or CC O
BRCA2 NN B-NP
( -LRB- O
BRCAX NN O
) -RRB- O
after IN O
complete JJ O
sequencing NN O
and CC O
multiplex JJ O
ligation-dependent JJ O
probe NN O
amplification NN O
gene NN O
dosage NN O
assay NN O
( -LRB- O
MLPA NNP O
) -RRB- O
large JJ O
deletion NN O
testing NN O
of IN O
BRCA1 NN B-NP
and CC O
BRCA2 NN B-NP
. . O

Ten CD O
samples NNS O
, , O
carried VBD O
either DT O
BRCA1 NN B-NP
or CC O
BRCA2 NN B-NP
sequence NN O
germline NN O
variants VBZ O
considered VBN O
from IN O
multifactorial JJ O
likelihood NN O
classification NN O
to TO O
be VB O
LCS NNP O
( -LRB- O
BRCA1 NN B-NP
3582 CD O
G>C NNP O
D1155H NNP O
, , O
1605 CD O
C>T NNP O
R496C NNP O
, , O
5236 CD O
G>C NNP O
G1706A NNP O
( -LRB- O
2 CD O
samples NNS O
) -RRB- O
; : O
BRCA2 NN B-NP
353 CD O
A>G NNP O
Y42C NNP O
, , O
2834 CD O
C>T NNP O
S869L NNP O
, , O
3031 CD O
G>A NNP O
D935N NNP O
( -LRB- O
3 CD O
samples NNS O
) -RRB- O
, , O
8795 CD O
A>C JJ O
E2856A NNS O
) -RRB- O
[16] VBP O
,[19] RP O
,[21] JJ O
,[22](unpublished JJ O
data NNS O
) -RRB- O
. . O

The DT O
remaining VBG O
17 CD O
samples NNS O
carried VBD O
no DT O
BRCA1 NN B-NP
or CC O
BRCA2 NN B-NP
sequence NN O
variants VBZ O
other JJ O
than IN O
common JJ O
polymorphisms NNS O
. . O

Gene NNP O
Expression NNP O
Profiling NNP O

LCLs NNS O
were VBD O
grown VBN O
in IN O
RPMI NNP O
1640 CD O
media NNS O
with IN O
15 CD O
% NN O
fetal NN O
bovine NN O
serum NN O
, , O
1 CD O
% NN O
penicillin-streptomycin NN O
and CC O
1 CD O
% NN O
L-glutamine NN O
. . O

The DT O
cell NN O
number NN O
was VBD O
normalised VBN O
and CC O
fresh JJ O
medium NN O
was VBD O
added VBN O
to TO O
cells NNS O
24hr JJ O
prior RB O
to TO O
irradiation NN O
with IN O
10Gy JJ O
, , O
using VBG O
a DT O
calibrated VBN O
Cs137 IN O
c-source NN O
delivering VBG O
1 CD O
Gy/1.5 DT O
min NN O
. . O

Total JJ O
RNA NNP O
was VBD O
harvested VBN O
30min IN O
later RB O
using VBG O
an DT O
RNeasy JJ O
kit NN O
( -LRB- O
Qiagen NNP O
, , O
Doncaster NNP O
, , O
VIC NNP O
) -RRB- O
. . O

The DT O
Illumina NNP O
Totalprep NNP O
RNA NNP O
amplification NN O
kit NN O
( -LRB- O
Ambion NN O
, , O
Austin NNP O
, , O
TX NNP O
) -RRB- O
was VBD O
used VBN O
to TO O
amplify VB O
and CC O
biotinylate VB O
450ng CD O
of IN O
total JJ O
RNA NNP O
. . O

Biotinylated NNP O
RNA NNP O
was VBD O
hybridised VBN O
overnight RB O
at IN O
55°C JJ O
to TO O
Illumina NNP O
Human-6 NNP O
version NN O
1 CD O
BeadChips NNP O
containing VBG O
>46,000 CD O
probes NNS O
( -LRB- O
Illumina NNP O
Inc. NNP O
, , O
San NNP O
Diego NNP O
, , O
CA NNP O
) -RRB- O
. . O

The DT O
microarrays NNS O
were VBD O
washed VBN O
, , O
stained VBN O
with IN O
streptavidin-Cy3 JJ O
, , O
and CC O
then RB O
scanned VBD O
with IN O
an DT O
Illumina NNP O
BeadArray NNP O
Scanner NNP O
. . O

Duplicate JJ O
arrays NNS O
were VBD O
performed VBN O
for IN O
eight CD O
cell NN O
lines NNS O
across IN O
the DT O
different JJ O
groups NNS O
for IN O
quality NN O
control NN O
purposes NNS O
, , O
with IN O
duplicates NNS O
performed VBN O
on IN O
different JJ O
days NNS O
. . O

All DT O
duplicate JJ O
arrays NNS O
showed VBD O
highest JJS O
correlation NN O
with IN O
each DT O
other JJ O
( -LRB- O
correlation NN O
>0.98 CD O
) -RRB- O
. . O

Duplicate JJ O
samples NNS O
were VBD O
not RB O
included VBN O
in IN O
analysis NN O
. . O

Comparative JJ O
real-time JJ O
PCR NN O
was VBD O
performed VBN O
for IN O
ten CD O
genes NNS O
on IN O
6–8 CD O
samples NNS O
, , O
using VBG O
GAPDH NNP B-NP
to TO O
normalise VB O
all DT O
data NNS O
, , O
and CC O
the DT O
comparative JJ O
cycle NN O
threshold NN O
method NN O
for IN O
analysis NN O
. . O

Paired JJ O
student NN O
t NN O
tests NNS O
were VBD O
performed VBN O
to TO O
determine VB O
the DT O
significance NN O
of IN O
gene NN O
expression NN O
changes NNS O
. . O

Expression NN O
differences NNS O
were VBD O
validated VBN O
for IN O
8/10 CD O
genes NNS O
tested VBN O
. . O

Data NNP O
Analysis NN O

Raw JJ O
data NNS O
was VBD O
imported VBN O
into IN O
Illumina NNP O
Beadstudio NNP O
and CC O
then RB O
exported VBD O
into IN O
Genespring NNP O
v7.3 CD O
( -LRB- O
Agilent NNP O
Technologies NNPS O
, , O
Forest NNP O
Hill NNP O
, , O
VIC NNP O
) -RRB- O
for IN O
further JJ O
analysis NN O
. . O

Data NNP O
was VBD O
normalised JJ O
( -LRB- O
per IN O
chip NN O
normalized JJ O
to TO O
50th JJ O
percentile NN O
and CC O
per IN O
gene NN O
normalized JJ O
to TO O
median NN O
) -RRB- O
and CC O
filtered VBD O
using VBG O
an DT O
Illumina NNP O
detection NN O
score NN O
of IN O
>0.99 CD O
in IN O
at IN O
least JJS O
one CD O
sample NN O
, , O
which WDT O
yielded VBD O
20,874 CD O
probes NNS O
that WDT O
were VBD O
used VBN O
in IN O
all DT O
further JJ O
analyses NNS O
. . O

The DT O
majority NN O
of IN O
these DT O
probes NNS O
used VBD O
in IN O
the DT O
analysis NN O
were VBD O
designed VBN O
by IN O
Illumina NNP O
to TO O
assay VB O
the DT O
curated JJ O
portion NN O
of IN O
the DT O
NIH NNP O
Ref NNP O
sequence NN O
database-16,923 NNS O
were VBD O
present JJ O
in IN O
the DT O
Ref NN O
sequence NN O
database NN O
, , O
comprising VBG O
65 CD O
% NN O
of IN O
all DT O
Ref NNP O
sequence-listed JJ O
probes NNS O
on IN O
the DT O
array NN O
. . O

Transcripts NNS O
which WDT O
had VBD O
a DT O
>2-fold JJ O
change NN O
versus VBZ O
the DT O
mean NN O
were VBD O
visualised VBN O
using VBG O
unsupervised JJ O
Hierarchical JJ O
Clustering NN O
( -LRB- O
Figures NNS O
1 CD O
and CC O
2 CD O
) -RRB- O
. . O

The DT O
clustering NN O
method NN O
used VBN O
was VBD O
a DT O
Pearson NNP O
correlation NN O
similarity NN O
measure NN O
with IN O
an DT O
average JJ O
linkage NN O
clustering NN O
algorithm NN O
. . O

Two CD O
different JJ O
methods NNS O
were VBD O
used VBN O
to TO O
classify VB O
LCLs NNS O
based VBN O
on IN O
mutation NN O
status NN O
: : O
( -LRB- O
1 LS O
) -RRB- O
A DT O
multi JJ O
comparison NN O
Gaussian NNP O
Process NNP O
Classifier NNP O
( -LRB- O
GPC NNP O
) -RRB- O
[42] VBP O
with IN O
Leave-One-Out JJ O
cross-validation NN O
to TO O
determine VB O
the DT O
prediction NN O
errors NNS O
, , O
as IN O
previously RB O
used VBN O
to TO O
predict VB O
BRCA1/BRCA2 NNP B-NP
mutation NN O
status NN O
of IN O
irradiated JJ O
fibroblasts NNS O
[31] JJ O
; : O
( -LRB- O
2 CD O
) -RRB- O
A DT O
linear NN O
classification NN O
method NN O
commonly RB O
used VBN O
for IN O
classification NN O
of IN O
microarray NN O
data NNS O
, , O
Support NNP O
Vector NNP O
Machines NNPS O
( -LRB- O
SVM NNP O
) -RRB- O
[43] VBP O
with IN O
Leave-One-Out NNP O
cross NN O
validation NN O
. . O

The DT O
GPC NNP O
analysis NN O
used VBN O
2031 CD O
genes NNS O
which WDT O
were VBD O
derived VBN O
from IN O
a DT O
t-test NN O
to TO O
select VB O
the DT O
genes NNS O
that WDT O
were VBD O
significantly RB O
over/under-expressed JJ O
at IN O
the DT O
5 CD O
% NN O
significance NN O
, , O
while IN O
the DT O
SVM NNP O
used VBD O
genes NNS O
from IN O
the DT O
20,874 CD O
detected VBN O
probes NNS O
which WDT O
differed VBD O
between IN O
groups NNS O
of IN O
LCLs NNS O
using VBG O
a DT O
t-test NN O
p NN O
of IN O
0.05 CD O
. . O

All DT O
resulting VBG O
gene NN O
lists NNS O
are VBP O
available JJ O
as IN O
supplementary JJ O
data NNS O
and CC O
all DT O
data NNS O
is VBZ O
available JJ O
via IN O
GEO NNP O
: : O
Accession NNP O
number NN O
GSE10905 NNP O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

In IN O
the DT O
present JJ O
study NN O
patients NNS O
included VBD O
in IN O
the DT O
Swedish JJ O
Polyposis NN O
Registry NNP O
were VBD O
subjected VBN O
to TO O
a DT O
thorough JJ O
clinical JJ O
characterization NN O
and CC O
mutational JJ O
screening NN O
of IN O
the DT O
APC NNP B-NP
gene NN O
including VBG O
screening VBG O
for IN O
large JJ O
deletions NNS O
and CC O
detection NN O
of IN O
low-frequency NN O
alleles NNS O
caused VBN O
by IN O
germline NN O
mosaicism NN O
. . O

Sixty-one CD O
mutations NNS O
, , O
including VBG O
27 CD O
not RB O
described VBN O
previously RB O
, , O
are VBP O
reported VBN O
. . O

Among IN O
the DT O
characterized VBN O
mutations NNS O
are VBP O
elusive JJ O
changes NNS O
such JJ O
as IN O
a DT O
case NN O
of IN O
mosaicism NN O
, , O
splicing NN O
defects NNS O
, , O
and CC O
a DT O
mutation NN O
in IN O
APC NNP B-NP
exon NN O
1 CD O
which WDT O
is VBZ O
the DT O
most RBS O
5' JJ O
APC NNP B-NP
mutation NN O
hitherto VBD O
reported VBN O
. . O

The DT O
detection NN O
of IN O
reduced VBN O
APC NNP B-NP
expression NN O
in IN O
one CD O
family NN O
is VBZ O
also RB O
described VBN O
. . O

A DT O
combination NN O
of IN O
mutation NN O
screening VBG O
techniques NNS O
was VBD O
used VBN O
to TO O
achieve VB O
as RB O
high JJ O
a DT O
mutation-detection NN O
frequency NN O
as IN O
possible JJ O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Seven CD O
of IN O
the DT O
identified VBN O
APC NNP B-NP
mutations NNS O
were VBD O
large JJ O
deletions NNS O
, , O
ranging VBG O
from IN O
a DT O
deletion NN O
of IN O
86 CD O
bp NN O
in IN O
exon NN O
15 CD O
to TO O
a DT O
deletion NN O
of IN O
the DT O
whole JJ O
APC NNP B-NP
gene NN O
( -LRB- O
Figure NN O
1C) CD O
. . O

Three CD O
of IN O
these DT O
deletions NNS O
have VBP O
not RB O
, , O
to TO O
the DT O
best JJS O
of IN O
the DT O
authors NNS O
' POS O
knowledge NN O
, , O
been VBN O
described VBN O
earlier RBR O
. . O

The DT O
deletion NN O
encompassing VBG O
APC NNP B-NP
exon NN O
4 CD O
in IN O
patient JJ O
3765 CD O
, , O
c.423-1662_531+1825del3595 CD O
, , O
was VBD O
detected VBN O
by IN O
RNA-based JJ O
PTT NNP O
with IN O
subsequent JJ O
cDNA NN O
sequencing NN O
and CC O
verified VBN O
by IN O
long-range JJ O
PCR NN O
on IN O
genomic JJ O
DNA NN O
. . O

We PRP O
could MD O
not RB O
detect VB O
this DT O
deletion NN O
with IN O
MLPA NNP O
even RB O
though IN O
a DT O
probe NN O
for IN O
exon NN O
4 CD O
is VBZ O
included VBN O
in IN O
the DT O
MLPA NNP O
kit NN O
( -LRB- O
see VB O
the DT O
discussion NN O
) -RRB- O
. . O

Detection NNP O
of IN O
the DT O
large JJ O
deletion NN O
in IN O
patient JJ O
C591 NNP O
, , O
encompassing VBG O
APC NNP B-NP
exons VBD O
13 CD O
through IN O
the DT O
5' JJ O
part NN O
of IN O
exon JJ O
15 CD O
, , O
was VBD O
carried VBN O
out RP O
with IN O
MLPA. NNP O

The DT O
deletion NN O
in IN O
patient NN O
2136 CD O
was VBD O
identified VBN O
by IN O
PTT NNP O
and CC O
subsequent JJ O
DNA NN O
sequencing NN O
. . O

A DT O
case NN O
of IN O
APC NNP B-NP
mosaicism NN O

Three CD O
patients NNS O
( -LRB- O
C107 NNP O
, , O
C257 NNP O
, , O
and CC O
C505 NNP O
) -RRB- O
, , O
negative JJ O
for IN O
mutations NNS O
in IN O
APC NNP B-NP
, , O
were VBD O
reported VBN O
as IN O
de IN O
novo NN O
cases NNS O
with IN O
no DT O
known VBN O
family NN O
history NN O
of IN O
FAP. NNP O

These DT O
patients NNS O
where WRB O
all DT O
screened VBD O
for IN O
APC NNP B-NP
mutations NNS O
present JJ O
as IN O
low-frequency JJ O
alleles NNS O
using VBG O
SSCP/HD. NNP O

We PRP O
did VBD O
not RB O
detect VB O
any DT O
signs NNS O
of IN O
low-frequency NN O
mutations NNS O
in IN O
patients NNS O
C257 . O
and CC O
C505 PRP O
. . O

However RB O
, , O
in IN O
patient JJ O
C107 NNP O
, , O
aberrant JJ O
bands NNS O
, , O
possibly RB O
originating VBG O
from IN O
formation NN O
of IN O
heteroduplexes NNS O
, , O
was VBD O
detected VBN O
by IN O
SSCP/HD NNP O
in IN O
a DT O
very RB O
low JJ O
fraction NN O
of IN O
her PRP$ O
blood NN O
lymphocytes NNS O
. . O

The DT O
c.2700_2701delTC JJ O
mutation NN O
, , O
which WDT O
results VBZ O
in IN O
frame NN O
shift NN O
at IN O
codon NN O
900 CD O
, , O
was VBD O
found VBN O
by IN O
sequencing NN O
of IN O
the DT O
aberrant JJ O
bands NNS O
excised VBN O
from IN O
the DT O
SSCP/HD NNP O
gel NNP O
( -LRB- O
Figure NN O
2A JJ O
) -RRB- O
. . O

The DT O
mutation NN O
was VBD O
detected VBN O
in IN O
approximately RB O
one-third JJ O
of IN O
the DT O
analyzed VBN O
tumor-derived JJ O
cells NNS O
extracted VBN O
from IN O
paraffin-embedded JJ O
tissue NN O
by IN O
DNA NN O
sequencing NN O
( -LRB- O
Figure NN O
2B CD O
) -RRB- O
. . O

The DT O
mutation NN O
was VBD O
not RB O
detectable JJ O
at IN O
all DT O
in IN O
the DT O
sequence NN O
determination NN O
of IN O
DNA NNP O
extracted VBD O
from IN O
blood NN O
lymphocytes NNS O
from IN O
the DT O
patient NN O
( -LRB- O
Figure NN O
2C JJ O
) -RRB- O
. . O

Detection NNP O
of IN O
the DT O
mosaic NN O
c.2700_2701delTC IN O
mutation NN O
in IN O
patient JJ O
C107 NNP O
. . O

Nucleotide NNP O
2700 CD O
is VBZ O
indicated VBN O
with IN O
an DT O
arrow NN O
. . O

( -LRB- O
A DT O
) -RRB- O
The DT O
aberrant JJ O
bands NNS O
indicated VBN O
by IN O
the DT O
bracket NN O
were VBD O
excised VBN O
from IN O
the DT O
SSCP/HD NNP O
gel NNP O
. . O

The DT O
resulting VBG O
DNA NNP O
sequence NN O
is VBZ O
shown VBN O
to TO O
the DT O
right NN O
. . O

( -LRB- O
B NN O
) -RRB- O
DNA NN O
sequence NN O
from IN O
DNA NNP O
extracted VBN O
from IN O
tumor-derived JJ O
cells NNS O
from IN O
the DT O
patient NN O
. . O

( -LRB- O
C NNP O
) -RRB- O
The DT O
DNA NN O
sequence NN O
from IN O
DNA NNP O
isolated VBN O
from IN O
the DT O
patient NN O
's POS O
blood NN O
lymphocytes NNS O
. . O

Mutation NN O
at IN O
the DT O
far JJ O
5'end CC O

DNA NNP O
sequencing NN O
of IN O
APC NNP B-NP
exon NN O
1 CD O
in IN O
patient JJ O
C157 NNS O
revealed VBD O
the DT O
c.70C JJ O
> NN O
T NNP O
substitution NN O
which WDT O
introduces VBZ O
a DT O
nonsense NN O
mutation NN O
in IN O
codon NN O
24 CD O
( -LRB- O
Figure NN O
1 CD O
) -RRB- O
. . O

The DT O
mutation NN O
was VBD O
also RB O
detectable JJ O
by IN O
SSCP/HD NNP O
analysis NN O
but CC O
was VBD O
not RB O
detectable JJ O
by IN O
PTT NNP O
due JJ O
to TO O
its PRP$ O
localization NN O
close NN O
to TO O
the DT O
5' JJ O
end NN O
of IN O
the DT O
PTT NNP O
fragment NN O
. . O

However RB O
, , O
indication NN O
for IN O
a DT O
mutation NN O
was VBD O
observed VBN O
as RB O
lowered VBN O
intensity NN O
of IN O
the DT O
full-length JJ O
fragment NN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Pedigree NNP O
presenting VBG O
a DT O
part NN O
of IN O
family NN O
1 CD O
of IN O
the DT O
Swedish NNP O
Polyposis NNP O
Registry NNP O
. . O

Family NNP O
members NNS O
where WRB O
positive JJ O
linkage NN O
to TO O
APC NNP B-NP
has VBZ O
been VBN O
confirmed VBN O
are VBP O
indicated VBN O
with IN O
asterisks NNS O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

A DT O
case NN O
of IN O
APC NNP B-NP
mosaicism NN O

Screening VBG O
for IN O
mosaic NN O
mutations NNS O
in IN O
the DT O
three CD O
APC- NNP B-NP
and CC O
MUTYH-negative JJ B-NP
patients NNS O
with IN O
de NNP O
novo , O
mutations NNS O
revealed VBD O
the DT O
c.2700_2701delTC JJ O
mutation NN O
in IN O
patient JJ O
C107 NNP O
. . O

This DT O
mutation NN O
was VBD O
detected VBN O
in IN O
a DT O
very RB O
low JJ O
fraction NN O
of IN O
the DT O
lymphocytes NNS O
and CC O
was VBD O
only RB O
detectable JJ O
using VBG O
the DT O
SSCP/HD NN O
analysis NN O
( -LRB- O
Figure NN O
2A JJ O
) -RRB- O
. . O

Owing VBG O
to TO O
the DT O
subtle JJ O
appearance NN O
of IN O
this DT O
mutation NN O
it PRP O
could MD O
easily RB O
have VB O
been VBN O
overlooked VBN O
. . O

The DT O
phenotype NN O
of IN O
patient JJ O
C107 NNP O
does VBZ O
not RB O
fit VB O
the DT O
generally RB O
accepted VBN O
genotype-phenotype JJ O
correlation NN O
of IN O
AFAP NNP O
, , O
in IN O
which WDT O
the DT O
disease-causing JJ O
mutations NNS O
are VBP O
situated VBN O
either RB O
in IN O
the DT O
5' JJ O
or CC O
3' JJ O
regions NNS O
or CC O
the DT O
alternatively NN O
spliced VBD O
part NN O
of IN O
exon NN O
9 CD O
( -LRB- O
see VB O
the DT O
introduction NN O
) -RRB- O
. . O

A DT O
speculative JJ O
reason NN O
for IN O
the DT O
attenuated VBN O
phenotype NN O
could MD O
be VB O
that IN O
the DT O
patient NN O
is VBZ O
mosaic JJ O
in IN O
the DT O
epithelial JJ O
cells NNS O
of IN O
the DT O
colon NN O
. . O

The DT O
parents NNS O
of IN O
patient JJ O
C107 NNS O
of IN O
age NN O
73 CD O
and CC O
80 CD O
years NNS O
as RB O
well RB O
as IN O
her PRP$ O
three CD O
children NNS O
, , O
age NN O
31–40 CD O
years NNS O
, , O
were VBD O
free JJ O
of IN O
polyps NNS O
. . O

No DT O
CRC NNP O
has VBZ O
been VBN O
diagnosed VBN O
on IN O
either CC O
the DT O
maternal JJ O
or CC O
paternal JJ O
side NN O
of IN O
the DT O
family NN O
. . O

The DT O
mutation NN O
was VBD O
not RB O
detected VBN O
in IN O
blood NN O
samples NNS O
from IN O
the DT O
patient NN O
's POS O
parents NNS O
or CC O
from IN O
her PRP$ O
three CD O
children NNS O
. . O

It PRP O
is VBZ O
possible JJ O
that IN O
either DT O
gonadal NN O
or CC O
somatic JJ O
mosaicism NN O
exists VBZ O
in IN O
patient JJ O
C107 NNP O
. . O

APC NNP B-NP
mutational JJ O
mosaicism NN O
could MD O
be VB O
a DT O
reason NN O
for IN O
the DT O
quite RB O
large JJ O
number NN O
of IN O
de FW O
novo FW O
or CC O
sporadic JJ O
FAP NNP O
cases NNS O
that WDT O
exist VBP O
[23-25,40] JJ O
. . O

In IN O
the DT O
family NN O
of IN O
C107 NNP O
the DT O
mutation NN O
has VBZ O
not RB O
been VBN O
passed VBN O
on IN O
to TO O
the DT O
offspring NN O
of IN O
the DT O
patient NN O
and CC O
, , O
thus RB O
, , O
this DT O
appears VBZ O
to TO O
be VB O
a DT O
sporadic JJ O
case NN O
, , O
but CC O
, , O
generally RB O
, , O
the DT O
existence NN O
of IN O
mosaicism NN O
is VBZ O
a DT O
risk NN O
of IN O
error NN O
in IN O
predictive JJ O
diagnosis NN O
in IN O
FAP/AFAP NNP O
families NNS O
[43] VBD O
. . O

In IN O
the DT O
initial JJ O
stages NNS O
, , O
the DT O
molecular JJ O
screening NN O
procedure NN O
of IN O
FAP/AFAP NNP O
patients NNS O
uses VBZ O
mainly RB O
PCR-based JJ O
methods NNS O
for IN O
analysis NN O
of IN O
the DT O
APC NNP B-NP
gene NN O
in IN O
DNA NNP O
from IN O
isolated JJ O
blood NN O
samples NNS O
. . O

Therefore RB O
, , O
the DT O
chances NNS O
of IN O
detecting VBG O
pathogenic JJ O
low-frequency NN O
APC NNP B-NP
mutations NNS O
that WDT O
are VBP O
present JJ O
only RB O
in IN O
a DT O
small JJ O
fraction NN O
of IN O
the DT O
peripheral JJ O
blood NN O
cells NNS O
or CC O
only RB O
in IN O
the DT O
colon NN O
are VBP O
poor JJ O
. . O

Approximately RB O
25 CD O
% NN O
of IN O
neurofibromatosis NN O
type NN O
2 CD O
( -LRB- O
NF2 NN O
) -RRB- O
patients NNS O
have VBP O
been VBN O
shown VBN O
to TO O
be VB O
cases NNS O
of IN O
mosaicism NN O
[44] NN O
. . O

When WRB O
investigating VBG O
NF2 NNP O
mutational JJ O
mosaicism NN O
, , O
the DT O
search NN O
for IN O
constitutional JJ O
mutations NNS O
is VBZ O
preferably RB O
carried VBN O
out RB O
initially RB O
in IN O
tumor NN O
cells NNS O
. . O

Detected NNP O
mutations NNS O
could MD O
subsequently RB O
be VB O
verified VBN O
in IN O
blood NN O
leukocyte NN O
samples NNS O
. . O

However RB O
, , O
this DT O
approach NN O
would MD O
not RB O
be VB O
applicable JJ O
for IN O
FAP NNP O
mosaisicm , O
as IN O
somatic JJ O
APC NNP B-NP
mutations NNS O
are VBP O
frequently RB O
found VBN O
in IN O
tumors NNS O
. . O

Splice-site JJ O
affecting VBG O
mutations NNS O

Two CD O
novel JJ O
germline NNP O
APC NNP B-NP
mutations NNS O
that WDT O
introduce VBP O
different JJ O
cryptic JJ O
splice NN O
sites NNS O
are VBP O
characterized VBN O
in IN O
this DT O
study NN O
. . O

Both DT O
mutations NNS O
result VBP O
in IN O
the DT O
aberrant JJ O
splicing NN O
of IN O
APC NNP B-NP
exons VBD O
7 CD O
and CC O
8 CD O
and CC O
prematurely RB O
truncated VBD O
APC NNP B-NP
protein NN O
, , O
and CC O
both DT O
are VBP O
defined VBN O
as IN O
pathogenic JJ O
. . O

The DT O
aberrant JJ O
splicing NN O
identified VBN O
in IN O
patient JJ O
C496 NNS O
( -LRB- O
c.835-7T JJ O
> NN O
G NNP O
) -RRB- O
is VBZ O
caused VBN O
by IN O
an DT O
introduction NN O
of IN O
a DT O
new JJ O
active JJ O
splice NN O
site NN O
6 CD O
bp , O
upstream RB O
of IN O
the DT O
wildtype JJ O
AG NNP O
splice NN O
site NN O
of IN O
intron NN O
7. . O

This DT O
acceptor NN O
site NN O
is VBZ O
apparently RB O
preferred VBN O
by IN O
the DT O
splicing NN O
machinery NN O
, , O
as IN O
shown VBN O
by IN O
the DT O
results NNS O
of IN O
the DT O
cDNA NN O
sequencing NN O
( -LRB- O
Figure NN O
3 CD O
) -RRB- O
. . O

The DT O
c.834G JJ O
> NN O
C NNP O
substitution NN O
at IN O
the DT O
last JJ O
nucleotide NN O
of IN O
exon NN O
7 CD O
in IN O
patient NN O
C633 NN O
, , O
would MD O
theoretically RB O
introduce VB O
a DT O
missense NN O
mutation NN O
at IN O
codon NN O
278 CD O
. . O

However RB O
, , O
as IN O
demonstrated VBN O
by IN O
the DT O
cDNA NN O
sequencing NN O
results NNS O
( -LRB- O
Figure NN O
4 CD O
) -RRB- O
the DT O
mutation NN O
leads VBZ O
to TO O
the DT O
use NN O
of IN O
a DT O
cryptic JJ O
splice NN O
donor NN O
site NN O
11 CD O
bp NN O
upstream RB O
in IN O
exon NN O
7. . O

This DT O
real JJ O
outcome NN O
of IN O
the DT O
mutation NN O
would MD O
easily RB O
have VB O
been VBN O
overlooked VBN O
unless IN O
the DT O
RNA-based JJ O
methods NNS O
had VBD O
been VBN O
used VBN O
. . O

Other JJ O
examples NNS O
of IN O
aberrant JJ O
splicing NN O
of IN O
the DT O
APC NNP B-NP
gene NN O
due JJ O
to TO O
missense NN O
mutations NNS O
have VBP O
recently RB O
been VBN O
described VBN O
[16] JJ O
. . O

One CD O
case NN O
of IN O
use NN O
of IN O
aberrant JJ O
splice-acceptor NN O
site NN O
of IN O
APC NNP B-NP
exon NN O
8 CD O
has VBZ O
been VBN O
reported VBN O
previously RB O
in IN O
a DT O
patient NN O
with IN O
classical JJ O
polyposis NN O
[15] NN O
. . O

However RB O
, , O
an DT O
alternative JJ O
acceptor NN O
splice NN O
site NN O
( -LRB- O
c.845-17A JJ O
> NN O
G NNP O
) -RRB- O
in IN O
intron NN O
7 CD O
has VBZ O
been VBN O
reported VBN O
from IN O
a DT O
patient NN O
with IN O
a DT O
milder NN O
phenotype NN O
, , O
multiple JJ O
synchronous JJ O
colorectal NN O
adenomas NNS O
[45] VBP O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Owing VBG O
to TO O
the DT O
fact NN O
that IN O
RNA-based JJ O
PTT NNP O
was VBD O
used VBN O
at IN O
the DT O
initial JJ O
stage NN O
of IN O
the DT O
mutational JJ O
screening NN O
, , O
detection NN O
of IN O
the DT O
disease-causing JJ O
splice-site JJ O
mutations NNS O
was VBD O
straightforward RB O
. . O

Sequencing NN O
of IN O
genomic JJ O
DNA NN O
was VBD O
then RB O
used VBN O
to TO O
pinpoint VB O
the DT O
genetic JJ O
alteration NN O
causing VBG O
the DT O
aberrant JJ O
mRNA NN O
sequence NN O
that WDT O
was VBD O
visualized VBN O
in IN O
the DT O
PTT JJ O
experiments NNS O
. . O

The DT O
use NN O
of IN O
both DT O
DNA NNP O
- : O
and CC O
mRNA-based JJ O
methods NNS O
is VBZ O
a DT O
prerequisite JJ O
for IN O
high-quality JJ O
investigation NN O
of IN O
splice-site JJ O
mutations NNS O
. . O

A DT O
case NN O
of IN O
reduced VBN O
APC NNP B-NP
expression NN O

The DT O
study NN O
of IN O
mRNA NN O
levels NNS O
was VBD O
the DT O
next JJ O
step NN O
in IN O
the DT O
line NN O
of IN O
investigation NN O
of IN O
the DT O
cause NN O
of IN O
disease NN O
in IN O
patients NNS O
with IN O
no DT O
detected VBN O
APC NNP B-NP
mutation NN O
. . O

Family NNP O
1 CD O
is VBZ O
the DT O
largest JJS O
kindred NN O
in IN O
the DT O
Swedish NNP O
Polyposis NNP O
Registry NNP O
; : O
this DT O
family NN O
includes VBZ O
150 CD O
individuals NNS O
of IN O
whom WP O
57 CD O
are VBP O
affected VBN O
by IN O
the DT O
disease NN O
( -LRB- O
Figure NN O
6 CD O
shows VBZ O
part NN O
of IN O
the DT O
pedigree NN O
) -RRB- O
. . O

However RB O
, , O
no DT O
pathogenic JJ O
mutation NN O
had VBD O
been VBN O
detected VBN O
after IN O
screening VBG O
the DT O
whole JJ O
coding NN O
region NN O
of IN O
the DT O
APC NNP B-NP
gene NN O
but CC O
as IN O
the DT O
family NN O
did VBD O
show VB O
positive JJ O
linkage NN O
to TO O
the DT O
APC NNP B-NP
locus NN O
we PRP O
decided VBD O
to TO O
perform VB O
expression NN O
analyses NNS O
and CC O
evidence NN O
of IN O
lowered VBN O
APC NNP B-NP
expression NN O
was VBD O
obtained VBN O
by IN O
quantitative JJ O
real-time NN O
PCR NN O
( -LRB- O
Figure NN O
5A JJ O
) -RRB- O
. . O

The DT O
result NN O
was VBD O
supported VBN O
by IN O
the DT O
indication NN O
of IN O
a DT O
lower JJR O
expression NN O
from IN O
the DT O
T-allele JJ O
from IN O
analysis NN O
of IN O
the DT O
APC NNP B-NP
c.5465A IN O
> NNP O
T NNP O
polymorphism NN O
in IN O
the DT O
cDNA NN O
sequencing NN O
diagram NN O
of IN O
two CD O
affected JJ O
family NN O
members NNS O
( -LRB- O
Figure NN O
5B CD O
) -RRB- O
. . O

The DT O
search NN O
for IN O
mutations NNS O
in IN O
the DT O
DNA NNP O
sequence NN O
of IN O
the DT O
APC NNP B-NP
promoters NNS O
has VBZ O
been VBN O
initiated VBN O
, , O
but CC O
no DT O
pathogenic JJ O
change NN O
has VBZ O
been VBN O
detected VBN O
to TO O
this DT O
date NN O
. . O

The DT O
possibility NN O
of IN O
the DT O
pathogenic JJ O
change NN O
being VBG O
epigenetic JJ O
will MD O
have VB O
to TO O
be VB O
investigated VBN O
further RB O
. . O

Hypermethylation NNP O
of IN O
CpG NNP O
sites NNS O
in IN O
the DT O
promoter NN O
of IN O
APC NNP B-NP
has VBZ O
been VBN O
reported VBN O
as IN O
a DT O
means NN O
of IN O
gene NN O
silencing NN O
in IN O
colorectal NN O
tumors NNS O
[46-49] JJ O
. . O

To TO O
the DT O
best JJS O
of IN O
the DT O
authors NNS O
' POS O
knowledge NN O
no DT O
germ-line NN O
inactivation NN O
of IN O
APC NNP B-NP
caused VBD O
by IN O
promoter NN O
hypermethylation NN O
has VBZ O
been VBN O
reported VBN O
. . O

However RB O
, , O
cases NNS O
of IN O
pathogenic JJ O
germline NN O
epimutations NNS O
have VBP O
been VBN O
identified VBN O
in IN O
the DT O
MLH1 NNP B-NP
gene NN O
, , O
which WDT O
causes VBZ O
hereditary JJ O
non-polyposis NN O
CRC NNP O
[50,51] CD O
. . O

Mutation-detection NNP O
frequency NN O

The DT O
61 CD O
different JJ O
APC NNP B-NP
mutations NNS O
listed VBN O
in IN O
Additional JJ O
file NN O
2 CD O
were VBD O
identified VBN O
among IN O
81 CD O
of IN O
the DT O
96 CD O
families NNS O
of IN O
the DT O
Swedish NNP O
Polyposis NNP O
Registry NNP O
that WDT O
were VBD O
screened VBN O
for IN O
APC NNP B-NP
mutations NNS O
. . O

Fifteen CD O
of IN O
the DT O
cases NNS O
shown VBN O
to TO O
be VB O
APC-mutation NNP B-NP
negative JJ O
where WRB O
all DT O
subjected VBN O
to TO O
mutational JJ O
screening NN O
of IN O
the DT O
MUTYH NNP B-NP
gene NN O
and CC O
six CD O
of IN O
them PRP O
were VBD O
shown VBN O
to TO O
carry VB O
biallelic JJ O
MUTYH NN B-NP
mutations NNS O
( -LRB- O
reported VBN O
in IN O
Kanter NNP O
Smoler NNP O
et CC O
al[31] DT O
) -RRB- O
. . O

The DT O
overall JJ O
mutation-detection NN O
rate NN O
in IN O
APC NNP B-NP
and CC O
MUTYH NNP B-NP
among IN O
the DT O
families NNS O
in IN O
our PRP$ O
study NN O
was VBD O
thus RB O
90 CD O
% NN O
. . O

In IN O
total JJ O
, , O
84 CD O
% NN O
of IN O
the DT O
families NNS O
carried VBD O
APC NNP B-NP
mutations NNS O
while IN O
6 CD O
% NN O
where WRB O
positive JJ O
for IN O
biallelic JJ O
MUTYH NNP B-NP
mutations NNS O
. . O

The DT O
mutation-detection NN O
rate NN O
we PRP O
have VBP O
reached VBN O
in IN O
this DT O
study NN O
is VBZ O
notably RB O
high JJ O
. . O

In IN O
fact NN O
, , O
a DT O
disease-causing JJ O
mutation NN O
was VBD O
detected VBN O
in IN O
all DT O
cases NNS O
who WP O
presented VBD O
with IN O
a DT O
classical JJ O
FAP NNP O
phenotype NN O
( -LRB- O
except IN O
for IN O
family NN O
1 CD O
( -LRB- O
C152 NN O
) -RRB- O
, , O
where WRB O
we PRP O
have VBP O
clear JJ O
indications NNS O
for IN O
inactivation NN O
of IN O
the DT O
APC JJ B-NP
transcription NN O
) -RRB- O
. . O

The DT O
mutation-negative JJ O
patients NNS O
all DT O
display VBP O
an DT O
attenuated VBN O
form NN O
of IN O
disease NN O
. . O

However RB O
, , O
as IN O
we PRP O
have VBP O
also RB O
found VBN O
subtle JJ O
mutations NNS O
in IN O
the DT O
APC NNP B-NP
gene NN O
in IN O
patients NNS O
with IN O
attenuated JJ O
FAP NNP O
, , O
we PRP O
have VBP O
to TO O
consider VB O
inactivation NN O
of IN O
APC NNP B-NP
to TO O
be VB O
responsible JJ O
for IN O
some DT O
of IN O
these DT O
FAP JJ O
cases NNS O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

In IN O
comparison NN O
to TO O
MLH1 NNP B-NP
and CC O
MSH2 NNP B-NP
, , O
the DT O
phenotype NN O
of IN O
MSH6 NNP B-NP
is VBZ O
characterised VBN O
by IN O
a DT O
later JJ O
age NN O
of IN O
onset NN O
of IN O
CRC NNP O
, , O
incomplete JJ O
penetrance NN O
, , O
and CC O
a DT O
higher JJR O
risk NN O
and CC O
later RB O
age NN O
of IN O
onset NN O
of IN O
EC NNP O
in IN O
female NN O
MSH6 IN B-NP
carriers15,21 NN O
. . O

MSH6 IN B-NP
mutation NN O
carriers NNS O
may MD O
be VB O
missed VBN O
amongst IN O
analysis NN O
of IN O
HNPCC NNP O
families NNS O
if IN O
the DT O
Amsterdam NNP O
criteria NNS O
are VBP O
used VBN O
as IN O
selection NN O
criteria22 NN O
It PRP O
is VBZ O
likely JJ O
that IN O
MSH6 NNP B-NP
mutations NNS O
may MD O
occur VB O
at IN O
a DT O
higher JJR O
prevalence NN O
in IN O
a DT O
cohort NN O
of IN O
EC NNP O
patients NNS O
in IN O
comparison NN O
to TO O
HNPCC NNP O
cohorts NNS O
that WDT O
have VBP O
been VBN O
selected VBN O
by IN O
the DT O
Amsterdam NNP O
criteria NNS O
which WDT O
are VBP O
characteristic JJ O
of IN O
HNPCC NNP O
families NNS O
with IN O
a DT O
mutation NN O
in IN O
MLH1 NNP B-NP
or CC O
MSH2 NNP B-NP
. . O

A DT O
few JJ O
studies NNS O
have VBP O
looked VBN O
at IN O
the DT O
prevalence NN O
of IN O
MSH6 NNP B-NP
mutations NNS O
in IN O
EC NNP O
patients NNS O
with IN O
estimates NNS O
between IN O
1.7 CD O
% NN O
of IN O
patients NNS O
with IN O
EC NNP O
less JJR O
than IN O
50 CD O
years23 CD O
, , O
and CC O
4.7 CD O
% NN O
identified VBN O
in IN O
EC NNP O
patients NNS O
un-selected JJ O
for IN O
age NN O
or CC O
family NN O
history24 NN O
. . O

In IN O
this DT O
study NN O
we PRP O
sought VBD O
to TO O
determine VB O
the DT O
prevalence NN O
of IN O
MSH6 NNP B-NP
mutations NNS O
in IN O
our PRP$ O
Northern NNP O
Ireland NNP O
HNPCC NNP O
cohort NN O
with IN O
less JJR O
restrictive JJ O
inclusion NN O
criteria NNS O
than IN O
the DT O
Amsterdam NNP O
II NNP O
criteria NNS O
, , O
in IN O
an DT O
attempt NN O
to TO O
include VB O
as IN O
many JJ O
MSH6 IN B-NP
phenotype JJ O
families NNS O
as IN O
possible JJ O
given VBN O
the DT O
probable JJ O
later JJ O
onset NN O
of IN O
colon NN O
cancers NNS O
; : O
and CC O
also RB O
determine VB O
the DT O
prevalence NN O
of IN O
mutations NNS O
in IN O
an DT O
unselected JJ O
cohort NN O
of IN O
EC NNP O
patients NNS O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

All DT O
DNA NNP O
was VBD O
or CC O
had VBD O
been VBN O
extracted VBN O
by IN O
the DT O
Nucleic NNP O
Acid NNP O
Extraction NNP O
Centre NNP O
( -LRB- O
NAEC NNP O
) -RRB- O
, , O
Belfast NNP O
City NNP O
Hospital NNP O
, , O
and CC O
stored VBN O
at IN O
−80°C. VBG O

Working NNP O
dilutions NNS O
in IN O
X1 NNP O
TE VB O
were VBD O
made VBN O
at IN O
5ng/μl JJ O
. . O

All DT O
ten CD O
exons NNS O
and CC O
at IN O
least JJS O
20 CD O
base NN O
pair NN O
( -LRB- O
bp NN O
) -RRB- O
of IN O
flanking VBG O
intronic JJ O
sequence NN O
was VBD O
subject JJ O
to TO O
direct JJ O
sequencing NN O
analysis NN O
. . O

PCR NN O
products NNS O
for IN O
nine CD O
of IN O
ten CD O
exons NNS O
of IN O
MSH6 NNP B-NP
were VBD O
obtained VBN O
using VBG O
Applied NNP O
Biosystems NNP O
VariantSEQr™ NNP O
Requencing NN O
System NNP O
( -LRB- O
product NN O
number NN O
: : O
RSS000012234_02 NN O
) -RRB- O
. . O

All DT O
reactions NNS O
were VBD O
carried VBN O
out RP O
using VBG O
standard JJ O
reaction NN O
mix NN O
and CC O
conditions NNS O
as IN O
determined VBN O
by IN O
ABI. NNP O

Exon NNP O
1 CD O
primers NNS O
were VBD O
as IN O
follows VBZ O
: : O
1F JJ O
PCR NN O
; : O
TCCGTCCGACAGAACGGTTG NNP O
, , O
1R JJ O
PCR NN O
; : O
ATGCTCCAGACTCGACCCG NNP O
, , O
using VBG O
a DT O
standard NN O
25μl JJ O
reaction NN O
mix NN O
with IN O
3.4μl CD O
of IN O
25mm JJ O
MgCl2 NNP O
and CC O
0.4μl CD O
of IN O
5U/μl JJ O
Expand NNP O
DNA NN O
polymerase NN O
( -LRB- O
ABI NNP O
) -RRB- O
at IN O
an DT O
annealing NN O
temperature NN O
of IN O
60°C. VBG O

All DT O
PCR NN O
products NNS O
were VBD O
subject JJ O
to TO O
clean VB O
up RP O
using VBG O
ExoSAPIT®† NNP O
to TO O
remove VB O
excess JJ O
primer JJ O
dimer NN O
, , O
unincorporated JJ O
dNTPs NNS O
, , O
and CC O
non-specific JJ O
DNA NN O
products NNS O
. . O

Sequencing VBG O
reactions NNS O
were VBD O
carried VBN O
out RP O
using VBG O
BigDye® NNP O
terminator NN O
Ready JJ O
Reaction NN O
Mix NNP O
v1.1 CD O
from IN O
ABI® NNP O
, , O
according VBG O
to TO O
manufacturer NN O
's POS O
instructions NNS O
. . O

Additional JJ O
primers NNS O
were VBD O
required VBN O
to TO O
sequence NN O
exons NNS O
7 CD O
and CC O
8 CD O
because IN O
of IN O
a DT O
poly NN O
T NNP O
at IN O
the DT O
5′ JJ O
end NN O
of IN O
exon NN O
7 CD O
, , O
which WDT O
resulted VBD O
in IN O
slippage NN O
during IN O
the DT O
sequencing NN O
reaction NN O
, , O
and CC O
polymorphisms NNS O
situated VBN O
at IN O
the DT O
3′ NN O
, , O
( -LRB- O
c.3646 IN O
+35_38delATCT) NN O
of IN O
exon NN O
7 CD O
, , O
and CC O
5′ CD O
, , O
( -LRB- O
c.3647 IN O
−51_−35 CD O
del FW O
17 CD O
) -RRB- O
, , O
and CC O
3′ JJ O
( -LRB- O
c.3802–42insT NN O
) -RRB- O
end NN O
of IN O
exon JJ O
8 CD O
, , O
which WDT O
made VBD O
sequence NN O
of IN O
the DT O
exons NNS O
unreadable JJ O
when WRB O
the DT O
polymorphisms NNS O
were VBD O
present JJ O
in IN O
the DT O
heterozygous JJ O
state NN O
. . O

Additional JJ O
sequencing NN O
primers NNS O
for IN O
exon NN O
7 CD O
( -LRB- O
7F IN O
Seq NNP O
; : O
TTGTGATTTTTTTTTTTTTAAG NNP O
, , O
7R NNP O
Seq NNP O
; : O
TAGTCTTCAAATGAGAAG NNP O
) -RRB- O
and CC O
8 CD O
(8F NN O
Seq NN O
; : O
GAGTTACTTCCTTATGCA NNP O
, , O
8R JJ O
Seq NNP O
; : O
GAAGTGCCCTCTCAAAAAACC NNP O
) -RRB- O
were VBD O
designed VBN O
. . O

Electrophoresis NNP O
was VBD O
carried VBN O
out RP O
by IN O
the DT O
Queen NNP O
's POS O
University NNP O
Belfast NNP O
genomic NNP O
core NN O
facility NN O
on IN O
an DT O
ABI JJ O
3730 CD O
DNA NNP O
analyser NN O
. . O

MLPA NNP O
Analysis NN O

All DT O
samples NNS O
were VBD O
subject JJ O
to TO O
MLPA NNP O
analysis NN O
using VBG O
SALSA NNP O
MLPA NNP O
KIT NNP O
POO8 CD O
MSH6/PMS2 . B-NP
from IN O
MRC-Holland NNP O
. . O

Reaction NN O
mix NN O
and CC O
conditions NNS O
are VBP O
as IN O
determined VBN O
by IN O
MRC-Holland NNP O
. . O

Electrophoresis NNP O
was VBD O
carried VBN O
on IN O
an DT O
ABI NNP O
3100 CD O
Avant JJ O
DNA NNP O
analyzer NN O
using VBG O
a DT O
GeneScan™ NNP O
- : O
500 CD O
ROX™ NNP O
size NN O
standard NN O
. . O

From IN O
the DT O
raw JJ O
data NNS O
generated VBD O
, , O
peak JJ O
heights NNS O
of IN O
each DT O
amplification NN O
product NN O
were VBD O
exported VBN O
to TO O
Excel NNP O
worksheets NNS O
designed VBN O
by IN O
Dr NNP O
Andrew NNP O
Wallace NNP O
, , O
National NNP O
Genetics NNP O
Reference NNP O
Laboratory NNP O
, , O
Manchester NNP O
, , O
so RB O
that IN O
the DT O
result NN O
of IN O
each DT O
sample NN O
could MD O
be VB O
‘normalised’ VBN O
. . O

Statistical NNP O
Methods NNPS O

The DT O
cohort NN O
sizes VBZ O
necessary JJ O
to TO O
obtain VB O
estimates NNS O
with IN O
adequate JJ O
precision NN O
were VBD O
initially RB O
calculated VBN O
using VBG O
a DT O
Normal JJ O
approximation NN O
to TO O
the DT O
binomial JJ O
sampling NN O
distribution NN O
provided VBN O
by IN O
the DT O
StatCalc NNP O
program NN O
in IN O
the DT O
EpiInfo NNP O
package NN O
( -LRB- O
) -RRB- O
. . O

The DT O
Stata NNP O
package NN O
( -LRB- O
) -RRB- O
was VBD O
used VBN O
to TO O
give VB O
the DT O
exact JJ O
binomial JJ O
confidence NN O
limits NNS O
for IN O
a DT O
proportion NN O
( -LRB- O
Table NN O
I PRP O
) -RRB- O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

CONCLUSION NN O

From IN O
this DT O
study NN O
we PRP O
have VBP O
identified VBN O
the DT O
minimum JJ O
prevalence NN O
of IN O
pathogenic JJ O
mutations NNS O
in IN O
MSH6 CD B-NP
to TO O
be VB O
higher JJR O
in IN O
an DT O
unselected JJ O
cohort NN O
of IN O
EC NNP O
patients NNS O
, , O
than IN O
a DT O
cohort NN O
of IN O
HNPCC NNP O
patients NNS O
who WP O
have VBP O
been VBN O
selected VBN O
by IN O
criteria NNS O
‘widened VBN O
’ RB O
from IN O
the DT O
traditional JJ O
Amsterdam NNP O
II NNP O
criteria NNS O
, , O
in IN O
keeping VBG O
with IN O
the DT O
described VBN O
phenotype NN O
of IN O
MSH6 NNP B-NP
. . O

Unlike IN O
the DT O
other JJ O
more JJR O
common JJ O
MMR NNP B-NP
genes NNS O
, , O
genomic JJ O
rearrangements NNS O
do VBP O
not RB O
contribute VB O
to TO O
a DT O
large JJ O
proportion NN O
of IN O
mutations NNS O
in IN O
MSH6 NNP B-NP
. . O

HNPCC NNP O
families NNS O
may MD O
not RB O
be VB O
identified VBN O
if IN O
patients NNS O
present VBP O
with IN O
HNPCC NNP O
associated JJ O
cancers NNS O
, , O
such JJ O
as IN O
gynaecological JJ O
cancer NN O
, , O
rather RB O
than IN O
the DT O
more JJR O
commonly RB O
recognised VBN O
phenotype NN O
of IN O
CRC. NNP O

Clinicians NNS O
should MD O
be VB O
vigilant NN O
to TO O
this DT O
possibility NN O
when WRB O
presented VBN O
with IN O
a DT O
history NN O
of IN O
endometrial JJ O
cancer NN O
in IN O
young JJ O
women NNS O
. . O

Further JJ O
work NN O
on IN O
immunohistochemistry NN O
of IN O
possible JJ O
missense NN O
variants NNS O
may MD O
increase VB O
the DT O
true JJ O
frequency NN O
of IN O
mutations NNS O
in IN O
MSH6 NNP B-NP
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

To TO O
understand VB O
more JJR O
precisely RB O
the DT O
mechanistic JJ O
roles NNS O
that IN O
Mlh3 NNP B-NP
and CC O
Pms2 NNP B-NP
play NN O
in IN O
GI NNP O
tumor NN O
suppression NN O
, , O
we PRP O
generated VBD O
Mlh3−/−;Apc1638N NNP B-NP
( -LRB- O
MA NNP O
) -RRB- O
and CC O
Mlh3−/−;Pms2−/−;Apc1638N NNP B-NP
( -LRB- O
MPA NNP O
) -RRB- O
mice NNS O
. . O

We PRP O
show VBP O
that IN O
in IN O
vivo JJ O
Mlh3 CD B-NP
mutations NNS O
significantly RB O
increase VB O
frameshift NN O
mutation NN O
rates NNS O
in IN O
Apc NNP B-NP
, , O
and CC O
increase VB O
GI NNP O
tumorigenesis NN O
. . O

Unlike IN O
typical JJ O
MSI-induced JJ O
mutations NNS O
, , O
Mlh3 CC B-NP
deficiency NN O
also RB O
results VBZ O
in IN O
frameshift NN O
mutations NNS O
in IN O
non-repetitive JJ O
sequences NNS O
, , O
a DT O
unique JJ O
mutational JJ O
signature NN O
among IN O
MMR NNP B-NP
deficient NN O
mice NNS O
found VBD O
only RB O
in IN O
Mlh3 CD B-NP
deficient JJ O
mice NNS O
. . O

Consistent NNP O
with IN O
the DT O
role NN O
of IN O
Pms2 NNP B-NP
in IN O
SBR NNP O
, , O
combined VBN O
Mlh3 NNP B-NP
and CC O
Pms2 NNP B-NP
mutations NNS O
proportionally RB O
increase VB O
point NN O
mutations NNS O
and CC O
show VB O
a DT O
sequence NN O
preference NN O
for IN O
a DT O
CpG NNP O
mutation NN O
hotspot NN O
also RB O
previously RB O
seen VBN O
in IN O
Mlh1−/ NNP B-NP
− NNP O
mice NNS O
. . O

Because IN O
MPA NNP O
mutant JJ O
mice NNS O
also RB O
have VBP O
significantly RB O
increased VBN O
rates NNS O
of IN O
GI NNP O
adenocarcinomas NNS O
vs. IN O
Apc1638N NNP B-NP
or CC O
MA NNP O
mice NNS O
, , O
we PRP O
investigated VBD O
mechanisms NNS O
of IN O
tumor NN O
progression NN O
. . O

Using VBG O
array-CGH NN O
, , O
we PRP O
identified VBD O
a DT O
recurrent JJ O
5-Mb JJ O
amplification NN O
on IN O
chromosome NN O
12 CD O
in IN O
GI NNP O
tumors NNS O
from IN O
MPA NNP O
mice NNS O
. . O

We PRP O
defined VBD O
the DT O
amplicon NN O
critical JJ O
interval NN O
and CC O
demonstrated VBD O
that IN O
it PRP O
contains VBZ O
a DT O
previously RB O
uncharacterized JJ O
member NN O
of IN O
the DT O
Transducin NNP O
enhancer NN O
of IN O
Split NNP O
( -LRB- O
TLE)/Groucho NNP B-NP
family NN O
of IN O
transcriptional JJ O
co-regulators NNS O
, , O
Tle6-like JJ B-NP
, , O
that IN O
contributes NNS O
to TO O
tumor NN O
progression NN O
. . O

Tle6-like JJ B-NP
overexpression IN O
in IN O
colon NN O
cancer NN O
cell NN O
lines NNS O
increases VBZ O
cell NN O
proliferation NN O
, , O
colony-formation NN O
ability NN O
, , O
cell NN O
migration NN O
and CC O
xenograft NN O
tumorigenicity NN O
. . O

Human NNP O
TLE6D NNP B-NP
, , O
an DT O
alternatively RB O
spliced VBN O
isoform NN O
of IN O
TLE6 NNP B-NP
, , O
with IN O
a DT O
domain NN O
structure NN O
similar JJ O
to TO O
Tle6-like JJ B-NP
, , O
has VBZ O
functional JJ O
activity NN O
similar JJ O
to TO O
Tle6-like JJ B-NP
. . O

Both DT O
Tle6-like JJ B-NP
and CC O
TLE6D JJ B-NP
interact NN O
with IN O
GI NNP O
tumor NN O
suppressor NN O
, , O
RUNX3 NNP B-NP
[34] NNP O
, , O
and CC O
antagonize VB O
RUNX3 NNP B-NP
gene NN O
target NN O
tranactivation NN O
. . O

TLE6D NNP B-NP
is VBZ O
overexpressed VBN O
in IN O
multiple JJ O
human JJ O
microsatellite NN O
stable NN O
( -LRB- O
MSS) NNP O
and CC O
microsatellite JJ O
unstable JJ O
( -LRB- O
MSI-H) JJ O
CRCs NNP O
, , O
and CC O
TLE6D NNP B-NP
expression NN O
levels NNS O
correlate VBP O
with IN O
RUNX3 JJ B-NP
expression NN O
levels NNS O
. . O

Collectively RB O
, , O
these DT O
findings NNS O
provide VBP O
important JJ O
insights NNS O
into IN O
the DT O
molecular JJ O
mechanisms NNS O
through IN O
which WDT O
MMR-deficiency NNP B-NP
contributes VBZ O
to TO O
GI VB O
tumorigenesis NN O
and CC O
implicate VB O
a DT O
novel JJ O
association NN O
between IN O
TLE6 DT B-NP
isoforms NNS O
and CC O
antagonism NN O
of IN O
RUNX NNP B-NP
target NN O
gene NN O
expression NN O
in IN O
CRC NNP O
tumor NN O
progression NN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

RUNX NNP B-NP
family NN O
genes NNS O
regulate VB O
lineage NN O
and CC O
stage NN O
specific JJ O
gene NN O
transcription NN O
by IN O
direct JJ O
binding JJ O
to TO O
DNA NNP O
promoters NNS O
and CC O
enhancer VB O
elements NNS O
[44] IN O
,[45] NN O
. . O

Loss NN O
of IN O
Runx3 NNP B-NP
in IN O
the DT O
mouse NN O
results NNS O
in IN O
the DT O
development NN O
of IN O
gastric JJ O
mucosal NN O
hyperplasia NN O
, , O
decreased VBD O
apoptosis NN O
and CC O
attenuated VBD O
TGF-β NNP B-NP
anti-proliferative JJ O
signaling NN O
. . O

Consistent NNP O
with IN O
previous JJ O
observations NNS O
of IN O
interactions NNS O
between IN O
RUNX3 NNP B-NP
and CC O
TLE NNP B-NP
family NN O
members NNS O
mediated VBN O
through IN O
the DT O
Runt NNP B-NP
and CC O
WD NNP B-NP
repeat VBP O
domains NNS O
, , O
respectively RB O
[46] JJ O
,[48] NN O
, , O
we PRP O
detected VBD O
an DT O
interaction NN O
between IN O
RUNX3 NNP B-NP
and CC O
Tle6-like/TLE6D NNP B-NP
by IN O
co-immunoprecipitation NN O
. . O

Furthermore RB O
, , O
we PRP O
demonstrated VBD O
that IN O
Tle6-like/TLE6D JJ B-NP
antagonized JJ O
RUNX3 NNS B-NP
regulated VBN O
transcriptional JJ O
targets NNS O
. . O

However RB O
, , O
while IN O
these DT O
experiments NNS O
show VBP O
an DT O
association NN O
between IN O
RUNX3∶TLE6D NNP B-NP
interactions NNS O
and CC O
tumor NN O
progression NN O
, , O
they PRP O
do VBP O
not RB O
demonstrate VB O
mechanistically RB O
the DT O
functional JJ O
importance NN O
of IN O
this DT O
interaction NN O
in IN O
accelerating VBG O
tumor NN O
progression NN O
. . O

Alternative JJ O
mRNA NN O
splicing NN O
allows VBZ O
multiple JJ O
gene NN O
products NNS O
to TO O
be VB O
produced VBN O
from IN O
a DT O
single JJ O
coding NN O
sequence NN O
, , O
and CC O
through IN O
this DT O
mechanism NN O
a DT O
higher JJR O
diversity NN O
of IN O
mammalian JJ O
genes NNS O
is VBZ O
generated VBN O
[68] JJ O
. . O

Several JJ O
distinct JJ O
TLE/Grg NNP B-NP
gene NN O
alternative JJ O
splice NN O
forms NNS O
, , O
such JJ O
as IN O
Grg-1s NNP B-NP
, , O
QD NNP B-NP
of IN I-NP
TLE4 NNP I-NP
, , O
and CC O
Grg3b NNP B-NP
[42] VBD O
,[69] JJ O
,[70] NN O
, , O
have VBP O
been VBN O
reported VBN O
. . O

While IN O
the DT O
human JJ O
genome NN O
does VBZ O
not RB O
encode VB O
a DT O
TLE6-LIKE JJ B-NP
ortholog NN O
, , O
a DT O
structurally RB O
equivalent JJ O
protein NN O
, , O
TLE6D NNP B-NP
, , O
is VBZ O
generated VBN O
through IN O
alternative JJ O
splicing NN O
. . O

The DT O
observation NN O
that IN O
GI JJ O
adenocarcinomas NNS O
from IN O
both DT O
humans NNS O
and CC O
mice NNS O
use VBP O
two CD O
very RB O
distinct JJ O
mechanisms NNS O
to TO O
amplify VB O
Tle6-like/TLE6D JJ B-NP
activity NN O
suggests VBZ O
a DT O
strong JJ O
growth NN O
advantage NN O
and CC O
selective JJ O
pressure NN O
for IN O
this DT O
TLE JJ B-NP
isoform NN O
in IN O
tumor NN O
progression NN O
. . O

Similarly RB O
, , O
the DT O
correlation NN O
between IN O
TLE6D NNP B-NP
and CC O
RUNX3 NNP B-NP
expression NN O
in IN O
human JJ O
CRC NNP O
suggests VBZ O
a DT O
model NN O
whereby WRB O
RUNX3 NNS B-NP
inactivation NN O
by IN O
TLE6D NNP B-NP
could MD O
be VB O
an DT O
important JJ O
factor NN O
driving VBG O
this DT O
growth NN O
advantage NN O
in IN O
both DT O
MSI-H NNP O
and CC O
MSS NNP O
CRC. . O

Future JJ O
studies NNS O
will MD O
be VB O
required VBN O
to TO O
understand VB O
the DT O
mechanistic JJ O
implications NNS O
of IN O
the DT O
interaction NN O
between IN O
these DT O
two CD O
proteins NNS O
in IN O
CRC NNP O
progression NN O
in IN O
more RBR O
precise JJ O
detail NN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Materials NNS O
and CC O
Methods NNS O

Mouse NN O
Lines NNP O
and CC O
Survival NNP O
Analyses NNP O
, , O
Tumor NNP O
Analysis NNP O
, , O
and CC O
Apc NNP B-NP
Mutation NNP O
Analysis . O

Wild-type NNP O
( -LRB- O
Wt NN O
) -RRB- O
, , O
Pms2+/ NNP B-NP
− NNP O
and CC O
Mlh3+/ NNP B-NP
− NNP O
mice NNS O
were VBD O
maintained VBN O
on IN O
the DT O
129 CD O
Sv/Ev NNP O
genetic JJ O
background NN O
and CC O
intercrossed VBD O
to TO O
generate VB O
Mlh3+/−;Pms2+/ JJ B-NP
− JJ O
mice NNS O
as IN O
described VBN O
before IN O
[13] NNS O
. . O

Apc1638N NNP B-NP
mice NNS O
were VBD O
backcrossed VBN O
four CD O
times NNS O
to TO O
129 CD O
Sv/Ev NNP O
and CC O
subsequently RB O
intercrossed VBN O
with IN O
Mlh3+/− NNP B-NP
; : O
Pms2+/ NNP B-NP
− VBD O
to TO O
generate VB O
Mlh3−/−;Apc1638N NNP B-NP
and CC O
Mlh3−/−;Pms2−/−;Apc1638N NNP B-NP
mice NNS O
. . O

Kaplan-Meier JJ O
survival NN O
curves NNS O
were VBD O
generated VBN O
and CC O
statistical JJ O
significance NN O
between IN O
genotypes NNS O
was VBD O
determined VBN O
using VBG O
the DT O
Log NNP O
Rank NNP O
test NN O
as IN O
previously RB O
performed VBN O
[13] NN O
. . O

All DT O
lines NNS O
of IN O
mice NNS O
were VBD O
necropsied VBN O
when WRB O
they PRP O
became VBD O
morbid NN O
or CC O
moribund NN O
. . O

Sacrificed NNP O
mice NNS O
were VBD O
surveyed VBN O
for IN O
tumors NNS O
and CC O
suspicious JJ O
masses NNS O
were VBD O
histology RB O
analyzed VBN O
as IN O
previously RB O
performed VBN O
. . O

Statistical NNP O
analyses NNS O
of IN O
tumor NN O
onset NN O
and CC O
incidence NN O
among IN O
the DT O
different JJ O
mouse NN O
lines NNS O
were VBD O
performed VBN O
using VBG O
the DT O
Mann-Whitney NNP O
test NN O
as IN O
previously RB O
described VBN O
[23] JJ O
,[32] JJ O
,[33] JJ O
,[35] JJ O
,[71] JJ O
,[72] JJ O
,[73] JJ O
,[74] JJ O
,[75] JJ O
,[76] NN O
. . O

Tumors NNS O
from IN O
stomach NN O
, , O
small JJ O
intestine NN O
, , O
and CC O
colon NN O
were VBD O
cut VBN O
into IN O
two CD O
parts NNS O
. . O

One CD O
part NN O
of IN O
the DT O
tumor NN O
was VBD O
processed VBN O
for IN O
histopathological JJ O
analysis NN O
and CC O
the DT O
other JJ O
part NN O
was VBD O
used VBN O
for IN O
DNA/RNA NNP O
extractions NNS O
. . O

Genomic JJ O
DNA NN O
samples NNS O
were VBD O
extracted VBN O
using VBG O
Puregene NNP O
DNA NNP O
Isolation NNP O
kit NN O
( -LRB- O
Gentra NNP O
Systems NNPS O
, , O
Minneapolis NNP O
, , O
MN) NNP O
and CC O
subjected VBN O
to TO O
mutational JJ O
analysis NN O
of IN O
Apc NNP B-NP
gene NN O
between IN O
codons NNS O
677–1674 CD O
as IN O
previously RB O
described VBN O
[33] JJ O
. . O

Array NNP O
Comparative NNP O
Genomic NNP O
Hybridization NNP O
Analysis . O

Genomic NNP O
DNAs NNP O
were VBD O
isolated VBN O
from IN O
tumor NN O
tissue NN O
and CC O
tail NN O
tissue NN O
from IN O
each DT O
mouse NN O
using VBG O
PUREGENE NNP O
DNA NNP O
Isolation NNP O
kit NN O
( -LRB- O
Gentra NNP O
Systems NNPS O
, , O
Minneapolis NNP O
, , O
MN) NNP O
. . O

DNAs NNP O
were VBD O
digested VBN O
with IN O
DpnII NNP O
and CC O
subsequently RB O
purified VBN O
using VBG O
the DT O
QIAquick JJ O
PCR NN O
Purification NN O
kit NN O
( -LRB- O
Qiagen NNP O
) -RRB- O
. . O

The DT O
quality NN O
of IN O
the DT O
DNA NNP O
samples NNS O
was VBD O
evaluated VBN O
using VBG O
the DT O
Agilent NNP O
2100 CD O
BioAnalyzer NNP O
. . O

The DT O
purified VBN O
fragmented JJ O
DNA NN O
samples NNS O
were VBD O
random-prime JJ O
labeled VBN O
with IN O
either DT O
Cy5 NNP O
or CC O
Cy3 NNP O
and CC O
hybridized VBD O
as IN O
previously RB O
described VBN O
[77] . O

Briefly RB O
, , O
for IN O
each DT O
labeling NN O
reaction NN O
, , O
2 CD O
µg NN O
of IN O
purified VBN O
digested JJ O
DNA NN O
were VBD O
used VBN O
. . O

Each DT O
sample NN O
was VBD O
dye-swap JJ O
labeled VBN O
for IN O
hybridization NN O
to TO O
mouse NN O
70-mer JJ O
oligonucleotide JJ O
microarrays NNS O
( -LRB- O
Agilent NNP O
Technologies NNP O
, , O
Palo NNP O
Alto NNP O
, , O
CA NNP O
) -RRB- O
containing VBG O
20,281 CD O
clones NNS O
. . O

After IN O
hybridization NN O
, , O
the DT O
arrays NNS O
were VBD O
scanned VBD O
using VBG O
an DT O
Agilent JJ O
Microarray NNP O
DNA NN O
scanner NN O
( -LRB- O
Agilent JJ O
Technologies NNPS O
) -RRB- O
and CC O
the DT O
spot NN O
intensity NN O
was VBD O
extracted VBN O
from IN O
slide NN O
images NNS O
using VBG O
Agilent JJ O
Feature NNP O
Extraction NNP O
Software NNP O
7.0. . O

The DT O
data NNS O
were VBD O
further RB O
analyzed VBN O
using VBG O
the DT O
procedures NNS O
of IN O
Automatic NNP O
Data NNP O
Analysis NNP O
Pipeline NNP O
( -LRB- O
ADAP NNP O
) -RRB- O
. . O

Only RB O
spots NNS O
with IN O
fluorescence NN O
intensities NNS O
statistically RB O
different JJ O
from IN O
the DT O
surrounding VBG O
background NN O
( -LRB- O
P<0.001 CD O
) -RRB- O
were VBD O
considered VBN O
reliable JJ O
, , O
taking VBG O
up RP O
>85 CD O
% NN O
of IN O
total JJ O
spots NNS O
on IN O
the DT O
chip NN O
. . O

For IN O
further JJ O
analysis NN O
the DT O
fluorescence NN O
intensity NN O
values NNS O
of IN O
reliable JJ O
spots NNS O
were VBD O
transformed VBN O
to TO O
log2 VB O
. . O

To TO O
minimize VB O
the DT O
effect NN O
of IN O
the DT O
variations NNS O
, , O
the DT O
log2 NN O
intensity NN O
ratios NNS O
of IN O
remaining VBG O
spots NNS O
were VBD O
subjected VBN O
to TO O
normalization NN O
by IN O
Lowess NNP O
fitting VBG O
. . O

Gene NNP O
copy VBP O
number NN O
changes NNS O
for IN O
each DT O
sample NN O
was VBD O
calculated VBN O
by IN O
taking VBG O
the DT O
median NN O
of IN O
the DT O
normalized JJ O
log2 NN O
intensity NN O
ratios NNS O
of IN O
dye-swapped JJ O
chip NN O
experiments NNS O
for IN O
the DT O
corresponding JJ O
sample NN O
. . O

The DT O
gene NN O
copy NN O
numbers NNS O
were VBD O
ordered VBN O
along IN O
chromosomes NNS O
by IN O
the DT O
map NN O
positions NNS O
of IN O
corresponding JJ O
genes NNS O
. . O

To TO O
eliminate VB O
systematic JJ O
noise NN O
, , O
gene NN O
copy NN O
number NN O
changes NNS O
( -LRB- O
log2Ratios NNS O
) -RRB- O
along IN O
the DT O
chromosomes NNS O
were VBD O
smoothed VBN O
by IN O
taking VBG O
a DT O
moving VBG O
median NN O
of IN O
symmetric JJ O
5-nearest NN O
neighbors NNS O
, , O
followed VBN O
by IN O
Lowess NNP O
fitting VBG O
( -LRB- O
f NN O
= SYM O
0.2 CD O
) -RRB- O
. . O

The DT O
mean NN O
and CC O
standard JJ O
deviation NN O
( -LRB- O
SD NN O
) -RRB- O
of IN O
smoothed VBN O
log2Ratios NNS O
for IN O
all DT O
genes NNS O
in IN O
all DT O
the DT O
samples NNS O
were VBD O
calculated VBN O
. . O

The DT O
copy NN O
number NN O
profiles NNS O
of IN O
at IN O
least JJS O
5 CD O
consecutive JJ O
genes NNS O
that WDT O
deviated VBD O
significantly RB O
above IN O
mean+3SD PRP O
were VBD O
interpreted VBN O
as IN O
regional JJ O
gains NNS O
, , O
below RB O
mean-3SD JJ O
as IN O
regional JJ O
losses NNS O
. . O

The DT O
threshold NN O
for IN O
whole JJ O
chromosomal NN O
gain/loss NN O
was VBD O
mean±2SD. . O

The DT O
ideograms NNS O
of IN O
chromosomal NN O
aberrations NNS O
were VBD O
drawn VBN O
using VBG O
mapping NN O
information NN O
of IN O
cytogenetic JJ O
bands NNS O
to TO O
the DT O
mouse NN O
genome NN O
(NCBI IN O
Mapview NNP O
Build NNPS O
32 CD O
) -RRB- O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Given VBN O
the DT O
above JJ O
unanticipated JJ O
characteristics NNS O
of IN O
the DT O
newly RB O
discovered VBN O
mutations—especially RB O
their PRP$ O
low JJ O
frequency NN O
and CC O
high JJ O
rate NN O
of IN O
heterozygosity—we PRP O
performed VBD O
an DT O
initial JJ O
survey NN O
to TO O
characterize VB O
the DT O
epigenetic JJ O
status NN O
of IN O
genes NNS O
in IN O
colon NN O
cancer NN O
on IN O
a DT O
genome-wide JJ O
level NN O
. . O

To TO O
this DT O
end NN O
, , O
we PRP O
developed VBD O
an DT O
expression NN O
microarray NN O
technique NN O
to TO O
characterize VB O
the DT O
spectrum NN O
of IN O
hypermethylated JJ O
genes NNS O
in IN O
cancers NNS O
[15] VBP O
. . O

In IN O
the DT O
present JJ O
paper NN O
, , O
we PRP O
have VBP O
utilized VBN O
our PRP$ O
global JJ O
approach NN O
to TO O
comprehensively RB O
compare VB O
the DT O
epigenetic JJ O
alteration NN O
of IN O
the DT O
CAN NNP O
genes NNS O
in IN O
both DT O
breast NN O
and CC O
colon NN O
cancers NNS O
, , O
and CC O
included VBD O
analyses NNS O
in IN O
the DT O
specific JJ O
breast NN O
cancer NN O
lines NNS O
where WRB O
individual JJ O
mutations NNS O
were VBD O
identified VBN O
by IN O
Sjoblom NNP O
et NNP O
al NN O
. . O
[7] '' O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Genes NNP O
Targeted NNP O
by IN O
Mutation NNP O
and CC O
Hypermethylation NNP O

Common NNP O
Gene NNP O
Targets NNP O
of IN O
Mutation NNP O
and CC O
Hypermethylation NNP O
in IN O
Breast NNP O
Cancer NNP O

MSP NNP O
and CC O
RT-PCR JJ O
expression NN O
analysis NN O
of IN O
selected VBN O
genes NNS O
. . O

Each DT O
set NN O
of IN O
MSP NNP O
and CC O
expression NN O
analyses NNS O
are VBP O
labeled VBN O
with IN O
the DT O
corresponding JJ O
gene NN O
name NN O
. . O

U NNP O
denotes VBZ O
the DT O
unmethylated JJ O
band NN O
, , O
and CC O
M NNP O
denotes VBZ O
the DT O
methylated JJ O
band NN O
. . O

In IN O
vitro NN O
methylated JJ O
DNA NN O
( -LRB- O
IVD NNP O
) -RRB- O
was VBD O
used VBN O
as IN O
a DT O
positive JJ O
control NN O
for IN O
methylation NN O
. . O

cDNA NN O
from IN O
normal JJ O
breast NN O
( -LRB- O
NB) NNP O
and CC O
normal JJ O
colon NN O
(NC NN O
) -RRB- O
( -LRB- O
Figure NN O
3 CD O
) -RRB- O
was VBD O
used VBN O
to TO O
determine VB O
the DT O
expression NN O
of IN O
the DT O
genes NNS O
in IN O
normal JJ O
tissue NN O
. . O

DKO NNP O
corresponds NNS O
to TO O
DNMT NNP O
1/3b CD O
double JJ O
knockout NN O
HCT116 IN O
cells NNS O
. . O

All DT O
RT-PCR JJ O
experiments NNS O
were VBD O
performed VBN O
in IN O
parallel RB O
without IN O
reverse JJ O
transcriptase NN O
as IN O
a DT O
control NN O
, , O
and CC O
in IN O
all DT O
cases NNS O
, , O
no DT O
PCR NNP O
product NN O
was VBD O
generated VBN O
(unpublished JJ O
data NNS O
) -RRB- O
. . O

The DT O
control NN O
experiment NN O
performed VBN O
without IN O
RT NNP O
for IN O
normal JJ O
breast NN O
is VBZ O
shown VBN O
( -LRB- O
NB NNP O
no DT O
RT NNP O
) -RRB- O
for IN O
each DT O
gene NN O
. . O

RT-PCR NNP O
was VBD O
performed VBN O
for IN O
all DT O
cancer NN O
lines NNS O
with IN O
beta-actin JJ O
primers NNS O
to TO O
control VB O
for IN O
the DT O
amount NN O
of IN O
cDNA NN O
( -LRB- O
Figure NN O
3 CD O
, , O
bottom NN O
) -RRB- O
. . O

Common NNP O
Gene NNP O
Targets NNP O
of IN O
Mutation NNP O
and CC O
Hypermethylation NNP O
in IN O
Colon NNP O
Cancer NNP O

MSP NNP O
and CC O
RT-PCR JJ O
expression NN O
analysis NN O
of IN O
selected VBN O
genes NNS O
. . O

Each DT O
set NN O
of IN O
MSP NNP O
and CC O
expression NN O
analyses NNS O
are VBP O
labeled VBN O
with IN O
the DT O
corresponding JJ O
gene NN O
name NN O
. . O

U NNP O
denotes VBZ O
the DT O
unmethylated JJ O
band NN O
, , O
and CC O
M NNP O
denotes VBZ O
the DT O
methylated JJ O
band NN O
. . O

In IN O
vitro NN O
methylated JJ O
DNA NN O
( -LRB- O
IVD NNP O
) -RRB- O
was VBD O
used VBN O
as IN O
a DT O
positive JJ O
control NN O
for IN O
methylation NN O
. . O

cDNA NN O
from IN O
normal JJ O
breast NN O
( -LRB- O
NB) NNP O
and CC O
normal JJ O
colon NN O
(NC NNS O
) -RRB- O
was VBD O
used VBN O
to TO O
determine VB O
the DT O
expression NN O
of IN O
the DT O
genes NNS O
in IN O
normal JJ O
tissue NN O
. . O

DKO NNP O
corresponds NNS O
to TO O
DNMT NNP O
1/3b CD O
double JJ O
knockout NN O
HCT116 IN O
cells NNS O
. . O

All DT O
RT-PCR JJ O
experiments NNS O
were VBD O
performed VBN O
in IN O
parallel RB O
without IN O
reverse JJ O
transcriptase NN O
as IN O
a DT O
control NN O
, , O
and CC O
in IN O
all DT O
cases NNS O
, , O
no DT O
PCR NNP O
product NN O
was VBD O
generated VBN O
(unpublished JJ O
data NNS O
) -RRB- O
. . O

The DT O
control NN O
experiment NN O
performed VBN O
without IN O
RT NNP O
for IN O
normal JJ O
colon NN O
is VBZ O
shown VBN O
(NC IN O
no DT O
RT NNP O
) -RRB- O
for IN O
each DT O
gene NN O
. . O

RT-PCR NNP O
was VBD O
performed VBN O
for IN O
all DT O
cancer NN O
lines NNS O
with IN O
beta-actin JJ O
primers NNS O
to TO O
control VB O
for IN O
the DT O
amount NN O
of IN O
cDNA NN O
. . O

From IN O
the DT O
analysis NN O
of IN O
methylation NN O
and CC O
expression NN O
status NN O
of IN O
the DT O
36 CD O
common JJ O
target NN O
genes NNS O
, , O
it PRP O
is VBZ O
clear JJ O
that IN O
, , O
although IN O
hypermethylation NN O
was VBD O
accompanied VBN O
by IN O
loss NN O
of IN O
gene NN O
expression NN O
in IN O
nearly RB O
all DT O
cases NNS O
, , O
loss NN O
of IN O
gene NN O
expression NN O
in IN O
the DT O
overlap JJ O
genes NNS O
can MD O
occur VB O
by IN O
mechanisms NNS O
other JJ O
than IN O
methylation NN O
( -LRB- O
Table NN O
S1 NNP O
) -RRB- O
. . O

Potential JJ O
mechanisms NNS O
include VBP O
repressive JJ O
chromatin NN O
modifications NNS O
, , O
mutational JJ O
changes NNS O
outside IN O
the DT O
coding NN O
regions NNS O
that WDT O
destabilize VBP O
the DT O
mRNA NN O
, , O
or CC O
coordinate VB O
downregulation NN O
of IN O
relevant JJ O
pathways NNS O
. . O

For IN O
example NN O
, , O
p21 WDT B-NP
expression NN O
is VBZ O
frequently RB O
decreased VBN O
in IN O
tumors NNS O
with IN O
inactivating VBG O
p53 NN B-NP
mutations NNS O
[25] VBD O
. . O

To TO O
confirm VB O
our PRP$ O
MSP NNP O
results NNS O
, , O
we PRP O
analyzed VBD O
the DT O
methylation NN O
status NN O
of IN O
selected VBN O
genes NNS O
using VBG O
sequencing NN O
of IN O
bisulfite-treated JJ O
genomic JJ O
DNA NN O
from IN O
samples NNS O
that WDT O
were VBD O
used VBN O
in IN O
the DT O
MSP NNP O
studies NNS O
. . O

In IN O
all DT O
cases NNS O
, , O
bisulfite NN O
sequencing NN O
confirmed VBD O
the DT O
results NNS O
obtained VBN O
with IN O
MSP NNP O
( -LRB- O
Figure NN O
4) CD O
. . O

For IN O
another DT O
control NN O
, , O
we PRP O
also RB O
studied VBD O
the DT O
methylation NN O
and CC O
expression NN O
status NN O
of IN O
the DT O
genes NNS O
in IN O
a DT O
derivative JJ O
of IN O
HCT116 CD O
human JJ O
colon NN O
cancer NN O
cells NNS O
in IN O
which WDT O
the DT O
DNMT1 NNP O
and CC O
DNMT3b NNP O
DNA NNP O
methyltransferases NNS O
were VBD O
homozygously RB O
deleted VBN O
( -LRB- O
DKO NN O
cells NNS O
) -RRB- O
. . O

These DT O
simultaneous JJ O
deletions NNS O
result VBP O
in IN O
nearly RB O
complete JJ O
lack NN O
of IN O
DNA NNP O
methylation NN O
and CC O
the DT O
promoter NN O
DNA NN O
demethylation NN O
and CC O
re-expression NN O
of IN O
all DT O
known VBN O
DNA NNP O
hypermethylated VBD O
genes NNS O
examined VBN O
in IN O
these DT O
cells NNS O
[26] VBP O
. . O

In IN O
all DT O
cases NNS O
, , O
the DT O
loss NN O
or CC O
absence NN O
of IN O
methylation NN O
at IN O
the DT O
promoter NN O
regions NNS O
of IN O
the DT O
36 CD O
DNA NNP O
hypermethylated VBD O
loci NNS O
in IN O
DKO NNP O
cells NNS O
was VBD O
associated VBN O
with IN O
expression NN O
of IN O
these DT O
genes NNS O
( -LRB- O
Figures NNS O
2 CD O
and CC O
3 CD O
and CC O
unpublished JJ O
data NNS O
) -RRB- O
. . O

Importantly RB O
, , O
in IN O
all DT O
cases NNS O
, , O
these DT O
36 CD O
overlap JJ O
genes NNS O
were VBD O
also RB O
found VBN O
to TO O
be VB O
expressed VBN O
in IN O
normal JJ O
colon NN O
and CC O
breast NN O
tissue NN O
( -LRB- O
Figures NNPS O
2 CD O
and CC O
3 CD O
and CC O
Table NN O
S1 NNS O
) -RRB- O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

The DT O
above IN O
data NNS O
may MD O
be VB O
particularly RB O
significant JJ O
because IN O
the DT O
vast JJ O
majority NN O
of IN O
CAN NNP O
gene NN O
mutations NNS O
identified VBN O
are VBP O
heterozygous JJ O
missense NN O
mutations NNS O
. . O

It PRP O
is VBZ O
possible JJ O
that IN O
many JJ O
of IN O
these DT O
mutations NNS O
result VBP O
in IN O
haploinsufficiency NN O
or CC O
cause VB O
small JJ O
decreases NNS O
in IN O
protein NN O
or CC O
transcript NN O
abundance NN O
that WDT O
may MD O
be VB O
functionally RB O
meaningful JJ O
for IN O
driving VBG O
tumorigenesis NN O
. . O

Small JJ O
changes NNS O
in IN O
expression NN O
of IN O
a DT O
number NN O
of IN O
tumor NN O
suppressor NN O
genes NNS O
( -LRB- O
such JJ O
as IN O
APC NNP B-NP
, , O
SMAD4 NNP B-NP
, , O
MSH2 NNP B-NP
, , O
etc. NN O
) -RRB- O
have VBP O
now RB O
been VBN O
well RB O
described VBN O
to TO O
have VB O
tumorigenic JJ O
effects NNS O
[8,29,30] VBP O
. . O

Consistent NNP O
with IN O
the DT O
hemizygous JJ O
nature NN O
of IN O
the DT O
mutations NNS O
, , O
it PRP O
seems VBZ O
likely JJ O
that IN O
DNA NNP O
methylation NN O
deepens VBZ O
the DT O
haploinsufficiency NN O
status NN O
of IN O
the DT O
genes NNS O
when WRB O
both DT O
changes NNS O
are VBP O
found VBN O
in IN O
the DT O
same JJ O
tumor NN O
or CC O
, , O
more RBR O
often RB O
just RB O
with IN O
the DT O
epigenetic JJ O
changes NNS O
alone RB O
. . O

The DT O
accompanying JJ O
loss NN O
of IN O
function NN O
can MD O
compound VB O
, , O
and CC O
thus RB O
progressively RB O
contribute VB O
to TO O
, , O
tumorigenesis NN O
. . O

Functional JJ O
Associations NNP O
of IN O
Common NNP O
Target NNP O
Genes NNP O

Next JJ O
, , O
we PRP O
analyzed VBD O
the DT O
functional JJ O
associations NNS O
of IN O
the DT O
18 CD O
common JJ O
target NN O
genes NNS O
that WDT O
demonstrate VBP O
cancer-specific JJ O
hypermethylation NN O
. . O

We PRP O
utilized VBD O
Gene NNP O
Ontology NNP O
( -LRB- O
GO NNP O
) -RRB- O
classification NN O
and CC O
available JJ O
data NNS O
in IN O
the DT O
literature NN O
to TO O
describe VB O
the DT O
functional JJ O
associations NNS O
of IN O
the DT O
genes NNS O
( -LRB- O
Figure NN O
8 CD O
) -RRB- O
. . O

A DT O
number NN O
of IN O
genes NNS O
are VBP O
involved VBN O
in IN O
cell NN O
adhesion NN O
and CC O
motility NN O
and/or CC O
signal NN O
transduction NN O
. . O

Examination NN O
of IN O
the DT O
literature NN O
revealed VBD O
that IN O
at IN O
least JJS O
six CD O
of IN O
these DT O
genes NNS O
possess VBP O
known VBN O
tumor NN O
suppressive NN O
properties NNS O
, , O
defined VBN O
as IN O
the DT O
ability NN O
to TO O
modulate VB O
known VBN O
tumor NN O
suppressor NN O
( -LRB- O
i FW O
.e FW O
. . O
, , O
p53 NN B-NP
, , O
wnt NN B-NP
, , O
etc. FW O
) -RRB- O
function NN O
or CC O
inhibit VB O
cancer NN O
cell NN O
growth NN O
in IN O
vitro NN O
and/or CC O
in IN O
vivo FW O
( -LRB- O
Figure NN O
8 CD O
) -RRB- O
. . O

We PRP O
then RB O
determined VBD O
the DT O
chromosomal NN O
location NN O
of IN O
these DT O
18 CD O
genes NNS O
. . O

We PRP O
compared VBD O
these DT O
chromosomal JJ O
locations NNS O
to TO O
those DT O
that WDT O
have VBP O
been VBN O
shown VBN O
to TO O
be VB O
deleted VBN O
in IN O
primary JJ O
human JJ O
tumors NNS O
in IN O
the DT O
literature NN O
using VBG O
standard JJ O
genetic JJ O
mapping NN O
or CC O
comparative JJ O
genomic JJ O
hybridization NN O
( -LRB- O
CGH) NNP O
. . O

Sixteen CD O
out IN O
of IN O
18 CD O
(89 CD O
% NN O
, , O
next JJ O
to TO O
last JJ O
panel NN O
) -RRB- O
of IN O
these DT O
genes NNS O
map VBP O
to TO O
loci NNS O
that WDT O
have VBP O
been VBN O
found VBN O
to TO O
be VB O
deleted VBN O
in IN O
cancers NNS O
( -LRB- O
including VBG O
colon NN O
, , O
breast NN O
, , O
prostate NN O
, , O
Wilm NNP O
's POS O
tumor NN O
, , O
hematopoietic JJ O
tumors NNS O
, , O
and CC O
medulloblastoma NN O
) -RRB- O
. . O

For IN O
example NN O
, , O
Yang NNP O
et NNP O
al NN O
. . O
demonstrated VBD O
that IN O
19p13.3 CD O
, , O
the DT O
location NN O
of IN O
APC2 NNP B-NP
, , O
is VBZ O
a DT O
common JJ O
site NN O
of IN O
LOH NNP O
or CC O
deletion NN O
in IN O
breast NN O
carcinoma NN O
[31] NN O
. . O

Similarly RB O
, , O
SYNE1 NNP B-NP
localizes VBZ O
to TO O
6p25 CD O
, , O
a DT O
location NN O
that WDT O
is VBZ O
subject JJ O
to TO O
frequent JJ O
deletion NN O
in IN O
a DT O
number NN O
of IN O
tumors NNS O
[32,33] VBP O
. . O

CHD5 PRP O
is VBZ O
a DT O
well-documented JJ O
tumor NN O
suppressor NN O
gene NN O
located VBN O
on IN O
1p36 CD O
, , O
a DT O
region NN O
that WDT O
is VBZ O
commonly RB O
lost VBN O
in IN O
malignancies NNS O
of IN O
epithelial NN O
, , O
neural JJ O
, , O
and CC O
hematopoietic JJ O
origin NN O
[34] NN O
. . O

Referenced VBN O
data NNS O
are VBP O
summarized VBN O
in IN O
Table NN O
S4 NNP O
. . O

Thus RB O
, , O
the DT O
18 CD O
genes NNS O
we PRP O
have VBP O
identified VBN O
are VBP O
genes NNS O
that WDT O
are VBP O
found VBN O
to TO O
be VB O
mutated JJ O
in IN O
breast NN O
and CC O
colon NN O
cancer NN O
, , O
silenced VBN O
by IN O
hypermethylation NN O
in IN O
these DT O
tumors NNS O
, , O
and CC O
reside VB O
at IN O
locations NNS O
subject JJ O
to TO O
LOH NNP O
or CC O
deletion NN O
in IN O
a DT O
number NN O
of IN O
human JJ O
neoplasms NNS O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Statistical NNP O
Analyses NNS O

Unpaired JJ O
t NN O
test NN O
, , O
z NN O
test NN O
, , O
and CC O
χ2 CD O
test NN O
were VBD O
used VBN O
. . O

The DT O
data NNS O
were VBD O
calculated VBN O
with IN O
Statistica NNP O
6 CD O
( -LRB- O
StatSoft NNP O
, , O
Tulsa NNP O
, , O
OK JJ O
, , O
USA NNP O
) -RRB- O
. . O

Values NNS O
are VBP O
presented VBN O
as IN O
arithmetrical JJ O
mean JJ O
± NN O
SEM. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

The DT O
present JJ O
study NN O
describes VBZ O
a DT O
population NN O
based VBN O
analysis NN O
of IN O
the DT O
frequency NN O
of IN O
variants NNS O
of IN O
unknown JJ O
significance NN O
in IN O
hMLH1 NN B-NP
and CC O
hMSH2 NN B-NP
in IN O
Danish NNP O
patients NNS O
with IN O
sporadic JJ O
CRC NNP O
and CC O
in IN O
a DT O
sub-cohort JJ O
of IN O
controls NNS O
. . O

Some DT O
of IN O
the DT O
variants NNS O
have VBP O
been VBN O
described VBN O
in IN O
other JJ O
studies NNS O
, , O
and CC O
some DT O
are VBP O
, , O
to TO O
our PRP$ O
knowledge NN O
, , O
new JJ O
variants NNS O
unique JJ O
to TO O
the DT O
Danish JJ O
population NN O
. . O

We PRP O
have VBP O
analyzed VBN O
the DT O
allele JJ O
frequencies NNS O
of IN O
29 CD O
variants NNS O
in IN O
hMLH1 JJ B-NP
and CC O
hMSH2 JJ B-NP
to TO O
reveal VB O
whether IN O
they PRP O
cause VBP O
increased VBN O
susceptibility NN O
to TO O
sporadic JJ O
CRC NNP O
in IN O
the DT O
Danish JJ O
population NN O
or CC O
whether IN O
they PRP O
are VBP O
private JJ O
variants/mutations NNS O
found VBD O
only RB O
in IN O
the DT O
families NNS O
where WRB O
they PRP O
were VBD O
originally RB O
identified VBN O
. . O

In IN O
addition NN O
to TO O
the DT O
29 CD O
variants NNS O
identified VBN O
in IN O
Danish NNP O
individuals NNS O
, , O
six CD O
variants NNS O
identified VBN O
in IN O
other JJ O
Caucasian JJ O
populations NNS O
were VBD O
also RB O
investigated VBN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

MLH1 NNP B-NP
and CC O
MSH2 NNP B-NP
variants NNS O

* SYM O
identified VBN O
in IN O
CRC NNP O
families NNS O
from IN O
other JJ O
Caucasian JJ O
populations NNS O
than IN O
the DT O
Danish NNP O

Genotyping VBG O
using VBG O
Single NNP O
Base NN O
Extension NNP O
( -LRB- O
SBE)-tag NN O
arrays NNS O

Primer NNP O
design NN O

The DT O
multiplex JJ O
PCR NN O
primers NNS O
were VBD O
designed VBN O
using VBG O
Oligo NNP O
6 CD O
[22] NN O
. . O

The DT O
PCR NN O
products NNS O
were VBD O
between IN O
100 CD O
and CC O
450 CD O
bp NN O
. . O

The DT O
optimal JJ O
annealing NN O
temperature NN O
( -LRB- O
Ta NNP O
) -RRB- O
was VBD O
set VBN O
to TO O
~50°C VB O
, , O
the DT O
GC NNP O
content NN O
to TO O
~40 CD O
% NN O
and CC O
the DT O
primer NN O
Tm NN O
difference NN O
to TO O
≤1 CD O
. . O

The DT O
single JJ O
base NN O
extension NN O
( -LRB- O
SBE NN O
) -RRB- O
primers NNS O
contained VBD O
5' JJ O
20-bp JJ O
'tag PRP O
' '' O
sequences NNS O
that WDT O
were VBD O
from IN O
the DT O
Affymetrix NNP O
GeneChip NNP O
® NNP O
Tag NNP O
Collection NNP O
. . O

The DT O
gene NN O
specific JJ O
part NN O
of IN O
the DT O
SBE NNP O
primers NNS O
had VBD O
a DT O
Tm NN O
of IN O
~50–60°C NNP O
( -LRB- O
calculated VBN O
using VBG O
PrimerExpress NNP O
2.0)( CD O
Applied NNP O
Biosystems NNP O
, , O
Foster NNP O
City NNP O
, , O
CA NNP O
) -RRB- O
. . O

The DT O
tagged VBN O
SBE NNP O
primers NNS O
were VBD O
tested VBN O
for IN O
major JJ O
hairpin NN O
loop NN O
formation NN O
using VBG O
Oligo6 NNP O
. . O

All DT O
variants NNS O
were VBD O
typed VBN O
using VBG O
SBE-primers NNS O
for IN O
both DT O
DNA NNP O
strands NNS O
. . O

The DT O
primers NNS O
were VBD O
synthesized VBN O
by IN O
DNA NNP O
Technology NNP O
( -LRB- O
Aarhus NNP O
, , O
Denmark NNP O
) -RRB- O
. . O

The DT O
multiplex JJ O
PCR NN O
primer NN O
and CC O
the DT O
SBE NNP O
primer NN O
sequences NNS O
are VBP O
available JJ O
on IN O
request NN O
. . O

Multiplex NNP O
PCR NN O

The DT O
multiplex JJ O
PCR NN O
amplification NN O
was VBD O
performed VBN O
with IN O
6–9 CD O
primer JJ O
pairs NNS O
per IN O
reaction NN O
. . O

Twenty CD O
ng NN O
of IN O
genomic JJ O
DNA NN O
with IN O
0.5 CD O
μl JJ O
Accuprime™ NNP O
DNA NN O
polymerase NN O
( -LRB- O
Invitrogen NN O
, , O
Carlsbad NNP O
, , O
CA NNP O
) -RRB- O
, , O
1× JJ O
Accuprime™ NNP O
Buffer NNP O
I PRP O
, , O
and CC O
0.08–1 CD O
μM NNP O
primers NNS O
was VBD O
amplified VBN O
in IN O
25 CD O
μl JJ O
volumes NNS O
using VBG O
the DT O
following VBG O
PCR NN O
conditions NNS O
: : O
1 CD O
cycle NN O
of IN O
95°C NNP O
for IN O
10 CD O
min NN O
; : O
13 CD O
cycles NNS O
of IN O
95°C NNP O
for IN O
30 CD O
sec. NN O
, , O
67°C JJ O
(-1°C/cycle NN O
) -RRB- O
for IN O
45 CD O
sec. NN O

and CC O
72°C NNP O
for IN O
45 CD O
sec. NN O
; : O
20 CD O
cycles NNS O
of IN O
95°C NNP O
for IN O
30 CD O
sec. NN O
, , O
55°C JJ O
for IN O
45 CD O
sec. NN O

and CC O
72°C NNP O
for IN O
45 CD O
sec. NN O
; : O
1 CD O
cycle NN O
of IN O
72°C CD O
for IN O
10 CD O
min NN O
. . O

A DT O
subset NN O
of IN O
the DT O
multiplex JJ O
PCR NN O
products NNS O
were VBD O
analysed VBN O
on IN O
a DT O
2100 CD O
Bioanalyzer NNP O
( -LRB- O
Agilent NNP O
Technologies NNP O
, , O
Santa NNP O
Clara NNP O
, , O
CA NNP O
) -RRB- O
to TO O
test VB O
the DT O
performance NN O
of IN O
the DT O
multiplex JJ O
PCR. . O

The DT O
multiplex JJ O
PCR NN O
products NNS O
from IN O
each DT O
sample NN O
were VBD O
pooled VBN O
for IN O
further JJ O
analysis NN O
. . O

Single NNP O
Base NN O
Extension NNP O
( -LRB- O
SBE NN O
) -RRB- O
reaction NN O

The DT O
pooled JJ O
PCR NN O
products NNS O
from IN O
each DT O
sample NN O
were VBD O
treated VBN O
with IN O
Exonuclease NN O
I PRP O
and CC O
shrimp VB O
alkaline NN O
phosphatase NN O
and CC O
used VBD O
for IN O
template NN O
in IN O
the DT O
SBE JJ O
reaction NN O
( -LRB- O
mini-sequencing NN O
) -RRB- O
as IN O
described VBN O
by IN O
Lindross NNP O
et NNP O
al NN O
. . O
[23] '' O
. . O

The DT O
fluorescent JJ O
labelled JJ O
ddNTP NNS O
were VBD O
Cyanine NNP O
5 CD O
( -LRB- O
Cy5)-ddCTP NNP O
, , O
TAMRA-ddUTP NNP O
, , O
Texas NNP O
Red®-5-ddATP NNP O
and CC O
R110-ddGTP NNP O
( -LRB- O
PerkinElmer NNP O
Life NNP O
and CC O
Analytical NNP O
Sciences NNPS O
, , O
Inc NNP O
, , O
Wellesley NNP O
, , O
Ma NNP O
) -RRB- O
. . O

Preparation NN O
of IN O
microarrays NNS O

' POS O
Anti-tag NNP O
' '' O
oligonucleotides NNS O
complimentary JJ O
to TO O
the DT O
'tag JJ O
' POS O
sequences NNS O
of IN O
the DT O
SBE NNP O
primers NNS O
modified VBN O
with IN O
NH2 JJ O
groups NNS O
in IN O
their PRP$ O
3' JJ O
ends NNS O
, , O
and CC O
containing VBG O
a DT O
3'-spacer NN O
of IN O
15 CD O
T NNP O
residues NNS O
were VBD O
coupled VBN O
covalently RB O
to TO O
CodeLink NNP O
Activated NNP O
Slides NNS O
( -LRB- O
Amersham NNP O
Biosciences NNP O
, , O
Uppsala NNP O
, , O
Sweden NNP O
) -RRB- O
according VBG O
to TO O
manufacturer NN O
instructions NNS O
. . O

The DT O
only JJ O
exception NN O
was VBD O
that IN O
the DT O
'anti-tag JJ O
' POS O
oligonucleotides NNS O
were VBD O
dissolved VBN O
in IN O
150 CD O
mM JJ O
sodium NN O
carbonate NN O
buffer NN O
, , O
pH RB O
8.5 CD O
with IN O
1 CD O
mM JJ O
betaine NN O
at IN O
a DT O
concentration NN O
of IN O
20 CD O
μM. . O

The DT O
oligonucleotides NNS O
were VBD O
printed VBN O
onto IN O
the DT O
slides NNS O
using VBG O
a DT O
VersArray NNP O
ChipWriter NN O
( -LRB- O
BioRad NNP O
, , O
Hercules NNP O
, , O
CA NNP O
) -RRB- O
with IN O
3 CD O
Stealth NNP O
Micro NNP O
Spotting NNP O
Pins NNP O
( -LRB- O
TeleChem NNP O
International NNP O
Inc. NNP O
, , O
Sunnyvale NNP O
, , O
CA NNP O
) -RRB- O
. . O

Each DT O
slide NN O
consists VBZ O
of IN O
75 CD O
sub-arrays NNS O
with IN O
13 CD O
× JJ O
12 CD O
spots NNS O
in IN O
each DT O
subarray NN O
. . O

The DT O
spots NNS O
were VBD O
130–150 CD O
μM NNS O
in IN O
diameter NN O
and CC O
the DT O
centre-to-centre NN O
distance NN O
between IN O
two CD O
spots NNS O
was VBD O
200 CD O
μM. . O

The DT O
'anti-tag JJ O
' POS O
oligonucleotides NNS O
were VBD O
printed VBN O
in IN O
duplicates NNS O
in IN O
each DT O
sub-array NN O
. . O

The DT O
spot NN O
quality NN O
was VBD O
tested VBN O
after IN O
each DT O
series NN O
of IN O
microarray JJ O
preparation NN O
using VBG O
a DT O
Cy3 JJ O
labelled JJ O
random JJ O
oligonucleotide JJ O
hybridizing NN O
to TO O
all DT O
spots NNS O
on IN O
the DT O
slide NN O
independent JJ O
on IN O
the DT O
'anti-tag JJ O
' POS O
sequence NN O
. . O

The DT O
printed VBN O
slides NNS O
were VBD O
stored VBN O
at IN O
room NN O
temperature NN O
until IN O
use NN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Linkage NN O
disequilibrium NN O
( -LRB- O
LD NN O
) -RRB- O
analysis NN O
showed VBD O
high JJ O
LD NN O
in IN O
the DT O
genomic JJ O
regions NNS O
covering VBG O
hMLH1 NN B-NP
and CC O
most JJS O
of IN O
the DT O
genomic JJ O
region NN O
covering VBG O
hMSH2 NN B-NP
in IN O
the DT O
Danish JJ O
population NN O
. . O

We PRP O
therefore RB O
conclude VBP O
that IN O
common JJ O
variants NNS O
in IN O
the DT O
two CD O
genes NNS O
in IN O
general JJ O
are VBP O
not RB O
associated VBN O
with IN O
susceptibility NN O
to TO O
sporadic JJ O
CRC NNP O
in IN O
a DT O
Danish JJ O
population NN O
. . O

The DT O
age NN O
of IN O
the DT O
cohort NN O
of IN O
cases NNS O
with IN O
sporadic JJ O
CRC NNP O
is VBZ O
relatively RB O
young JJ O
( -LRB- O
mean JJ O
~58 CD O
years NNS O
) -RRB- O
compared VBN O
to TO O
the DT O
mean JJ O
age NN O
of IN O
onset NN O
of IN O
colorectal JJ O
CRC NNP O
in IN O
the DT O
general JJ O
Danish JJ O
population NN O
( -LRB- O
mean VBP O
~70 CD O
years NNS O
) -RRB- O
[49] VBP O
. . O

Consequently RB O
, , O
the DT O
results NNS O
obtained VBN O
in IN O
the DT O
present JJ O
study NN O
do VBP O
not RB O
rule VB O
out RP O
that IN O
variants NNS O
in IN O
hMLH1 NN B-NP
and CC O
hMSH2 NN B-NP
might MD O
be VB O
associated VBN O
with IN O
sporadic JJ O
colorectal NN O
cancer NN O
at IN O
an DT O
older JJR O
age NN O
. . O

However RB O
, , O
generally RB O
cancers NNS O
reflecting VBG O
an DT O
inherited VBN O
susceptibility NN O
seem VBP O
to TO O
occur VB O
in IN O
a DT O
relatively RB O
young JJ O
age NN O
. . O

Using VBG O
in IN O
silico NN O
analysis NN O
several JJ O
of IN O
the DT O
analyzed VBN O
variants NNS O
were VBD O
predicted VBN O
to TO O
either DT O
abolish VB O
or CC O
introduce VB O
ESEs NNS O
( -LRB- O
data NNS O
not RB O
shown VBN O
) -RRB- O
. . O

It PRP O
has VBZ O
, , O
however RB O
, , O
been VBN O
shown VBN O
that IN O
only RB O
a DT O
minor JJ O
fraction NN O
of IN O
the DT O
variants NNS O
predicted VBD O
to TO O
change VB O
ESEs NNP O
in IN O
hMLH1 JJ B-NP
and CC O
hMSH2 JJ B-NP
using VBG O
in IN O
silico NN O
analysis NN O
do VBP O
indeed RB O
change VB O
the DT O
pre-mRNA JJ O
splice NN O
pattern NN O
in IN O
vivo JJ O
[14,15] NN O
. . O

In IN O
the DT O
study NN O
by IN O
Auclair NNP O
et NNP O
al NN O
. . O
, , O
only RB O
ESEs NNP O
at IN O
or CC O
close VB O
to TO O
5' CD O
splice NN O
sites NNS O
were VBD O
found VBN O
to TO O
cause VB O
aberrant JJ O
splicing NN O
. . O

None NN O
of IN O
the DT O
variants NNS O
analysed CC O
in IN O
the DT O
present JJ O
study NN O
affected VBD O
5' JJ O
splice NN O
sites NNS O
. . O

Nevertheless RB O
, , O
no DT O
final JJ O
conclusions NNS O
regarding VBG O
splicing NN O
can MD O
be VB O
drawn VBN O
from IN O
the DT O
in IN O
silico NN O
analyses NNS O
. . O

Twenty CD O
two CD O
variants NNS O
were VBD O
not RB O
detected VBN O
in IN O
the DT O
sporadic JJ O
CRC NNP O
cases NNS O
and CC O
in IN O
the DT O
sub-cohort JJ O
. . O

Among IN O
those DT O
were VBD O
the DT O
six CD O
variants NNS O
originally RB O
identified VBN O
more RBR O
or CC O
less RBR O
frequently RB O
in IN O
other JJ O
populations NNS O
( -LRB- O
Table NN O
2 CD O
) -RRB- O
. . O

All PDT O
except IN O
one CD O
variant NN O
( -LRB- O
c.380 CD O
A>G NNP O
, , O
p.Asn127Ser NN O
) -RRB- O
performed VBN O
very RB O
well RB O
in IN O
the DT O
SBE-tag NNP O
array NN O
assay NN O
. . O

This DT O
rules NNS O
out IN O
that DT O
failure NN O
in IN O
detecting VBG O
the DT O
variants NNS O
caused VBD O
their PRP$ O
absence NN O
in IN O
the DT O
present JJ O
cohorts NNS O
. . O

Consequently RB O
, , O
these DT O
six CD O
variants NNS O
are VBP O
not RB O
polymorphic JJ O
in IN O
the DT O
Danish JJ O
population NN O
. . O

The DT O
remaining VBG O
variants NNS O
were VBD O
rare JJ O
variants NNS O
in IN O
the DT O
Danish JJ O
population NN O
. . O

They PRP O
were VBD O
only RB O
detected VBN O
in IN O
individuals NNS O
with IN O
familiar JJ O
CRC NNP O
and CC O
some DT O
of IN O
them PRP O
have VBP O
been VBN O
classified VBN O
as IN O
pathogenic JJ O
mutations NNS O
or CC O
neutral JJ O
variants NNS O
in IN O
other JJ O
populations NNS O
( -LRB- O
see VBP O
Table NN O
2 CD O
for IN O
references NNS O
) -RRB- O
. . O

Four CD O
rare JJ O
missense NN O
variants VBZ O
i IN O
.e NN O
. . O
hMLH1 '' B-NP
c.1379 CD O
A>C NNPS O
( -LRB- O
p.Glu460Ala NN O
) -RRB- O
and CC O
c.1689 CD O
A>G NNP O
( -LRB- O
p.Ile563Met NN O
) -RRB- O
and CC O
, , O
hMSH2 IN B-NP
c.2062 CD O
A>G NNP O
( -LRB- O
p.Met688Val NN O
) -RRB- O
and CC O
c.2542 CD O
G>T NNP O
( -LRB- O
p.Ala848Ser NN O
) -RRB- O
were VBD O
unclassified JJ O
and CC O
have VBP O
to TO O
our PRP$ O
knowledge NN O
never RB O
been VBN O
described VBN O
previously RB O
neither RB O
in IN O
the DT O
Danish JJ O
population NN O
nor CC O
in IN O
other JJ O
populations NNS O
. . O

Other JJ O
disease NN O
causing VBG O
mutations NNS O
have VBP O
been VBN O
identified VBN O
in IN O
the DT O
families NNS O
harbouring VBG O
the DT O
two CD O
hMLH1 JJ B-NP
variants NNS O
changing VBG O
non-conserved JJ O
amino IN O
acids NNS O
i IN O
.e NN O
. . O
pGlu460Ala '' O
and CC O
p.Ile563Met JJ O
(unpublished JJ O
results NNS O
) -RRB- O
consequently RB O
, , O
these DT O
variants NNS O
are VBP O
most RBS O
likely JJ O
neutral JJ O
and CC O
not RB O
involved VBN O
in IN O
HNPCC. VBG O

However RB O
, , O
no DT O
other JJ O
disease NN O
causing VBG O
mutations NNS O
have VBP O
been VBN O
identified VBN O
in IN O
the DT O
families NNS O
harbouring VBG O
the DT O
hMSH2 JJ B-NP
variants NNS O
changing VBG O
conserved VBN O
amino IN O
acids NNS O
i IN O
.e JJ O
. . O
p.Met688Val JJ O
and CC O
p.Ala848Ser JJ O
variants NNS O
. . O

Further JJ O
characterization NN O
of IN O
these DT O
variants NNS O
such JJ O
as IN O
functional JJ O
studies NNS O
and CC O
segregations NNS O
analysis NN O
are VBP O
needed VBN O
before IN O
any DT O
final JJ O
conclusion NN O
can MD O
be VB O
drawn VBN O
regarding VBG O
their PRP$ O
pathogenicity NN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

In IN O
conclusion NN O
, , O
high JJ O
penetrance NN O
cancer NN O
susceptibility NN O
genes NNS O
involved VBN O
in IN O
hereditary JJ O
syndromes NNS O
have VBP O
rarely RB O
emerged VBN O
as IN O
definitive JJ O
low-penetrance NN O
genes NNS O
as IN O
a DT O
result NN O
of IN O
common JJ O
variants NNS O
increasing VBG O
disease NN O
susceptibility NN O
[19] NN O
. . O

The DT O
results NNS O
shown VBN O
in IN O
the DT O
present JJ O
study NN O
demonstrate VBP O
that IN O
the DT O
high-penetrance NN O
HNPCC NNP O
genes NNS O
hMLH1 . B-NP
and CC O
hMSH2 PRP B-NP
also RB O
do VBP O
not RB O
appear VB O
to TO O
be VB O
low JJ O
penetrance NN O
genes NNS O
involved VBN O
in IN O
sporadic JJ O
CRC NNP O
in IN O
the DT O
Danish JJ O
population NN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Design NNP O
considerations NNS O
in IN O
a DT O
sib-pair NN O
study NN O
of IN O
linkage NN O
for IN O
susceptibility NN O
loci NNS O
in IN O
cancer NN O

Abstract NN O

Background CC O

Modern JJ O
approaches NNS O
to TO O
identifying VBG O
new JJ O
genes NNS O
associated VBN O
with IN O
disease NN O
allow VBP O
very RB O
fine JJ O
analysis NN O
of IN O
associaton NN O
and CC O
can MD O
be VB O
performed VBN O
in IN O
population NN O
based VBN O
case-control JJ O
studies NNS O
. . O

However RB O
, , O
the DT O
sibpair NN O
design NN O
is VBZ O
still RB O
valuable JJ O
because IN O
it PRP O
requires VBZ O
few JJ O
assumptions NNS O
other JJ O
than IN O
acceptably RB O
high JJ O
penetrance NN O
to TO O
identify VB O
genetic JJ O
loci NNS O
. . O

Methods NNS O

We PRP O
conducted VBD O
simulation RB O
studies NNS O
to TO O
assess VB O
the DT O
impact NN O
of IN O
design NN O
factors NNS O
on IN O
relative JJ O
efficiency NN O
for IN O
a DT O
linkage NN O
study NN O
of IN O
colorectal JJ O
cancer NN O
. . O

We PRP O
considered VBD O
two CD O
test NN O
statistics NNS O
, , O
one CD O
comparing VBG O
the DT O
mean JJ O
IBD NNP O
probability NN O
in IN O
affected JJ O
pairs NNS O
to TO O
its PRP$ O
null JJ O
value NN O
of IN O
0.5 CD O
, , O
and CC O
one CD O
comparing VBG O
the DT O
mean JJ O
IBD NNP O
probabilities NNS O
between IN O
affected JJ O
and CC O
discordant JJ O
pairs NNS O
. . O

We PRP O
varied JJ O
numbers NNS O
of IN O
parents NNS O
available JJ O
, , O
numbers NNS O
of IN O
affected JJ O
and CC O
unaffected JJ O
siblings NNS O
, , O
reconstructing VBG O
the DT O
genotype NN O
of IN O
an DT O
unavailable JJ O
affected JJ O
sibling NN O
by IN O
a DT O
spouse NN O
and CC O
offspring NN O
, , O
and CC O
elimination NN O
of IN O
sibships NNS O
where WRB O
the DT O
proband NN O
carries VBZ O
a DT O
mutation NN O
at IN O
another DT O
locus NN O
. . O

Results NNS O

Power NN O
and CC O
efficiency NN O
were VBD O
most RBS O
affected VBN O
by IN O
the DT O
number NN O
of IN O
affected JJ O
sibs NNS O
, , O
the DT O
number NN O
of IN O
sib NN O
pairs NNS O
genotyped VBD O
, , O
and CC O
the DT O
risk NN O
attributable JJ O
to TO O
linked VBN O
and CC O
unlinked VBN O
loci NNS O
. . O

Genotyping VBG O
unaffected JJ O
siblings NNS O
added VBD O
little JJ O
power NN O
for IN O
low JJ O
penetrance NN O
models NNS O
, , O
but CC O
improved VBD O
validity NN O
of IN O
tests NNS O
when WRB O
there EX O
was VBD O
genetic JJ O
heterogeneity NN O
and CC O
for IN O
multipoint JJ O
testing NN O
. . O

The DT O
efficiency NN O
of IN O
the DT O
concordant-only JJ O
test NN O
was VBD O
nearly RB O
always RB O
better JJR O
than IN O
the DT O
concordant-discordant JJ O
test NN O
. . O

Replacement NNP O
of IN O
an DT O
unavailable JJ O
affected JJ O
sibling NN O
by IN O
a DT O
spouse NN O
and CC O
offspring NN O
recovered VBD O
some DT O
linkage NN O
information NN O
, , O
particularly RB O
if IN O
several JJ O
offspring NN O
were VBD O
available JJ O
. . O

In IN O
multipoint JJ O
analysis NN O
, , O
the DT O
concordant-only JJ O
test NN O
was VBD O
showed VBN O
a DT O
small JJ O
anticonservative JJ O
bias NN O
at IN O
5 CD O
cM NNS O
, , O
while IN O
the DT O
multipoint JJ O
concordant-discordant JJ O
test NN O
was VBD O
generally RB O
the DT O
most RBS O
powerful JJ O
test NN O
, , O
and CC O
was VBD O
not RB O
biased VBN O
away RB O
from IN O
the DT O
null NN O
at IN O
5 CD O
cM. . O

Conclusion NN O

Genotyping VBG O
parents NNS O
and CC O
unaffected JJ O
siblings NNS O
is VBZ O
useful JJ O
for IN O
detecting VBG O
genotyping JJ O
errors NNS O
and CC O
if IN O
allele JJ O
frequencies NNS O
are VBP O
uncertain JJ O
. . O

If IN O
adequate JJ O
allele JJ O
frequency NN O
data NNS O
are VBP O
available JJ O
, , O
we PRP O
suggest VBP O
a DT O
single-point JJ O
affecteds-only JJ O
analysis NN O
for IN O
an DT O
initial JJ O
scan NN O
, , O
followed VBN O
by IN O
a DT O
multipoint JJ O
analysis NN O
of IN O
affected JJ O
and CC O
unaffected JJ O
members NNS O
of IN O
all DT O
available JJ O
sibships NNS O
with IN O
additional JJ O
markers NNS O
around IN O
initial JJ O
hits NNS O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Methods NNS O

The DT O
choice NN O
of IN O
sampling VBG O
schemes NNS O
for IN O
a DT O
colon NN O
sibpair NN O
study NN O
requires VBZ O
evaluation NN O
, , O
as IN O
several JJ O
different JJ O
options NNS O
exist VBP O
simultaneously RB O
for IN O
the DT O
sampling NN O
plan NN O
( -LRB- O
how WRB O
many JJ O
families NNS O
and CC O
which WDT O
relatives NNS O
to TO O
sample NN O
) -RRB- O
, , O
disease NN O
model NN O
( -LRB- O
penetrance NN O
, , O
allele DT O
frequency NN O
, , O
etc FW O
) -RRB- O
, , O
and CC O
statistical JJ O
test NN O
of IN O
linkage NN O
. . O

These DT O
aspects NNS O
, , O
in IN O
addition NN O
to TO O
the DT O
method NN O
of IN O
generating VBG O
the DT O
data NNS O
sets NNS O
for IN O
the DT O
simulations NNS O
comprise VBP O
the DT O
methods NNS O
of IN O
determining VBG O
an DT O
optimal JJ O
design NN O
strategy NN O
for IN O
a DT O
colon NN O
sibpair NN O
study NN O
. . O

In IN O
our PRP$ O
analysis NN O
of IN O
design NN O
issues NNS O
we PRP O
have VBP O
pursued VBN O
a DT O
deterministic JJ O
simulation NN O
approach NN O
. . O

The DT O
first JJ O
step NN O
was VBD O
to TO O
check VB O
that IN O
the DT O
tests NNS O
we PRP O
considered VBD O
had VBD O
appropriate JJ O
size NN O
, , O
using VBG O
extensive JJ O
simulations NNS O
. . O

For IN O
those DT O
tests NNS O
that WDT O
were VBD O
valid JJ O
, , O
we PRP O
then RB O
performed VBD O
a DT O
moderate JJ O
number NN O
of IN O
simulations NNS O
of IN O
a DT O
large JJ O
number NN O
of IN O
families NNS O
, , O
to TO O
obtain VB O
the DT O
noncentrality NN O
parameters NNS O
describing VBG O
the DT O
behavior NN O
of IN O
each DT O
design NN O
configuration NN O
and CC O
test NN O
. . O

We PRP O
were VBD O
then RB O
able JJ O
to TO O
compare VB O
the DT O
attributes NNS O
of IN O
these DT O
studies NNS O
across IN O
the DT O
different JJ O
design NN O
configurations NNS O
genetic JJ O
models NNS O
and CC O
tests NNS O
by IN O
fitting JJ O
regression NN O
models NNS O
, , O
as IN O
further RBR O
described VBN O
below IN O
. . O

Disease NN O
Model NNP O
Parameter NNP O
Choices NNS O

Genetic JJ O
Heterogeneity NN O

The DT O
genetic JJ O
basis NN O
of IN O
many JJ O
complex JJ O
human JJ O
diseases NNS O
, , O
including VBG O
some DT O
common JJ O
cancers NNS O
, , O
is VBZ O
known VBN O
to TO O
include VB O
mutations NNS O
in IN O
loci NNS O
that WDT O
confer VBP O
a DT O
high JJ O
penetrance NN O
to TO O
carriers NNS O
. . O

In IN O
order NN O
to TO O
minimize VB O
the DT O
impact NN O
that IN O
such JJ O
genetic JJ O
heterogeneity NN O
may MD O
have VB O
on IN O
the DT O
statistical JJ O
efficiency NN O
to TO O
identify VB O
novel JJ O
loci NNS O
, , O
gene-hunting JJ O
studies NNS O
are VBP O
often RB O
restricted VBN O
to TO O
those DT O
cases NNS O
that WDT O
have VBP O
been VBN O
determined VBN O
not RB O
to TO O
be VB O
related VBN O
to TO O
any DT O
known VBN O
susceptibility NN O
locus NN O
. . O

For IN O
example NN O
, , O
the DT O
second JJ O
susceptibility NN O
locus NN O
for IN O
breast NN O
cancer NN O
, , O
BRCA2 NN B-NP
, , O
was VBD O
mapped VBN O
by IN O
Wooster NNP O
et NNP O
al NN O
. . O
[37] VBD O
based VBN O
on IN O
high-risk JJ O
families NNS O
for IN O
whom WP O
BRCA1 NNP B-NP
linkage NN O
was VBD O
excluded VBN O
. . O

Genetic JJ O
syndromes NNS O
such JJ O
as IN O
juvenile JJ O
polyposis NN O
, , O
Peutz-Jeghers NNP O
syndrome NN O
and CC O
familial JJ O
adenomatous JJ O
polyposis NN O
can MD O
be VB O
readily RB O
eliminated VBN O
prior RB O
to TO O
sample NN O
collection NN O
on IN O
the DT O
basis NN O
of IN O
phenotypic JJ O
characteristics NNS O
. . O

However RB O
, , O
mutations NNS O
in IN O
mismatch NN O
repair NN O
( -LRB- O
MMR NNP B-NP
) -RRB- O
loci NNS O
such JJ O
as IN O
hMSH2 NN B-NP
or CC O
hMLH1 NN B-NP
cannot MD O
be VB O
excluded VBN O
without IN O
performing VBG O
molecular JJ O
studies NNS O
. . O

( -LRB- O
Measures NNS O
of IN O
tumor NN O
microsatellite NN O
instability NN O
or CC O
immunohistochemistry NN O
can MD O
be VB O
helpful JJ O
in IN O
identifying VBG O
likely JJ O
carriers NNS O
, , O
but CC O
are VBP O
neither RB O
fully RB O
sensitive JJ O
nor CC O
specific JJ O
. . O
) -RRB- O

Estimating VBG O
the DT O
proportion NN O
of IN O
affected JJ O
families NNS O
that WDT O
might MD O
be VB O
excluded VBN O
from IN O
analysis NN O
because IN O
they PRP O
carry VBP O
MMR NNP B-NP
mutations NNS O
is VBZ O
difficult JJ O
. . O

Population-based JJ O
estimates NNS O
of IN O
the DT O
prevalence NN O
of IN O
germ-line NN O
MMR NNP B-NP
mutations NNS O
among IN O
subjects NNS O
diagnosed VBD O
with IN O
colorectal JJ O
cancer NN O
vary VBP O
widely RB O
even RB O
within IN O
populations NNS O
of IN O
European JJ O
descent NN O
[38-41] JJ O
, , O
and CC O
only RB O
a DT O
few JJ O
estimates NNS O
are VBP O
available JJ O
for IN O
other JJ O
ethnic JJ O
groups NNS O
[42,43] VBP O
. . O

Moreover RB O
, , O
recruiting VBG O
from IN O
high-risk JJ O
clinics NNS O
may MD O
lead VB O
to TO O
disproportionate JJ O
over-representation NN O
of IN O
families NNS O
who WP O
have VBP O
MMR NNP B-NP
mutations NNS O
. . O

One CD O
large JJ O
study NN O
in IN O
Finland NNP O
[44] NNP O
found VBD O
that IN O
12 CD O
% NN O
of IN O
affected JJ O
sib NN O
pairs NNS O
( -LRB- O
ASP) IN O
showed VBN O
MMR NNP B-NP
defects NNS O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

The DT O
number NN O
of IN O
families NNS O
F NNP O
required VBN O
for IN O
a DT O
desired VBN O
level NN O
of IN O
power NN O
sample NN O
was VBD O
calculated VBN O
in IN O
the DT O
standard JJ O
way NN O
[59] NNS O
by IN O
solving VBG O

Zα+Z1−βF=ZsimFsim . O

for IN O
F NNP O
, , O
where WRB O
Zα NNP O
and CC O
Z1-β NNP O
are VBP O
the DT O
quantiles NNS O
of IN O
the DT O
standard JJ O
normal JJ O
distribution NN O
for IN O
selected VBN O
values NNS O
of IN O
α NN O
and CC O
β NN O
, , O
and CC O
Zsim NNP O
is VBZ O
the DT O
sample NN O
mean NN O
of IN O
the DT O
Z-scores NNP O
( -LRB- O
Zc NNP O
or CC O
Zp NNP O
) -RRB- O
based VBN O
on IN O
the DT O
sample NN O
size NN O
Fsim NNP O
of IN O
the DT O
simulation NN O
run NN O
. . O

Comparison NNP O
of IN O
Sampling NNP O
Strategies NNS O

The DT O
relative JJ O
efficiency NN O
and CC O
absolute JJ O
power NN O
comparisons NNS O
were VBD O
evaluated VBN O
over IN O
a DT O
range NN O
of IN O
assumptions NNS O
about IN O
disease NN O
allele DT O
frequency NN O
, , O
penetrance NN O
, , O
and CC O
heterogeneity NN O
. . O

Summaries NNS O
are VBP O
provided VBN O
for IN O
the DT O
relative JJ O
efficiency NN O
from IN O
the DT O
non-null JJ O
simulations NNS O
of IN O
each DT O
combination NN O
of IN O
parameters NNS O
and CC O
sample NN O
sizes NNS O
required VBD O
to TO O
attain VB O
80 CD O
% NN O
power NN O
. . O

Our PRP$ O
simulations NNS O
involved VBN O
the DT O
manipulation NN O
of IN O
16 CD O
parameters NNS O
, , O
with IN O
over IN O
725,000 CD O
possible JJ O
combinations NNS O
arising VBG O
just RB O
among IN O
the DT O
limited JJ O
set NN O
of IN O
settings NNS O
we PRP O
chose VBD O
for IN O
each DT O
parameter NN O
. . O

In IN O
practice NN O
, , O
we PRP O
were VBD O
able JJ O
to TO O
simulate VB O
20 CD O
replicates NNS O
for IN O
332 CD O
actual JJ O
parameter NN O
combinations NNS O
. . O

In IN O
order NN O
to TO O
assess VB O
the DT O
impact NN O
of IN O
each DT O
variable JJ O
parameter NN O
setting VBG O
on IN O
the DT O
power NN O
and CC O
efficiency NN O
of IN O
each DT O
study NN O
design NN O
, , O
and CC O
to TO O
facilitate VB O
generalization NN O
of IN O
our PRP$ O
results NNS O
to TO O
other JJ O
similar JJ O
situations NNS O
that IN O
we PRP O
did VBD O
not RB O
specifically RB O
simulate JJ O
, , O
we PRP O
constructed VBD O
linear NN O
regression NN O
models NNS O
of IN O
the DT O
square JJ O
root NN O
of IN O
the DT O
per-family NN O
contribution NN O
to TO O
the DT O
noncentrality NN O
parameter NN O
( -LRB- O
Zsim/Fsim NNP O
) -RRB- O
and CC O
ARE VBP O
estimates NNS O
resulting VBG O
from IN O
each DT O
simulation NN O
as IN O
a DT O
function NN O
of IN O
the DT O
simulation NN O
parameters NNS O
. . O

Residuals NNS O
from IN O
the DT O
models NNS O
were VBD O
approximately RB O
normally RB O
distributed VBN O
, , O
and CC O
scale-location NN O
plots NNS O
did VBD O
not RB O
suggest VB O
the DT O
data NNS O
were VBD O
heteroscedastic JJ O
. . O

We PRP O
evaluated VBZ O
the DT O
fit NN O
of IN O
alternative NN O
regression NN O
models NNS O
with IN O
quadratic JJ O
, , O
inverse JJ O
, , O
or CC O
logarithmic JJ O
transformations NNS O
of IN O
both DT O
the DT O
predictor NN O
and CC O
outcome NN O
variables NNS O
; : O
none NN O
fit VBP O
the DT O
observed VBN O
data NNS O
better JJR O
than IN O
a DT O
simple JJ O
linear NN O
multiple JJ O
regression NN O
model NN O
. . O

The DT O
proportion NN O
of IN O
variance NN O
in IN O
ZsimFsim NNP O
explained VBD O
by IN O
the DT O
linear NN O
regression NN O
( -LRB- O
R2 NN O
) -RRB- O
ranged VBD O
from IN O
70–75 CD O
% NN O
. . O

The DT O
open JJ O
source NN O
statistical JJ O
package NN O
R NN O
[60] NN O
was VBD O
used VBN O
to TO O
perform VB O
all DT O
regression NN O
analyses NNS O
. . O

In IN O
order NN O
to TO O
facilitate VB O
interpretation NN O
, , O
the DT O
genetic JJ O
effects NNS O
( -LRB- O
baseline NN O
disease NN O
prevalence NN O
, , O
allele JJ O
frequencies NNS O
, , O
and CC O
relative JJ O
risks NNS O
of IN O
the DT O
linked VBN O
and CC O
unlinked VBN O
loci) NNS O
were VBD O
collapsed VBN O
into IN O
"attributable JJ O
risks NNS O
" '' O
( -LRB- O
AR NN O
) -RRB- O
for IN O
the DT O
linked VBN O
and CC O
unlinked VBN O
loci NNS O
respectively RB O
. . O

The DT O
attributable JJ O
risk NN O
is VBZ O
the DT O
proportion NN O
of IN O
the DT O
total JJ O
disease NN O
risk NN O
attributable JJ O
to TO O
variation NN O
at IN O
each DT O
genetic JJ O
locus NN O
. . O

The DT O
fit NN O
of IN O
linear NN O
regression NN O
models NNS O
employing VBG O
the DT O
two CD O
AR NN O
values NNS O
is VBZ O
as RB O
good JJ O
as IN O
those DT O
employing VBG O
the DT O
five CD O
original JJ O
terms NNS O
to TO O
fit VB O
the DT O
data NNS O
, , O
using VBG O
the DT O
Akaike NNP O
Information NN O
Criterion NN O
( -LRB- O
not RB O
shown VBN O
; : O
[61] JJ O
) -RRB- O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Effect NN O
of IN O
design NN O
and CC O
population NN O
parameters NNS O
or CC O
non-centrality NN O
parameters NNS O

Multiple NNP O
linear NN O
regression NN O
of IN O
Z/F NNP O
on IN O
simulation NN O
parameters NNS O
. . O

aStandard JJ O
error NN O
of IN O
Estimate NNP O
; : O
bNumber NN O
available JJ O
for IN O
Zc NNP O
, , O
number NN O
genotyped VBD O
for IN O
Zp NNP O
; : O
cIndicator NN O
variable JJ O
. . O

In IN O
general JJ O
, , O
the DT O
effects NNS O
on IN O
power NN O
of IN O
changes NNS O
to TO O
the DT O
genetic JJ O
and CC O
design NN O
parameters NNS O
were VBD O
very RB O
similar JJ O
for IN O
the DT O
discordant JJ O
test NN O
. . O

Increasing VBG O
the DT O
number NN O
of IN O
unaffected JJ O
sibs NNS O
typed VBN O
did VBD O
yield VB O
a DT O
small JJ O
increase NN O
in IN O
power NN O
, , O
but CC O
increasing VBG O
the DT O
number NN O
of IN O
affected JJ O
sibs NNS O
, , O
parents NNS O
or CC O
offspring NN O
proxies NNS O
increased VBD O
power NN O
by IN O
a DT O
larger JJR O
amount NN O
, , O
even RB O
with IN O
the DT O
discordant NN O
pair NN O
test NN O
. . O

The DT O
effect NN O
of IN O
experimental JJ O
screening NN O
for IN O
the DT O
unlinked JJ O
syndrome NN O
varied VBN O
substantially RB O
depending VBG O
on IN O
the DT O
relative JJ O
magnitude NN O
of IN O
the DT O
effects NNS O
of IN O
the DT O
unlinked JJ O
syndrome NN O
: : O
if IN O
the DT O
unlinked JJ O
syndrome NN O
had VBD O
an DT O
attributable JJ O
risk NN O
greater JJR O
than IN O
or CC O
equal JJ O
to TO O
that DT O
of IN O
the DT O
linked VBN O
syndrome NN O
, , O
experimental JJ O
screening NN O
resulted VBD O
in IN O
a DT O
large JJ O
increase NN O
in IN O
power NN O
. . O

Otherwise RB O
, , O
the DT O
effect NN O
of IN O
experimental JJ O
screening NN O
was VBD O
negligible JJ O
. . O

Power NN O
for IN O
a DT O
given VBN O
sample NN O
size NN O
F NNP O
and CC O
test NN O
size NN O
α VBZ O
with IN O
a DT O
specified VBN O
combination NN O
of IN O
design NN O
and CC O
genetic JJ O
parameters NNS O
can MD O
be VB O
derived VBN O
from IN O
the DT O
regression NN O
models NNS O
in IN O
Table NN O
5 CD O
by IN O
first RB O
obtaining VBG O
an DT O
estimate NN O
of IN O
the DT O
noncentrality NN O
parameter NN O
Z/F NN O
from IN O
the DT O
appropriate JJ O
column NN O
of IN O
Table NNP O
4 CD O
, , O
multiplying JJ O
by IN O
F NNP O
to TO O
obtain VB O
z^ NN O
, , O
and CC O
then RB O
solving VBG O
for IN O
β NN O
in IN O
the DT O
equation NN O
below IN O
: : O

β=Φ( JJ O
Zα−z^ NNP O
) -RRB- O
, , O

where WRB O
β NN O
is VBZ O
the DT O
probability NN O
of IN O
Type NNP O
II NNP O
error NN O
( -LRB- O
hence RB O
power NN O
is VBZ O
1-β JJ O
) -RRB- O
and CC O
Φ(z NN O
) -RRB- O
is VBZ O
the DT O
cumulative JJ O
standard NN O
normal JJ O
distribution NN O
. . O

A DT O
script NN O
for IN O
computing VBG O
the DT O
predicted VBN O
power NN O
for IN O
any DT O
particular JJ O
combination NN O
of IN O
these DT O
parameters NNS O
, , O
using VBG O
the DT O
statistical JJ O
languages NNS O
S-plus JJ O
or CC O
R NN O
is VBZ O
also RB O
available JJ O
from IN O
the DT O
website JJ O
[65] NN O
. . O

Figures NNS O
1 CD O
, , O
2 CD O
, , O
3 CD O
, , O
4 CD O
, , O
5 CD O
, , O
6 CD O
show NN O
estimated VBN O
power NN O
of IN O
the DT O
Zc JJ O
test NN O
for IN O
varying VBG O
sample NN O
sizes VBZ O
given VBN O
several JJ O
values NNS O
of IN O
AR NN O
for IN O
the DT O
linked VBN O
and CC O
unlinked VBN O
loci NNS O
, , O
recombination NN O
fraction NN O
( -LRB- O
θ NN O
) -RRB- O
, , O
number NN O
of IN O
parents NNS O
genotyped VBD O
, , O
and CC O
number NN O
of IN O
offspring NN O
proxies NNS O
. . O

Except IN O
as IN O
noted VBN O
, , O
the DT O
power NN O
estimates NNS O
are VBP O
based VBN O
on IN O
the DT O
following VBG O
settings NNS O
of IN O
the DT O
genetic JJ O
and CC O
design NN O
parameters NNS O
: : O
two CD O
total JJ O
affected JJ O
sibs NNS O
, , O
both DT O
sampled VBN O
, , O
two CD O
unaffected JJ O
sibs NNS O
( -LRB- O
not RB O
sampled VBN O
) -RRB- O
, , O
no DT O
parents NNS O
or CC O
offspring NN O
proxies NNS O
, , O
AR1 NNP O
( -LRB- O
linked VBN O
locus NN O
) -RRB- O
= SYM O
0.1 CD O
, , O
AR2 DT O
(unlinked JJ O
locus NN O
) -RRB- O
= SYM O
0.05 CD O
, , O
θ NNP O
= SYM O
0.05 CD O
, , O
and CC O
no DT O
screening NN O
to TO O
exclude VB O
unlinked JJ O
families NNS O
. . O

Effect NN O
of IN O
sample NN O
size NN O
and CC O
varying VBG O
attributable JJ O
risk NN O
at IN O
the DT O
linked VBN O
locus NN O
on IN O
estimated VBN O
power NN O
. . O

Effect NN O
of IN O
sample NN O
size NN O
and CC O
varying VBG O
attributable JJ O
risk NN O
at IN O
the DT O
unlinked JJ O
locus NN O
on IN O
estimated VBN O
power NN O
. . O

Effect NN O
of IN O
sample NN O
size NN O
and CC O
varying VBG O
recombination NN O
fraction NN O
on IN O
estimated VBN O
power NN O
. . O

Effect NN O
of IN O
sample NN O
size NN O
and CC O
varying VBG O
number NN O
of IN O
typed JJ O
parents NNS O
on IN O
estimated VBN O
power NN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Effect NN O
of IN O
varying VBG O
number NN O
of IN O
offspring NN O
proxies NNS O
on IN O
power NN O
for IN O
families NNS O
of IN O
two CD O
affected JJ O
siblings NNS O
. . O

Effect NN O
of IN O
sample NN O
size NN O
and CC O
varying VBG O
numbers NNS O
of IN O
offspring NN O
proxies NNS O
( -LRB- O
1 CD O
or CC O
2 CD O
) -RRB- O
on IN O
estimated VBN O
power NN O
, , O
families NNS O
with IN O
two CD O
affected JJ O
sibs NNS O
, , O
with IN O
only RB O
one CD O
available JJ O
for IN O
genotyping VBG O
( -LRB- O
1 CD O
or CC O
2 CD O
) -RRB- O
, , O
compared VBN O
with IN O
families NNS O
with IN O
both DT O
affected JJ O
sibs NNS O
available JJ O
for IN O
genotyping VBG O
( -LRB- O
S NNP O
= SYM O
2 CD O
) -RRB- O
. . O

Effect NN O
of IN O
varying VBG O
number NN O
of IN O
offspring NN O
proxies NNS O
on IN O
power NN O
for IN O
families NNS O
of IN O
three CD O
affected JJ O
siblings NNS O
. . O

Effect NN O
of IN O
sample NN O
size NN O
and CC O
varying VBG O
numbers NNS O
of IN O
offspring NN O
proxies NNS O
( -LRB- O
O UH O
) -RRB- O
on IN O
estimated VBN O
power NN O
, , O
families NNS O
with IN O
three CD O
affected JJ O
sibs NNS O
, , O
with IN O
only RB O
two CD O
available JJ O
for IN O
genotyping VBG O
( -LRB- O
O UH O
= SYM O
0, CD O
1 CD O
, , O
or CC O
2 CD O
) -RRB- O
, , O
compared VBN O
with IN O
families NNS O
with IN O
all DT O
three CD O
affected JJ O
sibs NNS O
available JJ O
for IN O
genotyping VBG O
( -LRB- O
S NNP O
= SYM O
3 CD O
) -RRB- O
. . O

Relative JJ O
Efficiency NN O
of IN O
Alternative NNP O
Designs NNS O

Because IN O
the DT O
power NN O
of IN O
the DT O
discordant JJ O
test NN O
was VBD O
rarely RB O
much RB O
greater JJR O
than IN O
that DT O
of IN O
the DT O
concordant JJ O
test NN O
, , O
and CC O
the DT O
concordant NN O
test NN O
requires VBZ O
genotyping NN O
of IN O
only RB O
the DT O
affected JJ O
sibs NNS O
, , O
the DT O
ARE NN O
of IN O
the DT O
concordant NN O
test NN O
was VBD O
always RB O
greater JJR O
on IN O
average JJ O
than IN O
that IN O
of IN O
the DT O
discordant JJ O
test NN O
. . O

Nevertheless RB O
, , O
we PRP O
were VBD O
interested VBN O
in IN O
specific JJ O
combinations NNS O
of IN O
design NN O
and CC O
genetic JJ O
parameters NNS O
that WDT O
might MD O
have VB O
resulted VBN O
in IN O
better JJR O
relative JJ O
efficiency NN O
for IN O
the DT O
discordant JJ O
test NN O
. . O

Overall RB O
, , O
the DT O
ARE NN O
for IN O
the DT O
discordant JJ O
test NN O
was VBD O
larger JJR O
than IN O
that IN O
for IN O
the DT O
concordant JJ O
test NN O
in IN O
13 CD O
% NN O
of IN O
the DT O
replications NNS O
. . O

We PRP O
used VBD O
a DT O
logistic JJ O
regression NN O
model NN O
with IN O
the DT O
same JJ O
parameters NNS O
as IN O
those DT O
in IN O
Tables NNP O
2 CD O
, , O
3 CD O
and CC O
4 CD O
to TO O
predict VB O
the DT O
probability NN O
that IN O
Zp NNP O
would MD O
outperform VB O
Zc NNP O
in IN O
terms NNS O
of IN O
relative JJ O
efficiency NN O
( -LRB- O
not RB O
shown VBN O
) -RRB- O
. . O

Only RB O
under IN O
circumstances NNS O
that WDT O
would MD O
result VB O
in IN O
very RB O
low JJ O
power NN O
, , O
such JJ O
as IN O
attributable JJ O
risks NNS O
for IN O
the DT O
unlinked JJ O
locus NN O
more JJR O
than IN O
twice RB O
as RB O
large JJ O
as IN O
attributable JJ O
risks NNS O
for IN O
the DT O
linked VBN O
locus NN O
, , O
or CC O
recombination NN O
fractions NNS O
> VBD O
0.1 CD O
, , O
was VBD O
Zp NNP O
predicted VBD O
to TO O
outperform JJ O
Zc NN O
in IN O
our PRP$ O
simulated JJ O
sample NN O
of IN O
500 CD O
families NNS O
. . O

In IN O
principle NN O
, , O
including VBG O
genotype JJ O
data NNS O
from IN O
unaffected JJ O
siblings NNS O
can MD O
improve VB O
the DT O
ability NN O
to TO O
estimate VB O
haplotypes NNS O
and CC O
thereby RB O
improve VB O
power NN O
when WRB O
multipoint JJ O
data NNS O
are VBP O
studied VBN O
. . O

Table NN O
6 CD O
compares VBZ O
estimates NNS O
of IN O
Zc NNP O
and CC O
Zp NNP O
for IN O
a DT O
selected VBN O
set NN O
of IN O
simulations NNS O
with IN O
multipoint JJ O
Zm NNP O
scores NNS O
for IN O
the DT O
same JJ O
families NNS O
as IN O
calculated VBN O
by IN O
the DT O
computer NN O
program NN O
Merlin NNP O
[58] NNP O
. . O

In IN O
these DT O
simulations NNS O
, , O
when WRB O
markers NNS O
were VBD O
spaced VBN O
no RB O
closer RBR O
than IN O
10 CD O
cM NNS O
from IN O
one CD O
another DT O
, , O
as IN O
is VBZ O
usually RB O
the DT O
case NN O
in IN O
an DT O
initial JJ O
genome NN O
scan NN O
, , O
we PRP O
observed VBD O
no DT O
improvement NN O
in IN O
power NN O
with IN O
the DT O
concordant NN O
multipoint JJ O
statistic JJ O
, , O
but CC O
an DT O
improvement NN O
in IN O
power NN O
with IN O
the DT O
discordant JJ O
test NN O
. . O

When WRB O
markers NNS O
were VBD O
spaced VBN O
at IN O
5 CD O
cM NN O
intervals NNS O
, , O
however RB O
, , O
the DT O
power NN O
of IN O
both DT O
multipoint JJ O
statistics NNS O
to TO O
detect VB O
linkage NN O
exceeded VBD O
that IN O
of IN O
both DT O
Zc NNP O
and CC O
Zp NNP O
. . O

The DT O
conservative JJ O
bias NN O
of IN O
Zmc NNP O
noted VBD O
in IN O
Tables NNP O
2 CD O
and CC O
3 CD O
appears VBZ O
to TO O
decrease VB O
as IN O
marker NN O
intervals NNS O
become VBP O
smaller JJR O
. . O

To TO O
test VB O
this DT O
, , O
we PRP O
conducted VBD O
additional JJ O
simulations NNS O
under IN O
the DT O
null JJ O
hypothesis NN O
as IN O
described VBN O
above IN O
for IN O
Tables NNP O
2 CD O
and CC O
3 CD O
, , O
with IN O
1000 CD O
repetitions NNS O
and CC O
markers NNS O
spaced VBD O
at IN O
5 CD O
, , O
10 CD O
, , O
and CC O
20 CD O
cM. . O

The DT O
magnitude NN O
of IN O
the DT O
conservative JJ O
bias NN O
in IN O
Zmc NNP O
decreases VBZ O
consistently RB O
( -LRB- O
mean JJ O
Zmc NN O
= SYM O
-0.58 FW O
at IN O
20 CD O
cM NNS O
, , O
-0.23 CC O
at IN O
10 CD O
cM NNS O
, , O
and CC O
0.06 CD O
at IN O
5 CD O
cM NN O
) -RRB- O
as IN O
marker NN O
intervals NNS O
contract NN O
, , O
becoming VBG O
significantly RB O
anti-conservative JJ O
at IN O
5 CD O
cM. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Discussion NN O

In IN O
studying VBG O
a DT O
disease NN O
like IN O
colon NN O
cancer NN O
with IN O
both DT O
incomplete JJ O
penetrance NN O
and CC O
a DT O
high JJ O
incidence NN O
of IN O
sporadics NNS O
, , O
prior JJ O
studies NNS O
have VBP O
shown VBN O
that IN O
to TO O
be VB O
efficient JJ O
, , O
families NNS O
must MD O
include VB O
two CD O
or CC O
more JJR O
individuals NNS O
with IN O
the DT O
same JJ O
disease NN O
from IN O
whom WP O
samples NNS O
can MD O
be VB O
obtained VBN O
. . O

The DT O
practical JJ O
experience NN O
of IN O
many JJ O
investigators NNS O
suggests VBZ O
that IN O
once RB O
an DT O
initial JJ O
entree NN O
is VBZ O
gained VBN O
into IN O
a DT O
family NN O
, , O
the DT O
chances NNS O
of IN O
enrolling VBG O
other JJ O
members NNS O
are VBP O
quite RB O
high JJ O
. . O

Close JJ O
relatives NNS O
are VBP O
often RB O
very RB O
motivated JJ O
to TO O
participate VB O
in IN O
research NN O
into IN O
a DT O
disease NN O
that WDT O
has VBZ O
afflicted VBN O
their PRP$ O
family NN O
, , O
especially RB O
when WRB O
the DT O
commitment NN O
is VBZ O
minimal JJ O
, , O
involving VBG O
only RB O
a DT O
blood NN O
specimen NN O
and CC O
a DT O
signed JJ O
consent NN O
, , O
which WDT O
are VBP O
all DT O
that DT O
are VBP O
required VBN O
for IN O
a DT O
linkage NN O
study NN O
of IN O
diseases NNS O
that WDT O
have VBP O
an DT O
easily RB O
established VBN O
phenotype NN O
, , O
like IN O
cancer NN O
. . O

In IN O
our PRP$ O
simulations NNS O
, , O
we PRP O
considered VBD O
inclusion NN O
of IN O
unaffected JJ O
sibs NNS O
and CC O
the DT O
use NN O
of IN O
spouse NN O
and CC O
offspring NN O
to TO O
replace VB O
missing VBG O
affected JJ O
sibs NNS O
. . O

Including VBG O
unaffected JJ O
siblings NNS O
in IN O
the DT O
design NN O
of IN O
a DT O
study NN O
can MD O
improve VB O
the DT O
power NN O
to TO O
detect VB O
linkage NN O
for IN O
highly-penetrant JJ O
diseases NNS O
[53,66] VBP O
. . O

However RB O
, , O
our PRP$ O
simulation NN O
studies NNS O
demonstrate VBP O
that IN O
for IN O
the DT O
model-free JJ O
linkage NN O
tests NNS O
we PRP O
studied VBD O
, , O
for IN O
low JJ O
penetrance NN O
loci NNS O
, , O
and CC O
with IN O
no DT O
genotyping NN O
error NN O
, , O
little JJ O
increase NN O
in IN O
power NN O
can MD O
be VB O
gained VBN O
by IN O
including VBG O
unaffected JJ O
siblings NNS O
in IN O
the DT O
design NN O
of IN O
a DT O
sib-pair NN O
study NN O
of IN O
a DT O
late JJ O
onset NN O
, , O
complex JJ O
disease NN O
such JJ O
as IN O
colorectal JJ O
cancer NN O
. . O

The DT O
inclusion NN O
of IN O
unaffected JJ O
siblings NNS O
can MD O
be VB O
useful JJ O
, , O
however RB O
, , O
in IN O
reducing VBG O
anti-conservative JJ O
biases NNS O
arising VBG O
from IN O
heterogeneity NN O
or CC O
misspecification NN O
of IN O
marker NN O
allele JJ O
frequencies NNS O
or CC O
genotyping JJ O
errors NNS O
, , O
and CC O
conservative JJ O
biases NNS O
arising VBG O
if IN O
multipoint JJ O
statistics NNS O
are VBP O
used VBN O
with IN O
an DT O
insufficiently RB O
dense JJ O
marker NN O
set NN O
. . O

Table NN O
2 CD O
shows VBZ O
that IN O
, , O
with IN O
markers NNS O
spaced VBN O
at IN O
10 CD O
cM NN O
intervals NNS O
, , O
Zmc NNP O
is VBZ O
conservatively RB O
biased VBN O
, , O
while IN O
exhibiting VBG O
an DT O
anticonservative JJ O
bias NN O
in IN O
Table NN O
3 CD O
under IN O
conditions NNS O
of IN O
heterogeneity NN O
in IN O
marker NN O
allele JJ O
frequencies NNS O
. . O

In IN O
Table NNP O
6 CD O
, , O
Zmp NNP O
outperforms VBZ O
with IN O
markers NNS O
spaced VBN O
at IN O
10 CD O
and CC O
20 CD O
cM. . O

At IN O
5 CD O
cM NN O
, , O
Zmc NNP O
becomes VBZ O
anticonservatively RB O
biased VBN O
, , O
as IN O
noted VBN O
above IN O
. . O

It PRP O
may MD O
be VB O
useful JJ O
to TO O
perform VB O
simulations NNS O
to TO O
assess VB O
the DT O
characteristics NNS O
of IN O
the DT O
tests NNS O
when WRB O
the DT O
marker NN O
spacing NN O
decreases VBZ O
, , O
as RB O
would MD O
be VB O
possible JJ O
with IN O
the DT O
newer JJR O
SNP NNP O
array-based JJ O
platforms NNS O
. . O

Further RB O
, , O
since IN O
genome-wide-association NN O
studies NNS O
do VBP O
not RB O
utilize VB O
the DT O
full JJ O
power NN O
of IN O
the DT O
sibpair NN O
design NN O
, , O
future JJ O
research NN O
should MD O
be VB O
aimed VBN O
at IN O
assessing VBG O
the DT O
optimal JJ O
setting NN O
for IN O
relying VBG O
on IN O
the DT O
sibpair NN O
design NN O
, , O
as IN O
it PRP O
is VBZ O
premature JJ O
to TO O
move VB O
completely RB O
away RB O
from IN O
this DT O
study NN O
design NN O
[15] NN O
. . O

If IN O
a DT O
secondary JJ O
goal NN O
of IN O
a DT O
study NN O
is VBZ O
to TO O
estimate VB O
the DT O
penetrance NN O
, , O
then RB O
unaffected JJ O
relatives NNS O
should MD O
be VB O
included VBN O
in IN O
the DT O
design NN O
of IN O
the DT O
study NN O
; : O
also RB O
unaffected JJ O
siblings NNS O
could MD O
help VB O
in IN O
evaluating VBG O
the DT O
impact NN O
of IN O
environmental JJ O
factors NNS O
upon IN O
disease NN O
risk NN O
. . O

Genotyping VBG O
errors NNS O
for IN O
microsatellites NNS O
scans NNS O
are VBP O
currently RB O
very RB O
low JJ O
but CC O
are VBP O
hard JJ O
to TO O
assess VB O
without IN O
the DT O
availability NN O
of IN O
parents NNS O
or CC O
siblings NNS O
. . O

Our PRP$ O
findings NNS O
parallel RB O
those DT O
of IN O
Holmans NNP O
et NNP O
al NN O
. . O
[67] CD O
, , O
who WP O
suggested VBD O
that IN O
genotyping VBG O
affected VBN O
individuals NNS O
only RB O
is VBZ O
efficient JJ O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Crude NN O
stratification NN O
by IN O
recruitment NN O
center NN O
is VBZ O
unlikely JJ O
to TO O
be VB O
reliable JJ O
enough RB O
for IN O
controlling VBG O
population NN O
heterogeneity NN O
without IN O
additional JJ O
adjustment NN O
. . O

Stratification NNP O
by IN O
ethnicity NN O
is VBZ O
generally RB O
more RBR O
crucial JJ O
than IN O
by IN O
geography NN O
, , O
although IN O
both DT O
factors NNS O
should MD O
ideally RB O
be VB O
incorporated VBN O
. . O

However RB O
, , O
collection NN O
of IN O
ethnicity NN O
is VBZ O
not RB O
entirely RB O
trivial JJ O
if IN O
it PRP O
is VBZ O
to TO O
be VB O
worthwhile JJ O
. . O

Although IN O
various JJ O
coding VBG O
systems NNS O
have VBP O
been VBN O
established VBN O
by IN O
different JJ O
agencies NNS O
, , O
no DT O
consensus NN O
has VBZ O
been VBN O
established VBN O
regarding VBG O
the DT O
level NN O
of IN O
detail NN O
required VBN O
on IN O
ethnicity NN O
data NNS O
in IN O
genetic JJ O
research NN O
, , O
e.g NN O
. . O

category NN O
distinctions NNS O
, , O
mixed-race JJ O
marriages NNS O
. . O

Mandal NNP O
et NNP O
al NN O
. . O
[81] '' O
have VBP O
shown VBN O
that IN O
marker NN O
allele JJ O
frequencies NNS O
are VBP O
less RBR O
important JJ O
if IN O
there EX O
are VBP O
four CD O
or CC O
more JJR O
persons NNS O
per IN O
family NN O
, , O
especially RB O
when WRB O
very RB O
polymorphic JJ O
markers NNS O
are VBP O
used VBN O
. . O

When WRB O
the DT O
parents NNS O
of IN O
the DT O
sibpair NN O
have VBP O
been VBN O
genotyped VBN O
, , O
then RB O
there EX O
is VBZ O
no DT O
dependence NN O
on IN O
population NN O
marker NN O
allele IN O
frequencies NNS O
and CC O
no DT O
source NN O
of IN O
bias NN O
in IN O
linkage NN O
analysis NN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

CpG NNP O
Island NNP O
Methylation NNP O
in IN O
Familial NNP O
Colorectal NNP O
Cancer NNP O
Patients NNPS O
Not RB O
Fulfilling VBG O
the DT O
Amsterdam NNP O
Criteria NNPS O

Abstract NN O

To TO O
determine VB O
the DT O
role NN O
of IN O
methylation NN O
in IN O
colorectal JJ O
cancer NN O
patients NNS O
with IN O
a DT O
family NN O
history NN O
, , O
we PRP O
enrolled VBD O
25 CD O
colorectal JJ O
cancer NN O
patients NNS O
with IN O
a DT O
family NN O
history NN O
of IN O
colorectal NN O
cancer NN O
but CC O
without IN O
a DT O
mutation NN O
in IN O
the DT O
hMLH1 JJ B-NP
and CC O
hMSH2 JJ B-NP
genes NNS O
. . O

Thirty CD O
patients NNS O
with IN O
sporadic JJ O
colorectal NN O
cancer NN O
were VBD O
included VBN O
as IN O
control NN O
. . O

The DT O
methylation NN O
status NN O
of IN O
COX2 NNP B-NP
, , O
MGMT NNP B-NP
, , O
hMLH1 PRP B-NP
, , O
TIMP3 NNP B-NP
, , O
p16 VBD B-NP
, , O
and CC O
MINT2 NNP B-NP
in IN O
normal JJ O
mucosa NN O
and CC O
tumor NN O
were VBD O
assessed VBN O
using VBG O
methylation-specific JJ O
PCR. . O

In IN O
patients NNS O
with IN O
a DT O
family NN O
history NN O
, , O
the DT O
methylation NN O
frequency NN O
ranged VBD O
from IN O
4.0 CD O
% NN O
for IN O
TIMP3 NNP B-NP
to TO O
44.4 CD O
% NN O
for IN O
MGMT NNP B-NP
, , O
whereas IN O
, , O
in IN O
patients NNS O
with IN O
sporadic JJ O
colorectal NN O
cancer NN O
, , O
it PRP O
ranged VBD O
from IN O
6.7 CD O
% NN O
for IN O
TIMP3 NNP B-NP
to TO O
50.0 CD O
% NN O
for IN O
p16 NNS B-NP
. . O

Nine CD O
of IN O
the DT O
25 CD O
patients NNS O
with IN O
family NN O
history NN O
( -LRB- O
36.0 CD O
% NN O
) -RRB- O
were VBD O
classified VBN O
as IN O
methylation-prone JJ O
, , O
and CC O
nine CD O
of IN O
the DT O
30 CD O
patients NNS O
with IN O
sporadic JJ O
cancers NNS O
( -LRB- O
30.0 CD O
% NN O
) -RRB- O
were VBD O
as IN O
methylation-prone NN O
, , O
making VBG O
their PRP$ O
methylation NN O
indices NNS O
0.19 CD O
and CC O
0.16 CD O
, , O
respectively RB O
( -LRB- O
p=0.522 NN O
) -RRB- O
. . O

As IN O
for IN O
the DT O
individual JJ O
genes NNS O
, , O
the DT O
methylation NN O
rate NN O
of IN O
MGMT NNP B-NP
was VBD O
higher JJR O
in IN O
colorectal JJ O
cancer NN O
patients NNS O
with IN O
family NN O
history NN O
( -LRB- O
44.0 CD O
% NN O
vs. IN O
13.0 CD O
% NN O
, , O

p=0.016 NNS O
) -RRB- O
, , O
whereas IN O
the DT O
methylation NN O
rate NN O
of IN O
p16 DT B-NP
was VBD O
higher JJR O
in IN O
sporadic JJ O
colorectal NN O
cancers NNS O
( -LRB- O
50.0 CD O
% NN O
vs. IN O
8.7 CD O
% NN O
, , O
p=0.046 NNS O
) -RRB- O
. . O

While IN O
CpG VBG O
island NN O
methylation NN O
of IN O
tumor NN O
suppressor NN O
genes NNS O
may MD O
play VB O
a DT O
role NN O
in IN O
colorectal JJ O
carcinogenesis NN O
, , O
the DT O
genes NNS O
involved VBN O
may MD O
be VB O
different JJ O
between IN O
tumors NNS O
of IN O
patients NNS O
with IN O
and CC O
without IN O
a DT O
family NN O
history NN O
of IN O
colorectal JJ O
cancer NN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

RESULTS NNS O

Methylation NNP O
in IN O
colorectal JJ O
cancer NN O
patients NNS O
with IN O
family NN O
history NN O

We PRP O
determined VBD O
CpG VBG O
island NN O
methylation NN O
at IN O
six CD O
loci NNS O
and CC O
MSI NNP O
in IN O
paired VBN O
normal JJ O
mucosa NN O
and CC O
tumor NN O
tissue NN O
from IN O
25 CD O
colorectal JJ O
cancer NN O
patients NNS O
with IN O
family NN O
history NN O
. . O

Of IN O
the DT O
25 CD O
tumors NNS O
, , O
16 CD O
( -LRB- O
64.0 CD O
% NN O
) -RRB- O

showed VBD O
promoter NN O
methylation NN O
of IN O
at IN O
least JJS O
one CD O
gene NN O
, , O
ranging VBG O
to TO O
four CD O
genes NNS O
. . O

Seven CD O
tumors NNS O
showed VBD O
methylation NN O
at IN O
one CD O
gene NN O
, , O
seven CD O
at IN O
two CD B-NP
genes NNS I-NP
, , O
one CD O
at IN O
three CD B-NP
genes NNS I-NP
, , O
and CC O
one CD O
at IN O
four CD B-NP
genes NNS I-NP
. . O

In IN O
contrast NN O
, , O
of IN O
the DT O
25 CD O
samples NNS O
of IN O
normal JJ O
colonic JJ O
mucosa NN O
, , O
12 CD O
( -LRB- O
48.0 CD O
% NN O
) -RRB- O

showed VBD O
promoter NN O
methylation NN O
: : O
eight CD O
samples NNS O
at IN O
one CD B-NP
gene NN I-NP
, , O
and CC O
four CD O
samples NNS O
at IN O
two CD B-NP
genes NNS I-NP
. . O

When WRB O
patients NNS O
with IN O
a DT O
family NN O
history NN O
were VBD O
categorized VBN O
as IN O
having VBG O
0-1 FW O
( -LRB- O
MR NN O
group NN O
) -RRB- O
or CC O
≥2 CD O
( -LRB- O
MP NNP O
group NN O
) -RRB- O
methylated VBN O
loci NNS O
, , O
we PRP O
found VBD O
that IN O
36.0 CD O
% NN O
of IN O
the DT O
tumors NNS O
and CC O
16.0 CD O
% NN O
of IN O
the DT O
normal JJ O
mucosa NN O
samples NNS O
could MD O
be VB O
categorized VBN O
as IN O
MP. NNP O

The DT O
mean JJ O
methylation NN O
index NN O
( -LRB- O
the DT O
number NN O
of IN O
methylated JJ O
loci NNS O
divided VBN O
by IN O
the DT O
total JJ O
number NN O
of IN O
tested VBN O
loci) NN O
was VBD O
0.11 CD O
(0-0.33 CD O
) -RRB- O
in IN O
normal JJ O
mucosa NN O
and CC O
0.19 CD O
(0-0.66 CD O
) -RRB- O
in IN O
tumors NNS O
( -LRB- O
p=0.078 NNS O
) -RRB- O
. . O

A DT O
high JJ O
proportion NN O
of IN O
tumors NNS O
( -LRB- O
44.0 CD O
% NN O
) -RRB- O
were VBD O
methylated VBN O
at IN O
the DT O
MGMT NNP B-NP
locus NN O
, , O
whereas IN O
20.0 CD O
% NN O
, , O
20.0 CD O
% NN O
, , O
and CC O
16.0 CD O
% NN O
were VBD O
methylated VBN O
at IN O
the DT O
COX2 NNP B-NP
, , O
hMLH1 NN B-NP
, , O
and CC O
MINT2 NNP B-NP
loci NNS O
, , O
respectively RB O
. . O

In IN O
contrast NN O
, , O
only RB O
8.0 CD O
% NN O
of IN O
p16 DT B-NP
loci NNS O
and CC O
4.0 CD O
% NN O
of IN O
TIMP3 NNP B-NP
loci NNS O
were VBD O
methylated VBN O
( -LRB- O
Fig NNP O
. . O
2 CD O
) -RRB- O
. . O

We PRP O
found VBD O
that IN O
the DT O
COX2 NNP B-NP
, , O
MGMT NNP B-NP
, , O
and CC O
p16 VBD B-NP
loci NNS O
were VBD O
methylated VBN O
at IN O
28.0 CD O
% NN O
, , O
20.0 CD O
% NN O
, , O
and CC O
16.0 CD O
% NN O
, , O
respectively RB O
, , O
of IN O
normal JJ O
mucosa NN O
samples NNS O
of IN O
patients NNS O
with IN O
a DT O
family NN O
history NN O
, , O
whereas IN O
the DT O
hMLH1 NN B-NP
, , O
TIMP3 NNP B-NP
, , O
and CC O
MINT2 NNP B-NP
loci NNS O
were VBD O
not RB O
methylated VBN O
in IN O
any DT O
of IN O
the DT O
normal JJ O
mucosa NN O
samples NNS O
. . O

The DT O
frequency NN O
of IN O
methylation NN O
of IN O
the DT O
COX2 NNP B-NP
and CC O
p16 VBD B-NP
loci NNS O
was VBD O
higher JJR O
in IN O
normal JJ O
mucosa NN O
than IN O
in IN O
tumor NN O
, , O
but CC O
the DT O
difference NN O
did VBD O
not RB O
reach VB O
a DT O
statistical JJ O
significance NN O
. . O

Methylation NNP O
in IN O
sporadic JJ O
colorectal JJ O
cancer NN O
patients NNS O

We PRP O
also RB O
assayed VBD O
CpG NNP O
island NN O
methylation NN O
at IN O
these DT O
six CD O
loci NNS O
and CC O
MSI NNP O
in IN O
paired JJ O
tumors NNS O
and CC O
normal JJ O
mucosa NN O
from IN O
30 CD O
patients NNS O
with IN O
sporadic JJ O
colorectal NN O
cancer NN O
. . O

We PRP O
found VBD O
that IN O
16 CD O
( -LRB- O
53.0 CD O
% NN O
) -RRB- O
of IN O
the DT O
tumors NNS O
showed VBD O
promoter NN O
methylation NN O
of IN O
at IN O
least JJS O
one CD O
gene NN O
, , O
ranging VBG O
to TO O
three CD O
genes NNS O
. . O

Seven CD O
tumors NNS O
showed VBD O
methylation NN O
at IN O
one CD O
locus NN O
, , O
six CD O
at IN O
two CD O
loci NNS O
, , O
and CC O
one CD O
at IN O
three CD O
loci NNS O
. . O

In IN O
contrast NN O
, , O
only JJ O
7 CD O
( -LRB- O
23.0 CD O
% NN O
) -RRB- O
of IN O
the DT O
normal JJ O
colonic JJ O
mucosa NN O
samples NNS O
showed VBD O
promoter NN O
methylation NN O
, , O
each DT O
at IN O
one CD O
gene NN O
. . O

We PRP O
found VBD O
that IN O
30.0 CD O
% NN O
of IN O
the DT O
tumors NNS O
, , O
and CC O
none NN O
of IN O
the DT O
normal JJ O
mucosa NN O
, , O
could MD O
be VB O
classified VBN O
as IN O
MP. NNP O

The DT O
mean JJ O
methylation NN O
index NN O
was VBD O
0.04 CD O
(0-0.17 CD O
) -RRB- O
in IN O
normal JJ O
mucosa NN O
and CC O
0.16 CD O
(0-0.5 CD O
) -RRB- O
in IN O
tumors NNS O
( -LRB- O
p<0.001 NNS O
) -RRB- O
. . O

Methylation NNP O
of IN O
the DT O
p16 NN B-NP
locus NN O
was VBD O
observed VBN O
in IN O
a DT O
high JJ O
proportion NN O
( -LRB- O
33.3 CD O
% NN O
) -RRB- O
of IN O
sporadic JJ O
tumors NNS O
cases NNS O
, , O
whereas IN O
methylation NN O
of IN O
the DT O
COX2 NNP B-NP
, , O
MGMT NNP B-NP
, , O
and CC O
MINT2 NNP B-NP
loci NNS O
were VBD O
observed VBN O
in IN O
20.0 CD O
% NN O
, , O
13.3 CD O
% NN O
, , O
and CC O
13.3 CD O
% NN O
, , O
respectively RB O
, , O
of IN O
these DT O
tumors NNS O
. . O

In IN O
contrast NN O
, , O
only RB O
6.7 CD O
% NN O
of IN O
tumors NNS O
were VBD O
methylated VBN O
at IN O
the DT O
TIMP3 NN B-NP
promoter NN O
( -LRB- O
Fig NNP O
. . O
3 CD O
) -RRB- O
. . O

Methylation NNP O
of IN O
the DT O
p16 NNS B-NP
, , O
COX2 NNP B-NP
, , O
and CC O
MGMT NNP B-NP
loci NNS O
were VBD O
observed VBN O
in IN O
13.3 CD O
% NN O
, , O
6.7 CD O
% NN O
, , O
and CC O
3.4 CD O
% NN O
, , O
respectively RB O
, , O
of IN O
the DT O
normal JJ O
mucosa NN O
samples NNS O
, , O
whereas IN O
we PRP O
did VBD O
not RB O
observe VB O
methylation NN O
of IN O
the DT O
hMLH1 NN B-NP
, , O
TIMP3 NNP B-NP
, , O
and CC O
MINT2 NNP B-NP
loci NNS O
in IN O
any DT O
of IN O
these DT O
tissues NNS O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Several JJ O
reports NNS O
have VBP O
described VBN O
an DT O
association NN O
between IN O
the DT O
methylation NN O
status NN O
of IN O
multiple JJ O
genes NNS O
and CC O
a DT O
familial JJ O
tendency NN O
to TO O
colorectal NN O
cancer NN O
( -LRB- O
15 CD O
, , O
28 CD O
) -RRB- O
. . O

A DT O
recent JJ O
large JJ O
study NN O
, , O
however RB O
, , O
found VBD O
no DT O
evidence NN O
that IN O
patients NNS O
with IN O
heavily RB O
methylated VBN O
colorectal NN O
cancers NNS O
were VBD O
more RBR O
likely JJ O
to TO O
develop VB O
a DT O
second JJ O
malignancy NN O
or CC O
have VBP O
a DT O
positive JJ O
family NN O
history NN O
of IN O
cancer NN O
( -LRB- O
29 CD O
) -RRB- O
. . O

Aberrant NNP O
methylation NN O
may MD O
result VB O
from IN O
an DT O
inherited VBN O
defect NN O
in IN O
the DT O
methylation NN O
apparatus NN O
. . O

In IN O
this DT O
study NN O
, , O
considerable JJ O
proportions NNS O
of IN O
cancer NN O
in IN O
both DT O
groups NNS O
with IN O
or CC O
without IN O
familial JJ O
history NN O
of IN O
colorectal NN O
cancer NN O
presented VBD O
the DT O
methylated JJ O
genes NNS O
that WDT O
may MD O
involved VBN O
in IN O
carcinogenetic JJ O
pathways NNS O
. . O

It PRP O
still RB O
remains VBZ O
to TO O
be VB O
elucidated VBN O
whether IN O
promoter NN O
methylation NN O
in IN O
multiple JJ O
genes NNS O
is VBZ O
one CD O
of IN O
main JJ O
mechanism NN O
to TO O
evoke VB O
cancer NN O
or CC O
simple JJ O
bystander NN O
. . O

However RB O
, , O
our PRP$ O
results NNS O
confirm VBP O
that DT O
CpG NNP O
island NN O
promoter NN O
methylation NN O
may MD O
be VB O
a DT O
universal JJ O
event NN O
in IN O
sporadic JJ O
or CC O
familial JJ O
colorectal NN O
cancer NN O
, , O
and CC O
is VBZ O
suggested VBN O
as IN O
one CD O
of IN O
the DT O
mechanisms NNS O
for IN O
'second JJ O
hits NNS O
' '' O
by IN O
which WDT O
tumor NN O
suppressor NN O
genes NNS O
are VBP O
inactivated VBN O
. . O

Evidence NN O
for IN O
this DT O
mechanism NN O
in IN O
familial JJ O
colorectal NN O
cancers NNS O
was VBD O
previously RB O
reported VBN O
in IN O
studies NNS O
showing VBG O
aberrant JJ O
methylation NN O
of IN O
individual JJ O
genes NNS O
, , O
including VBG O
CDH1 NNP B-NP
, , O
VHL NNP B-NP
, , O
and CC O
hMLH1 JJ B-NP
, , O
in IN O
hereditary JJ O
cancer NN O
syndromes NNS O
( -LRB- O
30-32 CD O
) -RRB- O
. . O

Cancer NNP O
is VBZ O
a DT O
genetic JJ O
disease NN O
. . O

Most JJS O
cancer-causing NN O
mutations NNS O
are VBP O
somatic JJ O
, , O
occurring VBG O
in IN O
the DT O
affected JJ O
tissue NN O
during IN O
the DT O
course NN O
of IN O
carcinogenesis NN O
. . O

However RB O
, , O
most RBS O
cancers NNS O
also RB O
have VBP O
a DT O
hereditary JJ O
component NN O
, , O
caused VBN O
by IN O
predisposing VBG O
mutations NNS O
that WDT O
affect VBP O
the DT O
germline NN O
, , O
are VBP O
heritable JJ O
, , O
contribute VB O
to TO O
the DT O
initiation NN O
of IN O
carcinogenesis NN O
, , O
and CC O
influence NN O
the DT O
carcinogenesis NN O
pathway NN O
. . O

Although IN O
hypermethylation NN O
is VBZ O
not RB O
a DT O
rare JJ O
event NN O
, , O
either CC O
in IN O
sporadic JJ O
colorectal NN O
cancers NNS O
or CC O
in IN O
colorectal JJ O
cancers NNS O
with IN O
family NN O
history NN O
, , O
predisposing VBG O
germline NN O
alterations NNS O
can MD O
affect VB O
detailed VBN O
aspects NNS O
of IN O
methylation NN O
. . O

Our PRP$ O
data NNS O
showed VBD O
two CD O
of IN O
the DT O
genes NNS O
methylated VBN O
at IN O
their PRP$ O
promoters NNS O
, , O
p16 '' B-NP
and CC O
MGMT NNP B-NP
, , O
differ VBP O
according VBG O
to TO O
the DT O
tumor NN O
type NN O
. . O

These DT O
findings NNS O
suggest VBP O
that IN O
the DT O
methylation NN O
of IN O
p16 NNS B-NP
, , O
leading VBG O
to TO O
its PRP$ O
loss NN O
of IN O
function NN O
, , O
may MD O
be VB O
a DT O
dominant JJ O
and CC O
necessary JJ O
event NN O
for IN O
sporadic JJ O
colorectal NN O
carcinogenesis NN O
, , O
whereas IN O
methylation NN O
of IN O
MGMT NNP B-NP
may MD O
be VB O
dominant JJ O
and CC O
necessary JJ O
in IN O
colorectal JJ O
carcinogenesis NN O
in IN O
individuals NNS O
with IN O
a DT O
family NN O
history NN O
. . O

It PRP O
was VBD O
reported VBN O
that IN O
the DT O
frequency NN O
and CC O
pattern NN O
of IN O
gene NN O
methylation NN O
varied VBN O
between IN O
HNPCC NNP O
syndrome NN O
and CC O
sporadic JJ O
adenomas NNS O
, , O
implying VBG O
differences NNS O
in IN O
the DT O
molecular JJ O
pathogenesis NN O
of IN O
tumors NNS O
( -LRB- O
33 CD O
) -RRB- O
. . O

MGMT NNP B-NP
has VBZ O
been VBN O
considered VBN O
as IN O
a DT O
critical JJ O
step NN O
of IN O
genetic JJ O
instability NN O
and CC O
methylation NN O
of IN O
MGMT NNP B-NP
are VBP O
proposed VBN O
to TO O
show VB O
a DT O
distinctive JJ O
phenotype NN O
of IN O
MSI-L NNP O
or CC O
mild JJ O
family NN O
history NN O
of IN O
colorectal NN O
cancer NN O
( -LRB- O
34 CD O
, , O
35 CD O
) -RRB- O
. . O

The DT O
present JJ O
study NN O
also RB O
showed VBD O
a DT O
possibility NN O
that IN O
different JJ O
pathways NNS O
to TO O
cancer NN O
may MD O
exit VB O
according VBG O
to TO O
the DT O
molecular JJ O
background NN O
and CC O
some DT O
subgroup NN O
of IN O
familial JJ O
colorectal NN O
cancer NN O
are VBP O
related VBN O
to TO O
the DT O
loss NN O
of IN O
function NN O
of IN O
MGMT. NNP B-NP

Thus RB O
, , O
genes NNS O
selected VBN O
for IN O
methylation-induced JJ O
functional JJ O
loss NN O
may MD O
differ VB O
according VBG O
to TO O
the DT O
genetic JJ O
background NN O
. . O

While IN O
methylation NN O
seems VBZ O
to TO O
be VB O
a DT O
universal JJ O
mechanism NN O
by IN O
which WDT O
gene NN O
function NN O
is VBZ O
inactivated VBN O
, , O
the DT O
germline NN O
mutations NNS O
in IN O
familial JJ O
tumors NNS O
confer VBP O
a DT O
selective JJ O
advantage NN O
for IN O
their PRP$ O
tumorigenic JJ O
growth NN O
, , O
but CC O
other JJ O
genetic JJ O
and CC O
epigenetic JJ O
lesions NNS O
are VBP O
also RB O
necessary JJ O
. . O

Genetic JJ O
predisposition NN O
to TO O
CpG NNP O
island NN O
methylation NN O
may MD O
be VB O
a DT O
modifying JJ O
factor NN O
that WDT O
contributes VBZ O
to TO O
the DT O
penetrance NN O
of IN O
HNPCC. NNP O

Our PRP$ O
findings NNS O
thus RB O
expand VBP O
these DT O
early JJ O
observations NNS O
on IN O
methylation NN O
in IN O
familial JJ O
colorectal NN O
cancer NN O
and CC O
highlight NN O
the DT O
selective JJ O
advantage NN O
of IN O
epigenetic JJ O
gene NN O
silencing NN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Impact NN O
of IN O
BRAF NNP B-NP
, , O
MLH1 NNP B-NP
on IN O
the DT O
incidence NN O
of IN O
microsatellite NN O
instability NN O
high JJ O
colorectal NN O
cancer NN O
in IN O
populations NNS O
based VBN O
study NN O

Abstract NN O

We PRP O
have VBP O
identified VBN O
an DT O
alternative JJ O
pathway NN O
of IN O
tumorigenesis NN O
in IN O
sporadic JJ O
colon NN O
cancer NN O
, , O
involving VBG O
microsatellite NN O
instability NN O
due JJ O
to TO O
mismatched JJ O
repair NN O
methylation NN O
, , O
which WDT O
may MD O
be VB O
driven VBN O
by IN O
mutations NNS O
in IN O
the DT O
BRAF NN B-NP
gene NN O
( -LRB- O
V600E CD O
) -RRB- O
. . O

Colorectal JJ O
cancer NN O
( -LRB- O
CRC NNP O
) -RRB- O
is VBZ O
the DT O
most RBS O
common JJ O
cancer NN O
in IN O
the DT O
world NN O
, , O
and CC O
African NNP O
Americans NNPS O
show VBP O
a DT O
higher JJR O
incidence NN O
than IN O
other JJ O
populations NNS O
in IN O
the DT O
United NNP O
States NNP O
. . O

We PRP O
analyzed VBD O
sporadic JJ O
CRCs NNS O
in IN O
Omani NNP O
( -LRB- O
of IN O
African JJ O
origin NN O
, , O
N NNP O
= SYM O
61 CD O
) -RRB- O
, , O
Iranian JJ O
( -LRB- O
of IN O
Caucasian NNP O
origin NN O
, , O
N NNP O
= SYM O
53 CD O
) -RRB- O
and CC O
African JJ O
American NNP O
( -LRB- O
N NNP O
= SYM O
95 CD O
) -RRB- O
patients NNS O
for IN O
microsatellite JJ O
instability NN O
, , O
expression NN O
status NN O
of IN O
mismatched VBN O
repair NN O
genes NNS O
( -LRB- O
hMLH1 NNS B-NP
, , O
hMSH2 NN B-NP
) -RRB- O
and CC O
presence NN O
of IN O
the DT O
BRAF NNP B-NP
( -LRB- O
V600E NN O
) -RRB- O
mutation NN O
. . O

In IN O
the DT O
Omani NNP O
group NN O
, , O
all DT O
tumors NNS O
with IN O
BRAF NNP B-NP
mutations NNS O
were VBD O
located VBN O
in IN O
the DT O
left JJ O
side NN O
of IN O
the DT O
colon NN O
, , O
and CC O
for IN O
African JJ O
Americans NNPS O
, , O
88 CD O
% NN O
[7 IN O
] NN O
of IN O
tumors NNS O
with IN O
BRAF NNP B-NP
mutations NNS O
were VBD O
found VBN O
in IN O
the DT O
right JJ O
side NN O
of IN O
the DT O
colon NN O
. . O

In IN O
African JJ O
Americans NNPS O
, , O
31 CD O
% NN O
of IN O
tumors NNS O
displayed VBN O
microsatellite JJ O
instability NN O
at IN O
two CD O
or CC O
more JJR O
markers NNS O
( -LRB- O
MSI-H) NNP O
, , O
while IN O
this DT O
rate NN O
was VBD O
26 CD O
% NN O
and CC O
13 CD O
% NN O
for IN O
tumors NNS O
in IN O
the DT O
Iranian JJ O
and CC O
Omani JJ O
groups NNS O
, , O
respectively RB O
. . O

A DT O
majority NN O
of IN O
these DT O
MSI-H JJ O
tumors NNS O
were VBD O
located VBN O
in IN O
the DT O
proximal JJ O
colon NN O
( -LRB- O
right JJ O
side NN O
) -RRB- O
in IN O
African JJ O
American NNP O
and CC O
Iranian JJ O
subjects NNS O
, , O
whereas IN O
most RBS O
were VBD O
located VBN O
in IN O
the DT O
distal JJ O
colon NN O
( -LRB- O
left JJ O
side NN O
) -RRB- O
in IN O
Omani NNP O
subjects NNS O
. . O

Defects NNS O
in IN O
hMLH1 JJ B-NP
gene NN O
expression NN O
were VBD O
found VBN O
in IN O
77 CD O
% NN O
of IN O
MSI-H NNP O
tumors NNS O
in IN O
both DT O
African JJ O
Americans NNPS O
and CC O
Iranians NNPS O
and CC O
in IN O
38 CD O
% NN O
of IN O
tumors NNS O
in IN O
Omanis NNP O
. . O

BRAF NN B-NP
mutations NNS O
were VBD O
observed VBN O
in IN O
all DT O
subjects NNS O
: : O
10 CD O
% NN O
of IN O
tumors NNS O
in IN O
African JJ O
Americans NNPS O
( -LRB- O
8/8 NN O
2 CD O
) -RRB- O
, , O
2 CD O
% NN O
of IN O
tumors NNS O
in IN O
Iranians NNS O
( -LRB- O
1/53 CD O
) -RRB- O
, , O
and CC O
19 CD O
% NN O
of IN O
tumors NNS O
in IN O
Omanis NNP O
( -LRB- O
11/59 CD O
) -RRB- O
. . O

Our PRP$ O
findings NNS O
suggest VBP O
that IN O
CRC NNP O
occurs VBZ O
at IN O
a DT O
younger JJR O
age NN O
in IN O
Omani NNP O
and CC O
Iranian JJ O
patients NNS O
, , O
and CC O
these DT O
groups NNS O
showed VBD O
a DT O
lower JJR O
occurrence NN O
of IN O
MSI-H NNP O
than IN O
did VBD O
African JJ O
American NNP O
patients NNS O
. . O

Our PRP$ O
multivariate JJ O
model NN O
suggests VBZ O
an DT O
important JJ O
and CC O
significant JJ O
role NN O
of IN O
hMLH1 JJ B-NP
expression NN O
and CC O
BRAF NN B-NP
mutation NN O
in IN O
MSI-H NNP O
CRC NNP O
in IN O
these DT O
populations NNS O
. . O

The DT O
high JJ O
occurrence NN O
of IN O
MSI-H NNP O
tumors NNS O
in IN O
African NNP O
Americans NNPS O
may MD O
have VB O
significant JJ O
implications NNS O
for IN O
treatment NN O
, , O
since IN O
patients NNS O
with IN O
MSI-H NNP O
lesions NNS O
display VBP O
a DT O
different JJ O
response NN O
to TO O
chemotherapeutic JJ O
agents NNS O
such JJ O
as IN O
5-fluorouracil NN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

In IN O
the DT O
present JJ O
study NN O
, , O
we PRP O
analyzed VBD O
samples NNS O
from IN O
two CD O
different JJ O
populations NNS O
of IN O
African JJ O
descent NN O
( -LRB- O
African JJ O
American NNP O
and CC O
Omani NNP O
) -RRB- O
and CC O
a DT O
Caucasian JJ O
population NN O
( -LRB- O
Iranian JJ O
) -RRB- O
for IN O
microsatellite NN O
instability NN O
and CC O
BRAF NNP B-NP
mutations NNS O
. . O

We PRP O
correlated VBD O
our PRP$ O
findings NNS O
with IN O
the DT O
silencing NN O
of IN O
genes NNS O
involved VBN O
in IN O
DNA NNP O
MMR. . B-NP

We PRP O
evaluated VBD O
and CC O
compared VBD O
the DT O
demographic JJ O
and CC O
clinicopathological JJ O
data NNS O
in IN O
relation NN O
to TO O
molecular JJ O
alterations NNS O
in IN O
specific JJ O
genes NNS O
( -LRB- O
BRAF NN B-NP
, , O
DNA NN O
MMR NNP B-NP
) -RRB- O
to TO O
improve VB O
our PRP$ O
understanding NN O
of IN O
colon NN O
tumorgenesis NN O
in IN O
people NNS O
living VBG O
in IN O
different JJ O
environments NNS O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Methods NNS O

Patients NNS O

A DT O
total NN O
of IN O
95 CD O
African JJ O
American JJ O
CRC NNP O
patients NNS O
( -LRB- O
from IN O
Howard NNP O
University NNP O
and CC O
Johns NNP O
Hopkins NNP O
Hospital NNP O
between IN O
1997 CD O
and CC O
2004 CD O
; : O
self-identified VBN O
as IN O
African JJ O
American NNP O
) -RRB- O
, , O
61 CD O
Omani NNP O
CRC NNP O
patients NNS O
( -LRB- O
from IN O
the DT O
two CD O
tertiary JJ O
referral NN O
hospitals NNS O
in IN O
Oman NNP O
Sultan NNP O
Qaboos NNP O
University NNP O
Hospital NNP O
and CC O
the DT O
Royal NNP O
Hospital NNP O
between IN O
2000 CD O
and CC O
2004 CD O
who WP O
underwent VBD O
surgical JJ O
resection NN O
) -RRB- O
and CC O
53 CD O
Iranian JJ O
CRC NNP O
patients NNS O
( -LRB- O
from IN O
the DT O
two CD O
referral NN O
hospitals NNS O
in IN O
Shiraz NNP O
, , O
Iran NNP O
Namazi NNP O
Hospital NNP O
and CC O
Saadi NNP O
Hospital NNP O
) -RRB- O
were VBD O
included VBN O
in IN O
this DT O
study NN O
. . O

Formalin-fixed JJ O
, , O
paraffin-embedded JJ O
archival JJ O
tissue NN O
was VBD O
collected VBN O
( -LRB- O
with IN O
approval NN O
from IN O
all DT O
above IN O
sites NNS O
' POS O
Institutional NNP O
Review NNP O
Boards NNP O
) -RRB- O
and CC O
clinical JJ O
data NNS O
was VBD O
obtained VBN O
( -LRB- O
including VBG O
race NN O
, , O
age NN O
, , O
site NN O
of IN O
primary JJ O
tumor NN O
, , O
mucin JJ O
production NN O
and CC O
tumor NN O
differentiation NN O
) -RRB- O
. . O

In IN O
addition NN O
, , O
the DT O
family NN O
history NN O
of IN O
cancer NN O
was VBD O
analyzed VBN O
to TO O
identify VB O
those DT O
pedigrees NNS O
that WDT O
met VBD O
either CC O
the DT O
Amsterdam NN O
I PRP O
or CC O
Amsterdam NNP O
II NNP O
criteria NNS O
for IN O
HNPCC. NNP O

The DT O
study NN O
was VBD O
performed VBN O
on IN O
unselected JJ O
and CC O
serially RB O
collected VBD O
specimens NNS O
. . O

All DT O
cases NNS O
underwent IN O
surgery NN O
within IN O
the DT O
given VBN O
collection NN O
. . O

DNA NNP O
isolation NN O
and CC O
MSI NNP O
analysis NN O

Archived NNP O
and CC O
fresh JJ O
tumor NN O
blocks NNS O
were VBD O
cut VBN O
into IN O
5-μm JJ O
sections NNS O
on IN O
Superfrost NNP O
slides NNS O
( -LRB- O
Fisher NNP O
Scientific NNP O
, , O
Pittsburgh NNP O
, , O
PA NNP O
) -RRB- O
. . O

The DT O
tumor NN O
and CC O
normal JJ O
area NN O
were VBD O
diagnosed VBN O
by IN O
a DT O
pathologist NN O
using VBG O
the DT O
H&E NNP O
matched VBD O
slide NN O
and CC O
microdissected JJ O
to TO O
pinpoint VB O
the DT O
tumor NN O
areas NNS O
as RB O
well RB O
as IN O
normal JJ O
areas NNS O
from IN O
at IN O
least JJS O
two CD O
slides NNS O
. . O

A DT O
pinpoint NN O
DNA NN O
extraction NN O
kit NN O
was VBD O
used VBN O
as IN O
recommended VBN O
by IN O
the DT O
manufacturers NNS O
( -LRB- O
Zymo NN O
Research NN O
) -RRB- O
. . O

The DT O
extracted VBD O
tumor NN O
and CC O
normal JJ O
matched VBN O
DNA NN O
were VBD O
used VBN O
as IN O
template JJ O
in IN O
PCR NNP O
reactions NNS O
where WRB O
five CD O
microsatellite JJ O
markers NNS O
( -LRB- O
Cancer NNP O
Research NNP O
58:5248–5257 CD O
, , O
1998 CD O
;[21] CD O
; : O
BAT25 CD O
, , O
BAT26 NNP O
, , O
D17S250 CD O
, , O
D5S346 CD O
and CC O
D2S123 CD O
) -RRB- O
were VBD O
used VBN O
to TO O
evaluate VB O
MSI JJ O
status NN O
. . O

PCR NN O
products NNS O
were VBD O
analyzed VBN O
in IN O
a DT O
3130 CD O
ABI NNP O
GeneScan NNP O
. . O

Those DT O
displaying VBG O
DNA NNP O
instability NN O
at IN O
only RB O
one CD O
of IN O
the DT O
markers NNS O
( -LRB- O
including VBG O
the DT O
dinucleotides NNS O
) -RRB- O
were VBD O
labeled VBN O
MSI-L NNP O
, , O
those DT O
displaying VBG O
instability NN O
with IN O
two CD O
or CC O
more JJR O
markers NNS O
were VBD O
labeled VBN O
MSI-H, JJ O
and CC O
those DT O
displaying VBG O
no DT O
instability NN O
with IN O
any DT O
of IN O
the DT O
five CD O
markers NNS O
tested VBN O
were VBD O
labeled VBN O
MSS. . O

Due JJ O
to TO O
unclear JJ O
characteristics NNS O
of IN O
MSI-L NNP O
, , O
we PRP O
combined VBD O
MSS NNP O
and CC O
MSI-L NNP O
as IN O
one CD O
group NN O
( -LRB- O
non-MSI-H) JJ O
. . O

Methylation-specific NNP O
PCR NN O

The DT O
presence NN O
or CC O
absence NN O
of IN O
hMLH1 NNS B-NP
and CC O
p16 VB B-NP
methylation NN O
in IN O
cancers NNS O
was VBD O
determined VBN O
by IN O
comparing VBG O
the DT O
signals NNS O
from IN O
tumor-derived JJ O
tissues NNS O
with IN O
those DT O
from IN O
normal JJ O
, , O
non-cancerous JJ O
tissues NNS O
, , O
as IN O
previously RB O
described VBN O
[3,4] JJ O
. . O

DNA NN O
was VBD O
extracted VBN O
from IN O
the DT O
samples NNS O
using VBG O
a DT O
Gentra NNP O
DNA NNP O
extraction NN O
kit NN O
( -LRB- O
Gentra NNP O
) -RRB- O
and CC O
was VBD O
modified VBN O
using VBG O
DNA NNP O
modification NN O
kits VBD O
as IN O
recommended VBN O
by IN O
the DT O
manufacturers NNS O
( -LRB- O
Zymo NN O
Research NN O
) -RRB- O
. . O

MSP NNP O
was VBD O
used VBN O
to TO O
distinguish VB O
unmethylated JJ O
from IN O
methylated VBN O
alleles NNS O
, , O
based VBN O
on IN O
sequence NN O
alterations NNS O
produced VBN O
by IN O
bisulfite JJ O
treatment NN O
of IN O
DNA NNP O
, , O
to TO O
convert VB O
unmethylated JJ O
cytosines NNS O
to TO O
uracil VB O
. . O

These DT O
changes NNS O
are VBP O
identified VBN O
by IN O
subsequent JJ O
PCR NN O
using VBG O
primers NNS O
specific JJ O
to TO O
the DT O
methylated JJ O
(unchanged JJ O
) -RRB- O
or CC O
unmethylated JJ O
( -LRB- O
changed JJ O
) -RRB- O
DNA NN O
. . O

Briefly RB O
, , O
1 CD O
μg NN O
of IN O
genomic JJ O
DNA NNP O
was VBD O
denatured VBN O
by IN O
treatment NN O
with IN O
NaOH NNP O
and CC O
was VBD O
modified VBN O
by IN O
the DT O
addition NN O
of IN O
sodium NN O
bisulfite NN O
. . O

DNA NN O
samples NNS O
were VBD O
purified VBN O
using VBG O
Wizard NNP O
DNA NNP O
purification NN O
resin NN O
according VBG O
to TO O
the DT O
manufacturer NN O
's POS O
instructions NNS O
( -LRB- O
Promega NNP O
) -RRB- O
. . O

These DT O
DNA NNP O
samples NNS O
were VBD O
again RB O
treated VBN O
with IN O
NaOH NNP O
, , O
then RB O
precipitated VBD O
with IN O
ethanol NN O
and CC O
resuspended VBD O
in IN O
water NN O
. . O

PCR JJ O
reactions NNS O
were VBD O
performed VBN O
using VBG O
the DT O
primer JJ O
pairs NNS O
described VBD O
below IN O
in IN O
the DT O
following JJ O
reaction NN O
mix NN O
: : O
10× CD O
PCR NN O
buffer NN O
[16.6 IN O
mM NNS O
ammonium NN O
sulfate NN O
, , O
67 CD O
mM JJ O
Tris NNP O
( -LRB- O
pH NN O
8.8 CD O
) -RRB- O
, , O
6.7 CD O
mM NNS O
MgCl2 NNP O
, , O
and CC O
10 CD O
mM NNS O
2-mercaptoethanol] JJ O
, , O
dNTPs NNS O
( -LRB- O
each DT O
at IN O
1.25 CD O
mM) NN O
, , O
primers NNS O
( -LRB- O
50 CD O
pmol NN O
each DT O
per IN O
reaction NN O
) -RRB- O
, , O
and CC O
bisulfite-modified JJ O
DNA NN O
( -LRB- O
50 CD O
ng NN O
) -RRB- O
in IN O
a DT O
final JJ O
volume NN O
of IN O
50 CD O
μl NN O
. . O

Reactions NNS O
were VBD O
hot-started JJ O
at IN O
95°C NNP O
for IN O
5 CD O
min NN O
, , O
after IN O
which WDT O
1.25 CD O
units NNS O
of IN O
Taq NNP O
polymerase NN O
( -LRB- O
Life NNP O
Technologies NNP O
, , O
Inc. NNP O
) -RRB- O
were VBD O
added VBN O
. . O

Amplification NNP O
was VBD O
carried VBN O
out RP O
in IN O
an DT O
Applied NNP O
Biosystem NNP O
temperature NN O
cycler NN O
for IN O
40 CD O
cycles NNS O
( -LRB- O
30 CD O
sec NN O
at IN O
95°C NNP O
, , O
30 CD O
sec NN O
at IN O
59°C CD O
then RB O
30 CD O
sec NN O
at IN O
72°C JJ O
) -RRB- O
, , O
followed VBN O
by IN O
a DT O
final JJ O
4-min JJ O
extension NN O
at IN O
72°C. VBG O

Two CD O
sets NNS O
of IN O
primers NNS O
were VBD O
used VBN O
simultaneously RB O
to TO O
check VB O
for IN O
methylated JJ O
or CC O
unmethylated JJ O
CpG NN O
islands NNS O
at IN O
the DT O
level NN O
of IN O
hMLH1 JJ B-NP
and CC O
p16 JJ B-NP
promoters NNS O
. . O

The DT O
primer NN O
sequences NNS O
were VBD O
as RB O
in IN O
our PRP$ O
previous JJ O
study NN O
[4] NN O
. . O

Controls NNS O
for IN O
methylated JJ O
and CC O
unmethylated JJ O
DNA NN O
were VBD O
DNA NNP O
from IN O
the DT O
SW48 NNS O
colon NN O
cancer NN O
cell NN O
line NN O
and CC O
normal JJ O
lymphocytes NNS O
, , O
respectively RB O
. . O

Each DT O
PCR NN O
reaction NN O
product NN O
( -LRB- O
10 CD O
μl NN O
) -RRB- O
was VBD O
directly RB O
loaded VBN O
into IN O
a DT O
2 CD O
% NN O
agarose IN O
gel NNP O
, , O
which WDT O
was VBD O
later RB O
stained VBN O
with IN O
ethidium NN O
bromide NN O
to TO O
allow VB O
DNA NNP O
visualization NN O
under IN O
UV NN O
illumination NN O
. . O

The DT O
presence NN O
of IN O
a DT O
band NN O
in IN O
unmethylated JJ O
tumor NN O
and CC O
matched VBD O
normal JJ O
with IN O
the DT O
absence NN O
of IN O
a DT O
methylation NN O
band NN O
in IN O
the DT O
tumor NN O
was VBD O
defined VBN O
as IN O
unmethylated JJ O
. . O

However RB O
, , O
when WRB O
a DT O
methylated JJ O
band NN O
was VBD O
present JJ O
for IN O
tumor NN O
and CC O
absent JJ O
for IN O
the DT O
normal JJ O
, , O
we PRP O
defined VBD O
the DT O
sample NN O
as IN O
methylated VBN O
( -LRB- O
or CC O
semi-methylated JJ O
if IN O
both DT O
unmethylated JJ O
or CC O
methylated VBN O
bands NNS O
were VBD O
present JJ O
in IN O
the DT O
tumor NN O
) -RRB- O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Multivariate VB O
analysis NN O
for IN O
the DT O
risk NN O
factors NNS O
associated VBN O
with IN O
MSI-H NNP O
occurrence NN O
( -LRB- O
Model NNP O
including VBG O
single JJ O
term NN O
and CC O
interactions NNS O
effect NN O
) -RRB- O

* NN O
indicates VBZ O
the DT O
interaction NN O
term NN O
between IN O
two CD O
variables NNS O
. . O

Correlation NN O
between IN O
hMLH1 JJ B-NP
protein NN O
expression NN O
and CC O
MSI JJ O
status NN O

Expression NN O
of IN O
the DT O
hMLH1 JJ B-NP
and CC O
hMSH2 JJ B-NP
nuclear JJ O
proteins NNS O
was VBD O
examined VBN O
immunohistochemically RB O
in IN O
paraffin-embedded JJ O
tissue NN O
sections NNS O
[4] VBD O
. . O

In IN O
all DT O
cases NNS O
, , O
non-neoplastic JJ O
cells NNS O
displayed VBN O
positive JJ O
nuclear JJ O
staining NN O
for IN O
both DT O
hMLH1 NNS B-NP
and CC O
hMSH2 NN B-NP
. . O

The DT O
nuclear JJ O
stained JJ O
slides NNS O
were VBD O
read VBN O
by IN O
two CD O
different JJ O
pathologists NNS O
, , O
and CC O
normal JJ O
tissue NN O
on IN O
slides NNS O
where WRB O
no DT O
primary JJ O
antibody NN O
stained VBD O
was VBD O
used VBN O
as IN O
negative JJ O
control NN O
. . O

In IN O
total JJ O
, , O
76 CD O
African JJ O
American NNP O
, , O
61 CD O
Omani NNP O
, , O
and CC O
25 CD O
Iranian JJ O
cases NNS O
were VBD O
analyzed VBN O
. . O

Thirty-five CD O
and CC O
11 CD O
% NN O
of IN O
African JJ O
American NNP O
tumors NNS O
assayed VBD O
showed VBN O
loss NN O
of IN O
staining VBG O
for IN O
hMLH1 NN B-NP
and CC O
hMSH2 NN B-NP
, , O
respectively RB O
. . O

Moreover RB O
, , O
loss NN O
of IN O
hMLH1 JJ B-NP
and CC O
hMSH2 JJ B-NP
staining NN O
was VBD O
observed VBN O
in IN O
77 CD O
% NN O
and CC O
5 CD O
% NN O
of IN O
MSI-H JJ O
African JJ O
American JJ O
tumors NNS O
, , O
respectively RB O
( -LRB- O
Table NN O
1 CD O
) -RRB- O
. . O

The DT O
loss NN O
of IN O
hMLH1 JJ B-NP
and CC O
hMSH2 JJ B-NP
staining NN O
was VBD O
observed VBN O
in IN O
17 CD O
% NN O
and CC O
13 CD O
% NN O
of IN O
non-MSI-H JJ O
African JJ O
American JJ O
tumors NNS O
, , O
respectively RB O
( -LRB- O
Table NN O
1 CD O
) -RRB- O
. . O

In IN O
Omani NNP O
tumors NNS O
: : O
38 CD O
% NN O
( -LRB- O
n NN O
= SYM O
3 CD O
) -RRB- O
of IN O
the DT O
MSI-H NNP O
tumors NNS O
showed VBD O
absences NNS O
of IN O
hMLH1 JJ B-NP
expression NN O
( -LRB- O
Table NN O
2 CD O
) -RRB- O
; : O
30 CD O
% NN O
( -LRB- O
n NN O
= SYM O
16 CD O
) -RRB- O
of IN O
the DT O
non-MSI-H JJ O
tumors NNS O
had VBD O
negative JJ O
hMLH1 NNS B-NP
. . O

Fifty-six CD O
cases NNS O
of IN O
Omani NNP O
patient NN O
tested VBN O
for IN O
the DT O
presence NN O
of IN O
hMSH2 JJ B-NP
protein NN O
by IN O
immunohistochemical JJ O
staining NN O
, , O
seven CD O
Omani JJ O
cases NNS O
were VBD O
MSI-H. . O

In IN O
Iranian JJ O
patients NNS O
, , O
77 CD O
% NN O
[10] NN O
of IN O
the DT O
MSI-H NNP O
tumors NNS O
were VBD O
negative JJ O
for IN O
hMLH1 JJ B-NP
expression NN O
( -LRB- O
Table NN O
3 CD O
) -RRB- O
; : O
all DT O
of IN O
non-MSI-H JJ O
tumors NNS O
were VBD O
positive JJ O
for IN O
hMLH1 JJ B-NP
expression NN O
, , O
while IN O
for IN O
hMSH2 VBG B-NP
these DT O
figures NNS O
were VBD O
8 CD O
% NN O
[1 CD O
] NNS O
and CC O
0, JJ O
respectively RB O
. . O

In IN O
multivariate JJ O
analysis NN O
, , O
including VBG O
the DT O
interaction NN O
terms NNS O
, , O
the DT O
hMLH1 JJ B-NP
expression NN O
has VBZ O
a DT O
significant JJ O
preventive JJ O
effect NN O
on IN O
MSI-H NNP O
occurrence NN O
( -LRB- O
OR JJ O
= SYM O
0.13(0.04–0.41 CD O
) -RRB- O
; : O

p NN O
< NN O
0.0001 CD O
; : O
( -LRB- O
Table NN O
4) JJ O
) -RRB- O
. . O

Correlation NN O
between IN O
BRAF NNP B-NP
mutation NN O
and CC O
MSI NN O
status NN O

Samples NNS O
were VBD O
analyzed VBN O
for IN O
the DT O
presence NN O
of IN O
a DT O
point NN O
mutation NN O
that IN O
frequently RB O
occurs VBZ O
in IN O
the DT O
oncogene NN O
BRAF NN B-NP
leading VBG O
to TO O
the DT O
change NN O
of IN O
valine NN O
to TO O
glutamic JJ O
acid NN O
at IN O
position NN O
600 CD O
of IN O
the DT O
BRAF NNP B-NP
protein NN O
. . O

In IN O
all DT O
samples NNS O
only RB O
10 CD O
% NN O
[8 IN O
] JJ O
African JJ O
American NNP O
, , O
19 CD O
% NN O
[11] IN O
Omani NNP O
and CC O
2 CD O
% NN O
[1 NN O
] JJ O
Iranian JJ O
samples NNS O
displayed VBD O
the DT O
mutation NN O
by IN O
sequencing NN O
( -LRB- O
Table NN O
1 CD O
, , O
2 CD O
, , O
3 CD O
) -RRB- O
. . O

In IN O
the DT O
MSI-H NNP O
group NN O
, , O
the DT O
BRAF NNP B-NP
mutation NN O
was VBD O
32 CD O
% NN O
[7 IN O
] NNP O
in IN O
African NNP O
Americans NNPS O
, , O
25 CD O
% NN O
[2 CD O
] SYM O
in IN O
Omani NNP O
, , O
and CC O
7 CD O
% NN O
[1 CD O
] NN O
in IN O
Iranian JJ O
, , O
respectively RB O
. . O

Eighteen CD O
percent NN O
and CC O
2 CD O
% NN O
of IN O
non-MSI-H JJ O
tumors NNS O
carry VBP O
the DT O
BRAF NN B-NP
mutation NN O
in IN O
African NNP O
Americans NNPS O
and CC O
Omanis NNP O
, , O
respectively RB O
, , O
while IN O
none NN O
of IN O
the DT O
Iranians NNPS O
carried VBD O
a DT O
BRAF NN B-NP
mutation NN O
in IN O
this DT O
group NN O
. . O

A DT O
BRAF NNP B-NP
mutation NN O
is VBZ O
a DT O
significant JJ O
risk NN O
factor NN O
for IN O
MSI-H NNP O
occurrence NN O
even RB O
after IN O
controlling VBG O
for IN O
other JJ O
factors NNS O
in IN O
the DT O
multivariate JJ O
model NN O
( -LRB- O
OR JJ O
= SYM O
12.11( JJ O
2.82–52.03 CD O
) -RRB- O
; : O

p NN O
= SYM O
0.001 CD O
; : O
( -LRB- O
Table NN O
4) JJ O
) -RRB- O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Discussion NN O

DNA NNP O
MMR NNP B-NP
gene NN O
silencing NN O
and/or CC O
mutation NN O
are VBP O
the DT O
main JJ O
factors NNS O
leading VBG O
to TO O
accumulation NN O
of IN O
mutations NNS O
within IN O
genes NNS O
and CC O
general JJ O
genome NN O
instability NN O
[19] NN O
. . O

The DT O
MSI NNP O
phenotype NN O
resulting VBG O
from IN O
such JJ O
alterations NNS O
is VBZ O
one CD O
of IN O
the DT O
early JJ O
events NNS O
leading VBG O
to TO O
the DT O
development NN O
of IN O
certain JJ O
cancers NNS O
. . O

It PRP O
occurs VBZ O
in IN O
patients NNS O
with IN O
Lynch NNP O
syndrome NN O
and CC O
in IN O
those DT O
that IN O
acquire VB O
such JJ O
alterations NNS O
somatically RB O
[24] VBD O
. . O

Another DT O
event NN O
occurring VBG O
in IN O
adenoma NN O
polyp NN O
is VBZ O
mutation NN O
in IN O
oncogenes NNS O
, , O
specifically RB O
in IN O
K-ras NNP B-NP
and CC O
BRAF NNP B-NP
genes NNS O
in IN O
the DT O
case NN O
of IN O
colon NN O
cancer NN O
[24-26] JJ O
. . O

The DT O
linkage NN O
between IN O
BRAF NNP B-NP
mutations NNS O
and CC O
MSI NNP O
was VBD O
previously RB O
reported VBN O
[27-30] JJ O
. . O

In IN O
general JJ O
, , O
Omani NNP O
people NNS O
have VBP O
a DT O
mixed JJ O
Asian JJ O
and CC O
African JJ O
ethnic JJ O
background NN O
[10] NN O
and CC O
Iranians NNPS O
are VBP O
of IN O
Caucasian NNP O
ethnicity NN O
. . O

Here RB O
we PRP O
demonstrate VBP O
that IN O
in IN O
African NNP O
Americans NNPS O
, , O
Omanis NNP O
and CC O
Iranians NNPS O
, , O
the DT O
MSI NNP O
phenotype NN O
occurs VBZ O
in IN O
31 CD O
% NN O
, , O
26 CD O
% NN O
and CC O
13 CD O
% NN O
of IN O
CRC NNP O
tumors NNS O
, , O
respectively RB O
. . O

In IN O
addition NN O
, , O
the DT O
locations NNS O
of IN O
the DT O
tumors NNS O
in IN O
African JJ O
Americans NNPS O
and CC O
Iranians NNPS O
were VBD O
primarily RB O
proximal JJ O
compared VBN O
to TO O
distal JJ O
for IN O
Omanis NNP O
; : O
and CC O
BRAF NNP B-NP
mutations NNS O
were VBD O
more RBR O
prevalent JJ O
in IN O
Omanis NNP O
than IN O
African NNP O
Americans NNPS O
or CC O
Iranians NNPS O
( -LRB- O
19 CD O
% NN O
, , O
10 CD O
% NN O
and CC O
2 CD O
% NN O
, , O
respectively RB O
) -RRB- O
. . O

While IN O
the DT O
MSI NNP O
phenotype NN O
in IN O
this DT O
sample NN O
of IN O
African JJ O
Americans NNPS O
is VBZ O
less JJR O
than IN O
we PRP O
previously RB O
reported VBD O
( -LRB- O
43–45 CD O
% NN O
) -RRB- O
, , O
[3,4] IN O
it PRP O
appears VBZ O
to TO O
be VB O
more JJR O
prevalent JJ O
in IN O
African NNP O
Americans NNPS O
than IN O
in IN O
others NNS O
and CC O
still RB O
high JJ O
in IN O
the DT O
general JJ O
US NNP O
population NN O
[31-33] NN O
. . O

The DT O
current JJ O
sample NN O
contained VBN O
more RBR O
African JJ O
Americans NNS O
and CC O
more JJR O
right-sided JJ O
than IN O
left-sided JJ O
tumors NNS O
. . O

The DT O
MSI NNP O
phenotype NN O
was VBD O
more RBR O
common JJ O
in IN O
proximal JJ O
tumors NNS O
than IN O
in IN O
distal JJ O
ones NNS O
( -LRB- O
p NN O
= SYM O
0.47 CD O
) -RRB- O
, , O
strengthening VBG O
earlier RB O
findings NNS O
of IN O
such JJ O
an DT O
association NN O
[31-33] NN O
. . O

The DT O
prevalence NN O
of IN O
MSI-H NNP O
tumors NNS O
indicates VBZ O
the DT O
importance NN O
of IN O
BRAF NNP B-NP
mutations NNS O
, , O
particularly RB O
in IN O
the DT O
African JJ O
Americans NNPS O
, , O
since IN O
they PRP O
represent VBP O
a DT O
higher JJR O
mutation NN O
profile NN O
than IN O
Iranians NNPS O
and CC O
Omanis NNP O
. . O

This DT O
finding NN O
suggests VBZ O
that IN O
, , O
at IN O
least JJS O
within IN O
the DT O
MSI-H NNP O
group NN O
of IN O
patients NNS O
, , O
the DT O
BRAF NNP B-NP
V600E NNP O
mutation NN O
in IN O
exon NN O
15 CD O
is VBZ O
the DT O
major JJ O
event NN O
leading VBG O
to TO O
tumor NN O
development NN O
. . O

In IN O
addition NN O
, , O
the DT O
distal JJ O
location NN O
of IN O
Omani NNP O
MSI-H NNP O
tumors NNS O
may MD O
also RB O
play VB O
an DT O
important JJ O
role NN O
in IN O
the DT O
presentation NN O
of IN O
the DT O
disease NN O
compared VBN O
to TO O
proximal JJ O
ones NNS O
in IN O
the DT O
African JJ O
American NNP O
and CC O
Iranian JJ O
populations NNS O
. . O

The DT O
lower JJR O
frequency NN O
of IN O
MSI-H NNP O
tumors NNS O
observed VBD O
in IN O
Omani NNP O
patients NNS O
could MD O
be VB O
related VBN O
to TO O
the DT O
higher JJR O
frequency NN O
of IN O
the DT O
distal JJ O
location NN O
. . O

This DT O
needs VBZ O
to TO O
be VB O
verified VBN O
in IN O
a DT O
larger JJR O
sample NN O
size NN O
. . O

The DT O
absence NN O
of IN O
hMLH1 JJ B-NP
expression NN O
was VBD O
more RBR O
pronounced VBN O
in IN O
MSI-H NNP O
tumors NNS O
from IN O
African JJ O
American NNP O
and CC O
Iranian JJ O
patients NNS O
( -LRB- O
77 CD O
% NN O
of IN O
tumors NNS O
in IN O
these DT O
groups NNS O
showed VBD O
no DT O
hMLH1 JJ B-NP
expression NN O
) -RRB- O
. . O

However RB O
, , O
for IN O
Omanis NNP O
, , O
the DT O
moderate JJ O
hMLH1expression NN B-NP
( -LRB- O
62 CD O
% NN O
) -RRB- O
in IN O
MSI-H NNP O
may MD O
indicate VB O
some DT O
other JJ O
defects NNS O
in IN O
the DT O
component NN O
of IN O
base NN O
excision NN O
repair NN O
( -LRB- O
Oxidative JJ O
DNA NN O
damaged VBN O
markers NNS O
such JJ O
as IN O
8-hydroxyguanosine JJ O
) -RRB- O
, , O
or CC O
distinct JJ O
lymphangiogenic JJ O
phenotype NN O
associated VBN O
with IN O
MSI NNP O
other JJ O
than IN O
in IN O
mismatch NN O
repair NN O
genes NNS O
. . O

The DT O
tumors NNS O
that IN O
we PRP O
have VBP O
studied VBN O
included VBN O
MSI-H NNP O
tumors NNS O
that WDT O
were VBD O
negative JJ O
using VBG O
immunohistochemistry NN O
for IN O
hMLH1 NN B-NP
. . O

This DT O
incidence NN O
is VBZ O
less JJR O
than IN O
compared VBN O
to TO O
that DT O
described VBN O
in IN O
the DT O
literature NN O
( -LRB- O
77 CD O
% NN O
[34] NN O
) -RRB- O
, , O
although IN O
the DT O
numbers NNS O
described VBN O
are VBP O
small JJ O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Survival NNP O
of IN O
hereditary PRP$ O
non-polyposis NN O
colorectal JJ O
cancer NN O
patients NNS O
compared VBN O
with IN O
sporadic JJ O
colorectal JJ O
cancer NN O
patients NNS O

Abstract NN O

Background CC O

Patients NNS O
with IN O
hereditary JJ O
non-poliposys NNS O
colorectal NN O
cancer NN O
( -LRB- O
HNPCC NNP O
) -RRB- O
have VBP O
better JJR O
prognosis NN O
than IN O
sporadic JJ O
colorectal NN O
cancer NN O
( -LRB- O
CRC NNP O
) -RRB- O
. . O

Aim VB O
of IN O
our PRP$ O
retrospective JJ O
study NN O
was VBD O
to TO O
compare VB O
the DT O
overall JJ O
survival NN O
between IN O
sporadic JJ O
CRC NNP O
and CC O
HNPCC NNP O
patients NNS O
. . O

Methods NNS O

We PRP O
analyzed VBD O
a DT O
cohort NN O
of IN O
40 CD O
( -LRB- O
25 CD O
males NNS O
and CC O
15 CD O
females NNS O
) -RRB- O
HNPCC NNP O
cases NNS O
with IN O
a DT O
hospital NN O
consecutive JJ O
series NN O
of IN O
573 CD O
( -LRB- O
312 CD O
males NNS O
and CC O
261 CD O
females NNS O
) -RRB- O
sporadic JJ O
CRC NNP O
observed VBD O
during IN O
the DT O
period NN O
1970–1993 CD O
. . O

In IN O
15 CD O
HNPCC JJ O
patients NNS O
we PRP O
performed VBD O
mutational JJ O
analysis NN O
for IN O
microsatellite JJ O
instability NN O
. . O

Survival JJ O
rates NNS O
were VBD O
calculated VBN O
by IN O
Kaplan-Meier NNP O
method NN O
and CC O
compared VBN O
with IN O
log NN O
rank NN O
test NN O
. . O

Results NNS O

The DT O
median JJ O
age NN O
at IN O
diagnosis NN O
of IN O
the DT O
primary JJ O
CRC NNP O
was VBD O
46.8 CD O
years NNS O
in IN O
the DT O
HNPCC NNP O
series NN O
versus IN O
61 CD O
years NNS O
in IN O
sporadic JJ O
CRC NNP O
group NN O
. . O

In IN O
HNPCC NNP O
group NN O
85 CD O
% NN O
had VBD O
a DT O
right NN O
cancer NN O
location NN O
, , O
vs. IN O
57 CD O
% NN O
in IN O
the DT O
sporadic JJ O
cancer NN O
group NN O
. . O

In IN O
the DT O
sporadic JJ O
cancer NN O
group NN O
61.6 CD O
% NN O
were VBD O
early-stages JJ O
cancer NN O
( -LRB- O
Dukes NNP O
' POS O
A NNP O
and CC O
B) NNP O
vs. IN O
70 CD O
% NN O
in IN O
the DT O
HNPCC NNP O
group NN O
( -LRB- O
p NN O
= SYM O
ns NNS O
) -RRB- O
. . O

The DT O
crude JJ O
5-years JJ O
cumulative JJ O
survival NN O
after IN O
the DT O
primary JJ O
CRC NNP O
was VBD O
94.2 CD O
% NN O
in IN O
HNPCC NNP O
patients NNS O
vs. IN O
75.3 CD O
% NN O
in IN O
sporadic JJ O
cancer NN O
patients NNS O
( -LRB- O
p NN O
< JJ O
0.0001 CD O
) -RRB- O
. . O

Conclusion NN O

Our PRP$ O
results NNS O
show VBP O
that IN O
overall JJ O
survival NN O
of IN O
colorectal JJ O
cancer NN O
in IN O
patients NNS O
with IN O
HNPCC NNP O
is VBZ O
better JJR O
than IN O
sporadic JJ O
CRC NNP O
patients NNS O
. . O

The DT O
different JJ O
outcome NN O
probably RB O
relates VBZ O
to TO O
the DT O
specific JJ O
tumorigenesis NN O
involving VBG O
DNA NNP O
mismatch NN O
repair NN O
dysfunction NN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Background CC O

Colorectal NNP O
cancer NN O
is VBZ O
one CD O
of IN O
the DT O
most RBS O
common JJ O
neoplasm NN O
in IN O
humans NNS O
[1,2] JJ O
. . O

It PRP O
's VBZ O
known VBN O
that IN O
a DT O
definite JJ O
fraction NN O
, , O
ranging VBG O
between IN O
1 CD O
and CC O
5 CD O
% NN O
of IN O
all DT O
cases NNS O
of IN O
colorectal NN O
tumors NNS O
, , O
is VBZ O
transmitted VBN O
from IN O
one CD O
generation NN O
to TO O
another DT O
in IN O
accordance NN O
with IN O
an DT O
autosomal JJ O
dominant JJ O
model NN O
; : O
this DT O
is VBZ O
the DT O
case NN O
of IN O
Hereditary NNP O
Non-Polyposis NNP O
Colorectal NNP O
Cancer NNP O
( -LRB- O
HNPCC NN O
) -RRB- O
and CC O
of IN O
Familial NNP O
Adenomatous NNP O
Polyposis NNP O
( -LRB- O
FAP NNP O
) -RRB- O
[2] VBP O
. . O

HNPCC NNP O
is VBZ O
an DT O
autosomal JJ O
dominant JJ O
disease NN O
characterized VBN O
by IN O
early JJ O
appearance NN O
of IN O
cancer NN O
usually RB O
of IN O
the DT O
right JJ O
colon NN O
, , O
frequent JJ O
occurrence NN O
of IN O
multiple JJ O
lesions NNS O
( -LRB- O
both DT O
synchronous JJ O
and CC O
metachronous JJ O
) -RRB- O
and CC O
a DT O
striking JJ O
association NN O
with IN O
tumours NNS O
of IN O
other JJ O
organs NNS O
, , O
in IN O
particular JJ O
endometrium NN O
, , O
urinary JJ O
tract NN O
, , O
ovary JJ O
, , O
stomach NN O
and CC O
small JJ O
bowel NN O
. . O

The DT O
Amsterdam NNP O
criteria NNS O
, , O
currently RB O
used VBN O
for IN O
the DT O
diagnosis NN O
of IN O
HNPCC NNP O
, , O
were VBD O
introduced VBN O
in IN O
1989 CD O
to TO O
provide VB O
a DT O
uniform JJ O
evaluation NN O
of IN O
familial NN O
and CC O
personal JJ O
history NN O
. . O

They PRP O
were VBD O
revised VBN O
in IN O
1999 CD O
and CC O
included VBD O
various JJ O
extra-colonic JJ O
tumours NNS O
: : O
1 CD O
) -RRB- O
at IN O
least JJS O
three CD O
or CC O
more JJR O
relatives NNS O
with IN O
histological JJ O
verified JJ O
tumour NN O
in IN O
the DT O
spectrum NN O
of IN O
HNPCC NNP O
, , O
one CD O
of IN O
whom WP O
is VBZ O
a DT O
first-degree JJ O
relative JJ O
of IN O
the DT O
other JJ O
two CD O
; : O
2 CD O
) -RRB- O
at IN O
least JJS O
two CD O
generations NNS O
should MD O
be VB O
affected VBN O
; : O
3 CD O
) -RRB- O
one CD O
or CC O
more JJR O
tumours NNS O
diagnosed VBD O
when WRB O
under IN O
the DT O
age NN O
of IN O
50 CD O
years NNS O
; : O
4 CD O
) -RRB- O
FAP NNP O
should MD O
be VB O
excluded VBN O
[3,4] JJ O
. . O

Colorectal JJ O
tumours NNS O
with IN O
microsatellite NN O
instability NN O
( -LRB- O
MS NNP O
I PRP O
phenotype VBP O
) -RRB- O
have VBP O
mutations NNS O
in IN O
mismatch NN B-NP
repair NN I-NP
( -LRB- O
MMR NNP B-NP
) -RRB- O
genes NNS O
and CC O
in IN O
particular JJ O
in IN O
the DT O
MSH2 NNP B-NP
and CC O
MLH1 NNP B-NP
genes NNS O
, , O
respectively RB O
found VBD O
on IN O
chromosome NN O
arms NNS O
2p JJ O
and CC O
3p JJ O
[5-9] JJ O
. . O

These DT O
mutations NNS O
lead VBP O
to TO O
inactivation NN O
of IN O
the DT O
genes NNS O
and CC O
thus RB O
to TO O
a DT O
defect NN O
in IN O
replication/repair NN O
of IN O
DNA NNP O
and CC O
an DT O
accumulation NN O
in IN O
the DT O
cancer NN O
cell NN O
genome NN O
of IN O
ubiquitous JJ O
somatic JJ O
clonal JJ O
mutations NNS O
[10] VBP O
. . O

Constitutional NNP O
mutations NNS O
of IN O
MMR NNP B-NP
genes NNS O
are VBP O
found VBN O
in IN O
50–70 CD O
% NN O
of IN O
hereditary JJ O
non-polyposis NN O
colorectal NN O
cancer NN O
( -LRB- O
HNPCC NNP O
) -RRB- O
and CC O
in IN O
the DT O
Muir-Torre JJ O
syndrome NN O
; : O
90 CD O
% NN O
of IN O
them PRP O
MLH1 . B-NP
and CC O
MSH2 JJ B-NP
positive JJ O
[11,12] NN O
. . O

A DT O
certain JJ O
proportion NN O
(around IN O
12–15 CD O
% NN O
) -RRB- O
of IN O
sporadic JJ O
colon NN O
cancers NNS O
also RB O
display VBP O
MSI NNP O
phenotype NN O
[13-17] NN O
. . O

Otherwise RB O
, , O
MSI NNP O
seems VBZ O
to TO O
be VB O
important JJ O
in IN O
the DT O
development NN O
of IN O
various JJ O
human JJ O
cancer NN O
such JJ O
as IN O
sporadic JJ O
endometrial NN O
cancer NN O
[18] VBP O
and CC O
oral JJ O
squamous JJ O
cell NN O
carcinoma NN O
[19] NN O
. . O

Colorectal JJ O
cancer NN O
( -LRB- O
CRC NNP O
) -RRB- O
in IN O
HNPCC NNP O
more RBR O
often RB O
have VBP O
a DT O
better JJR O
prognosis NN O
than IN O
in IN O
sporadic JJ O
colorectal NN O
carcinoma NN O
[3,4,20-22] JJ O
, , O
but CC O
it PRP O
has VBZ O
been VBN O
unclear JJ O
whether IN O
this DT O
could MD O
be VB O
due JJ O
to TO O
difference NN O
in IN O
stage NN O
at IN O
diagnosis NN O
or CC O
to TO O
a DT O
more RBR O
favourable JJ O
prognosis NN O
of IN O
cancer NN O
in IN O
HNPCC NNP O
and CC O
FAP. NNP O

The DT O
aim NN O
of IN O
our PRP$ O
retrospective JJ O
study NN O
was VBD O
to TO O
compare VB O
stage NN O
and CC O
overall JJ O
survival NN O
between IN O
patients NNS O
with IN O
hereditary JJ O
and CC O
sporadic JJ O
colorectal JJ O
cancer NN O
patients NNS O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Conclusion NN O

In IN O
conclusion NN O
, , O
our PRP$ O
findings NNS O
appear VBP O
to TO O
confirm VB O
previous JJ O
studies NNS O
[30,31] IN O
which WDT O
detected VBD O
that IN O
an DT O
improved JJ O
survival NN O
for IN O
colon NN O
cancer NN O
in IN O
HNPCC NNP O
, , O
compared VBN O
to TO O
sporadic JJ O
CRC NNP O
, , O
usually RB O
occur VBP O
. . O

In IN O
fact NN O
, , O
our PRP$ O
series NN O
of IN O
HNPCC NNP O
patients NNS O
reveals VBZ O
a DT O
marked VBN O
overall JJ O
survival NN O
advantage NN O
, , O
which WDT O
persisted VBD O
also RB O
after IN O
stratification NN O
by IN O
Dukes NNP O
' POS O
stage NN O
. . O

Therefore RB O
, , O
survival NN O
of IN O
HNPCC NNP O
patients NNS O
not RB O
always RB O
depends VBZ O
on IN O
an DT O
early JJ O
diagnosis NN O
, , O
but CC O
probably RB O
also RB O
on IN O
distinct JJ O
biologic NN O
features NNS O
. . O

In IN O
this DT O
context NN O
, , O
MSI JJ O
mutation NN O
pattern NN O
plays VBZ O
an DT O
important JJ O
prognostic JJ O
role NN O
since IN O
colon NN O
cancer NN O
with IN O
MSI NNP O
has VBZ O
a DT O
better JJR O
prognosis NN O
than IN O
tumours NNS O
without IN O
MSI. NNP O

A DT O
large JJ O
series NN O
of IN O
HNPCC NNP O
should MD O
be VB O
examined VBN O
to TO O
confirm VB O
this DT O
data NN O
. . O

Furthermore RB O
, , O
we PRP O
need VBP O
more JJR O
information NN O
about IN O
MSI NNP O
in IN O
all DT O
kind NN O
of IN O
colorectal JJ O
carcinomas NNS O
, , O
in IN O
order NN O
to TO O
establish VB O
postoperative NN O
surveillance NN O
thus RB O
improving VBG O
patients NNS O
' POS O
prognosis NN O
and CC O
allowing VBG O
clinicians NNS O
to TO O
plan VB O
more RBR O
accurate JJ O
and CC O
targeted JJ O
therapy NN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Mutation NNP O
Rates NNP O
of IN O
and CC O
Coding VBG O
Microsatellites NNS O
in IN O
Human NNP O
Cells NNP O
with IN O
Defective NNP O
DNA NNP O
Mismatch NNP O
Repair NNP O

Abstract NN O

Microsatellite NNP O
instability NN O
promotes VBZ O
colonic JJ O
tumorigenesis NN O
through IN O
generating VBG O
frameshift NN O
mutations NNS O
at IN O
coding VBG O
microsatellites NNS O
of IN O
tumor NN O
suppressor NN O
genes NNS O
, , O
such JJ O
as IN O
TGFBR2 NNP B-NP
and CC O
ACVR2 NNP B-NP
. . O

As IN O
a DT O
consequence NN O
, , O
signaling VBG O
through IN O
these DT O
TGFβ JJ B-NP
family NN O
receptors NNS O
is VBZ O
abrogated VBN O
in IN O
DNA NNP O
Mismatch NNP O
repair NN O
( -LRB- O
MMR)-deficient JJ B-NP
tumors NNS O
. . O

How WRB O
these DT O
mutations NNS O
occur VBP O
in IN O
real JJ O
time NN O
and CC O
mutational JJ O
rates NNS O
of IN O
these DT O
human JJ O
coding NN O
sequences NNS O
have VBP O
not RB O
previously RB O
been VBN O
studied VBN O
. . O

We PRP O
utilized VBD O
cell NN O
lines NNS O
with IN O
different JJ O
MMR NNP B-NP
deficiencies NNS O
( -LRB- O
hMLH1−/− NN B-NP
, , O
hMSH6−/− JJ B-NP
, , O
hMSH3−/− JJ B-NP
, , O
and CC O
MMR-proficient NNP B-NP
) -RRB- O
to TO O
determine VB O
mutation NN O
rates NNS O
. . O

Plasmids NNS O
were VBD O
constructed VBN O
in IN O
which WDT O
exon NN O
3 CD O
of IN O
TGFBR2 NNP B-NP
and CC O
exon JJ O
10 CD O
of IN O
ACVR2 NNP B-NP
were VBD O
cloned VBN O
+1 TO O
bp VB O
out IN O
of IN O
frame NN O
, , O
immediately RB O
after IN O
the DT O
translation NN O
initiation NN O
codon NN O
of IN O
an DT O
enhanced JJ O
GFP NNP O
( -LRB- O
EGFP NNP O
) -RRB- O
gene NN O
, , O
allowing VBG O
a DT O
−1 JJR O
bp NN O
frameshift NN O
mutation NN O
to TO O
drive VB O
EGFP NNP O
expression NN O
. . O

Mutation-resistant JJ O
plasmids NNS O
were VBD O
constructed VBN O
by IN O
interrupting VBG O
the DT O
coding NN O
microsatellite NN O
sequences NNS O
, , O
preventing VBG O
frameshift NN O
mutation NN O
. . O

Stable JJ O
cell NN O
lines NNS O
were VBD O
established VBN O
containing VBG O
portions NNS O
of IN O
TGFBR2 NNP B-NP
and CC O
ACVR2 NNP B-NP
, , O
and CC O
nonfluorescent JJ O
cells NNS O
were VBD O
sorted JJ O
, , O
cultured JJ O
for IN O
7–35 CD O
days NNS O
, , O
and CC O
harvested VBD O
for IN O
flow NN O
cytometric JJ O
mutation NN O
detection NN O
and CC O
DNA NN O
sequencing NN O
at IN O
specific JJ O
time NN O
points NNS O
. . O

DNA NN O
sequencing NN O
revealed VBD O
a DT O
−1 JJ O
bp NN O
frameshift NN O
mutation NN O
( -LRB- O
A9 CC O
in IN O
TGFBR2 NNP B-NP
and CC O
A7 NNP O
in IN O
ACVR2 NNP B-NP
) -RRB- O
in IN O
the DT O
fluorescent JJ O
cells NNS O
. . O

Two CD O
distinct JJ O
fluorescent NN O
populations NNS O
, , O
M1 NNP O
( -LRB- O
dim JJ O
, , O
representing VBG O
heteroduplexes NNS O
) -RRB- O
and CC O
M2 JJ O
( -LRB- O
bright JJ O
, , O
representing VBG O
full JJ O
mutants NNS O
) -RRB- O
were VBD O
identified VBN O
, , O
with IN O
the DT O
M2 NNP O
fraction NN O
accumulating VBG O
over IN O
time NN O
. . O

hMLH1 JJ B-NP
deficiency NN O
revealed VBD O
11 CD O
( -LRB- O
5.91×10−4 CD O
) -RRB- O
and CC O
15 CD O
( -LRB- O
2.18×10−4 CD O
) -RRB- O
times NNS O
higher JJR O
mutation NN O
rates NNS O
for IN O
the DT O
TGFBR2 NNP B-NP
and CC O
ACVR2 NNP B-NP
microsatellites NNS O
compared VBN O
to TO O
hMSH6 VB B-NP
deficiency NN O
, , O
respectively RB O
. . O

The DT O
mutation NN O
rate NN O
of IN O
the DT O
TGFBR2 NNP B-NP
microsatellite NN O
was VBD O
∼3 CD O
times NNS O
higher JJR O
in IN O
both DT O
hMLH1 NNS B-NP
and CC O
hMSH6 NNS B-NP
deficiencies NNS O
than IN O
the DT O
ACVR2 NNP B-NP
microsatellite NN O
. . O

The DT O
−1 JJ O
bp NN O
frameshift NN O
mutation NN O
rates NNS O
of IN O
TGFBR2 NNP B-NP
and CC O
ACVR2 NNP B-NP
microsatellite NN O
sequences NNS O
are VBP O
dependent JJ O
upon IN O
the DT O
human JJ O
MMR NNP B-NP
background NN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Colon NN O
cancer NN O
cell NN O
models NNS O
highlight NN O
the DT O
relationship NN O
between IN O
defective JJ O
DNA NN O
MMR NNP B-NP
and CC O
TGFBR2 NNP B-NP
and CC O
ACVR2 NNP B-NP
frameshift NN O
mutations NNS O
. . O

Both DT O
genes NNS O
commonly RB O
have VBP O
a DT O
−1 JJ O
bp NN O
frameshift NN O
mutation NN O
with IN O
defective JJ O
MMR. . B-NP

Restoration NN O
of IN O
wild JJ O
type NN O
( -LRB- O
WT NNP O
) -RRB- O
TGFBR2 NNP B-NP
and CC O
ACVR2 NNP B-NP
by IN O
chromosome NN O
transfer NN O
reveals VBZ O
growth NN O
suppression NN O
in IN O
the DT O
cells NNS O
and CC O
slower JJR O
growth NN O
in IN O
xenografts NNS O
in IN O
nude JJ O
mice NNS O
[22] '' O
, , O
[23] NNP O
. . O

Interestingly RB O
, , O
HCT116+chr3 IN O
cells NNS O
, , O
which WDT O
have VBP O
two CD O
mutant JJ O
hMLH1 NNS B-NP
and CC O
two CD O
mutant JJ O
TGFBR2 NN B-NP
alleles NNS O
plus CC O
one CD O
WT NNP O
hMLH1 NN B-NP
and CC O
one CD O
WT NNP O
TGFBR2 NNP B-NP
allele NN O
, , O
express VB O
∼33 CD O
% NN O
WT NNP O
TGFBR2 NNP B-NP
mRNA NN O
and CC O
∼67 CD O
% NN O
mutant JJ O
TGFBR2 NNP B-NP
mRNA NNS O
(unpublished JJ O
data NNS O
) -RRB- O
. . O

On IN O
the DT O
other JJ O
hand NN O
, , O
HCT116+chr2 NNP O
cells NNS O
, , O
which WDT O
have VBP O
two CD O
mutant JJ O
hMLH1 NNS B-NP
and CC O
two CD O
mutant JJ O
ACVR2 NNP B-NP
alleles NNS O
plus CC O
one CD O
WT NNP O
ACVR2 NNP B-NP
allele NN O
, , O
express VB O
∼20 CD O
% NN O
WT NNP O
ACVR2 NNP B-NP
mRNA NN O
[22] NN O
, , O
suggesting VBG O
a DT O
slow JJ O
but CC O
steady JJ O
mutation NN O
of IN O
the DT O
transferred VBN O
ACVR2 NNP B-NP
allele NN O
in IN O
hMLH1 JJ B-NP
deficiency NN O
. . O

Determining VBG O
mutation NN O
rates NNS O
of IN O
actual JJ O
human JJ O
coding NN O
genes NNS O
in IN O
human JJ O
MMR NNP B-NP
deficiency NN O
has VBZ O
not RB O
been VBN O
previously RB O
performed VBN O
, , O
although IN O
model NN O
systems NNS O
using VBG O
noncoding JJ O
sequences NNS O
with IN O
human JJ O
cell NN O
and CC O
yeast NN O
MMR NNP B-NP
systems NNS O
have VBP O
been VBN O
utilized VBN O
[24]–[27] JJ O
. . O

To TO O
test VB O
the DT O
hypothesis NN O
that IN O
TGFBR2 NNP B-NP
and CC O
ACVR2 NNP B-NP
frameshift NN O
mutations NNS O
are VBP O
dependent JJ O
on IN O
the DT O
human JJ O
MMR NNP B-NP
background NN O
, , O
we PRP O
constructed VBD O
EGFP NNP O
plasmids NNS O
in IN O
which WDT O
a DT O
−1 JJ O
bp NN O
frameshift NN O
mutation NN O
at IN O
coding VBG O
microsatellites NNS O
of IN O
TGFBR2 DT B-NP
exon NN O
3 CD O
and CC O
ACVR2 NNP B-NP
exon NN O
10 CD O
was VBD O
detected VBN O
by IN O
EGFP NNP O
expression NN O
in IN O
human JJ O
colon NN O
cancer NN O
cells NNS O
with IN O
MMR NNP B-NP
deficiency NN O
. . O

With IN O
this DT O
new JJ O
cell NN O
model NN O
, , O
we PRP O
were VBD O
able JJ O
to TO O
calculate VB O
a DT O
human JJ O
gene NN O
mutation NN O
rate NN O
in IN O
each DT O
human JJ O
MMR-deficient NNP B-NP
background NN O
, , O
and CC O
could MD O
directly RB O
compare VB O
the DT O
mutation NN O
rate NN O
between IN O
TGFBR2 NNP B-NP
and CC O
ACVR2 NNP B-NP
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

EGFP JJ O
expression NN O
of IN O
stably NN O
transfected VBN O
HCT116 CD O
cell NN O
lines NNS O
( -LRB- O
hMLH1−/− NN B-NP
) -RRB- O
containing VBG O
exon NN O
3 CD O
of IN O
TGFBR2 DT B-NP
sequences NNS O
. . O

( -LRB- O
A DT O
) -RRB- O
MR NNP O
TGFBR2 NNP B-NP
IF IN O
cells NNS O
, , O
a DT O
postive JJ O
control NN O
, , O
showed VBD O
99 CD O
% NN O
EGFP JJ O
expression NN O
. . O

( -LRB- O
B NNP O
) -RRB- O
MR NNP O
TGFBR2 NNP B-NP
OF IN O
cells NNS O
, , O
a DT O
negative JJ O
control NN O
, , O
showed VBD O
no DT O
visible JJ O
fluorescence NN O
. . O

( -LRB- O
C NNP O
) -RRB- O
TGFBR2 VB B-NP
OF IN O
cells NNS O
showed VBD O
1.22 CD O
% NN O
net JJ O
fluorescence NN O
. . O

Photomicrographs NNS O
of IN O
stable JJ O
HCT116 CD O
cell NN O
lines NNS O
are VBP O
representative JJ O
of IN O
the DT O
other JJ O
stable JJ O
cell NN O
lines NNS O
containing VBG O
TGFBR2 NNP B-NP
exon NN O
3 CD O
or CC O
ACVR2 NNP B-NP
exon NN O
10 CD O
sequences NNS O
. . O

Photomicrographs NNS O
in IN O
top JJ O
panels NNS O
were VBD O
taken VBN O
with IN O
a DT O
fluorescence NN O
microscope NN O
( -LRB- O
Zeiss NNP O
, , O
Germany NNP O
) -RRB- O
and CC O
photomicrographs NNS O
in IN O
bottom NN O
panels NNS O
were VBD O
taken VBN O
with IN O
a DT O
light JJ O
microscope NN O
of IN O
the DT O
identical JJ O
area NN O
under IN O
40× JJ O
magnification NN O
. . O

TGFBR2 DT B-NP
exon NN O
3 CD O
and CC O
ACVR2 NNP B-NP
exon NN O
10 CD O
coding NN O
microsatellite NN O
mutations NNS O
are VBP O
dependent JJ O
on IN O
the DT O
MMR NNP B-NP
background NN O

To TO O
determine VB O
mutation JJ O
frequencies NNS O
of IN O
the DT O
TGFBR2 NNP B-NP
and CC O
ACVR2 NNP B-NP
coding NN O
microsatellites NNS O
in IN O
cells NNS O
with IN O
different JJ O
MMR NN B-NP
backgrounds NNS O
( -LRB- O
Table NN O
S1 NNP O
) -RRB- O
, , O
nonfluorescent JJ O
cells NNS O
containing VBG O
either DT O
MR NNP O
TGFBR2 NN B-NP
OF IN O
, , O
TGFBR2 VB B-NP
OF IN O
, , O
MR NNP O
ACVR2 NNP B-NP
OF IN O
or CC O
ACVR2 VB B-NP
OF IN O
were VBD O
sorted JJ O
and CC O
exponentially RB O
grown VBN O
for IN O
7 CD O
to TO O
35 CD O
days NNS O
. . O

At IN O
specific JJ O
time NN O
points NNS O
( -LRB- O
day NN O
7 CD O
, , O
14 CD O
, , O
21 CD O
, , O
28 CD O
, , O
and/or CC O
35 CD O
) -RRB- O
three CD O
cultures NNS O
of IN O
each DT O
cell NN O
line NN O
were VBD O
analyzed VBN O
in IN O
parallel JJ O
for IN O
EGFP JJ O
expression NN O
by IN O
using VBG O
flow NN O
cytometry NN O
to TO O
detect VB O
−1 NN O
bp NN O
frameshift NN O
mutations NNS O
. . O

Three CD O
different JJ O
populations NNS O
were VBD O
identified VBN O
according VBG O
to TO O
their PRP$ O
EGFP JJ O
fluorescence NN O
intensity NN O
( -LRB- O
Fig NNP O
. . O
3 CD O
) -RRB- O
. . O

The DT O
population NN O
with IN O
no DT O
fluorescence NN O
was VBD O
named VBN O
M0 NNP O
, , O
the DT O
population NN O
with IN O
low JJ O
fluorescence NN O
M1 NNS O
, , O
and CC O
the DT O
population NN O
with IN O
high JJ O
fluorescence NN O
M2. . O

EGFP NNP O
histograms NNS O
of IN O
MR NNP O
TGFBR2 NNP B-NP
OF IN O
and CC O
TGFBR2 VB B-NP
OF IN O
cells NNS O
in IN O
different JJ O
MMR NNP B-NP
backgrounds NNS O
at IN O
day NN O
21 CD O
are VBP O
shown VBN O
in IN O
Fig NNP O
. . O
3E NNP O
, , O
in IN O
which WDT O
hMLH1−/ JJ B-NP
− NN O
TGFBR2 NN B-NP
OF IN O
cells NNS O
showed VBN O
2 CD O
distinct JJ O
EGFP NNP O
cell NN O
populations NNS O
, , O
M1 NNP O
and CC O
M2. NNP O

M2 CD O
cells NNS O
from IN O
hMLH1−/ JJ B-NP
− NN O
TGFBR2 NN B-NP
OF IN O
showed VBD O
brighter JJR O
EGFP NNP O
expression NN O
compared VBN O
to TO O
M1 CD O
cells NNS O
( -LRB- O
Fig VB O
. . O
S1 NNP O
) -RRB- O
. . O

Mutation NN O
analysis NN O
by IN O
flow NN O
cytometry NN O
. . O

Nonfluorescent JJ O
cells NNS O
were VBD O
sorted JJ O
and CC O
cells NNS O
were VBD O
exponentially RB O
grown VBN O
for IN O
7 CD O
to TO O
35 CD O
days NNS O
. . O

At IN O
specific JJ O
time NN O
points NNS O
, , O
cells NNS O
were VBD O
harvested VBN O
, , O
and CC O
200,000 CD O
cells NNS O
were VBD O
analyzed VBN O
for IN O
EGFP JJ O
expression NN O
( -LRB- O
identifying VBG O
a DT O
−1 CD O
bp JJ O
mutation NN O
) -RRB- O
by IN O
flow NN O
cytometry NN O
. . O

For IN O
example NN O
, , O
with IN O
hMLH1−/ JJ B-NP
− NNS O
ACVR2 IN B-NP
OF IN O
cells NNS O
, , O
region NN O
R1 NNP O
, , O
R3 NNP O
, , O
and CC O
R2 NNP O
were VBD O
set VBN O
according VBG O
to TO O
( -LRB- O
A DT O
) -RRB- O
cell NN O
size NN O
, , O
( -LRB- O
B NNP O
) -RRB- O
live VBP O
cells NNS O
, , O
and CC O
( -LRB- O
C NN O
) -RRB- O
fluorescence NN O
. . O

Gated NNP O
R1 NNP O
and CC O
R3 NNP O
( -LRB- O
live JJ O
cells NNS O
) -RRB- O
, , O
and CC O
R2 NNP O
were VBD O
analyzed VBN O
on IN O
an DT O
EGFP JJ O
histogram NN O
( -LRB- O
D) NNP O
and CC O
two CD O
distinct JJ O
EGFP JJ O
populations NNS O
were VBD O
plotted VBN O
. . O

The DT O
population NN O
displaying VBG O
no DT O
fluorescence NN O
was VBD O
designated VBN O
M0 NNP O
, , O
the DT O
population NN O
with IN O
dim JJ O
EGFP NNP O
expression NN O
was VBD O
designated VBN O
M1 NNP O
, , O
and CC O
the DT O
population NN O
with IN O
bright JJ O
EGFP JJ O
expression NN O
was VBD O
designated VBN O
M2. NNP O
( -LRB- O
E NNP O
) -RRB- O
EGFP NNP O
histograms NNS O
of IN O
MR NNP O
TGFBR2 NNP B-NP
OF IN O
and CC O
TGFBR2 VB B-NP
OF IN O
cells NNS O
in IN O
different JJ O
MMR NNP B-NP
deficient NN O
backgrounds NNS O
at IN O
day NN O
21 CD O
were VBD O
shown VBN O
as IN O
representatives NNS O
of IN O
mutation JJ O
analysis NN O
. . O

Scaling NNP O
of IN O
cell NN O
counts NNS O
in IN O
each DT O
EGFP NNP O
histogram NN O
is VBZ O
different JJ O
for IN O
each DT O
MMR NNP B-NP
background NN O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

Frameshift NNP O
mutation NN O
at IN O
coding VBG O
microsatellites NNS O
of IN O
TGFBR2 DT B-NP
exon NN O
3 CD O
and CC O
ACVR2 NNP B-NP
exon NN O
10 CD O
in IN O
different JJ O
human JJ O
MMR NNP B-NP
deficient NN O
backgrounds NNS O
. . O

Cells NNP O
from IN O
the DT O
M1 NNP O
and/or CC O
M2 NNP O
populations NNS O
of IN O
hMLH1−/ JJ B-NP
− NN O
TGFBR2 NN B-NP
OF IN O
or CC O
ACVR2 VB B-NP
OF IN O
cells NNS O
, , O
hMSH6−/ JJ B-NP
− NN O
TGFBR2 NN B-NP
OF IN O
or CC O
ACVR2 VB B-NP
OF IN O
cells NNS O
, , O
and CC O
hMSH3−/ JJ B-NP
− NN O
TGFBR2 NN B-NP
OF IN O
cells NNS O
were VBD O
sorted JJ O
and CC O
cultured JJ O
. . O

DNA NN O
from IN O
each DT O
cell NN O
line NN O
was VBD O
amplified VBN O
by IN O
PCR NNP O
, , O
sub-cloned JJ O
and CC O
all DT O
single JJ O
cell NN O
clones NNS O
were VBD O
individually RB O
sequenced VBN O
to TO O
assess VB O
for IN O
frameshift NN O
mutation NN O
of IN O
the DT O
coding NN O
microsatellites NNS O
of IN O
TGFBR2 DT B-NP
exon NN O
3 CD O
and CC O
ACVR2 NNP B-NP
exon NN O
10 CD O
. . O

Sequence NN O
analysis NN O
of IN O
DNA NNP O
clones NNS O
from IN O
hMLH1 JJ B-NP
and CC O
hMSH6 PRP B-NP
deficiencies NNS O
revealed VBD O
mostly RB O
1 CD O
bp JJ O
deletion NN O
at IN O
microsatellites NNS O
( -LRB- O
A9 CC O
for IN O
TGFBR2 NNP B-NP
or CC O
A7 NNP O
for IN O
ACVR2 NNP B-NP
) -RRB- O
, , O
shifting VBG O
the DT O
EGFP JJ O
gene NN O
into IN O
the DT O
reading NN O
frame NN O
and CC O
leading VBG O
to TO O
its PRP$ O
expression NN O
( -LRB- O
A DT O
) -RRB- O
. . O

Note VB O
that DT O
M2 NNP O
clones NNS O
from IN O
hMLH1−/ JJ B-NP
− NN O
TGFBR2 NN B-NP
OF IN O
cells NNS O
revealed VBD O
100 CD O
% NN O
A9/T9 IN O
microsatellite JJ O
sequences NNS O
, , O
termed VBD O
a DT O
“full JJ O
mutant NN O
? . O

whereas IN O
M1 NNP O
clones NNS O
revealed VBD O
a DT O
mixture NN O
of IN O
A10/T10 NNP O
and CC O
A9/T9 DT O
microsatellite NN O
sequences NNS O
, , O
which WDT O
suggests VBZ O
the DT O
presence NN O
of IN O
an DT O
A10/T9 NNP O
heteroduplex NN O
, , O
termed VBD O
an DT O
“intermediate JJ O
mutant NN O
? . O

( -LRB- O
B NNP O
) -RRB- O
. . O

To TO O
determine VB O
the DT O
nature NN O
of IN O
the DT O
mutations NNS O
observed VBD O
in IN O
the DT O
M1 JJ O
population NN O
, , O
we PRP O
analyzed VBD O
pooled VBN O
cells NNS O
as RB O
well RB O
as IN O
single JJ O
cell NN O
clones NNS O
. . O

In IN O
pooled VBN O
samples NNS O
, , O
unlike IN O
fully RB O
mutant JJ O
sequences NNS O
observed VBD O
in IN O
the DT O
M2 NNP O
populations NNS O
, , O
M1 VBG O
population NN O
sequences NNS O
often RB O
revealed VBD O
two CD O
overlapping JJ O
sequences NNS O
, , O
suggestive JJ O
of IN O
heteroduplexes NNS O
( -LRB- O
A9/T10 CC O
in IN O
TGFBR2 NNP B-NP
and CC O
A7/T8 DT O
in IN O
ACVR2 NNP B-NP
) -RRB- O
( -LRB- O
Fig VB O
. . O
5B '' O
) -RRB- O
. . O

Single NNP O
cell NN O
clones NNS O
revealed VBD O
the DT O
presence NN O
of IN O
both DT O
WT NNP O
and CC O
−1 CD O
bp NN O
frameshift NN O
mutants NNS O
( -LRB- O
Fig VB O
. . O
5B) VB O
, , O
consistent JJ O
with IN O
heteroduplexes NNS O
that IN O
weakly JJ O
drive NN O
EGFP NNP O
expression NN O
. . O

Overall RB O
, , O
our PRP$ O
data NNS O
indicate VBP O
that IN O
hMLH1 JJ B-NP
deficiency NN O
has VBZ O
the DT O
highest JJS O
susceptibility NN O
for IN O
frameshift NN O
mutation NN O
at IN O
the DT O
coding NN O
microsatellites NNS O
of IN O
TGFBR2 DT B-NP
exon NN O
3 CD O
and CC O
ACVR2 NNP B-NP
exon VBD O
10 CD O
of IN O
the DT O
three CD O
different JJ O
MMR NNP B-NP
deficiencies NNS O
( -LRB- O
hMLH1−/− NN B-NP
, , O
hMSH6−/ JJ B-NP
− NN O
and CC O
hMSH3−/− NN B-NP
) -RRB- O
. . O

In IN O
addition NN O
, , O
the DT O
coding NN O
microsatellite NN O
of IN O
TGFBR2 NNP B-NP
exon NN O
3 CD O
has VBZ O
a DT O
higher JJR O
susceptibility NN O
to TO O
a DT O
1 CD O
bp NN O
frameshift NN O
mutation NN O
than IN O
that DT O
of IN O
ACVR2 NNP B-NP
exon NN O
10 CD O
in IN O
hMLH1 NNS B-NP
, , O
hMSH6 NN B-NP
, , O
( -LRB- O
and CC O
hMSH3 VB B-NP
) -RRB- O
deficiencies NNS O
. . O

The DT O
frameshift NN O
mutation NN O
rates NNS O
at IN O
the DT O
coding NN O
microsatellites NNS O
of IN O
TGFBR2 DT B-NP
exon NN O
3 CD O
and CC O
ACVR2 NNP B-NP
exon NN O
10 CD O
are VBP O
dependent JJ O
on IN O
the DT O
MMR NNP B-NP
background NN O

The DT O
M2 JJ O
population NN O
( -LRB- O
full JJ O
mutants NNS O
) -RRB- O
was VBD O
used VBN O
to TO O
calculate VB O
the DT O
mutation NN O
rates NNS O
at IN O
microsatellites NNS O
of IN O
TGFBR2 DT B-NP
exon NN O
3 CD O
and CC O
ACVR2 NNP B-NP
exon NN O
10 CD O
by IN O
the DT O
“method NN O
of IN O
the DT O
mean NN O
? . O

[28 CD O
] NN O
( -LRB- O
Table NN O
1 CD O
) -RRB- O
. . O

A DT O
single JJ O
mutation NN O
rate NN O
was VBD O
calculated VBN O
by IN O
taking VBG O
a DT O
weighted JJ O
average NN O
of IN O
the DT O
mutation NN O
rates NNS O
at IN O
the DT O
different JJ O
time NN O
points NNS O
, , O
the DT O
weights NNS O
of IN O
which WDT O
were VBD O
chosen VBN O
to TO O
minimize VB O
the DT O
variance NN O
of IN O
the DT O
estimate NN O
as IN O
previously RB O
described VBN O
[25] JJ O
. . O

As IN O
predicted VBN O
, , O
the DT O
mutation NN O
rate NN O
at IN O
the DT O
microsatellite NN O
of IN O
TGFBR2 NNP B-NP
in IN O
the DT O
hMLH1−/ JJ B-NP
− NN O
background NN O
was VBD O
highest JJS O
: : O
5.91×10−4±1.26×10−4 CD O
. . O

Mutation NN O
at IN O
the DT O
A10 NNP O
microsatellite NN O
of IN O
TGFBR2 NNP B-NP
is VBZ O
∼3 CD O
times NNS O
more RBR O
frequent JJ O
than IN O
mutation NN O
at IN O
the DT O
A8 NNS O
microsatellite NN O
of IN O
ACVR2 NNP B-NP
in IN O
hMLH1 JJ B-NP
deficiency NN O
( -LRB- O
P<0.01 CD O
) -RRB- O
. . O

In IN O
addition NN O
, , O
mutation NN O
at IN O
the DT O
microsatellite NN O
of IN O
TGFBR2 NNP B-NP
is VBZ O
∼4 CD O
times NNS O
higher JJR O
than IN O
mutation NN O
at IN O
the DT O
microsatellite NN O
of IN O
ACVR2 NNP B-NP
in IN O
hMSH6 VBG B-NP
deficiency NN O
. . O

Furthermore RB O
, , O
mutations NNS O
at IN O
the DT O
microsatellites NNS O
of IN O
TGFBR2 NNP B-NP
and CC O
ACVR2 NNP B-NP
are VBP O
∼11–15 CD O
times NNS O
higher JJR O
in IN O
hMLH1 JJ B-NP
deficiency NN O
than IN O
in IN O
hMSH6 NN B-NP
deficiency NN O
( -LRB- O
P<0.01 CD O
) -RRB- O
. . O

Mutation NN O
rates NNS O
from IN O
hMSH3−/ JJ B-NP
− NN O
and CC O
MMR-proficient JJ B-NP
cell NN O
lines NNS O
were VBD O
not RB O
calculated VBN O
due JJ O
to TO O
a DT O
lack NN O
of IN O
net JJ O
fluorescent NN O
M2 IN O
populations NNS O
. . O

These DT O
data NNS O
confirm VBP O
that IN O
hMLH1 JJ B-NP
deficiency NN O
allows VBZ O
a DT O
higher JJR O
susceptibility NN O
for IN O
mutation NN O
at IN O
the DT O
coding NN O
microsatellites NNS O
of IN O
TGFBR2 DT B-NP
exon NN O
3 CD O
and CC O
ACVR2 NNP B-NP
exon VBD O
10 CD O
than IN O
hMSH6 NNS B-NP
and CC O
hMSH3 VB B-NP
deficiencies NNS O
, , O
and CC O
that DT O
TGFBR2 NNP B-NP
exon NN O
3 CD O
has VBZ O
a DT O
higher JJR O
susceptibility NN O
to TO O
mutation NN O
at IN O
its PRP$ O
coding NN O
microsatellite NN O
over IN O
ACVR2 NNP B-NP
exon NN O
10 CD O
in IN O
both DT O
hMLH1 NNS B-NP
and CC O
hMSH6 VB B-NP
deficiencies NNS O
. . O

-DOCSTART- X X O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

** JJ O
IGNORE NNP O
LINE NNP O
** . O

As IN O
we PRP O
hypothesized VBD O
, , O
the DT O
mutational JJ O
frequencies NNS O
and CC O
rates NNS O
of IN O
TGFBR2 DT B-NP
exon NN O
3 CD O
and CC O
ACVR2 NNP B-NP
exon NN O
10 CD O
microsatellites NNS O
are VBP O
dependent JJ O
on IN O
the DT O
MMR NNP B-NP
deficient NN O
background NN O
with IN O
hMLH1−/−>hMSH6−/−>hMSH3−/− NN B-NP
. . O

As IN O
TGFBR2 NNP B-NP
and CC O
ACVR2 NNP B-NP
mutations NNS O
may MD O
drive VB O
the DT O
pathogenesis NN O
of IN O
colorectal JJ O
cancers NNS O
, , O
our PRP$ O
human JJ O
data NNS O
is VBZ O
consistent JJ O
with IN O
the DT O
virulence NN O
of IN O
tumor NN O
formation NN O
in IN O
Lynch NNP O
syndrome NN O
. . O

Patients NNS O
with IN O
germline NN O
mutation NN O
in IN O
hMLH1 NN B-NP
may MD O
present VB O
with IN O
cancer NN O
at IN O
younger JJR O
ages NNS O
compared VBN O
to TO O
those DT O
with IN O
a DT O
hMSH6 NN B-NP
germline NN O
mutation NN O
[29] NN O
. . O

Data NNP O
on IN O
mutation NN O
rates NNS O
for IN O
TGFBR2 DT B-NP
exon NN O
3 CD O
and CC O
ACVR2 NNP B-NP
exon NN O
10 CD O
( -LRB- O
Table NN O
1 CD O
) -RRB- O
showed VBD O
similar JJ O
results NNS O
. . O

hMLH1−/ JJ B-NP
− NN O
TGFBR2 NN B-NP
showed VBD O
the DT O
highest JJS O
mutation NN O
rate NN O
at IN O
its PRP$ O
coding NN O
microsatellite NN O
sequence NN O
( -LRB- O
5.91×10−4 CD O
) -RRB- O
. . O

This DT O
mutation NN O
rate NN O
is VBZ O
similar JJ O
to TO O
that DT O
calculated VBN O
for IN O
noncoding JJ O
( -LRB- O
CA)13 NN O
microsatellites NNS O
in IN O
hMLH1−/ JJ B-NP
− NN O
cells NNS O
[25] VBP O
, , O
suggesting VBG O
that IN O
this DT O
coding NN O
A10 IN O
and CC O
the DT O
noncoding JJ O
( -LRB- O
CA)13 NN O
microsatellites NNS O
are VBP O
equally RB O
vulnerable JJ O
to TO O
hMLH1 VB B-NP
deficiency NN O
. . O

The DT O
mutation NN O
rate NN O
for IN O
TGFBR2 NNP B-NP
was VBD O
3 CD O
fold NN O
higher JJR O
than IN O
that IN O
for IN O
ACVR2 NNP B-NP
in IN O
both DT O
hMLH1 NNS B-NP
( -LRB- O
5.91×10−4 CD O
) -RRB- O
and CC O
hMSH6 PRP B-NP
( -LRB- O
0.54×10−4 CD O
) -RRB- O
deficiencies NNS O
. . O

The DT O
rapid JJ O
rate NN O
for IN O
TGFBR2 DT B-NP
mutation NN O
with IN O
MMR NNP B-NP
deficiency NN O
might MD O
be VB O
due JJ O
partly RB O
to TO O
TGFBR2 NNP B-NP
's POS O
longer JJR O
polyadenine NN O
tract NN O
compared VBN O
to TO O
ACVR2 NNP B-NP
, , O
as RB O
longer RB O
microsatellite JJ O
tracts NNS O
mutate VBP O
more RBR O
frequently RB O
in IN O
MMR NNP B-NP
deficiency NN O
[7] NN O
. . O

In IN O
the DT O
case NN O
of IN O
ACVR2 NNP B-NP
exon NN O
10 CD O
, , O
even RB O
though IN O
the DT O
mutation NN O
rate NN O
is VBZ O
slower JJR O
than IN O
TGFBR2 DT B-NP
exon NN O
3 CD O
, , O
ultimately RB O
fully RB O
mutant JJ O
clones NNS O
accumulate VBP O
. . O

The DT O
rapid JJ O
rate NN O
for IN O
TGFBR2 DT B-NP
exon NN O
3 CD O
mutation NN O
is VBZ O
probably RB O
most JJS O
reflective JJ O
in IN O
the DT O
M1 JJ O
population NN O
, , O
as IN O
there EX O
is VBZ O
a DT O
rapid JJ O
heteroduplex NN O
formation NN O
particularly RB O
in IN O
hMLH1 JJ B-NP
deficiency NN O
, , O
followed VBN O
by IN O
full JJ O
mutation NN O
. . O

In IN O
ACVR2 NNP B-NP
exon NN O
10 CD O
, , O
heteroduplex JJ O
formation NN O
is VBZ O
relatively RB O
slower JJR O
. . O

With IN O
both DT O
TGFBR2 NNP B-NP
and CC O
ACVR2 NNP B-NP
constructs NNS O
, , O
heteroduplex JJ O
formation NN O
and CC O
subsequent JJ O
full JJ O
mutation NN O
are VBP O
slower RBR O
in IN O
the DT O
hMSH6−/ JJ B-NP
− NN O
background NN O
compared VBN O
to TO O
hMLH1−/ VB B-NP
− JJ O
background NN O
. . O

It PRP O
has VBZ O
been VBN O
shown VBN O
that IN O
MSH6 NNP B-NP
and CC O
MSH3 NNP B-NP
are VBP O
redundant JJ O
in IN O
regard NN O
to TO O
frameshift VB O
mutagenesis NN O
in IN O
a DT O
yeast NN O
model NN O
[30] CD O
, , O
which WDT O
supports VBZ O
our PRP$ O
finding NN O
that IN O
hMSH6 NNS B-NP
and CC O
hMSH3 JJ B-NP
defects NNS O
have VBP O
much RB O
lower JJR O
frameshift NN O
mutation NN O
rates NNS O
than IN O
the DT O
hMLH1 JJ B-NP
defect NN O
that WDT O
completely RB O
eliminates VBZ O
MMR. . B-NP

Lower NNP O
frameshift NN O
mutation NN O
rate NN O
in IN O
hMSH6 NN B-NP
deficiency NN O
would MD O
logically RB O
predict VB O
a DT O
lower JJR O
penetrance NN O
in IN O
Lynch NNP O
syndrome NN O
for IN O
which WDT O
no DT O
germline NN O
hMSH3 IN B-NP
mutation NN O
has VBZ O
been VBN O
reported VBN O
. . O

In IN O
summary NN O
, , O
we PRP O
established VBD O
and CC O
utilized VBD O
a DT O
cell NN O
model NN O
in IN O
which WDT O
actual JJ O
human JJ O
coding NN O
microsatellite NN O
sequences NNS O
of IN O
TGFBR2 DT B-NP
exon NN O
3 CD O
and CC O
ACVR2 NNP B-NP
exon NN O
10 CD O
were VBD O
evaluated VBN O
in IN O
real JJ O
time NN O
for IN O
frameshift NN O
mutation NN O
in IN O
different JJ O
human JJ O
MMR NNP B-NP
backgrounds NNS O
. . O

hMLH1 JJ B-NP
deficiency NN O
confers VBZ O
a DT O
significantly RB O
higher JJR O
mutation NN O
rate NN O
at IN O
the DT O
coding NN O
microsatellites NNS O
of IN O
TGFBR2 NNP B-NP
and CC O
ACVR2 NNP B-NP
compared VBN O
to TO O
hMSH6 VB B-NP
and CC O
hMSH3 VB B-NP
deficiencies NNS O
. . O

In IN O
addition NN O
, , O
TGFBR2 NNP B-NP
mutates NNS O
at IN O
a DT O
higher JJR O
rate NN O
than IN O
ACVR2 NNP B-NP
in IN O
both DT O
hMLH1 NNS B-NP
and CC O
hMSH6 VB B-NP
deficiencies NNS O
. . O

These DT O
bona-fide JJ O
human JJ O
genes NNS O
targeted VBN O
for IN O
mutation NN O
in IN O
MMR NNP B-NP
deficiency NN O
mutate NN O
at IN O
differing VBG O
rates NNS O
, , O
and CC O
lose VBP O
expression NN O
of IN O
their PRP$ O
encoded JJ O
proteins NNS O
in IN O
colonic JJ O
neoplastic JJ O
cells NNS O
. . O

Understanding VBG O
these DT O
targeted VBN O
genes NNS O
in IN O
MMR NNP B-NP
deficiency NN O
has VBZ O
implications NNS O
in IN O
understanding VBG O
the DT O
pathogenesis NN O
of IN O
MSI NNP O
colorectal NN O
tumors NNS O
. . O

-DOCSTART- X X O

Pedigree NNP O
for IN O
Family NNP O
# # O
3 CD O
( -LRB- O
CRC NNP O
: : O
Colorectal NNP O
cancer NN O
; : O
ESC NNP O
: : O
Oesophageal JJ O
cancer NN O
; : O
LC NNP O
: : O
Lung NNP O
cancer NN O
) -RRB- O
. . O

Of IN O
the DT O
17 CD O
CRC NNP O
patients NNS O
with IN O
the DT O
Lys618Ala NNP O
variant NN O
, , O
two CD O
had VBD O
MSI NNP O
( -LRB- O
11.8 CD O
% NN O
) -RRB- O
, , O
one CD O
in IN O
the DT O
familial JJ O
CRC NNP O
group NN O
( -LRB- O
1/8 CD O
) -RRB- O
and CC O
one CD O
in IN O
the DT O
sporadic JJ O
CRC NNP O
group NN O
( -LRB- O
1/9 CD O
) -RRB- O
. . O

The DT O
MSI-positive JJ O
patient NN O
from IN O
the DT O
familial JJ O
CRC NNP O
group NN O
showed VBD O
loss NN O
of IN O
immunohistochemical JJ O
expression NN O
of IN O
MLH1 NNP B-NP
. . O

This DT O
is VBZ O
the DT O
index NN O
subject NN O
( -LRB- O
II-3 NN O
) -RRB- O
for IN O
the DT O
third JJ O
family NN O
( -LRB- O
Figure NN O
4 CD O
) -RRB- O
and CC O
no DT O
hypermethylation NN O
of IN O
MLH1 NNP B-NP
gene NN O
promoter NN O
; : O
no DT O
BRAF NN B-NP
p.Val600Glu NN O
mutation NN O
were VBD O
detected VBN O
in IN O
this DT O
case NN O
. . O

-DOCSTART- X X O

As IN O
most JJS O
disease NN O
pedigrees NNS O
are VBP O
small JJ O
, , O
it PRP O
is VBZ O
difficult JJ O
to TO O
obtain VB O
a DT O
sufficient JJ O
number NN O
of IN O
samples NNS O
from IN O
affected JJ O
and CC O
informative JJ O
unaffected JJ O
individuals NNS O
. . O

Moreover RB O
, , O
LS NN O
deleterious JJ O
variants NNS O
are VBP O
not RB O
completely RB O
penetrant JJ O
. . O

For IN O
these DT O
reasons NNS O
, , O
it PRP O
is VBZ O
rarely RB O
possible JJ O
to TO O
categorize VB O
variants NNS O
as IN O
deleterious JJ O
based VBN O
on IN O
segregation NN O
alone RB O
. . O

The DT O
co-occurrence NN O
of IN O
another DT O
known VBN O
deleterious JJ O
variant NN O
reduces VBZ O
the DT O
likelihood NN O
that IN O
an DT O
UV NN O
is VBZ O
truly RB O
deleterious JJ O
, , O
especially RB O
when WRB O
both DT O
variants NNS O
are VBP O
located VBN O
in IN O
trans NNS O
[3] VBP O
. . O

To TO O
our PRP$ O
knowledge NN O
, , O
co-occurrence NN O
of IN O
a DT O
deleterious JJ O
variant NN O
in IN O
one CD O
of IN O
the DT O
LS NN O
genes NNS O
with IN O
the DT O
p.Lys618Ala NN O
variant NN O
has VBZ O
been VBN O
observed VBN O
in IN O
only RB O
two CD O
families NNS O
. . O

Liu NNP O
et NNP O
al JJ O
[14] NNS O
described VBD O
an DT O
index NN O
subject NN O
from IN O
a DT O
LS NN O
family NN O
with IN O
two CD O
heterozygous JJ O
variants NNS O
( -LRB- O
c.546-2A>G JJ O
and CC O
c.1852_1853AA>GC JJ O
) -RRB- O
; : O
only RB O
the DT O
former JJ O
segregated VBN O
with IN O
LS NN O
in IN O
the DT O
family NN O
. . O

Similarly RB O
, , O
Steinke NNP O
et CC O
al JJ O
[15] JJ O
, , O
described VBD O
the DT O
co-occurrence NN O
of IN O
the DT O
p.Lys618Ala NN O
( -LRB- O
c.1852_1853AA>GC NN O
) -RRB- O
variant NN O
with IN O
the DT O
MSH6 CD B-NP
p.Arg1068X NN O
( -LRB- O
c.3202C>T NN O
) -RRB- O
deleterious VBZ O
variant JJ O
. . O

Herein RB O
, , O
we PRP O
describe VBP O
the DT O
coexistence NN O
of IN O
the DT O
p.Lys618Ala NN O
variant NN O
with IN O
deleterious JJ O
variants NNS O
in IN O
another DT O
two CD O
unrelated JJ O
LS NN O
families NNS O
. . O

In IN O
one CD O
family NN O
, , O
the DT O
allele JJ O
distribution NN O
of IN O
the DT O
pathogenic JJ O
and CC O
unclassified JJ O
variant NN O
was VBD O
in IN O
trans NNS O
, , O
in IN O
the DT O
other JJ O
family NN O
the DT O
pathogenic JJ O
variant NN O
was VBD O
detected VBN O
in IN O
the DT O
MSH6 NNP B-NP
gene NN O
and CC O
only RB O
the DT O
deleterious JJ O
variant JJ O
co-segregated JJ O
with IN O
the DT O
disease NN O
in IN O
both DT O
families NNS O
. . O

This DT O
evidence NN O
indicates VBZ O
that IN O
the DT O
p.Lys618Ala NN O
variant NN O
is VBZ O
not RB O
deleterious JJ O
. . O

The DT O
molecular JJ O
hallmark NN O
of IN O
LS NN O
tumours NNS O
is VBZ O
an DT O
MSI NNP O
phenotype NN O
, , O
a DT O
functional JJ O
consequence NN O
of IN O
MMR NNP O
deficiency NN O
. . O

It PRP O
is VBZ O
expected VBN O
that IN O
the DT O
putative JJ O
germ-line NN O
mutation NN O
responsible JJ O
for IN O
LS NN O
would MD O
confer VB O
the DT O
MSI NNP O
phenotype NN O
. . O

We PRP O
tested VBD O
the DT O
MSI NNP O
status NN O
of IN O
17 CD O
tumours NNS O
from IN O
p.Lys618Ala NN O
carriers NNS O
and CC O
detected VBD O
only RB O
two CD O
cases NNS O
of IN O
MSI NNP O
( -LRB- O
11.8 CD O
% NN O
) -RRB- O
. . O

Taking VBG O
into IN O
consideration NN O
the DT O
bias NN O
caused VBN O
by IN O
the DT O
over-representation NN O
of IN O
Bethesda NNP O
Criteria-positive JJ O
tumours NNS O
in IN O
this DT O
subset NN O
of IN O
cases NNS O
( -LRB- O
8/17 NN O
) -RRB- O
, , O
the DT O
MSI NNP O
frequency NN O
was VBD O
not RB O
significantly RB O
different JJ O
from IN O
that DT O
in IN O
the DT O
unselected JJ O
CRC NNP O
group NN O
[7] NN O
. . O

This DT O
is VBZ O
further JJ O
proof NN O
that IN O
the DT O
presence NN O
of IN O
this DT O
variant NN O
is VBZ O
irrelevant JJ O
to TO O
the DT O
functional JJ O
inactivation NN O
of IN O
MLH1 NNP B-NP
in IN O
CRC NNP O
patients NNS O
. . O

Nonetheless RB O
, , O
we PRP O
cannot MD O
exclude VB O
the DT O
possibility NN O
that IN O
this DT O
variant NN O
may MD O
result VB O
in IN O
a DT O
small JJ O
increase NN O
in IN O
susceptibility NN O
to TO O
CRC NNP O
or CC O
adenomas RB O
, , O
as IN O
was VBD O
suggested VBN O
by IN O
Fearnhead NNP O
et NNP O
al JJ O
[16] NN O
. . O

Further JJ O
studies NNS O
with IN O
appropriate JJ O
sample NN O
sizes NNS O
are VBP O
required VBN O
to TO O
address VB O
the DT O
low JJ O
penetrance NN O
effect NN O
of IN O
this DT O
variant NN O
in IN O
CRC. NNP O

Finally RB O
, , O
we PRP O
hypothesize VBP O
that IN O
the DT O
clinical JJ O
significance NN O
of IN O
a DT O
genetic JJ O
variant NN O
may MD O
differ VB O
according VBG O
to TO O
genetic JJ O
background NN O
. . O

Gene NNP O
functionality NN O
may MD O
be VB O
the DT O
net JJ O
result NN O
of IN O
the DT O
effects NNS O
of IN O
allelic JJ O
structures NNS O
and CC O
their PRP$ O
interactions NNS O
with IN O
environmental JJ O
factors NNS O
. . O

It PRP O
is VBZ O
possible JJ O
that IN O
low-penetrance NN O
variants NNS O
behave VBP O
differently RB O
in IN O
different JJ O
populations NNS O
, , O
making VBG O
it PRP O
difficult JJ O
to TO O
make VB O
predictions NNS O
in IN O
terms NNS O
of IN O
conferred JJ O
risk NN O
. . O

-DOCSTART- X X O

Conclusions NNS O

Taken VBN O
together RB O
, , O
the DT O
results NNS O
of IN O
this DT O
study NN O
and CC O
others NNS O
indicate VBP O
that IN O
the DT O
c.1852_1853AA>GC JJ O
variant NN O
should MD O
be VB O
considered VBN O
a DT O
neutral JJ O
variant NN O
for IN O
LS. NN O

These DT O
findings NNS O
have VBP O
considerable JJ O
relevance NN O
for IN O
the DT O
clinical JJ O
management NN O
of IN O
CRC NNP O
probands NNS O
and CC O
their PRP$ O
relatives NNS O
. . O

